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Dissecting the genotype to phenotype 
relationships of Genomic Disorders 
 
SUMMARY 
Over the last decade, major advances in the development and application of microarray -based 
comparative genomic hybridisation (aCGH) technology have significantly contributed to our 
understanding of Genomic Disorders. My aims here were to provide insight into the genotype to 
phenotype relationships of three Genomic Disorders; CUL4B-deleted X-Linked Mental Retardation 
(XLMR), Wolf-Hirschhorn Syndrome (WHS) and 16p11.2 Copy Number Variant Disorder. CUL4B 
encodes a structural component of the Cullin-RING-ligase 4-containing class of E3 ubiquitin ligases. 
CUL4B-deleted XLMR represents a syndromal form of mental retardation whereby patients exhibit 
other clinical features aside from the MR, such as seizures, growth retardation and disrupted sexual 
development. I used CUL4B-deleted patient-derived cell lines to investigate the impacts of CUL4B 
loss on mitochondrial function. I have shown that loss of CUL4B is  associated with a distinct set of 
mitochondrial phenotypes, identifying CUL4B-deleted XLMR as a disorder associated with 
mitochondrial dysfunction. Furthermore, I have uncovered a reciprocal relationship between 
CUL4B and Cereblon, providing evidence of a potential role for the CUL4-CRBN E3 ligase complex in 
maintaining mitochondrial function. Deletion or duplication of the 16p11.2 region is associated 
with macro-/microcephaly respectively. Here, I have evaluated the cellular consequences of 
16p11.2 CNV, specifically with regards KCTD13 expression, DNA replication and checkpoint 
activation. WHS is typically caused by a small hemizygous telomeric deletion of the 4p16.1 region. 
Haploinsufficiency of 4p16.1 is associated with microcephaly, growth retardation and complex 
developmental abnormalities. I investigated the impacts of LETM1 copy number change in WHS 
patient-derived cells. Here, I have shown that copy number change of LETM1 specifically segregates 
with mitochondrial dysfunction, likely underlying the seizure phenotype exhibited by the large 
subgroup of WHS patients whose deletions incorporate LETM1 as well as the rarer instances of the 
reciprocal duplication. In this thesis I use patient-derived cell lines from three Genomic Disorders 
as a fundamental tool providing new pathomechanistic insight into the clinical presentation of 
these conditions.  
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Chapter One 
Introduction: Copy Number Variation and 
Genomic Disease 
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1.1: Introduction 
Genetic variation within the human genome can range from large microscopically 
visible chromosome anomalies (deletions, insertions, duplications and 
translocations) to single-nucleotide polymorphisms (SNPs). It was previously 
thought that any two ‘normal’ individuals are 99.9% similar genetically and that 
SNPs in DNA were the most prevalent and important source of genetic variation 
(Collins et al, 1997; Kwok et al, 1996). However, due to advances of the Human 
Genome Project and the advent of microarray based Comparative Genomic 
Hybridisation (aCGH), the significance of deletions, insertions, duplications and 
complex re-arrangements collectively termed Copy Number Variations (CNVs) was 
realised (Collins & Mansoura, 2001; Pinkel et al, 1998; Solinas-Toldo et al, 1997). 
In 2004, two separate studies revealed that CNVs are widespread and represent a  
significant source of genetic variation within the human genome (Iafrate et al, 
2004; Sebat et al, 2004). Current evidence suggests that locus specific rates of CNV 
formation occur at several orders of magnitude more frequently than SNPs, with 
estimates of CNV locus-specific mutation rates ranging from 1.7 x10 -6 to 1.0 x 10-4 
per locus per generation (Lupski, 2007; Stankiewicz & Lupski, 2010). 
Consequently, it is now widely appreciated that CNVs contribute to complex 
sporadic disease and relatively common conditions such as Autism, Schizophrenia, 
Idiopathic Intellectual Disability and Cancer (de Smith et al, 2007; Redon et al, 
2006; Tuzun et al, 2005; Wong et al, 2007).   
 
1.2: Copy Number Variation 
CNV’s are found in all humans and are defined as DNA segments that are present at 
variable copy number in comparison to a reference genome, wherein the usual 
copy number is 2. CNVs are generally >1kb in size and a significant proportion of 
the human genome (12%) appears to be subject to CNV (Iafrate et al, 2004; Redon 
et al, 2006; Sebat et al, 2004). CNVs often occur in regions containing, or flanked 
by, large homologous repeats termed “Low Copy Number Repeats” (LCRs) (Shaw & 
Lupski, 2004; Stankiewicz & Lupski, 2002). Up to 5% of the haploid reference 
genome is present in two or more copies  and these LCRs are defined as DNA 
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fragments of 10 to 300 kilobase in size and of ~95-97% sequence identity (Bailey 
et al, 2001).  LCRs may either be in direct or inverted orientation but can also be 
present in more complex forms consisting of multiple adjacent LCRs in tandem and 
reverse orientation which provide the structural basis for a variety of 
rearrangements (Fig.1.1).  
The distribution of these CNVs within the human genome is thought to be non-
random and several ‘hotspots’ have been identified. For example, Cooper et al 
report 250 regions of 1Mb DNA sequence within which >50% of bases are within 
variants (Cooper et al, 2007). Furthermore, CNVs tend to occur towards 
centromeres and telomeres which may be due to the repetitive nature of these 
regions (Nguyen et al, 2006). Despite extensive studies, the total number, size, 
position, gene content and distribution of CNVs within the human genome remains 
elusive. To date (June 2013), 66741  distinct benign and pathogenic CNVs have 
been reported and are catalogued in various databases such as DGV (The Database 
of Genomic Variants: http://projects.tcag.ca/variation/), DECIPHER (DatabasE of 
Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources: 
http://decipher.sanger.ac.uk/) and ECARUCA (European Cytogeneticists 
Association Register of Unbalanced Chromosome Aberrations: 
http://umcecaruca01.extern.umnc.nl:8080/ecaruca.jsp) (Feenstra et al, 2006; 
Firth et al, 2009; Swaminathan et al, 2012). 
Given the frequency and range of genes incorporated within CNVs it is now 
appreciated that CNVs make a considerable contribution to human disease. The 
pathological disorders arising from such genomic rearrangements of regions 
containing a dosage sensitive gene/s are collectively referred to as ‘Genomic 
Disorders’ (Lupski, 1998; Lupski & Stankiewicz, 2005; Turner et al, 2008). In some 
cases, a change in copy number of a single gene only is thought to underlie specific 
developmental anomalies. This is exemplified by the duplication of PMP22 in 
Charcot-Marie-Tooth Disease type 1A (CMT1A) and the deletion of RAI1 in Smith-
Magenis syndrome (SMS) (Lupski et al, 1992; Roa et al, 1991; Skre, 1974; Slager et 
al, 2003). In other cases, dosage changes of a contiguous set of genes is thought to 
contribute to the complex disorder phenotype, for example the 1.5-1.8Mb deletion 
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in Williams-Beuren syndrome, encompassing ~20-30 genes at chromosome 
7q11.23  (Peoples et al, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 - Low copy number repeats (LCRs). Orientations of LCRs can be direct, inverted or 
complex. LCRs are depicted by blue boxes with black arrows indicating their orientation.  
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1.3:  Recurrent and non-recurrent CNV formation 
The mechanisms underlying CNV formation have not yet been fully elucidated but 
it is apparent that there are different subgroups of CNVs within the human 
genome. CNVs can be categorized into two principal groups; (i). recurrent, and (ii). 
non-recurrent. Recurrent CNVs occur in multiple individuals sharing a common 
breakpoint size and exhibit stable regions flanked by consistent boundaries  (Fig 
1.2a). In contrast, non-recurrent rearrangements, some which can be highly 
complex, show more variable breakpoints with a smallest region of overlap (SRO) 
between affected individuals (Fig 1.2b). These different variant types are thought 
to occur through recombination-based mechanisms such as homologous/non-
homologous recombination and replicative-based mechanisms such as fork stalling 
and template switching. 
 
1.3.1: Recurrent CNVs: Low Copy Repeats and Non-Allelic Homologous 
Recombination 
Due to the high degree of sequence identity between LCRs, LCRs represent 
substrates of homologous recombination (HR). In addition complex LCRs, 
particularly those with inverted repeats, can also form structures such a 
cruciforms and β-quadriplexes which may trigger rearrangements. Non Allelic 
Homologous Recombination (NAHR) between region-specific LCRs is a frequent 
mechanism underlying common recurrent genomic rearrangements (Stankiewicz 
& Lupski, 2002; Stankiewicz & Lupski, 2010). Misalignment of chromosomes or 
chromatids as a result of utilising homologous sequences in different chromosomal 
positions can result in unequal crossing over and subsequent genomic 
rearrangement. Depending on the location and orientation of the LCRs, the 
outcome of NAHR between these repeats can vary (Fig 1.3a). Unequal crossing 
over between non-allelic, directly repeated, homologous sequences located on 
homologous chromosomes (interchromosomal) results in deletion and/or 
duplication of the genomic segment between them (Fig.1.3aA). Unequal crossing 
over between direct LCRs on sister chromatids, termed interchromatid, can also 
result in deletion and/or duplication (Fig.1.3aB). Intrachromatid NAHR, between 
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LCRs located on the same chromatid in direct orientation, can result in deletions 
and the formation of ring chromosomes whereas intrachromatid NAHR between 
LCRs in inverted orientation can lead to inversion of the intervening sequence 
(Fig.1.3aC and D). 
Importantly, the outcome of NAHR is not limited to these alterations; changes in 
copy number can convey phenotypes through their impact on gene function such 
as gene disruption, gene fusions and revealing a recessive allele or positional effect 
in the context of a deletion (Fig. 1.3b and Table 1.1) (Coman & Gardner, 2007; 
Henrichsen et al, 2009; Kleinjan & van Heyningen, 2005). Such rearrangements, 
when involving a dosage-sensitive gene, can impact on activity in complex ways 
(Veitia & Birchler, 2010). Aside from altering gene dosage of the genes located 
within the CNV interval, CNVs can also profoundly affect the expression of genes 
located within their vicinity and this effect can extend to over half a megabase into 
the neighbouring regions (Henrichsen et al, 2009; Merla et al, 2006).  
Interestingly, the NAHR mechanism of CNV formation predicts that for a Genomic 
Disorder caused by a deletion, there could also be a reciprocal duplication-
associated disorder. Indeed, the first reported instance for this was that of the 
Charcot-Marie-Tooth Disease Type 1A locus on chromosome 17q (Lupski et al, 
1991; Raeymaekers et al, 1991). Further examples include DG/VCF syndrome and 
Smith-Magenis syndrome (McDermid & Morrow, 2002; Potocki et al, 1999; Ricard 
et al, 2010). However, the frequency of deletion syndromes is higher than that of 
duplication disorders due to the fact that intrachromatid NAHR can only result in 
deletion. Table 1.2 lists some examples of deletions and their reciprocal 
duplication disorders. 
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Figure 1.2 – Recurrent and Non-recurrent rearrangements. (a) Recurrent rearrangements have 
same sized deletions/duplication and share breakpoints which map within low copy number 
repeats (LCRs). The dashed lines represent distinct patients. (b) Non recurrent rearrangements 
have scattering of breakpoints but share a smallest region of overlap (SRO). Sometimes, LCRs are 
present within the vicinity of the breakpoint. Dashed lines represent distinct patients. 
  
(a) 
(b) 
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Figure 1.3 – NAHR between LCRs can result in genomic rearrangement. (a). Schematic 
representation of reciprocal duplications and deletions mediated by interchromosomal (A), 
interchromatid (B) and intrachromatid (C) non-allelic homologous recombination (NAHR) using 
pairs in direct (A- C) or inverted orientation (D). Chromosomes are shown in black with the 
centromere depicted by the grey box. The orientation of the LCR is indicated by the direction of the 
arrow head. Interchromosomal and interchromatid NAHR between directly orientated LCRs results 
in deletion and duplication (A, B) whereas intrachromatid results only in deletion (C, D). 
Intrachromatid NAHR between LCRs in opposing orientation can result in re-arrangement (D). (b) 
NAHR can have complex consequences for gene function. NAHR not only results in deletion and 
duplication but can also impact on gene function through gene interruption, gene fusions, 
unmasking a recessive allele (asterix) and/or reveal recessive alleles which result in positional 
effects on the functions of distal genes (green segment). 
(a) 
(b) 
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Table 1.1 - Examples of diseases arising from differing consequences of altered genomic copy 
number. CMT1A/HNPP; Charcot-Marie Tooth Disease Type 1A/Hereditary Neuropathy with 
liability to Pressure Palsies. 
 
  
Mechanism 
Affected 
gene 
Disease Reference 
Gene dosage PMP22 CMT1A/HNPP 
(Lupski et al, 1992; Roa et al, 
1991) 
Gene 
interruption 
Red-green 
opsin genes 
Colour blindness (Nathans et al, 1986) 
Gene fusion CYP11B1/2 Hypertension (Lifton et al, 1992) 
Position effect SOX9 Campomelic dysplasia (Velagaleti et al, 2005) 
Unmasking a 
recessive allele 
FXII Sotos syndrome (Kurotaki et al, 2005) 
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Table 1.2 - Specific examples of copy number variation and the phenotypes (Genomic Disorders) 
they convey. HNPP; Hereditary Neuropathy with liability to Pressure Palsies, CMT1A; Charcot-
Marie Tooth Disease Type 1A. 
Phenotype Locus CNV Reference 
Williams Beuren 
Syndrome 
7q11.23 Deletion (Peoples et al, 2000) 
7q11.23 duplication 
syndrome 
7q11.23 Duplication (Berg et al, 2007) 
Smith Magenis 
Syndrome 
17p11.2/RAI1 Deletion (Chen et al, 1997) 
Potocki-Lupski 
syndrome 
17p11.2 Duplication (Potocki et al, 2007) 
HNPP 17p12/PMP22 Deletion 
(Chance et al, 1994; 
Reiter et al, 1996) 
CMT1A 17p12/PMP22 Duplication 
(Chance et al, 1994; 
Reiter et al, 1996) 
Miller-Dieker 
lissencephaly 
syndrome 
17p13.3/LIS1 Deletion (Cardoso et al, 2003) 
Di George 
Syndrome/VGF 
22q11.2/TBX1 Deletion (Edelmann et al, 1999) 
Microduplication 
22q11.2 
22q11.2 Duplication (Ensenauer et al, 2003) 
Schizophrenia 
1q21.2, 15q11.2, 
15q13.3 
Deletion 
(Magri et al, 2010; 
Stefansson et al, 2008) 
Alzhiemer Disease APP Duplication 
(Rovelet-Lecrux et al, 
2006) 
Autism 
3q24 
 
16p11.2 
Inherited homozygous 
deletion 
Deletion/duplication 
(Crepel et al, 2011; 
Shinawi et al, 2010) 
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NAHR in germ line cells (meiosis) resulting in unequal crossing over can lead to 
genomic rearrangements that represent benign polymorphisms or manifest as 
genomic disorders (Lupski & Stankiewicz, 2005; Turner et al, 2008). These 
genomic disorders can either be inherited or sporadic depending on when the 
rearrangement was transmitted (Lupski, 2007). One of the best characterised 
inherited Genomic Disorders caused by NAHR is that of Charcot-Marie-Tooth 
Disease type 1A, arising from a duplication encompassing the dosage sensitive 
gene PMP22, thus conferring a phenotype (Lupski et al, 1991; Raeymaekers et al, 
1991; Roa et al, 1991). Examples of sporadic genomic disorders include Potocki-
Lupski syndrome/Smith Magenis Syndrome caused by the duplication/deletion on 
17p11.2 respectively. NAHR can also occur in mitosis resulting in mosaicism of 
somatic cell populations. It is also well appreciated that many cancers are related 
to genomic rearrangements of somatic cells, some of which are due to NAHR 
(Darai-Ramqvist et al, 2008; Fridlyand et al, 2006). Genomic disorders which 
result from somatic rearrangements present with mosaic manifestations, one 
example is that of NF1 deletions causing neurofibromatosis (Steinmann et al, 
2007).  
The knowledge of NAHR between LCRs as a mechanism for CNV generation plays a 
pivotal role in uncovering novel Genomic Disorders. The recent use of BAC array 
techniques has enabled the identification of a number of novel genomic disorders 
caused by NAHR-mediated rearrangements. In a “genome-first” approach, Sharp et 
al developed a BAC-based array Comparative Genomic Hybridisation (aCGH) 
pipeline designed to interrogate 130 potential NAHR rearrangement sites or 
‘hotspots’ throughout the human genome (Sharp et al, 2006). Using  this approach, 
they screened patient cohorts with a defined phenotype of Idiopathic Mental 
Retardation and subsequently identified  five novel causative microdeletions 
(17q21.31, 1q21.1, 15q13, 15q25 and 17q12) (Sharp et al, 2006). Furthermore, the 
widespread usage of aCGH techniques has also aided the deeper characterisation 
of many well-known genomic disorders. (Carter, 2007; Cheung et al, 2005; Lee et 
al, 2007a; Shaffer et al, 2006) 
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1.3.2: Non-recurrent CNVs and Non-Homologous End Joining 
Some genomic rearrangements can be non-recurrent and show scattered 
breakpoints which share a smallest region of overlap (SRO) in clinically similar 
patients (Fig. 1.2b) (Gu et al, 2008; Stankiewicz & Lupski, 2002). However, the size 
of the breakpoint is variable and most non-recurrent CNVs occur at sites of limited 
homology (2-15bp). The mechanistic basis underlying non-recurrent 
rearrangements is thought to involve the DNA double strand break (DSB) repair 
pathway of Non-Homologous End-Joining (NHEJ) (see Fig 1.4). The canonical role 
of the NHEJ pathway is in V(D)J recombination, the process by which B and T cell 
receptor diversity is generated in the immune system (Gellert, 2002). During V (D) 
J recombination, hairpin capped DSBs are created by the RAG1/2 nucleases which 
cleave the DNA at recombination signal sequences. These are then opened by the 
Artemis nuclease and joined by NHEJ. This process couples “variable”, “diversity” 
and “joining” regions, which when assembled together create the variable region of 
a B-cell or T-cell receptor gene. The importance of the NHEJ pathway is highlighted 
by disorders arising from mutations in NHEJ genes which impart a SCID  (Severe 
Combined Immunodeficiency) phenotype in affected patients (O'Driscoll et al, 
2004; Revy et al, 2006) This is due to defective V(D)J recombination and the 
subsequent inability to produce functional B/T-cells. Several human syndromes 
are associated with dysfunctional NHEJ such as LIG4 syndrome and XLF-SCID 
(O'Driscoll et al, 2004; Revy et al, 2006).  
Unlike NAHR, NHEJ does not require substrates with extensive homology and the 
break ends are directly ligated with very little or often no need for homology. NHEJ 
utilizes short homologous DNA sequences termed ‘microhomologies’ to guide the 
repair. These microhomologies are frequently present in the single stranded 
overhangs on the ends of DSBs. When these overhangs are compatible the break is 
repaired accurately, however imprecise repair can lead to the loss of nucleotides at 
the re-joining point leaving a characteristic ‘molecular scar’ within the breakpoint. 
Although LCRs are not thought to be involved in the generation of non-recurrent 
rearrangements, NHEJ may still be stimulated by certain genomic architectures 
and LCRs are often found within the vicinity of the breakpoints.  
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Figure 1.4 – Non-Homologous End Joining. Double stranded breaks (DSB) are sensed by a 
heterodimer formed Ku70 and Ku80 proteins (blue and orange rings). These Ku proteins have a 
ring-like structure and are able to bind and stabilize the ends of DSB, acting as sensors.  
Subsequently, the Ku proteins recruits the transducer kinase, DNA-PKcs (DNA dependent protein 
kinase catalytic subunit, shown here as a green oval shape). DNA-PK is a large Ser/Thr kinase 
belonging to the PIKK family (PI3-kinase like family of protein kinases). Once located to the DSB it 
phosphorylates and activates the NHEJ effector complex – Ligase IV/XRCC4/XLF (purple pentagram 
shape). The effector complex is responsible for re-joining the two DNA ends. Ligase IV provides the 
catalytic activity, while XRCC4 stabilizes and stimulates its activity. 
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1.4 Complex Chromosomal rearrangements 
Some CNVs cannot be readily explained by NAHR/NHEJ mechanisms and are 
therefore termed Complex Chromosomal Rearrangements (CCRs). These CCRs are 
characterised by multiple breakpoints and exchanges interspersed within regions 
of normal copy number (Zhang et al, 2009b). Several mechanisms have been 
proposed to explain the origins of these CCRs including Fork Stalling and Template 
Switching (FoSTeS), Microhomology Mediated Break-Induced Repair (MMBIR) and 
the Break-fusion-bridge cycle (BFB) (reviewed in Hastings et al. 2009). I will now 
describe each in turn: 
 
1.4.1: Fork Stalling and Template Switching 
The study of stress-induced amplification of the lac genes using the E.coli system 
led Slack et al to propose that template switching is not confined to just single 
replication forks but can also occur between different forks via a process of 
template switching (Slack et al, 2006). In 2007, Lee et al analysed the junction 
sequences in patients with Pilizaeus-Merzbacher disease (PMD), an X-linked 
dysmyelinating disorder caused most frequently by the non-recurrent duplication 
of the PLP1 gene (Lee et al, 2007b). Their analysis uncovered evidence for 
sequence complexity at some junctions consistent with a replication based 
mechanism which they termed FoSTeS (Fork Stalling and Template Switching). 
They propose that complex rearrangements associated with PMD, and other 
nonrecurrent rearrangements, could be explained the FoSTeS mechanism (Lee et 
al, 2007b). This model proposes that upon stalling of a replication fork the lagging 
strand disengages and invades another nearby replication fork that shar es 
microhomology (4-15bp). The invading strand anneals via the 3’ end and primes 
its own template DNA synthesis thus causing deletion, duplication, inversion or 
translocation depending on the position of the other replication fork (Fig 1.5) 
(Hastings et al, 2009b; Lee et al, 2007b; Slack et al, 2006). Template switching to a 
downstream fork will result in deletion whereas switching to an upstream fork is 
causative of duplication. This mechanism of disengaging, invading and synthesising 
can occur multiple times in series and thus can further add to the complexity of the 
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rearrangement (x1,x2, x3 etc.). In fact, reanalysis of the breakpoint sequence data 
of 23 deletion CNVs published by Perry et al found that at least 22% of CNV 
breakpoints were highly complex and consistent with two or more FoSTeS events 
(Perry et al, 2008; Zhang et al, 2009c). In addition to the Pilizaeus-Merzbacher 
disease region on chromosome Xq22, the FoSTeS mechanism has been 
demonstrated in other genomic regions such as the MECP2 duplication in Xq28, 
deletions and duplications in 17p13.3 and deletions and duplications in 
17p11.2p12 (Bi et al, 2009; Carvalho et al, 2009; Nagamani et al, 2009; Zhang et al, 
2009d). 
 
1.4.2: Microhomology-Mediated Break-Induced Repair 
Recently, based on experimental observations from human, bacteria, yeast and 
other model organisms, the FoSTeS model has been refined into a more 
generalised replicative template-switch model termed the Microhomology-
Mediated Break-Induced Repair (MMBIR) model of CCR formation (Hastings et al, 
2009b). MMBIR is based upon the mechanism of Break Induced Repair (BIR) of 
single double-stranded ends (Hastings et al, 2009a) . When a replication fork 
encounters a nicked template, the resultant one sided DSB undergoes resection 
generating a single stranded DNA required to initiate the template switch to a 
proximal replication fork.  When Rad51 function is limiting, classical BIR cannot 
occur; BIR relies on Rad51 as it involves the invasion of a 3 ’ end into the dsDNA of 
the repair partner (Davis & Symington, 2004). MMBIR therefore postulates that 
when strand invasion is limited (Rad51 is down-regulated), the 3’ end of the 
collapsed fork will anneal to any single-stranded template sharing microhomology 
and in physical proximity (Fig 1.6). For example, this could be the ssDNA in the 
lagging strand template of another replication fork. This annealing reaction does 
not rely on Rad51 and requires very little homology, therefore this annealing may 
occur with the sister molecule either in front of or behind the originating collapsed 
replication fork leading to deletion ore duplication respectively. Microhomology 
may also be found on a different chromosome leading to translocation 
rearrangements whereas annealing with the homologous chromosome as opposed 
to the sister chromatid could be a cause of extensive loss of heterozygosity (LOH) 
16 
 
(Hastings et al, 2009a). Repeated extension and separation from the template 
strand may cause several of these changes to occur ultimately forming CCRs. The 
FoSTeS/MMBIR mechanism represents a major mechanism underlying non-
recurrent CNVs and CCRs (Hastings et al, 2009a). Furthermore, it has also been 
suggested as a mechanism for the formation of LCRs themselves (Hastings et al, 
2009b; Zhang et al, 2009a). 
 
1.4.3:  The Break-Fusion-Bridge Cycle 
The Break fusion bridge (BFB) cycle was originally described by Barbara 
McClintock more than 60 years ago to explain gene amplification (McClintock, 
1951). Replication of a chromosome that has lost its telomeric end due to a DSB 
can lead to initiation of the BFB cycle (Fig 1.7). After DNA replication, the ends of 
sister chromatids fuse, giving rise to a dicentric chromosome (i.e. two 
centromeres). During anaphase the two centromeres will be pulled to the two 
opposite poles of the mitotic spindle. The dicentric chromosome is then broken 
leading to the uneven distribution of genetic material between the two products. 
However, both products still lack telomeres which results in re-initiation of the 
BFB process, ultimately establishing a cycle (Fig 1.7). The BFB cycle is thought to 
underlie gene amplification in mammalian cells but may also be of relevance to 
cancer where large inverted repeats are a common characteristic (Pipiras et al, 
1998). 
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Figure 1.5 – The FoSTeS mechanism of CCR formation.  (a). FoSTeS: The lagging strand of 
replication Fork 1 stalls (green) and disengages. The exposed 3’ end may then invade a proximal 
replication fork that shares microhomology (Fork 2, shown in red) thus causing 
deletion/duplication/inversion/translocation depending on the position of the other replication 
fork (b). Repeated FoSTeS events further add to the complexity of the rearrangement. If Fork 1 
stalls and disengages again, the strand derived from Fork 1, which now also contains material 
derived from Fork 2, template switches into a distinct fork (Fork 3, shown in blue). (c) When 
synthesis resumes on Fork 1, the extra material derived from forks 1 and 2 contributes to the 
rearrangement. Each line represents a single DNA strand. 
  
(a) 
(b) 
(c) 
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Figure 1.6 – Microhomology mediated Break-induced Repair (MMBIR) model of CCR formation. 
Replication fork collapse can occur when the fork encounters a nicked template resulting in the 
formation of a one-sided double strand break (green). This DSB is recessed from the 5’ end, 
generating a 3’ tail. This 3’ tail (single stranded DNA) can then initiate template switch into a 
proximal replication fork (blue) sharing microhomology. Each line represents a single DNA strand. 
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1.5: CNVs, genome stability and cancer 
Until recently, it was not fully appreciated that CNV represents a fundamental 
contributor to cancer origin and progression. However, over recent years the 
combined contributions of aCGH and next generation sequence technologies have 
led researchers to propose several novel pathogenic models of cancer-associated 
genome instability: Chromothripsis and Kataegis (Stephens et al, 2011; Taylor et al, 
2013). As described in the previous sections, the mechanisms of CNV formation 
invariably involve DNA repair pathways such as NHEJ and HR. Therefore, if a CNV 
were to incorporate a gene or genes encoding a protein(s) involved in genome 
stability and/or the DNA damage response (DDR), this could disrupt those 
pathways resulting in genome-wide instability. In fact, there is increasing evidence 
from mouse models that haploinsufficiency of genes encoding key proteins 
involved in multiple DNA repair pathways are associated with cellular and 
organismal features (Cabelof, 2012). Furthermore, specific familial cancer 
predisposition syndromes highlight a pathological association between CNVs and 
genome stability pathways. For example, deletions incorporating CHEK2, an 
important effector of the ATM apical protein kinase of the DDR, are associated with 
breast and prostate cancer (Reviewed in Colnaghi et al, 2011). 
In 2008, Shlein and co-workers investigated the consequences of compromised 
genome stability on the CNV landscape in Li Fraumeni Syndrome (LFS)(Shlien et al, 
2008). LFS is an autosomal dominantly inherited cancer predisposition syndrome 
characterized by a strikingly increased risk to early onset of a wide array of 
malignancies in individuals harbouring germline TP53 mutations (p53: “The 
Guardian of the Genome”). The underlying basis of the highly variable clinical 
phenotype between affected family members has long remained a mystery. Using 
high density genome-wide oligonucleotide arrays, Shlein and colleagues 
interrogated the CNV landscape of LFS compared to the normal population. They 
subsequently found that whilst the number of CNVs within a healthy control 
population was well conserved, CNV frequency was strikingly increased in these 
cancer-prone individuals. The authors suggested that this constitutional variation 
may act as the genetic platform on which more variants build, ultimately leading to 
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the development of cancer. 
 
1.6: Summary 
To conclude, CNVs appear in the human genome at higher locus-specific rates than 
SNPs and significantly contribute to genetic variation. Sporadic and inherited 
disorders, common complex traits such as autism and schizophrenia, and disease 
susceptibility are a result of CNVs. CNV formation can arise from both 
recombination-based mechanisms such as NAHR and NHEJ and replicative-based 
mechanisms such as FoSTeS and MMBIR. It is hoped that the widespread use and 
continuing development of aCGH coupled with the explosive progression in next 
generation sequencing technology development and application, will significantly 
contribute to our understanding of both the causes and consequences of genomic 
structural variation.  Moreover, an important step in understanding the biological 
impact of CNV is to unravel the genotype-phenotype relationships within Genomic 
Disorders.  
The aims of my PhD studies were to investigate the genotype to phenotype 
relationships of three genomic disorders; CUL4B-deleted/mutated X-Linked 
Mental Retardation (XLMR), 16p11.2 microdeletion/duplication syndrome and 
Wolf Hirschhorn Syndrome (WHS). In the case of CUL4B-XLMR the CNV involves 
deletion of the CUL4B gene whereas in WHS and 16p11.2 
microdeletion/duplication syndrome, the CNV involves a change in 2 or more 
adjacent genes. All three Genomic Disorders are characterised by 
neurodevelopmental anomalies such as intellectual disability and developmental 
delay. They also present with other clinical features such as micro/macrocephaly, 
seizures, growth retardation and in some cases, distinctive clinical facial 
characteristics. Understanding the genotype-phenotype relationships in these 
disorders will not only further the understanding of the biological consequences of 
distinct CNVs and rearrangements, but may also provide insight into possible 
therapeutic interventions in the management of such disorders.   
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Chapter Two 
Materials and Methods 
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2.1: Cell culture 
LBLs were cultured in RPMI 1640 (without L-glutamine) supplemented with 2mM 
L-Glutamine, 500U/ml penicillin, 50µg/ml streptomycin and 15% FCS (foetal calf 
serum) at 37°C in humidified incubators with 5% CO2. C2C12 myoblasts and 
Neuro-2A (N2A) cells were maintained in Dulbecco’s Modified Eagle Medium 
supplemented with 2mM L-Glutamine, 500U/ml penicillin, 50µg/ml streptomycin 
and 10% FCS. Fibroblast cell lines were cultured in Minimum Essential Medium 
supplemented with 2mM L-Glutamine, 500U/ml penicillin, 50µg/ml streptomycin 
and 10% FCS. T98G human glioblastoma cells were cultured in Dulbecco’s 
Modified Eagle Medium supplemented with 10% FBS, 1% Non-Essential Amino 
Acid (NEAA) and 1% Sodium Pyruvate (NaP), 2mM L-Glutamine, 500U/ml 
penicillin and 50µg/ml streptomycin. Cell cultures were kept at 37°C in a 
humidified atmosphere containing 5% CO2. 
For long term storage, cells were pelleted and re-suspended in culture medium 
containing 10% DMSO. 2ml aliquots were transferred into cryotubes and cooled 
slowly at -80°C before being transferred into liquid nitrogen towers. 
 
2.2: Antibodies  
Antibodies used include; anti-CUL4B (HPA011880), anti-CRBN (HPA045910), anti-
-tubulin (T5168) were obtained from Sigma Aldrich Prestige Antibodies. Anti-
MCM2 (sc9839, N19), anti-LETM1 (sc271232, D5), anti--tubulin (sc9104, H235), 
anti-PCNA (sc-56), anti-Parkin (sc136989, H8), anti-AMBRA1 (sc130116, N18), 
anti-TAO2K (sc47447 and sc366021) and anti-KCTD13 (sc133706) were from 
Santa Cruz. Antibodies for anti-LC3A (4599, D5OG8), anti-p21 (12D1), anti-p27, 
anti-Hexokinase 1 (2024, C35C4), anti-phospho-AMPK (2603, 23A3), anti-AMPK 
(2535, 40H9), anti-ACC (3676, C83B10), anti-phospho-ACC (3661), anti-phospho-
p44/42 MAPK (4695,137F5), anti-p44/42 MAPK (9101), anti-phospho-Chk1 
(23445, S317), anti-phospho-Chk2 (2661S, T68), anti-phospho-TLK (s695) and 
anti-TLK (4125) were obtained from Cell Signalling Technology. Anti-FK2 (BML-
PW8810-0500) antibody was purchased from Enzo Life Sciences. A second 
KCTD13 (POLDIP1) antibody was obtained from Abcam (ab32974).  
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Table 2.1: Cell Lines used in this thesis. 
Cell Line Source/Reference 
Fibroblasts  
1BR.3 (WT) GDSC cell bank 
92025337 (CUL4B-deleted) 
Sent by Bertrand Isidor, Universitare De Nantes, 
France (Isidor et al, 2010) 
Lymphoblasts  
AG03987 (CUL4B-deleted) GDSC cell bank 
CV1845 
Established from patient blood under contract by The 
European Collection of Cell Cultures (ECACC), Porton 
Down, Wiltshire, UK 
329-01 
Sent by Dr F. Lucy Raymond, CIMR, Cambridge, UK 
(Tarpey et al, 2007) 
83273 (LBL 83) 
Obtained from Joris Vermeesch, KU Leuvin, Belgium 
(Maas et al, 2008) 
78522 (LBL 78) “ 
88219 (LBL 88) “ 
355618 (LBL 355) “ 
WHSCR-2 (LBL CR) 
Obtained from Prof. Dr. Med. Anita Rauch, University 
of Zurich, Switzerland (Rauch et al, 2001) 
GM04368 Coriell Cell Repositories, New Jersey, USA 
GM11907A “ 
GM13740 “ 
09-22 
Sent by Dr Evica Rajcan-Separovic, Children’s and 
Women’s Health Centre of BC, Vancouver, Canada 
06-32 “ 
12-32 “ 
12-33 “ 
12-14 “ 
12-56 “ 
Other  
C2C12 (mouse myoblast) 
Prof. Simon Morley, School of Life Sciences, University 
of Sussex, UK 
T98G (human glioblastoma) GDSC cell bank 
Neuro-2A (mouse neuroblastoma) GDSC cell bank 
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 2.3: Reagents 
5-Fluorouridine (47580), Bafilomycin A (B1793), valproate (P4543), α-tocopherol 
(258024), thalidomide (T144), nigericin (N7143) and Ionomycin (13909) were 
obtained from Sigma-Aldrich (Dorset, UK). All Mitotrackers (M7512, M7514, 
M36008), Cell ROX red (C10422), JC-1 (M34152) and Calcium-1 AM (C3012) 
probes were obtained from Life Technologies (Paisley, UK). 
 
2.4: siRNA knockdowns 
Stealth (Life Technologies) siRNAs were designed against the 3’UTR region using 
the BLOCK-IT™ RNAi designer (Life Technologies, Paisley, UK). Oligos (20nmol) 
were resuspended in 1ml of DPEC-treated water to a final concentration of 20M. 
Transfections were performed with 2 x 10µL (2 x 40nM) of siRNA against Cul4b or 
1 x 5µL (20nM) of siRNA against LETM1, using Metafectene Pro (Biontex). 
Transfections were performed in T25 flasks in the presence of 5mls of the 
appropriate growth medium. 
 
Cul4b (mouse): 5’-AUAUAAGGUACGAUGGAAGGAACUG-3’ 
LETM1 (human): 5’- CCACAGAAUCGUGUCUGGAUCCACA-3’ 
 
SMARTpool siRNAs (a mixture of 4 distinct oligonucleotides) against Letm1 (L-
049478-01-0005, mouse) and Crbn (L-048249-01-0005, mouse) were obtained 
from Thermo Scientific. ON-TARGETplus SMARTpool siRNAs (5nmol) were 
resuspended in 250L of DPEC-treated water to a concentration of 20M. 
Transfections were performed in T25 flasks with 1 x 5µL (20nM) siRNA against 
Letm1 or 2 x 10µL (2 x 40nM) against Crbn using metafectene pro (Biontex).  Sense 
targeting sequences are: 
Letm1: (1) AGGUAGACAACAAGGCGAA, (2) CCAACAACUUCCUGCGUUU,   
               (3) CUAAAUAGUCGGGUGACAUA, (4) CUGCCUAAUUCAUGAGUAA.  
 
Crbn:  (1) GAAAAGUGUAAGUACGUAA, (2) GAUCUAUGCCUAUCGAGAA,                 
             (3) GGAUGGAAAUUUACAGCCA, (4) GACCAGUAUUCAUGUAAAU.  
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2.5: Extract preparation: 
 2.5.1: Urea-based whole-cell extracts 
Cell pellets were washed 2X in PBS and stored immediately at -20°C or lysed in 
50µL-100µL (unless otherwise stated) of urea-based lysis buffer. Whole cell 
extracts were obtained following lysis in urea buffer (9M urea, 50mM Tris-HCl at 
pH 7.5 and 10mM 2-β-mercaptoethanol), followed by a 12 second sonication, 30% 
amplitude to solubilize. Protein concentration was determined using the Bradford 
assay at a UV absorbance of 595nm. Samples were then stored at -20°C or 
immediately boiled in 2X SDS-loading buffer (5% SDS, 10% glycerol, 10% 2-β-
mercaptoethanol, pH 6.8 and 0.2% bromophenol blue) and loaded onto SDS-PAGE 
gels. 
 2.5.2: Soluble extracts (for immunoprecipitation) 
Soluble extracts were obtained following treatment with detergent lysis buffer. 
Cell pellets were incubated in IP buffer [50mM Tris-HCl, pH 7.5, 150mM NaCl, 2mM 
EDTA, 2mM EGTA, 25mM NaF, 25mM β-glycerolphosphate, 0.1mM Na-
orthovanadate, 0.2% Triton-X-100, 0.3% IPEGAL and protease inhibitor cocktail 
tablets (Roche) for one hour on ice. Protein concentration was determined using 
the Bradford assay at a UV absorbance of 595nm (Bio-Rad). Samples were then 
stored at -20°C or immediately boiled in 2X SDS-loading buffer (5%SDS, 
10%glycerol, 10% β-mercaptoethanol, 125mM Tris-HCl, pH 6.8 and 0.2% 
bromophenol blue) and loaded onto SDS-PAGE gels. 
 
2.5.3: Mitochondrial extracts - µMACS Isolation Kit 
Mitochondrial extracts were obtained using the Miltenyi Biotech Human 
Mitochondrial Isolation Kit (Miltenyi Biotech, UK: Cat no – 130-094-532). 107 cells 
were lysed using the buffer provided and homogenized using a glass mini-stokes 
homogenizer, with 10-15 strokes per sample on ice. Lysate was incubated with 
Anti-TOM22 MicroBeads for 1 hour at 4°C with gentle shaking (Miltenyi Biotech). 
An LS column was placed in the magnetic field of a QuadroMACS separation unit 
and the lysate was then applied to the LS column (Miltenyi Biotech). Once the 
lysate had run through, the column was washed 3 times with the supplied buffer 
before being removed from the magnetic field and placed on a collection 
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tube/ependorff. The magnetically labelled mitochondria were then eluted and 
centrifuged at 13,000g for 2 minutes to pellet them. The mitochondria pellet was 
resuspended in 60µL urea lysis buffer and sonicated for 15 seconds at 30% 
amplitude to give a pure mitochondrial extract. Samples were then stored at -20°C 
or immediately boiled in 2X SDS-loading buffer (5%SDS, 10%glycerol, 10% β-
mercaptoethanol, 125mM Tris-HCl, pH 6.8 and 0.2% bromophenol blue) and 
loaded onto SDS-PAGE gels. 
 
2.6: Immunoprecipitation 
For immunoprecipitation, 400µg of soluble cell extracts was used. Following IP, 
reactions were incubated with 40µL Dynabeads (100-04D, Life Technologies) for 1 
hours on a rotating wheel at 4°C, magnetically recovered and eluted at 95°C using 
30µL SDS-PAGE sample loading buffer. Proteins were separated on a 10% SDS-
PAGE gel and immunoblotted using semi-dry transfer (BioRad) onto a PVDF 
membrane. 
 
2.7: 5-Fluorouridine incorporation and indirect immunofluorescence 
Well-proliferating cells were pulse labelled with 2mM 5-Fluorouridine for 0-15 
minutes. Cells were pelleted and resuspended in 1ml 75mM KCl and left at room 
temperature for 10 minutes to allow the cells to swell. Cells were pelleted by 
centrifugation and the supernatant removed by aspiration. Pellets were 
resuspended in 100µL 3.7% paraformaldehyde and incubated for 10 minutes. The 
supernatant was aspirated and samples were stored in 70% ethanol at 4°C until 
processing. ¼ of each sample was cytospun onto a Poly-Lysine coated slide at 500-
700 rpm for 5-7 minutes. Cells were lysed in 100-200µL of 0.2% Triton-X100/PBS 
for 1 minute and then washed in PBS. Cells were blocked for 10 minutes in 100-
200µL of BSA/PBS and then washed 1X PBS. 150µL of primary antibody (mouse 
monoclonal anti-BrdU, Sigma) was added to the slide and left for 25 minutes at 
room temperature following by 1X PBS wash. The secondary antibody (FITC/Cy3 
labelled) was added at a 1:200 dilution and left for 25 minutes in the dark 
following by 1X PBS wash. DAPI was added directly to the slides at a 1:50,000 
dilution of a 1mg/ml stock and left for 5 minutes in the dark. Following 3X PBS 
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wash, slides were mounted using Vectashield and coverslips sealed with nail 
polish. Slides were then stored in the dark until further analysis. 
  
2.8: Agarose-formamide gel electrophoresis 
TAE/formamide electrophoresis was performed in 1.2% agarose gels containing 1 
X TAE buffer (0.04M Tris-acetate, 1mM EDTA). Before electrophoresis RNA 
samples were mixed with deionized formamide in the amount giving a final 
concentration of at least 60% (v/v) formamide, with 1/10 sample volume of 10X 
loading dye (50mM Tris-HCl, pH 7.6, 0.25% bromophenol blue, 60% glycerol) and 
1µL ethidium bromide. Samples were denatured by heating at 65°C for 5 minutes 
and immediately chilled on ice for 5 minutes. Samples were loaded onto the gel 
and electrophoresis was performed at a voltage gradient of 5 V/cm 
 
2.9 Semi-quantitative duplex PCR 
To measure the mtDNA content in WT and CUL4B-deleted LBLs, total DNA was 
extracted. Primer sets for two mtDNA-encoded genes, ND2 and 16S RNA, were 
used for PCR analysis, together with a primer set for the nuclear DNA-encoded 
gene, 18s (Life Technologies). 500ng of template (DNA) was used and the PCR 
cycle consisted of; 3 minutes at 94°C, 25 x 30 seconds at 94°C, 30 seconds at 56°C, 
1 minute at 72°C and a final step of 8 minutes at 72°C. PCR products were 
electrophoresed on a 1% (w/v) agarose gel, stained with 0.5µg ethidium bromide, 
and visualised with an UV transilluminator. mtDNA content was assessed by 
determining the ratio of ND2:18s RNA and 16s:18s RNA by scanning and 
comparing intensities using Image J.  
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Table 2.2: Primers used for PCR. 
18S Forward 5’-TAGAGGGACAAGTGGCGTTC-3’ 
18S Reverse 5’- CGCTGAGCCAGTCAGTGT-3’ 
16S Forward 5’-CCAATTAAGAAAGCGTTCAAG-3’ 
16S Reverse 5’- CATGCCTGTGTTGGGTTGACA-3’ 
ND2 Forward 5’- CTAGCCCCCATCTCAATCATA-3’ 
ND2 Reverse 5’-GAATGCGGTAGTAGTTAGGAT-3’ 
 
2.10: Mitochondrial function; MitoTrackers 
Cells in suspension i.e. LBLs were pelleted by centrifugation and resuspended in 
pre-warmed growth medium containing the Mitotracker Red/Green/SOX probe 
(250nM). Cells were incubated for 15 minutes under growth conditions. After 
staining, cells were washed once in PBS. Cells were then resuspended in 500µL 1X 
PBS and filtered into BD FACS falcon tubes for immediate flow cytometry analysis 
using the BD FACS Canto flow cytometer. For microscopy based analysis of 
Mitotracker Red/Green, cells were resuspended into 600µL PBS and ¼ of the 
sample was cytospun onto a poly-lysine slide for microscopy based analysis.  
Attached cells (C2C12, T98G, and N2A) for microscopy-based analysis were grown 
on coverslips in a 6 well dish until 60% confluent. Cells were then incubated with 
250nM Mitotracker probe for 15 minutes and then washed in PBS. Cells were 
stained with DAPI and the coverslips were then mounted onto Poly-lysine slides 
for visualization using the Zeiss Axiovert microscope. For flow cytometry-based 
analysis, attached cells were incubated with 250nM of the Mitotracker probe (Red, 
Green/SOX) and washed once with PBS. Cells were then trypsinised or detached 
using a cell scraper and filtered into a BD FACS falcon tube for flow cytometry 
analysis using the BD FACS Canto flow cytometer. 
 
2.11: Mitochondrial membrane potential; JC-1 
For each sample, 1 x 106 cells were suspended in 1ml of warm 1X PBS and stained 
with 2µM JC-1 (5,5’ -6,6’-tetraethylbenzimidazol-carbocyanineiodide)(Molecular 
Probes) and incubated under growth conditions for 30 minutes. To confirm that 
the JC-1 probe was responding to changes in mitochondrial transmembrane 
30 
 
potential, cells were incubated with 50µM CCCP (supplied with the kit) 
simultaneously with JC-1. Cells were then pelleted by centrifugation and 
resuspended in 500µL 1X PBS and immediately analyzed using a BD FACS Canto 
flow cytometer. 
 
2.12: Complex I activity 
Extracts were made according to the manufacturers protocol (Abcam, cat #: 
ab109720) and varying amounts of protein were then loaded into the wells of a 
96-well plate. Once the dipstick had been incubated with the various buffers 
supplied in the kit, as per the protocol, 300µL of deionized water was added to 
stop the reaction. The dipsticks were then dried and the intensity of the Complex I 
capture mAb band (~7mm from the bottom) was scanned using a flat-bed scanner 
and the signal intensity measured in Image J. 
 
2.13: MitoProbe Transition Pore Assay 
For CUL4B-LBLs; LBLs were resuspended in pre-warmed HBSS/Ca2+ at a final 
concentration of 1 x 106 cells/ml. 6 x 1ml aliquots were prepared per cell line 
(Tubes 1-6). 10nM calcein AM was added to all 6 tubes, CoCl2 was added to tubes 
2-5, 500nM ionomycin was added to tube 3 only, 50nM ionomycin was added to 
tube 4, 5nM ionomycin was added to tube 5 and 0.5nM ionomycin was added to 
tube 6. Samples were incubated for 15 mins at 37°C, protected from light. Cells 
were pelleted by centrifugation, resuspended in 500µL 1X PBS and filtered into BD 
FACS Falcon tubes for flow cytometry analysis. Samples were analysed using 
488nm excitation and emission filters appropriate for fluorescein. A sa mple 
containing no added reagents was used for instrument set up. 
 
For WHS-LBLs; LBLs were resuspended in pre-warmed HBSS/Ca (Hanks balanced 
Salt Solution with Ca2+) at a final concentration of 1 x 106 cells/ml. 3 x 1ml aliquots 
were prepared per cell line (Tubes 1-3). 10nM calcein AM was added to each tube, 
400µM CoCl2 was added to tubes 2 and 3 and 500nM ionomycin was added to tube 
3. Samples were incubated for 15 mins at 37°C, protected from light. Cells were 
pelleted by centrifugation, resuspended in 500µL 1X PBS and filtered into BD FACS 
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Falcon tubes for flow cytometry analysis. Samples were analysed using 488nm 
excitation and emission filters appropriate for fluorescein. A sample containing no 
added reagents was used for instrument set up. 
 
2.14: Calcium measurements 
Cells were incubated with 10µM Calcium-1 AM probe (C-3012, Life Technologies) 
for 20 minutes under normal growth conditions. Cells were then washed with 1X 
PBS, resuspended in 500µL PBS and filtered into BD FACS Falcon tubes. Flow 
cytometry analysis was performed using 506/531nm excitation/emission filters . 
 
2.15: LETM1 overexpression 
T98G human glioblastoma cells were transfected with 2µg of a plasmid encoding 
LETM1 (pCMV6-XL4), purchased from OriGene, in the presence of 5µL Metafectene 
Pro (Biontex) under normal growth conditions. Cells were harvested 24 hours post 
transfection for flow cytometry, microscopy or Western blot-based analysis.  
 
2.16: LETM1 complementation 
T98G cells were transfected with 30nM siRNA against LETM1 in the presence of 
5µL Metafectene Pro (Biontex) ± 2µg plasmid encoding LETM1 under normal 
growth conditions. T98G controls were either treated with Metafectene Pro only, 
siRNA only, or the cDNA construct only. 24 hours post transfection, cells were 
incubated with 250nM MitoSOX and analysed by flow cytometry using the BD FACS 
Canto. To determine the efficiency of the siRNA-mediated knockdown and cDNA 
construct addback, cell were pelleted and washed twice in PBS and then 
resuspended in urea-based lysis buffer. Protein concentration was determined 
using the Bradford assay and 50µg of whole cell extract in 2X SDS loading buffer 
were boiled for 5 minutes. Samples were electrophoresed on an 8% SDS-PAGE gel 
followed by standard Western blot analysis. 
 
2.17: S-phase progression 
Logarithmically growing LBLs were pulse labeled for 30 minutes with 20µM BrdU. 
Colcemid (100µg/ml) was added to stop cells from cycling and BrdU incorporation 
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was monitored every two hours for up to 6 hours. Cells were then fixed with ice-
cold ethanol (100%) and left overnight at -20°C. Samples were then spun at 2500g 
for 10 minutes at 10°C and the pellet was resuspended in 1ml of 2M 
HCl/PBS/Triton X-100 drop-wise. Samples were then incubated at room 
temperature for 30 minutes. Samples were spun at 2500g for 10 minutes at 10 °C 
and the pellet resuspended in 1ml of 0.1M Na2B4O7x10H2O pH 8.5 (Borax) to 
neutralise the acid. Samples were spun again at 2500g for 10 minutes at 10°C and 
the pellet was resuspended in 500µL 1% BSA/0.05%Tween20/PBS. 10µL of anti-
BrdU-FITC was added to each sample and incubated for 30 minutes in the dark at 
room temperature. Samples were washed once with 1%BSA/0.05%Tween20/PBS 
and once with 600µL PBS/0.05%Tween20 + 5µg propidium iodide (PI) + 30µL 
RNase. Samples were stored at 4°C until FACS analysis. 
 
2.18: Recovery after HU treatment  
LBLs were treated with 250µM HU for up to 6 hours. S-phase efficiency was 
measured every two hours by incubating with 20µM BrdU for 30 minutes prior to 
the end of the time point. Cells were fixed in ice cold ethanol (100%) and left 
overnight at 20°C. Samples were prepared as above and stored at 4°C until FACS 
analysis. 
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Chapter Three 
X-Linked Mental Retardation and CUL4B; a 
pathomechanistic dissection of the impact of 
CUL4B deletion in human patient-derived cells  
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3.1: Introduction 
 
Mental Retardation (MR) or as it is now more frequently termed; Intellectual 
Disability (ID) (Schalock et al, 2007), is a lifelong disability which places heavy 
demands on society and the health service. From here on, in accordance with the 
referenced literature, I will use the originally designated term ‘MR’ rather than ID. 
There are three criteria that must be met when defining MR; 
1. There must be significant sub-average general intellectual functioning, 
defined by the intelligence quotient, IQ. 
a. IQ of 50-70; Mild MR 
b. IQ of 35-49; Moderate MR 
c. IQ of 20-34: Severe MR 
d. IQ of <20; Profound MR 
2. This must be accompanied by limitations in adaptive functioning in at least 
two areas such as self-care, health, social skills, communication; this refers 
to how well an individual copes with the common demands of life . 
3. The onset must occur before the age of 18. 
MR affects approximately 1-3% of the population, with it being ~3 fold more 
common in males due to many mutations being found on the X chromosome 
(Leonard & Wen, 2002). Approximately 16% of mutations are X-Linked leading to 
X-Linked Mental Retardation (XLMR) which can be classified as either syndromic 
or non-syndromic, whereby patients may or may not exhibit other clinical features 
aside from MR such as ataxia, short stature and distinct facial features (Chiurazzi et 
al, 2008). Figure 3.1 summarises the genes found on the X chromosome reported 
to cause XLMR, some of which are known to encode proteins that function in the 
ubiquitin proteasome pathway of protein degradation (Fig 3.1 - circled in red). 
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Figure 3.1 - An ideogram of the X chromosome with the position of 82 known XLMR genes. 
Adapted from Chiurazzi et al, 2008. Those genes in black cause syndromes characterized by 
multiple congenital abnormalities and defects, those in grey with a + cause neuromuscular 
conditions but no malformations and those in grey with * cause nonspecific (MRX) conditions 
where MR is the only consistent clinical manifestation among individuals. Those genes highlighted 
by red circles encode proteins known to be involved in the ubiquitin pathway. 
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3.1.1: The ubiquitin-proteasome pathway of protein degradation 
Many neurodevelopmental disorders such as Angelman’s Syndrome (UBE3A 
deficient) Alzheimer’s and Parkinson’s disease (various mutations) are associated 
with disruption to the ubiquitin-proteasome pathway (UPS) resulting in the 
altered degradation of target proteins. The UPS is a fundamental cellular 
mechanism for regulating protein activity and is therefore important in a variety of 
cellular processes. These include the regulation of cell cycle and division, 
involvement in the cellular response to stress, modulation of cell surface receptors 
and DNA repair (discussed further in section 3.1.1.1) and the regulation of 
neuronal morphogenesis. The UPS serves both proteolytic and non-proteolytic 
functions and the distinction between the two pathways is achieved through either 
mono (usually regulatory) or poly-ubiquitination (usually degradative) of target 
substrates on specific lysine residues. The conjugation of ubiquitin, a highly 
conserved 76-amino acid residue polypeptide, to a protein substrate proceeds 
through a cascade mechanism (Fig 3.2);  
1. Activation of ubiquitin through a two-step reaction involving an E1-
ubiquitin activating enzyme. The E1 enzyme activates the C-terminal 
glycine residue of ubiquitin which facilitates the transfer of ubiquitin to the 
active site of the E1 enzyme. This results in a thioester linkage between the 
C terminal of ubiquitin and the cysteine sulphydryl group of the E1. 
 
2. One of several E2-ubiquitin conjugating enzymes then transfers the active 
ubiquitin to the substrate which is bound by a member of the E3 ubiquitin 
ligase family. In this step, the transfer of ubiquitin can either be directly to 
the E3-bound substrate or via an additional E3-ubiquitin high-energy thiol 
ester intermediate. It is the specific combination of E2 and E3 enzymes that 
creates a plethora of enzymatic capability in this pathway. 
 
3. The final step creates an isopeptide bond between a lysine side chain of the 
target protein and the C-terminal glycine of ubiquitin in an E3 ligase-
dependent manner. Polyubiquitin chains typically serve as a recognition 
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marker for degradation pathways whereas a monoubiquitin chain usually 
serves regulatory roles on the substrate. 
 
4. Following conjugation, free and reusable ubiquitin is released by the action 
of deubiquitinating isopeptidases which liberate ubiquitin from its 
substrate. 
The organisational structure of the UPS appears hierarchical, where a single E1 
activates the ubiquitin required for all modifications and can subsequently transfer 
the ubiquitin to several E2 enzymes.  E2 enzymes then act in concert with E3 
ligases where E2’s can transfer the ubiquitin to one or several E3 proteins. The 
human genome contains four E1 enzymes, 21 E2 enzymes and numerous E3’s 
which can take many forms; HECT (Homologous to E6-associated protein C-
Terminus), U-box or RING domain (Really Interesting New Gene). Figure 3.3 
illustrates the various E1, E2 and E3 enzymes identified to date by the Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathway database 
(www.kegg.jp/kegg/pathway.html). 
 
3.1.1.1: The role of ubiquitin in the DNA Damage Response 
The ubiquitination of proteins has emerged as an important regulatory mechanism 
impacting on the DNA damage response (DDR). Many DDR repair and checkpoint 
pathways utilise the ubiquitin system in their response to genotoxic lesions 
highlighting the importance of functional cooperation between E3 ligases in 
genome maintenance and stability (Jackson & Durocher, 2013; Stone & Morris, 
2013). The ubiquitin system has key roles in the assembly of repair and signalling 
proteins at sites of double-strand DNA breaks (DSBs). Specifically, DSB’s are 
detected by the Mre11-Rad50-NBS1 (MRN) complex (de Jager et al, 2001; Panier & 
Durocher, 2009). The MRN complex initiates the DNA damage signalling response 
through a direct interaction with ATM resulting in its autophosphorylation and 
activation. Active ATM then functions to phosphorylate a wide set of proteins 
including the histone H2A variant H2AX on Ser139, forming H2AX (Fernandez-
Capetillo et al, 2004). This phosphorylated form of H2AX is recognised by MDC1 
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(mediator of DNA damage checkpoint), which through a direct interaction with 
ATM and NBS1 forms a positive feedback loop amplifying the H2AX signal (Lou et 
al, 2006; Stewart et al, 2003; Stucki et al, 2005). In addition, MDC1 itself is 
phosphorylated in an ATM-dependent manner leading to the recruitment of RING 
finger protein 8 (RNF8) to the double strand break (DSB) site (Kolas et al, 2007; 
Mailand et al, 2007). Chromatin bound RNF8 cooperates with UBC13 (ubiquitin 
conjugating enzyme) to mediate the ubiquitination of histone H2A and H2AX 
(Mailand et al, 2007; Wu et al, 2009).  RNF8 also interacts with the giant HECT type 
E3 ligase HERC2 through its FHA domain (N-terminal forkhead-associated) which 
acts to stabilise the RNF8/UBC13 interaction (Bekker-Jensen et al, 2010). 
Ubiquitinated histones are recognised by a second E3; RNF168 which functions to 
amplify the local concentration of lysine 63-linked ubiquitin (UbK63) conjugates at 
DNA lesions. It does so by promoting the formation of UbK63 conjugates and the 
recruitment of additional repair proteins (Doil et al, 2009). RNF8-RNF168 
mediated ubiquitination is critical for the recruitment of downstream checkpoint 
and repair proteins such as BRCA1 and 53BP1 (Doil et al, 2009; Stewart, 2009; 
Wang & Elledge, 2007).  BRCA1 does not contain any ubiquitin binding motifs itself 
but interacts with Abraxas and RAP80 to accumulate at DSB sites (Wang et al, 
2007). BRCA1 also associates with the RING domain protein BARD1, to form an 
active E3 ligase complex crucial for DNA repair (Morris & Solomon, 2004).  
The importance of the RNF8-RNF168 pathway is demonstrated by biallelic 
mutations in the RNF168 gene which cause a complex disorder originally termed 
RIDDLE (radiosensitivity, immunodeficiency, dysmorphic features and learning 
difficulties) (Stewart et al, 2009; Stewart et al, 2007).  However, a more recent 
report identified an individual with a homozygous truncating mutation of RNF168 
(Devgan et al, 2011). Interestingly, this patient did not present with the previously 
characterised RIDDLE syndrome but displayed ataxia, ocular and bronchial 
telangiectasia in addition to microcephaly, short stature and low IgA (Devgan et al, 
2011). The authors proposed that the difference between this case and the 
previous case reported by Stewart and colleagues was due to the absence of both 
MIU (Motif Interacting with Ubiquitin) domains in this second patient. In this same 
year, an Rnf168-/- mouse model was generated where Rnf168-deficient mice 
39 
 
exhibited immunodeficiency, increased radiosensitivity and defective 
spermatogenesis (in male mice) (Bohgaki et al, 2011). This mouse model has thus 
provided evidence for a role of RNF168 in V(D)J and class switch recombination , 
the processes responsible for B and T cell receptor diversity within the immune 
system (Bohgaki et al, 2011).  
DNA damage checkpoints function to arrest or slow down cell cycle progression in 
response to DNA damage allowing time for repair of the damaged DNA or 
controlled engagement of programmed apoptosis pathways. Two classes of 
ubiquitin ligases; the SCF (SKP2/Cul1/F-box) and the APC/C (Anaphase-promoting 
complex) complexes, regulate cell cycle progression and are therefore linked to 
checkpoint control (Cardozo & Pagano, 2004). One example of an SCF complex is 
the SCF βTrCP complex which is important for the DNA damage-induced degradation 
of CDC25A, resulting in CDK inhibition and cell cycle arrest (Mailand et al, 2000). 
The APC functions to regulate exit from the mitotic phase of the cell cycle and 
controls entry into S-phase (Sullivan & Morgan, 2007). All of the above examples 
provide insight into the fundamental roles of the ubiquitin-mediated cascade 
pathway in regulating DNA damage repair.  
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Figure 3.2 - Schematic illustration of the ubiquitin-proteasome pathway of protein degradation. 
Activation of ubiquitin is achieved by an E1 enzyme, an E2 then transfers the ubiquitin to the 
substrate (S) bound by an E3. RING E3’s (E3R) directly transfer the ubiquitin to the substrate 
whereas HECT E3’s (E3H) act as an adaptor molecule by bringing the target and the E2 into close 
proximity to allow ubiquitination of the target substrate. Multiple ubiquitin molecules are attached 
forming a polyubiquitin chain and the substrate is subsequently directed the 26S proteasome for 
degradation.  
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Figure 3.3 - Members of the E1, E2 and E3 families of enzymes. To date, four E1 ubiquitin-
activating enzymes and 21 E2 ubiquitin conjugating enzymes have been identified. Numerous E3 
ubiquitin ligases have been reported which can possess HECT, U-box or RING finger domains and 
these have specificity to their substrates. The RING finger type E3s can be further categorised into 
two groups; simple or multisubunit. The multisubunit RING-type E3s are exemplified by cullin-RBX 
E3s and APC/C. RING-type E3s consist of a RING-finger-containing subunit RBX1 or RBX2 that 
functions to bind E2s, a scaffold-like cullin backbone, adaptor proteins and a substrate binding 
receptor. The CUL4-containing E3 ligase complex family is highlighted in green.   
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3.1.2: The Cullin family of E3 ligases 
E3 ubiquitin ligases are a diverse group of proteins characterised by defining 
motifs. The HECT (Homologous to E6-associated protein C-terminus) domain E3 
ligases form a catalytic intermediate with ubiquitin and then directly transfer 
ubiquitin to the substrate, whereas RING and U-Box domain E3 ligases facilitate 
ubiquitination by acting as an adaptor molecule. They do so by bringing the E2 
enzyme and the target substrate into close proximity to promote ubiquitination of 
the target (See Fig 3.2; E3H vs. E3R).  The Cullin family of proteins encode the 
subunits for several RING domain E3 ligases involved in a series of ubiquitin-
protein ligase complexes regulating the programmed degradation of various 
cellular proteins including p21 and CDT1 (Abbas et al, 2008; Nishitani et al, 2006).  
Although cullins do not contain a RING domain themselves, they can bind to small 
RING proteins; ROC1 and ROC2 (ROC; Ring of Cullin) which then form the basis of a 
Cullin-Ring E3 Ligase (CRL) (Deshaies, 1999). Cullins also rely on substrate 
receptors, attached to the cullin backbone by a ‘linker’ protein, as they cannot bind 
their substrates directly (Fig 3.4). There are seven CUL isoforms (CUL -1, -2,-3, -4A, 
-4B, -5 and -7) and the very wide functional diversity of this class of enzyme is 
based on their interactions with various adaptor proteins and substrate specific 
receptors (Petroski & Deshaies, 2005b) and Fig 3.4). Cullin ligases are regulated by 
the CAND1-NEDD8 cycle in which CAND1, a 120kDa protein, negatively regulates 
cullins by preventing the binding of the adaptor protein and therefore preventing 
subsequent binding of substrates. Cullins are covalently modified by the addition 
of Nedd8 which dissociates CAND1. Once the polyubiquitinated substrate is 
degraded by the 26S proteasome, the COP9 signalosome is involved in the removal 
of Nedd8, allowing CAND1 to re-associate with the cullin and thus inhibition is 
resumed (Liu et al, 2002; Pan et al, 2004; Zheng et al, 2002a). 
In humans, CUL4 exists as two closely related paralogues: CUL4A and CUL4B . They 
are over 80% identical however CUL4B possesses a unique amino acid terminal 
extension whose function is still largely unknown. CUL4 differs from other cullins 
in that it interacts with the WD40-like repeat containing protein, DDB1, at its N 
terminal which acts as an adaptor protein (Angers et al, 2006; He et al, 2006; 
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McCall et al, 2005). DDB1 was originally identified as DNA damage binding protein 
due to its interactions with DDB2 to recognise UV-induced DNA lesions and 
employ the NER pathway to remove and repair the DNA damage (Chu & Chang, 
1988).  CRL4’s have been shown to play important roles in NER via the 
ubiquitination of histones, CSB, XPC and DDB2, where DDB1 can act either as a 
direct substrate receptor or an adaptor protein to bind specific substrate receptors 
(Dai & Wang, 2006; Hannah & Zhou, 2009). The substrate receptors conferring the 
specificity of  CRL4-containing E3 ligase complexes are still being identified 
however the identification of over 60 novel DCAFS (DDB1 and CUL4 associated 
factors) as putative substrate receptors implicates the CUL4-DDB1 complex in a 
wide and expanding variety of fundamental processes, ranging from DNA repair to 
transcription and translation (Lee & Zhou, 2007).  
Recently, Cereblon (CRBN) was identified as a component of a CRL4 complex 
involving CUL4 and DDB1 (Ito et al, 2010). CRBN encodes a protein containing a 
domain with 50% similarity to the ATP-dependent Lon protease family involved in 
the regulation of mitochondrial replication and transcription. Mutations in CRBN 
have been associated with a form of non-syndromal X-Linked Mental Retardation 
(Higgins et al, 2004b), the relevance of which will be discussed in further detail in 
Chapter 4. At present, approximately 20 CUL4 ligase substrates have been 
reported but it is likely that there are numerous unidentified substrates (Table 
3.1). Many of the known substrates to date are involved in the cell cycle and the 
DNA damage repair pathway (NER) but newly identified substrates play a role in  
non- DNA repair pathways such as sex-hormone signalling and the mTOR pathway 
(Ghosh et al, 2008; Hu et al, 2008b; Ohtake et al, 2007) (discussed later in Section 
3.1.4) 
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Table 3.1 – Some of the known CRL4 substrates identified to date (Homo sapiens); those which are 
CUL4B specific are indicated by purple text. 
 
Substrate Function Reference 
CDT1 DNA replication (Higa et al, 2003; Nishitani et al, 
2006; Zhong et al, 2003) 
p21 CDK inhibitor (Abbas et al, 2008; Kim et al, 2008b; 
Nishitani et al, 2008) 
p27 CDK inhibitor (Higa et al, 2006; Li et al, 2006) 
Merlin Tumour suppressor (Huang & Chen, 2008) 
UNG2 Uracil DNA glycosylase (Schrofelbauer et al, 2005) 
SMUG Uracil DNA glycosylase (Schrofelbauer et al, 2005) 
Histone H2A, H3, H4 Chromatin formation (Kapetanaki et al, 2006) (Wang, Zhai 
et al. 2006) 
XPC Nucleotide Excision 
Repair 
(El-Mahdy et al, 2006) 
DDB2 Nucleotide Excision 
Repair 
(El-Mahdy et al, 2006) 
TSC2 mTOR pathway (Hu et al, 2008a) 
STAT 1,2, 3 Transcription factor (Ulane & Horvath, 2002) 
ER-alpha Oestrogen receptor (Ohtake et al, 2007) 
c-Jun Proto-oncogenic TF (Wertz et al, 2004) 
HOXA9 Development (Zhang et al, 2003) 
CHK1 Cell cycle checkpoint (Leung-Pineda et al, 2009) 
GRK5 Serine/threonine kinase (Wu et al, 2012) 
Beta-catenin Development; Wnt 
signalling 
(Tripathi et al, 2007) 
WDR5 Histone modification (Nakagawa & Xiong, 2011) 
Peroxiredoxin III Mitochondrion-ROS 
scavenger 
(Li et al, 2011) 
CSN5 COP9 signalosome 
complex 
(He et al, 2013) 
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3.1.2.1: Mouse models of CRL4 deficiency 
CUL4A 
Previously, a Cul4a knock out mouse deleted for exon 1 was reported to be 
embryonically lethal leading to the suggestion that CUL4A and CUL4B are non-
redundantly functionally distinct (Li et al, 2002). However, this has recently been 
challenged by Liu et al who reported a viable Cul4a knockout mouse created by 
targeting exons 17-19 (Liu et al, 2009). It was suggested that the previous report of 
embryonic lethality could be explained by the additional, unanticipated and 
mistargeted disruption of the adjacent gene Pcid2, a gene essential for the 
proteasome. Unexpectedly, these Cul4a -/- mice displayed no gross phenotypic 
abnormalities however they exhibited dramatic resistance against UV-induced skin 
tumourigenesis (Liu et al, 2009). It was argued that Cul4b may in part compensate 
for the loss of Cul4a in mice due to the observation of rapid loss of viability 
resulting from silencing of Cul4b in Cul4a-/- mice. Independently of the above 
studies, Kopanja et al also generated a different Cul4a-/- mouse model by deleting 
exons 4-8 (Kopanja et al, 2009). Embryonic fibroblasts (MEFs) showed severe 
deficiency in cell proliferation after deletion of Cul4a and this therefore indicates 
that Cul4a is required for efficient cell proliferation, control of centrosome 
amplification and thus genome stability. Furthermore those cells also exhibit 
sensitivity to UV irradiation however the reasons underlying the differences 
observed between the various reported Cul4a-/- mouse models are unclear. More 
recent work has identified an essential role for Cul4a in spermatogenesis and male 
fertility (Kopanja et al, 2011). 
 
CUL4B 
 
Although many reports have suggested that CUL4A and CUL4B are functionally 
redundant and can compensate for each other’s loss; the one caveat to this is that 
there are clinically affected CUL4B-mutated and CUL4B-deleted XLMR patients 
(Kopanja et al, 2011; Sarikas et al, 2011; Tarpey et al, 2007a; Zhou). The existence 
of this essential clinically severe condition indicates that CUL4A cannot 
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redundantly compensate for CUL4B loss in humans supporting a distinct role for 
CUL4B in cognitive and physical development. Whilst human CUL4B XLMR 
patients live to adulthood, Cul4b knockout mice die as early as E7.5. Liu et al 
generated mice with targeted disruption of Cul4b (Cul4b-/Y) and observed 
embryonic lethality consistent with the lethality observed upon inactivation of the 
Cul4b by gene trapping (Cox et al, 2010; Liu et al, 2012). They reported a 
differential expression of Cul4a/b in extra-embryonic tissue and suggested that the 
embryonic lethality during early post-implantation development is due to defects 
in extra-embryonic tissues which express low levels of  Cul4a (Liu et al, 2012). In 
contrast the epiblast expresses both Cul4a and Cul4b which allows Cul4a to 
compensate for the loss of Cul4b and maintain viability of the embryo proper. Liu 
et al further showed that epiblast-specific deletion of Cul4b, achieved by crossing 
Cul4bf/y or Cul4b f/f mice with Sox2-Cre, prevented embryonic lethality giving rise 
to viable Cul4b null mice (Liu et al, 2012). Interestingly, these mice displayed no 
overt developmental abnormalities although behavioural and neurological 
analyses were not reported for this particular model. However, these results do 
suggest an important role for Cul4b during the early developmental stage.  
In the same year, Chen et al also generated a viable Cul4b mouse model using the 
exact same strategy previously employed by Liu et al (Chen et al, 2012). However 
in addition, they provided the first detailed behavioural, neurochemical and 
morphological features of adult Cul4b-/- mice (Cul4bΔ/Y). Cul4bΔ/Y mice appeared 
phenotypically normal but displayed specific impairments in spatial learning and 
memory as well as increased seizure susceptibility (Chen et al, 2012). Cul4bΔ/Y 
mice also displayed a decrease in parvalbumin- (PV) positive GABAergic 
interneurons in the hippocampus implying a PV-neuron-mediated decline of 
inhibitory regulation in the dentate gyrus which may permit disorganised 
neuronal firing. In addition, Chen et al further reported altered morphometric 
features in hippocampal neurons of Cul4bΔ/Y mice such as reduced dendritic 
complexity and spine density. They suggest that these alterations may disrupt 
conduction of neural signals along dendrites and affect transmission and 
integration of synaptic inputs in Cul4bΔ/Y mice. These alterations may account for 
the hippocampus-dependent learning deficits and increased epileptic susceptibility 
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seen in this mouse model. This report of a viable Cul4b null mouse, which models 
the core syndrome of CUL4B-patients, is a major advance that could potentially 
improve our understanding of the pathological and physiological functions of 
CUL4B which may underlie the aetiology of this disorder. 
 
3.1.3: CUL4B X-Linked Mental Retardation 
Interestingly, no disorder associated with CUL4A mutations has been reported to 
date, however mutations in CUL4B have been identified as causative of X-Linked 
Mental Retardation (XLMR). It is conceivable, considering the CRL4 substrates 
described, that a human disorder arising from a CUL4 mutation may display some 
clinical overlap with NER-defective conditions such as Xeroderma Pigmentosa and 
Cockayne Syndrome. However, as mentioned no such syndrome in humans has 
been described.  
As discussed previously in Section 3.1, many mutations associated with MR are 
found on the X chromosome. Identification of the causal genes for X-Linked Mental 
Retardation (XLMR) is challenging. However, a large project aiming to identify the 
genes associated with XLMR found mutations in CUL4B by sequencing the entire X 
chromosome in 250 families with XLMR (Tarpey et al, 2007b). CUL4B, as described 
previously, encodes an E3 ubiquitin ligase whose function has previously been 
linked to Nucleotide Excision Repair (NER) (Guerrero-Santoro et al, 2008). 
Mutations were found in 8 of the 250 families screened, one of which was 
originally identified by Cabezas et al (Cabezas et al, 2000); representing the most 
common identified genetic cause of syndromal XLMR to date (Fig 3.5). 
Simultaneously a nonsense mutation in CUL4B was reported by Zou et al in an 
XLMR family in the same year (Zou et al, 2007). Patients with CUL4B mutations 
exhibit a syndromal form of mental retardation thereby exhibiting other clinical 
features aside from MR including; growth retardation, sexual development 
problems, motor neuron impairment and muscle wasting (Table 3.2 and Fig 3.5). 
Recently the first report of a patient with a genomic deletion incorporating CUL4B 
was published, suggesting total loss of CUL4B is compatible with life (Isidor et al, 
2010) (Fig. 3.6a, 3.6b). Nevertheless, the male patient reported showed similar 
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signs to those possessing a mutation in the gene: syndromic MR, hypogonadism 
and ataxia. More recently, Ravn et al reported a 29kb deletion involving CUL4B in a 
Danish monozygotic (MZ) twin pair (Fig 3.6c and Table 3.2) (Ravn et al, 2012). 
This is the smallest deletion to date involving CUL4B; providing further evidence 
that complete loss of CUL4B function is compatible with viability, with severe and 
pleiotropic features (Ravn et al). Table 3.2 compares the clinical features of the 
various patients discussed above. 
The genotype-phenotype relationships in this condition are unexplored and are 
largely unclear, based on the previously described role of CUL4-containing E3 
ligases in Nucleotide Excision Repair.  CUL4B-mutated/deleted patients exhibit 
overlapping clinical features with other diseases such as Spinocerebellar Ataxia 
with Axonal Neuropathy (SCAN-1), Mitochondrial Depletion syndrome (MD) and 
androgen- related disorders such as Kennedy Disease and Androgen Insensitivity 
Syndrome (AIS). Overlapping clinical features include ataxia, seizures, sexual 
development problems and evidence of peripheral neuropathy. Growing evidence 
reporting interactions of CUL4B with components of various crucial pathways such 
as the mTOR signalling pathway, support a role for CUL4B in development and 
provide clues as to the underlying aetiology of specific features of this disorder  
(Ghosh et al, 2008; Ohtake et al, 2007; Zhao et al, 2012) 
 
3.1.4: CUL4A and CUL4B are functionally distinct; identification of 
CUL4B-specific substrates 
Much of the literature to date does not functionally distinguish between CUL4A 
and CUL4B, however recently a number of CUL4B-specific substrates have been 
identified. CUL4B-containing E3 ligases have been implicated in various cellular 
pathways including the regulation of dioxin-dependent aryl-hydrocarbon receptor 
(AhR) signalling, regulation of the mTOR signalling pathway, degradation of 
Peroxiredoxin III and also in the regulation of neuronal gene expression through 
ubiquitination of WDR5 ( See Table 3.1 purple text).  It is conceivable that the mis-
regulation of these substrates could begin to explain the patient phenotypes seen 
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in this disorder. In the subsequent sections I will speculate upon some of these 
potential associations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 – CUL4B-mutated XLMR patients: (a) Patients identified by Tarpey et al, 2007 showing 
abnormalities of the feet, obesity, kyphosis, micropenis and gynaecomastia, (b) A summary of the 
various pathogenic mutations in CUL4B identified by Tarpey et al, 2007. The p.R388X alteration has 
also been reported in a second patient by Zou et al, 2007. The mutation highlighted by the red circle 
indicates the patient cell line used to interrogate aspects of transcription and translation in the 
context of CUL4B-deficiency in the results section 3.2.1. 
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(a) 
(c) 
Figure 3.6 – CUL4B-deleted XLMR patients  
(a) Facial appearance of a CUL4B-deleted patient 
reported by Isidor et al 2010 (b) Agilent 44K array-
derived profile of chromosome X from this deleted 
patient. A detailed view of the region of interest is 
shown, the abnormal genomic region is shaded in blue 
(taken from Isidor et al, 2010) (c) MZ twin pair at age 14 
showing short stature, central obesity and characteristic 
facial dysmorphism as reported by Ravn et al 2012. 
(b) 
52 
 
Table 3.2 – Comparative summary of the clinical features between various CUL4B XLMR patients 
described in the literature, to date. NR; not reported. 
 
Clinical Feature 8 families 
(Tarpey et al, 
2007b) 
 
1 patient 
(Isidor et al, 
2010) 
 
MZ twins 
(Ravn et al, 
2012) 
Motor delay 5/5 + + 
Speech delay 18/18 + + 
Seizures before 2 years of 
age 
8/11 - + 
Height in adulthood <10th 
percentile 
7/11 + + 
Head circumference >97th 
percentile 
8/11 - + 
MR 22/22 + + 
Impaired speech/non 
verbal 
11/15 + + 
Aggressive outburst 12/15 + + 
Tremor 11/13 + + 
Truncal obesity 15/19 - + 
Abnormal toes 11/13 + NR 
Small feet 7/14 NR NR 
Pes Cavus 7/8 + + 
Muscle wasting in lower 
legs 
7/12 NR NR 
Small testes 10/15 + - 
Gynaecomastia 7/10 NR NR 
Prominent lower lip 6/17 + + 
Gait ataxia 6/12 + + 
Kyphosis 3/18 + NR 
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3.1.4.1: CUL4B and steroid sex hormone signalling 
Ohtake et al reported a CRL4-E3 involving the arylhydrocarbon receptor (AhR) 
specifically implicating CUL4B and not CUL4A, in the regulated turnover of steroid 
sex hormone receptors; the oestrogen and androgen receptors (ER and AR) 
(Ohtake et al, 2007). The AR is a tightly regulated transcription factor encoded on 
the X-chromosome whose degradation and rapid re-synthesis is an important 
regulatory mechanism (Lee & Chang, 2003; Li & Al-Azzawi, 2009). Mutations in the 
AR gene can result in Androgen Insensitivity Syndrome (androgen resistance; AIS). 
As the name suggests, this occurs when a genetically male individual is either 
completely or partially resistant to the male hormone, androgen and thus presents 
with external sex characteristics of a female.  AIS is divided into two categories; 
complete AIS and incomplete AIS. Major abnormalities associated with AIS range in 
severity from mild to severe but include; hypospadias (abnormally place urinary 
meatus or male external urethral orifice), microphallus (micropenis), 
cryptorchidism (the absence of one or both testes from the scrotum), azoospermia 
(complete absence of sperm in the ejaculate) and a degree of gynaecomastia 
(enlargement of the male breast tissue) at puberty (Amrhein et al, 1977; 
Wisniewski et al, 2000). Specifically, patients with incomplete AIS show partial 
sensitivity to the effects of androgens and can clinically present with the 
Reifenstein phenotype. Patients with the Reifenstein phenotype present with a 
phallus smaller than a typical penis yet larger than a normal clitoris (Amrhein et al, 
1977). In addition, the labioscrotal folds are partially fused producing a small 
perineal pouch termed a ‘pseudovagina’ and the testes often remain in the 
abdomen. Due to the considerable degree of ambiguity in these patients, they are 
not simply assumed to be normal female infants like those with complete AIS. 
Interestingly, CUL4B patients exhibit overlapping clinical features with AIS such as 
hypogonadism and gynaecomastia which may be a result of a skewed sex hormone 
axis.  
The androgen receptor (AR) is thought to be required for myogenesis (Wannenes 
et al, 2008) and studies in mice have shown that overexpression of wild-type AR 
results in atrophy and severe muscle weakness suggesting that excessive AR may 
be toxic to muscles (Monks et al, 2007). Furthermore, Kennedy Disease (also 
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termed spinal bulbar muscular atrophy) is caused by a polyglutamine tract 
expansion in the AR gene and patients present with muscle weakness, atrophy, 
denervation and gynaecomastia. CUL4B patients also present with muscle wasting, 
therefore mis-regulation of the AR in the context of CUL4B loss may contribute to 
the muscle wasting exhibited here. If confirmed, this could in theory also provide a 
route for possible therapeutic intervention.  However, it is important to note that 
other E3 ubiquitin ligases have been implicated in the regulation of the AR such as 
MDM2 and RNF6. Importantly however, the relative contributions of each are 
largely unknown. Nevertheless, it is tempting to speculate that mis-regulation of 
the AR as a consequence of CUL4B loss potentially contribute to both the muscle 
wasting and sexual development abnormalities experienced by these patients. The 
androgen receptor has also been implicated in regulating synaptic plasticity and 
function (Hajszan et al, 2008). Therefore, loss of CUL4B and subsequent mis-
regulation of the AR may contribute to the neurological deficits of CUL4B-patients 
such as seizures and MR. 
 
3.1.4.2: CUL4B and WDR5 
Among the estimated 100 human DCAFs (DDB1, Cullin- Associated Factors) is 
WDR5, a core subunit of histone H3 lysine 4 (H3K4) methyltransferase complexes. 
Studies looking to identify a substrate of the WDR5-CRL4 complex led to the 
unexpected finding that WDR5 itself is a substrate (Nakagawa & Xiong, 2011). 
Nakagawa et al reported that the ubiquitination and degradation of WDR5 was 
blocked by the knockdown of CUL4B but not CUL4A and furthermore, 
overexpression of CUL4B led to increased ubiquitination of WDR5 (Nakagawa & 
Xiong, 2011). In addition, they reported that the N terminal sequence of CUL4B is 
essential for the ubiquitination of WDR5 and when engineered into CUL4A, this 
conferred CUL4A the ability to ubiquitinate and degrade WDR5. This provides an 
explanation for the functional distinction between the two CUL4 genes, at least in 
this specific instance. Finally, they demonstrate that the ubiquitination of WDR5 by 
CUL4B is important for neural gene expression, neuronal differentiation and 
axonal arborisation of PC12 cells  (Nakagawa & Xiong, 2011). Their findings have 
pointed to a molecular defect of abnormal activation of neural gene expression as a 
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result of altered histone modification. WDR5 is also present in many other 
chromatin-modifying complexes such as the NIF-1 histone methyltransferase 
complex, RING1b histone ubiquitin ligase complex and the ATAC histone 
acetyltransferase complex (Garapaty et al, 2009; Sánchez et al, 2007; Wang et al, 
2008). As WDR5 has such a broad range of functions, CUL4B therefore may play 
more extensive roles in chromatin control. More recently, WDR5 was identified in 
a genome-wide association study as one of the candidate genes affecting cognitive 
ability. This suggests that CUL4B-mediated ubiquitination of WDR5 may 
potentially be involved in learning and memory (Davis et al, 2010).  
 
3.1.4.3: CUL4B and Peroxiredoxin III 
The peroxiredoxins (Prx’s) are a family of thiol-specific antioxidant proteins. 
Human Prx’s include six isoforms (PrxI-PrxVI) and Prx III has recently been 
identified as a novel substrate of a CUL4B-containing CRL4 ubiquitin ligase (Li et 
al, 2011). In addition, it was shown that the integrity of the DDB1-CUL4B-ROC1 
complex is essential for promoting CUL4B-mediated Prx III degradation. Silencing 
of CUL4B led to a striking decrease in ROS production and resulted in resistance to 
apoptosis after hypoxia and H2O2 treatments in HEK293 cells (Li et al, 2011).  
Recent evidence suggests that high ROS levels can promote proliferation and self -
renewal of certain stem cells (Le Belle et al, 2011). Furthermore, a decrease in 
normal cellular ROS levels has a negative effect on the self-renewal and 
differentiation potential that is required for normal neural stem cell functions (Le 
Belle et al, 2011). Li et al suggest that the reduction in ROS levels, as a consequence 
of accumulated PrxIII, may not be high enough to sustain normal neural stem cell  
proliferation and therefore may impair neurogenesis in CUL4B-mutated patients. 
These findings may have significant implications for the pathogenesis of many 
clinical features observed in CUL4B-patients. However, there may be numerous 
CUL4B specific substrates involved in brain development and neural functioning 
therefore further investigation is needed within this area. 
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3.1.4.4: A role for CRL4’s in the mTOR signalling pathway 
The PI3-kinase-mTOR (mammalian target of rapamycin) signalling pathway plays 
a central role in controlling cell growth through the regulation of protein 
translation. In addition to regulating cell growth, mTORC1 also regulates 
autophagy; the process by which cells break down organelles and cytosolic 
compartments in order to ensure there are sufficient metabolites when nutrients 
are running low.  The process of autophagy will be discussed further in the results 
section of this chapter. The mTOR pathway is activated by insulin, growth factors 
(EGF, FGF) and amino acids amongst other stimuli. Once activated, mTORC1 
(consisting of mTOR, Raptor and mLST8) phosphorylates PP2A, S6K1 (p70α) and 
eIF4E-BP. The phosphorylation of eIF4E-BP releases eIF4E to initiate protein 
synthesis and ribosome biogenesis. mTOR receives both inhibitory and activating 
signals from the tuberous sclerosis complex (TSC1-TSC2) and AKT respectively in 
order for the cell to co-ordinate it translational response to conditions such as 
energy sensing (AMP:ATP ratio), hypoxia and membrane receptor signalling (Fig 
3.7).  
It has recently been reported that the effects of CUL4B loss on the mTOR pathway 
mimic those of Raptor loss. Furthermore, the authors reported that siRNA-
mediated knockdown of CUL4B significantly reduced phosphorylation of S6K1, a 
process mediated by mTOR (Ghosh et al, 2008). These results suggest that the 
CUL4B-DDB1 E3 ligase activity plays an important role in the regulation of the 
mTOR pathway, although the authors did not reveal a precise molecular 
mechanism (i.e. a substrate) defining how this effect occurs (Ghosh et al, 2008). 
CRL4’s have been implicated in mediating the degradation of TSC2 and REDD1, 
both negative regulators of mTOR. With regards to TSC2, a CRL4 ubiquitin ligase 
complex containing DDB-ROC1-FBW5 has been shown to mediate the degradation 
of TSC2 however the relative contributions of CUL4A and CUL4B were not 
investigated (Hu et al, 2008b).  Furthermore, reports implicating the CUL4A-DDB1-
ROC1-βTRCP ligase complex in the degradation of REDD1 do not specifically 
exclude CUL4B as a component of the complex (Katiyar et al, 2009). However this 
year, Wang and colleagues reported that XLMR CUL4B-mutants are defective in 
promoting TSC2 degradation and augmenting mTOR signalling in neocortical 
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neurons of the frontal lobe (Wang et al, 2013). This suggests that CUL4B 
specifically plays fundamental roles in the regulation of the mTOR pathway. 
 
Correct mTOR signalling is crucial for many processes such as autophagy, protein 
translation and neuronal development, to name but a few. Therefore, loss of CUL4B 
could potentially have disastrous effects for its regulation impacting on multiple 
cellular processes. In neurons, increased mTORC1 activity is a result of several 
stimuli including growth factors such as brain derived neurotrophic factor (BDNF), 
leptin, influxes of calcium and neurotransmitters through the activation of 
receptors. The PI3-Kinase-mTOR pathway regulates the differentiation, maturation 
and survival of neurons and has also been implicated in long term potentiation, 
learning and memory through its regulation of ribosome biogenesis and protein 
synthesis (Crino, 2011; Garelick & Kennedy, 2011; Martin, 2004; Tang et al, 2002; 
Wang et al, 2010). Therefore, mis-regulation of the mTOR signalling pathway could 
potentially impart some effect on cognition and is believed to be one of the 
molecular mechanisms underlying intellectual disability or MR (Troca-Marin et al, 
2012). In fact, reduced neuronal mTOR function has been implicated in 
Huntington’s disease highlighting an important association between optimal 
mTOR pathway signalling and neuronal function (Ravikumar et al, 2004). 
However, whether disrupted mTOR signalling plays a role in the origin of MR 
associated with CUL4B mutation/deletion is unclear. 
Defects in negative regulators of mTOR are associated with several human 
disorders such as Tuberous Sclerosis (TSC1/TSC2) and Cowden Disease (PTEN) 
(Inoki et al, 2005). Although the severity of TSC is variable, many patients suffer 
from epilepsy and mental retardation, two key clinical features of CUL4B patients 
(Kwiatkowski, 2003; Tarpey et al, 2007b). Furthermore, a recent study identified 
that CUL4B mRNA and protein are highly expressed in the cerebral cortex, 
cerebellum and hippocampal regions of the mouse brain (Chen et al, 2012). In light 
of recent data presented by Wang et al in neocortical neurons (described above), it 
is likely that CUL4B regulates mTOR signalling activity in the cerebral cortex 
where it plays an essential role in mediating synaptic plasticity, memory and 
learning (Hoeffer & Klann, 2010; Swiech et al, 2008; Wang et al, 2013). This is 
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achieved via promoting the removal of TSC2 and positively regulating the mTOR 
signalling cascade. Loss of CUL4B here would impair TSC2 ubiquitination and 
degradation resulting in downregulation of mTOR signalling which may lead to 
malfunction of the frontal cortex and mental retardation. Consistent with this, 
Cul4b knockout mice display reduced dendritic arborisation and impaired spatial 
memory function (Chen et al, 2012). Defective mTOR signalling has also been 
linked to growth retardation in disorders such as Donohue and 3M syndromes 
(Huber et al, 2005; Kadowaki et al, 1988; Sarikas et al, 2008; Xu et al, 2008). As 
CUL4B patients exhibit short-stature, albeit modest in comparison to that of 3M 
and Donohue syndromes, it is possible that defective mTOR signalling could in part 
underlie this feature and is an area worthy of further investigation. 
 
3.1.5: CUL4B-dependent Topoisomerase I degradation 
In 2010, Kerzendorfer et al reported that the degradation of Topoisomerase  I 
(Topo I) following camptothecin (CPT) treatment was a CRL4-dependent process 
(Kerzendorfer et al, 2010). Topo I is an essential enzyme that introduces nicks into 
the DNA backbone to relieve torsional tension generated by DNA supercoiling. This 
occurs as a normal feature of replication and transcription (Fig 3.8a)  To allow the 
repair of these nicks, Topo I is partially degraded and then cleaved and released by 
TDP1 (Marin, 2009). Kerzendorfer at al reported delayed Topo I degradation and 
ubiquitination in response to CPT treatment in CUL4B-mutated LBLs 
(Kerzendorfer et al, 2010). CPT functions to stabilize Topo I complexes on the DNA. 
When these complexes collide with replication or transcription forks this leads to 
fork collapse and the generation of overt DNA double strand breaks. Hence in the 
absence of CUL4B, Topo I ubiquitination and degradation is impaired, allowing it to 
remain attached to the DNA, increasing the number of DNA breaks present (Fig 
3.8b).  
Impaired processing of Topo I has also been implicated in the peripheral 
neuropathy associated with SCAN1, a monogenic condition caused by a defect in 
the Topo I cleaving enzyme TDP1. The SCAN1-associated mutation in TDP1 results 
in a qualitative change in the enzymatic activity of the encoded protein allowing it 
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to become covalently attached on the DNA. In contrast, as modelled by the tdp1 
knock out mouse model; complete ablation of the protein has no effect therefore 
indicating that SCAN1 arises from a neomorphic TDP1 defect (Hirano et al, 2007; 
Takashima et al, 2002) and Fig 3.8. CUL4B patients exhibit overlapping clinical 
features (albeit more severe) to SCAN1 patients (Table 3.3). This highlights a 
potentially overlapping pathogenic mechanism between these disorders, involving 
prolonged Topo I cleavage complexes (CC’s), elevated levels of DNA breakage and 
subsequent neuronal death and/or dysfunction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 - A highly simplified summary of the mTOR-PI3K-signal transduction pathway. The 
mTOR pathway centres upon the activation of the mTORC1 complex, a kinase involved in regulating 
ribosome biogenesis and protein translation. An important negative regulator of mTORC is the 
TSC1-TSC2 complex. The mTOR pathway is activated by membrane-bound receptors such as the 
insulin receptor but also via voltage-gated neurotransmitter receptors such as the NMDA receptor. 
The sites of action of distinct CRL4’s are shown as indicated by the red dashed line. (CRL4=Cullin 
RING ligase 4 containing E3 ligase) (Kerzendorfer et al, 2011). 
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Figure 3.8 - A schematic illustration of the repair of Topo-I induced DNA nicks. (a) Removal of 
Topo I from DNA involves the partial degradation to facilitate optimal TDP1-induced Topo I 
cleavage and resealing of the Topo I-induced nicks by Base Excision Repair. (b) Loss of CUL4B 
impair ubiquitination and degradation of Topo I and allows Topo I complexes to remain attached to 
the DNA. This increases the likelihood of collision with DNA replication or transcription machinery 
(DNA/RNA Pol respectively) and thus can potentially turn Topo I –induced single strand nicks into 
DNA double strand breaks. CUL4B LBL’s exhibit elevated levels of CPT-induced DNA breaks. 
 
 
(a) 
(b) 
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Table 3.3 - Overlapping clinical features of CUL4B-XLMR and SCAN1 patients. 
 
  
 CUL4B SCAN1 
Gene CUL4B TDP1 
Gait Ataxia, tremor, muscle wasting Muscle weakness and mild ataxia 
Speech 
Non-verbal communication 
 
Dysarthria 
Topo I 
Impaired degradation and 
ubiquitination following CPT 
Impaired removal of DNA bound 
Topo I complexes 
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3.1.6: Mitochondria are dynamic organelles 
CUL4B-XLMR patients exhibit clinical overlap with many mitochondrial disorders. 
Overlapping features include ataxia, neuropathy and seizures (Tarpey et al, 2007b, 
Isidor et al, 2010). Mitochondria, considered as the “biochemical powerhouse” of 
the cell, are double-membrane subcellular organelles functioning to produce most, 
but not all, of the cellular energy (ATP) via oxidative phosphorylation. They also 
play an important role in other pathways such as urea production, steroid 
biogenesis, calcium regulation and apoptosis-programmed cell death. The two 
membranes give rise to different regions; the inner and outer membranes 
themselves (IMM and OMM), the cytosolic side of the OMM, the intermembranal 
space and the matrix (Fig 3.9). The IMM harbours the electron transport chain (or 
respiratory chain complexes), the OMM is protein-rich and small molecules can 
pass freely from the cytoplasm and the IMS due to the presence of a number of 
pores within the OMM. The IMM however, is completely impermeable to even 
small molecules. This enables the complexes of the respiratory chain to build up a 
proton gradient across the IMM; the details and relevance of which will be 
discussed further in results section 3.2.2.3. 
Mitochondria are dynamic organelles. Not only is their size and shape highly 
variable but they can also be actively transported to various subcellular regions. 
This is particularly evident in neurons where mitochondria are transported along 
cytoskeletal filaments by energy-dependent motors to areas with high demands 
for ATP and calcium buffering such as synapses and axon terminals (Cai & Sheng, 
2009; Fang et al, 2012; Hollenbeck & Saxton, 2005). Removing mitochondria from 
axon terminals results in aberrant synaptic transmission and many 
neurodegenerative diseases involve defects in the transport of mitochondria. This 
highlights the importance of mitochondrial transport for various neuronal 
processes (Ma et al, 2009; Stokin & Goldstein, 2006; Verstreken et al, 2005). The 
size and shape of the mitochondria is determined by two fundamentally regulated 
events known as fission (splitting) and fusion (merging). These processes enable 
them to respond to the energy demands of the cell and maintain their mtDNA copy 
number (Berman et al, 2008). At a steady state, these two events are balanced to 
maintain the population. Fission involves the splitting of one mitochondr ion into 
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two daughter mitochondrion, both containing multiple copies of mtDNA. 
Mitochondrial fission relies on the large dynamin related GTPase DRP1 (Dynamin -
related 1) which is recruited from the cytosol and also FIS1 (Fission-1), an outer 
mitochondrial membrane protein. DRP1 is further regulated by MARCH5, a 
mitochondrial E3 ubiquitin ligase functioning to promote the ubiquitination of 
DRP1. Parone et al reported that prevention of mitochondrial fission by down 
regulating the expression of DRP1 in HeLa cells lead to the loss of mtDNA and 
subsequent mitochondrial dysfunction (Parone et al, 2008). In contrast, 
mitochondrial fusion involves the merging of two mitochondria into one. This 
event frequently occurs when a mitochondrion becomes dysfunctional; fusion 
provides a means of allowing the exchange of intramitochondrial content therefore 
maintaining the health of the mitochondrial population. Fusion is essential for the 
maintenance of the mtDNA and relies on a set of components, mainly Mitofusins 1 
and 2 (MFN1/2) and Optic Atrophy-1 (OPA-1). Furthermore, inhibiting fusion has 
been shown to reduce the activity of the electron transport chain (ETC) (Chen et al, 
2005).  
Perturbations in mitochondrial dynamics result in specific developmental defects 
and several human diseases arising from mutations in the proteins carrying out 
the fission/fusion processes highlight their importance for cellular homeostasis. 
Examples include; Charcot Marie Tooth Disease 2A (mutations in MFN2) and 
Autosomal Dominant Optic Atrophy (mutations in OPA1) where neuropathy is a 
well noted clinical feature (Chance et al, 1994; Zheng et al, 2002b). In addition, 
evidence suggests that impairing the fission/fusion balance results in abnormally 
long or short mitochondria which can lead to neurodegeneration (Knott & Bossy-
Wetzel, 2008) 
 
3.1.6.1:  Mitochondrial disorders; disorders associated with disrupted mtDNA 
replication 
The mitochondrion differs from most other organelles as it has its own small, 
16.6kb, circular double-stranded genome which replicates independently of the 
cell (mtDNA) (Fig 3.10). Each organelle contains multiple mtDNA copies 
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(polyploidy) which encode a critical subset of genes necessary for the respiratory 
chain complex and subsequent ATP production (Chen & Butow, 2005).  
Mitochondria are inherited maternally and the tightly preserved mtDNA codes for 
37 genes; 13 polypeptides; 7 subunits of Complex I, 1 of Complex III,  3 of Complex 
IV and 2 of Complex 5V, 22 transfer RNA’s (tRNA) specific for mitochondrial 
protein synthesis and 2 mitochondrial specific ribosomal RNA’s (12S and 16S). The 
remaining mitochondrial proteins (>98%) are encoded by the nDNA and imported 
via specialised import systems (Anderson et al, 1981). 
Since the first association of a human disease with a mitochondrial defect in 1989 
by Holt (Holt et al, 1988), numerous mutations have been identified as causative of 
various ‘Mitochondrial Diseases’ such as MERRF (myoclonic epilepsy with ragged-
red fibres), MELAS (Mitochondrial encephalomyopathy, lactic acidosis, and stroke -
like episodes, Leigh Syndrome and KSS (Kearns Seyre Syndrome). Mutations in 
both the nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) can affect a 
number of genes essential for mitochondrial functioning such as those coding for 
a). mt-tRNA, b). subunits of the respiratory complexes, c). assembly factors or 
chaperones required for complex formation, d). transport of  fission and fusion 
proteins and e). the mtDNA replication machinery. With respect to mtDNA 
mutations, due to the large mtDNA copy number per cell (1000-10,000 per cell), 
for an mtDNA mutation to have a detrimental effect on function it must reach a 
minimum critical level of frequency before disruption to the electron transport 
chain occurs. Obviously, this threshold is lower in those tissues and organs with a 
high dependency on oxidative phosphorylation. mtDNA mutations frequently 
result in conditions where ataxia is a prominent and consistent feature in affected 
patients. Some of the most frequent and well characterised mtDNA-related 
syndromes associated with an ataxic phenotype are: Kearns Seyre Syndrome, 
Myoclonic Epilepsy with Ragged Red Fibres (MERRF) and Neurogenic weakness, 
Ataxia, and Retinitis Pigmentosa (NARP) (Zeviani et al, 2012) (Table 3.4).   
 The mitochondrial genome has no capacity for independent replication and 
therefore relies on the nuclear-encoded polymerase gamma (POLG), amongst 
other proteins such as the Twinkle helicase, in order to replicate (Petroski & 
Deshaies, 2005a). Mitochondrial diseases associated with defects of mtDNA 
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replication include; PEO (Progressive External Opthalmoplegia), Alpers Syndrome, 
MDS (Mitochondria Depletion Syndrome), MIRAS (Mitochondrial Recessive Ataxia 
Syndrome) and SANDO (Sensory Ataxia, Neuropathy, Dysarthria, Opthalmoplegia). 
Mitochondrial Disorders are among the most frequently inherited disorders and, in 
addition to ataxia, also commonly present with peripheral neuropathies, seizures 
and in some cases, mild cognitive impairment as frequent clinical features 
(McKenzie et al, 2004) (Table 3.4). Many of these are key overlapping phenotypes 
of CUL4B patients suggestive of an overlapping pathomechanism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 - The Mitochondrion: An Illustration of the mitochondria, indicating the various 
organelle compartments and membranes. 
 
 
 
 
 
 
 
 
 
  
Inner Membrane 
Outer Membrane 
Cristae 
Intermembrane space 
Matrix 
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Figure 3.10 - The Mitochondrial genome: A map of the mitochondrial genome. Genes encoding 
subunits of Complex I are shown in blue; cytochrome c oxidase in red; cytochrome b of complex III 
in dark green subunits of the ATP synthase in yellow. The two ribosomal RNA are shown in purple 
and the 22tRNAs are indicated by black lines and their single letter code. The displacement loop (D -
Loop) contains sequences crucial for the initiation of replication and transcription.  
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Table 3.4 - Mitochondrial disorders; MDs can result from mutations in both mitochondrial DNA 
(mtDNA) and nuclear DNA (nDNA) with a variety of clinical manifestations. 
 
  
Disorder Features 
MtDNA or nDNA 
mutation? 
Leigh Syndrome 
Severe failure of oxidative metabolism, 
dystonia 
Both 
Kearns Seyre Syndrome 
(KSS) 
Retinitis pigmentosa 
Progressive external Opthalmoplegia 
Ataxia 
mtDNA 
Mitochondrial 
encephalopathy, lactic 
acidosis and stroke-like 
episodes (MELAS) 
Muscle weakness, seizures, stroke-like 
episodes, lactic acidosis, ataxia 
mtDNA 
Myoclonic Epilepsy with 
Ragged Red Fibres (MERRF) 
Myoclonus, 
Proximal muscle wasting, generalised 
epilepsy, cerebellar ataxia 
mtDNA 
Mitochondrial Neuro-
Gastro-Intestinal leuko-
Encephalopathy (MNGIE) 
 
Intestinal malabsorption, cachexia, 
peripheral neuropathy, hearing loss 
 
nDNA 
Dominant Optic Atrophy 
Loss of visual acuity and legal 
blindness 
nDNA 
Charcot Marie Tooth 
Disease 2A (CMT2A) 
Peripheral neuropathy, scoliosis 
tremor, intestinal problems,  
nDNA 
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3.1.6.2: Mitochondrial Topoisomerase; Top1mt 
As previously discussed in section 3.1.5, Topoisomerase I degradation has recently 
been found to be CRL4-dependent (Kerzendorfer et al, 2010). Interestingly, Zhang 
et al reported that mitochondria possess their own dedicated topoisomerase -I, 
Top1mt, encoded by a gene distinct to that of nuclear Topo I  on chromosome 
8q24.3 (Zhang et al, 2001). Other reports suggest two other topoisomerases are 
also present in the mitochondria; Topand Top3; however Top1mt is the only 
one encoded by a nuclear gene specific for mitochondria and present in all 
vertebrates. Top1mt functions to relieve the torsional tension generated during 
replication and transcription of the mtDNA (Zhang et al, 2001). Recently, it was 
shown that Top1mt-deficiency is associated with the activation of mitophagy, DNA 
damage response pathways and increases in ROS levels and glycolysis; highlighting 
its importance for the maintenance of cellular homeostasis (Douarre et al, 2012). 
As nuclear Topo I has been identified as a CUL4B-dependent substrate, it is 
tempting to speculate that Top1mt could also be a CUL4B-dependent substrate. If 
so, loss of CUL4B could result in aberrant mtDNA replication and transcription 
resulting in a plethora of disastrous effects on mitochondrial dynamics and 
subsequent cellular homeostasis.   
 
3.1.7: Summary  
In light of the functional defects and various associations presented above, I sought 
to investigate whether CUL4B patients harbour mitochondrial defects which may 
in part underlie the ataxic and muscle wasting features they exhibit. Furthermore, 
since neurons rely heavily on mitochondria and their transportation along axons to 
sites of high energy demands is essential for neuronal function, any mitochondrial 
deficit could have a significant effect on neuronal development, function, 
maturation and maintenance and thus may play a contributing role in the 
pathogenesis of the MR and/or seizure phenotypes of CUL4B XLMR. In addition, 
the role of CUL4B in the mTOR signalling pathway, an important pathway in the 
brain, may contribute to the MR phenotype in these patients . CUL4B patients also 
exhibit clinical features indicative of skewed sex hormone signalling. Interestingly, 
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a CUL4B containing E3 complex has been implicated in the turnover of steroid sex 
hormone receptors suggesting that CUL4B may play important roles in sexual 
development. Figure 3.11 summarises the clinical features associated with CUL4B-
XLMR and the possible CUL4B-interacting factors that may potentially underlie or 
contribute to specific phenotypes. With these associations in mind, I set out to 
provide supportive experimental evidence for these in an attempt to understand 
genotype to phenotype relationships in the context of CUL4B loss. Specifically a 
key aim here was to uncover the cellular and biochemical consequences of 
defective CUL4B-function and how this relates to genomic instability and cell 
homeostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 - Clinical features associated with CUL4B XLMR and the possible CRL4 complexes 
implicated in each. CRBN – Cereblon; AhR - Arylhydrocarbon receptor; mTORC - mammalian target 
of rapamycin 1; mtTopo – mitochondrial topoisomerase. 
 
 
 
 
 
Clinical Features    Possible CUL4B-associated factor 
Relative macrocephaly    
Growth Retardation    CUL4B-DDB1: mTORC? 
Truncal Obesity 
Mental Retardation    CUL4B-TopoI/mtTopo? 
Impaired speech/non-verbal   CUL4B-DDB1-CRBN? 
Tremor       
Gait ataxia              
Gynaecomastia           CUL4B-DDB1-AhR?            
Small testes 
Peripheral Neuropathy         CUL4B-DDB1-CRBN? 
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3.2: Results 
 
3.2.1: Characterisation of defective CUL4B function in 
lymphoblastoid cells from an individual carrying a novel X-
chromosome deletion 
Recently the first report of a CUL4B-deleted patient was published suggesting that 
total loss of CUL4B is compatible with life (Isidor et al, 2010). The authors 
identified a 60kb, Xq24 deletion encompassing the 3’ portion of the CUL4B gene. 
They also reported that the MCTS1 gene was deleted in this child (Fig 3.6). I 
obtained EBV-transformed lymphoblastoid cells (LBLs) and primary fibroblasts 
from this patient. These are a novel tool and provide excellent models to study 
complete CUL4B ablation as the issue of residual CUL4B function is unlikely to be 
relevant due to the complete deletion of the CUL4B gene (Fig 3.6). 
Initially, I sought to characterize the line for CUL4B protein expression levels and 
as expected, I found that extracts from LBLs derived from this particular CUL4B-
deleted patient show no expression of CUL4B (Fig 3.12a) Consistent with previous 
findings from three CUL4B-mutated lines (Kerzendorfer et al, 2010), I found that 
extracts from LBLs derived from this CUL4B-deleted patient exhibit spontaneous 
overexpression of two well-known CRL4 substrates; p21 and p27 (Fig 3.12b). 
These findings are consistent with a known role for CRL4-containing E3 ubiquitin 
ligases in the ubiquitination and degradation of both these CDK inhibitors (Abbas 
et al, 2008; Higa et al, 2006; Kim et al, 2008b; Li et al, 2006; Nishitani et al, 2008). 
These findings confirm a molecular defect in this deletion case to substantiate 
defective CRL4 function.  This unique human patient-derived cellular model of 
complete CUL4B ablation was employed as my primary research tool in the 
subsequent analyses described here. 
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 (b) 
 
 
 
 
 
 
Figure 3.12 - Characterisation of CUL4B-deleted patient line (CV1845) by western blotting. Cell 
lysates were prepared using urea extraction buffer and increasing concentrations loaded.  
(a) Expression of CUL4B in Wild-type (AG093875 or WT) vs. CUL4B-deleted (CUL4B). CUL4B 
expression is absent in CUL4B deleted-patient line. The blot was reprobed for β-tubulin as a loading 
control. (b) Expression of p21 (upper panel) and p27 (lower panel) in Wild-type (WT) vs. CUL4B-
deleted patient derived LBLs (CUL4B); expression of both p21 and p27 are increased in the patient 
line. The blot was probed for p21 then reprobed for p27.  β-tubulin was used as a loading control. 
Grey hatched boxes represent increasing protein concentration loads; (a) 25, 50,100 µg and (b) 50-
75 µg. 
  
[protein] µg 
[protein] µg 
CUL4B 
β -tubulin 
    WT    CUL4B    WT   CUL4B   WT   CUL4B 
p27 
p21 
WT     CUL4B    WT    CUL4B 
β -tubulin 
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3.2.2: Understanding the impacts of CUL4B deficiency on 
mitochondrial function 
 
3.2.2.1: Mitochondrial topoisomerase; Top1mt 
CUL4B-XLMR patients exhibit many overlapping clinical features with various 
‘Mitochondrial Disorders’ such as ataxia, epilepsy, muscle wasting and peripheral 
neuropathy suggesting that mitochondrial dysfunction may play a role here 
(discussed in section 3.1.6) (Folbergrova & Kunz, 2012; Vital & Vital, 2012; Zeviani 
et al, 2012). Furthermore, mental retardation has been reported in some 
mitochondrial disorders including MEHMO (Mental Retardation, Epileptic 
Seizures, Hypogenitalism, Microcephaly, Obesity), MTS (Mohr-Tranebjaerg 
syndrome) and in disorders involving mutations in subunit 6 of the ATPase gene 
and the F1F0-ATPase gene (Bauer et al, 1999; de Coo I. F, 1996; Leshinsky-Silver et 
al, 2002; Puddu et al, 1993).  
As mitochondria possess their own genome and dedicated Topoisomerase 
(discussed in Section 3.1.6), one explanation for a possible mitochondrial defect is 
that overall mtDNA content in CUL4B-deleted mitochondria may differ as a result 
of defective Top1mt degradation impacting upon mtDNA replication. Using semi-
quantitative duplex PCR as previously shown by Ambrose et al (Ambrose et al, 
2007), genomic and mtDNA content was measured by PCR amplification using 
primers designed to target two mitochondrial encoded genes; NADH 
dehydrogenase 2 (ND2)  and 16S RNA (16S)  and one nuclear encoded gene; 18S 
RNA genome (18S). The results are interpreted by analysing the ratio of mtDNA: 
genomic DNA, i.e. ND2:18S and 16S:18S. The results shown in Figure 3.13a indicate 
that mitochondrial content did not grossly differ between Wild-type (lanes 1 and 
3) and CUL4B-deleted LBLs (lanes 2 and 4) therefore inconsistent with a major 
defect in mtDNA replication and propagation.  
Although mtDNA content does not differ, this does not rule out differences in 
mitochondrial mass (number of mitochondria present). To investigate aspects of 
mitochondrial functioning and physiology, various cell-permeant mitochondrion 
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specific probes known as “Mitotrackers” were used to analyse distinct aspects of 
mitochondrial membrane potential and functionality, localisation and abundance 
within CUL4B-deleted LBLs (Probes for Mitochondria-section 12.2, Molecular 
Probes, www.invitrogen.com). I also obtained LBLs from patients with 3 well-
known mitochondrial disorders to enable me to compare and contrast their 
Mitotracker profiles to those of CUL4B-deleted LBLs.  
 
 Leigh Syndrome (GM13740) – defect in MTATP6 (ATPase 6): p.L156R 
(mtDNA base pair 8993 T>G) (Coriell Cell Repositories NI, USA). 
 Myoclonic Epilepsy with Ragged Red Fibres (GM11907A, MERRF) – mutant 
tRNA; Lys A>G transition at mtDNA base pair 8344/WT (Coriell Cell 
Repositories NI, USA). 
 Kearns-Seyre Syndrome (GM04368, KSS) – a defect in MTND4; p.R340H 
(1178 G>A) (Coriell Cell Repositories NI, USA). 
 
3.2.2.2: Mitotracker Green FM as an indicator of mitochondrial mass 
Mitotracker Green FM accumulates in the lipid environment of the mitochondria 
regardless of membrane potential (discussed later in section 3.2.2.3) and exhibits a 
bright green, fluorescein-like fluorescence (FITC). Measurement of fluorescence 
intensity therefore allows determination of the mitochondrial mass or absolute 
mitochondrial content of a cell and/or population. As mtDNA content was not 
significantly different, I investigated whether the number of mitochondria present 
differed which may in turn indicate disrupted mitochondrial biogenesis. LBLs were 
incubated with 250nM Mitotracker Green for 15 minutes at 37°C and washed in 
PBS. Samples were then analysed for FITC fluorescence using the FACS Canto Flow 
Cytometer and BD FACS Diva analysis software. The FITC profiles for Mitotracker 
Green staining show a wider, right-shifted peak in the CUL4B-deleted patient LBLs 
compared to WT control LBLs with a proportion of events falling at very high FITC 
intensities. This is indicative of a slightly increased mitochondrial mass (Fig 3.13b). 
This same distribution is seen in the mitochondrial disorder Leigh Syndrome but 
the physiological significance is unclear. Looking further into this phenotype it 
becomes apparent that although there may be a subtle increase in mitochondrial 
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mass, this may be due to an excess of non-functional mitochondria. Some examples 
of processes which, when disrupted, could lead to the accumulation of non-
functional mitochondria are mitophagy, the mitochondrial membrane potential 
maintenance and/or the mitochondrial fission-fusion processes. 
Mitotracker Green can also be analysed by microscopy, giving an indication of the 
distribution of the mitochondria within a single cell. I obtained primary fibroblasts 
from the same CUL4B-deleted patient, again a novel tool and an excellent model for 
visualising fluorescent-labelling of mitochondria in attached cells. The 
mitochondrial distribution within wild-type control fibroblasts (1-BR) appeared to 
surround the nucleus of the cell with lesser staining being observed in the 
peripheries (Fig 3.14 left panels). However, the mitochondrial distribution in the 
CUL4B-deleted fibroblasts appeared more dispersed throughout the cell, many 
mitochondria surrounded the nucleus as in a WT however many mitochondria 
were distributed throughout the cytoplasm of the cell (Fig 3.14 right panels). The 
relevance of this difference in mitochondrial distribution for mitochondrial 
functioning in these cells is unclear. Nevertheless, abnormal mitochondrial 
distribution is a feature of certain mitochondrial disorders and so may be 
consistent with abnormal aspects of mitochondrial function in the context of 
CUL4B-deletion (Dias et al, 2002; Groisman et al, 2003; Kamura et al, 2004; 
Mahrour et al, 2008; Pick et al, 2007).  
It would be interesting to investigate mitochondrial distribution in a CUL4B-
deleted neuronal cell model. The local need for ATP and calcium handling is 
especially important at synapses and axon terminals and thus mitochondria ar e 
appropriately distributed to serve the different spatial and temporal demands of 
neurons. Altered mitochondrial distribution within neuronal cells in the context of 
CUL4B loss may have implications for neuronal excitability and synaptic 
transmission and thus may begin to explain the MR and seizures exhibited by  
CUL4B-patients. 
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Figure 3.13 – CUL4B-deleted LBLs show similar mitochondrial content to wild type control.  
(a) Semi quantitative PCR; total DNA was extracted and primers for two mitochondrial -DNA 
encoded genes; ND2 and 16S and one nuclear DNA encoded gene; 18S were used for analysis. The 
PCR program consisted of a 3 minute step at 94°C, 30 cycles of 30 seconds at 94°C, 1 minute at 72°C 
and a final step at 72°C for 8 minutes. PCR products were electrophoresed on a 1.5% agarose gel. 
Lanes 1 and 2; top band-ND2, bottom band-18S. Lanes 3 and 4; top band -16S, bottom band -18S. 
WT; Wild-type, CUL4B- CUL4B-deleted. (b) Wild type LBLs, CUL4B-deleted LBLs and LBLs from two 
patients with well-known mitochondrial disorders; MERRF and Leigh Syndrome were incubated 
with 250nM Mitotracker Green for 20 minutes and analysed for FITC fluorescence on the FACS 
Canto flow cytometer. The histogram represents the mean fold change in FITC mean fluorescence 
intensity (MFI) relative to wild-type controls (red dashed line). MERRF; Myoclonic Epilepsy with 
Ragged Red Fibres, Leigh; Leigh Syndrome.  
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Figure 3.14 - CUL4B-deleted hTERT fibroblasts exhibit altered mitochondrial distribution. Cells 
were grown on Poly-lysine coated coverslips and once semi-confluent cells were incubated with 
250nM Mitotracker Green for 20 minutes and analysed by microscopy using the Zeiss Axiovert 
microscope. Images were captured using the same exposure times. 1BR; wild type control 
fibroblasts, CUL4B; CUL4B-deleted hTERT fibroblasts (92025337) obtained from the CUL4B-
deleted patient described by Isidor et al, 2010. Cells were obtained from Bertrand Isidor, 
Universitare De Nantes. 
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3.2.2.3: CUL4B-deleted LBLs exhibit disruption of the mitochondrial membrane 
potential, Ψm 
Mitochondria utilize oxidisable substrates to produce what is known as a 
membrane potential (Ψm) across the inner mitochondrial membrane (IMM). This 
highly negative (~180mV) proton gradient is a key indicator of cellular viability 
and it is this electrochemical gradient that acts as the driving force behind ATP 
production. As mentioned briefly in the previous section, Mitotracker Green 
accumulates independently of the mitochondrial membrane potential and thus 
gives no indication of mitochondrial functionality in this population. The 
mitochondria, through their essential roles in ATP synthesis, are thought of as the 
biological ‘powerhouse’ of the cell. However, although the Ψ m is the basis of 
coupling oxidative phosphorylation and ATP production, it is also crucial for the 
handling of ions with signaling functions, most notable of which is calcium. 
Similarly, calcium is an overall positive regulator of Ψm and oxidative 
phosphorylation and thus a physiological stimulus for ATP synthesis.  
The generation of a Ψm   is achieved and maintained through the actions of the 
Electron Transport Chain (ETC). The ETC resides in the IMM and is composed of 5 
complexes that function as a series of electron donors and acceptors; Complexes I - 
IV and ATP synthase (Complex V). Electrons from NADH and succinate, generated 
via the citric acid cycle, are passed through the ETC to oxygen which is then 
reduced to water, a process known as oxidative phosphorylation (OXPHOS)  
(Fig 3.15). The energy released by electrons flowing through this ETC is used to 
transport protons across the IMM generating an electrical potential or Ψ m.  This 
Ψm is essential for ATP generation as ATP Synthase (Complex V) uses this proton 
potential to transport one proton back down the gradient, using the energy to 
complete the phosphorylation of ADP to ATP. Preservation of this membrane 
potential is also essential for intracellular calcium regulation and the generation of 
reactive oxygen species. This will be discussed in greater detail in section 3.2.2.5. 
The Ψm is a key indicator of mitochondrial functioning as it reflects the metabolic 
activity and integrity of the mitochondrial population. Many mitochondrial 
disorders are a consequence of ETC alterations and therefore highlight the 
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importance of Ψm maintenance for overall cellular homeostasis. Figure 3.15 
summarizes the events that take place during the ETC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 – The Electron Transport Chain (ETC). The ETC is composed of 5 complexes (I-V), each 
containing several different electron carriers. Complex I accepts electrons from NADH and serves as 
a link between glycolysis, the citric acid cycle, fatty acid oxidation and the electron transport chain. 
Ultimately, two electrons are transferred from this complex to Coenzyme Q (CoQ) resulting in the 
net transport of 4 protons (H+) from the matrix side to the intermembranal space where the H+ ions 
accumulate generating a proton motive force. Complex II, also known as succinate dehydrogenase, 
binds succinate and generates fumarate. This complex then transfers 2 electrons to coenzyme Q to 
produce CoQH2. CoQH2 is then passed to Complex III where it passes electrons from CoQH2 to 
cytochrome c via the Q-cycle. The net result of the Q cycle is 2 electrons are passed to cytochrome c 
and 4 protons are released into the intermembranal space. Cytochrome c is a mobile electron 
carrier that diffuses through the intermembranal space shuttling electrons from complex III to 
complex IV. Complex IV, also known as cytochrome c oxidase accepts electrons from cytochrome c 
and directs them towards the four electron reduction of molecular oxygen to form 2 molecules of 
water. The reduction of oxygen to water involves the transfer of four electrons and two protons are 
released into the intermembranal space. This forms the basis of the mitochondrial membrane 
potential and this is used to transport one proton back down the gradient to complete the 
phosphorylation of ADP to ATP. IMS; intermembranal space, IMM; inner mitochondrial membrane.  
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3.2.2.3.1: JC-1 and Ψm 
To investigate mitochondrial Ψm, I employed the cationic carbocyanine dye, JC-1 
(5’, 6 6’-tetrachloro-1, 1’, 3, 3’-tetraethylbenzimidazolylcarbocyanine iodide) as an 
indicator of membrane potential. The JC-1 dye accumulates within the 
mitochondria in a membrane potential-dependent manner. This is indicated by a 
shift in fluorescence emission from green to red. JC-1 exists as a monomer and at 
low concentrations/low membrane potential it yields a green fluorescence 
(529nm). In well-preserved mitochondria, JC-1 forms aggregates known as ‘J-
aggregates’ which yield red fluorescence (~590nm) due to the preservation of a 
higher membrane potential. This potential-sensitive fluorescence shift is a marker 
for membrane potential and depolarisation of the membrane (loss of membrane 
potential) is indicated by a reduction in red: green fluorescence intensity. Carbonyl 
cyanide-3 chlorophenylhydrazone (CCCP), a mitochondrial depolarising agent, can 
be used in conjunction with JC-1 to provide a positive green control indicative of 
complete membrane depolarisation. CCCP functions to inhibit respiration by 
blocking cytochrome oxidase (complex IV). CCCP-treated cells were used as a 
positive control for each cell line here and user-defined flow cytometry (FACS) 
gating was applied before analysing the test samples. 
As expected, Wild-type (WT) LBLs showed aggregation of JC-1 confirmed by a shift 
from green to red fluorescence in the absence of CCCP, indicative of a preserved 
membrane potential (Fig 3.16 top two panels; 43.6% aggregates). CUL4B LBLs also 
exhibited a shift from green to red fluorescence in the absence of CCCP, although 
the magnitude of this shift was reduced compared to WT controls (Fig 3.16 middle 
two panels; 34.1% aggregates). This suggests that the membrane potential is 
relatively depolarized compared to wild type controls, thus exhibiting a more 
negative membrane potential. LBLs from a patient with Leigh syndrome were 
analyzed as a positive ‘mitochondrial disorder’ control and were found to exhibit a 
striking reduction in the red: green ratio with only 7.2% of events exhibiting a red 
fluorescence (representing JC-1 aggregates) in the absence of CCCP, indicative of 
membrane potential depolarization (Fig 3.16 bottom two panels). The data 
presented here is suggestive of a potential disruption to the mitochondrial 
membrane potential in the context of CUL4B loss. These observations were the 
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basis for employing a more sensitive and sophisticated mitochondrial probe such 
as Mitotracker Red. 
 
3.2.2.3.2: Mitotracker Red and Ψm 
JC-1 staining revealed subtle differences in the membrane potential of CUL4B-
deleted LBLs. To investigate this further, I used Mitotracker Red CMXRos (MTR) to 
gain information regarding the membrane potential at a single-cell level. MTR only 
accumulates in actively respiring mitochondria where it emits a red fluorescence 
(PE) indicative of an intact and active membrane potential. A decrease in 
fluorescence represents a reduced membrane potential. LBLs were incubated with 
250nM MTR for 15 minutes and analysed by flow cytometry. Wild-type LBLs 
showed a defined PE peak at approx. 104 indicative of a well-preserved membrane 
potential. CUL4B LBLs however, exhibit a leftward- shift in the PE peak 
corresponding to a reduced membrane potential – consistent with JC-1 data 
(profiles not shown). This finding is similar to that of two well-known 
mitochondrial disorders; Leigh Syndrome and MERRF which also exhibit a reduced 
membrane potential (See figure 3.17 for mean of 3 independent repeats). These 
results indicate that CUL4B LBLs exhibit overlapping mitochondrial features with 
those of well-known mitochondrial disorders. 
As mentioned previously, CCCP is a mitochondrial depolarising agent. When cells 
are incubated with MTR in the presence of CCCP, this gives an indication as to the 
fluorescence intensity values associated with complete disruption of the 
membrane potential. Addition of CCCP uncouples the membrane resulting in a 
dramatic leftward-shift in the PE FACS profiles, corresponding to low intensity 
values. To investigate the percentage of the overall population that exhibited a 
reduced membrane potential,  CCCP was added to cells to induce complete 
depolarisation of the mitochondrial membrane. As expected, the FACS profiles of 
CCCP-treated cells exhibited a leftward shift (indicated by the red-dashed line in 
Fig 3.18). These profiles were then overlaid onto the profiles of untreated cells and 
the percentage of overlap was calculated. Wild-type LBLs overlapped with the 
CCCP profile by 15% whereas CUL4B LBLs showed a higher overlap, with 37% of 
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the total events falling within the CCCP-depolarised range (Fig 3.18). This confirms 
that a high proportion of CUL4B-deleted mitochondria exhibit mitochondrial 
depolarisation. 
Mitotracker Red (MTR) can also be analysed by fluorescence microscopy, giving a 
better indication of the polarisation and distribution at a single-cell level. LBLs 
were incubated with 250nM MTR for 15 minutes and fixed in 2% formalin. Wild-
Type LBLs displayed an even distribution of MTR fluorescence with mitochondria 
lining the periphery of the cell. This indicated well preserved and actively-
respiring mitochondria. In striking contrast, CUL4B-deleted LBLs displayed 
significantly reduced fluorescence intensity with a vast number of cells displaying 
very low or no mitotracker staining whatsoever. Staining also appeared to 
accumulate at one side of the cell as shown in the bottom right panel of Figure 
3.19a. Interestingly, a proportion of CUL4B LBLs exhibit an extremely high 
fluorescence in comparison to the majority of the population. Figure 3.19b 
represents the DAPI stained CUL4B LBLs s in the first panel and the Mitotracker 
Red labelling of the same CUL4B LBLs in the second panel. The majority of the 
population had a reduced membrane potential as indicated by those stained with 
DAPI but with very low MTR staining. However, there were a number of cells 
exhibiting extremely bright MTR staining in comparison to the overall population 
(Fig 3.19b).  By reducing the exposure time, visualisation of these bright cells was 
possible and in fact highlighted the extent of depolarisation in the majority of cells.  
It became apparent that although much of the CUL4B-deleted population exhibited 
depolarisation, a significant minority of cells were ‘hyperpolarised’. Whether these 
hyperpolarised cells were of similar fluorescence levels to ‘no rmal’ WT cells and 
therefore fully functional is unclear. Nevertheless this data has still uncovered a 
novel and extreme mitochondrial phenotype associated with CUL4B loss.  
Consistent with the findings observed in CUL4B-deleted LBLs, both mitochondrial 
membrane potential depolarisation and hyperpolarisation was also observed in 
CUL4B-deleted fibroblasts from the same CUL4B-deleted patient (Fig 3.20). Many 
CUL4B-deleted fibroblasts exhibited depolarisation of the mitochondrial 
membrane potential compared to wild type controls (Fig 3.20a-b). However, 
consistent with the phenotypes observed in CUL4B-deleted LBLs a substantial 
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proportion of CUL4B-deleted fibroblasts exhibited striking hyperpolarisation of the 
mitochondrial membrane (Fig 3.20c). The extent of this mitochondrial phenotype, 
consisting of both depolarisation and hyperpolarisation, was only manifest upon 
direct immunofluorescence-based microscopic analysis of single cells rather than 
the more conventional flow cytometry-based (FACS) analysis of whole 
populations. Examining whole-cell populations by FACS analysis masks this 
striking phenotype whereby those few hyperpolarised cells emit a substantial 
fluorescence which then skews the data. FACS analysis revealed significant 
depolarisation in CUL4B-deleted LBLs, however microscopy based analysis not 
only confirmed this depolarisation but also uncovered a much more novel and 
striking phenotype indicative of widespread mitochondrial membrane potential 
disruption.  These results provide the first evidence of a mitochondrial respiratory 
chain dysfunction in CUL4B-deficiency which may have many implications for 
cellular homeostasis ranging from disrupted ATP production and the generation of 
reactive oxygen species to defects in signalling pathways and ion regulation, 
specifically that of calcium which relies heavily on the presence of an intact 
mitochondrial membrane potential. 
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Figure 3.16: JC-1 aggregation as an indicator of mitochondrial membrane potential 
preservation. Cells were resuspended in 1ml warm RPMI -/+ 50µM CCCP and incubated at 37’ 
for 5 minutes. 2µM JC-1 reagent was then added and cells were incubated for 15 minutes. Cells 
were washed in PBS, resuspended in 500µL PBS and filtered into BD FACS Falcon tubes. Cells 
were analysed on the FACS Canto Flow Cytometer with 488nm excitation and 530/30nm and 
585/42nm band pass emission filters. Events falling within the user-defined ‘P1’ gate (gating is 
specific to each cell line) correspond to JC-1 monomers and those falling outside of this area 
correspond to JC-1 aggregates (indicative of an intact membrane potential). % of events falling 
outside the P1 gate are shown on each profile. Top two panels; WT, middle panels; CUL4B, 
bottom two panels; Leigh Syndrome.  Left hand panels + CCCP, right panels JC-1 only. X axis: PE, 
Y axis; FITC. 
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Figure 3.17 - CUL4B-deleted LBL’s exhibit depolarisation of the mitochondrial membrane similar 
to that of LBLs from a patient with MERRF (p<0.05 Student t-test).  Histograms showing mean PE-A 
fluorescence intensity (FACS measurement) normalized fold change relative to WT (red dashed 
line) for CUL4B LBL’s and control LBLs from three mitochondrial disorders; Leigh Syndrome 
(Leigh), Myoclonic Epilepsy with Ragged Red Fibres (MERRF) and Kearns Seyre Syndrome (KSS).  
Data represents the mean ± SD of 5 independent determinations.  CUL4B; CUL4B-deleted. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 –Mitotracker Red Flow Cytometry profiles (FACS). FACS PE-A profiles of (a) WT and 
(b) CUL4B-deleted LBL’s following Mitotracker Red CMXRos  (250nM) incubation for 15 minutes. 
The red dashed line indicates the profile of CCCP (50M) treated cells. The numbers (15/37) 
represent the percentage overlap between the two profiles. This overlap is indicative of depolarised 
cells within the whole population. 
(a) 
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Figure 3.19 - Microscopy-based analysis of Mitotracker Red staining of CUL4B-deleted LBLs. 
(a) Top two panels – Wild-type (left) and CUL4B-deleted (right) LBL’s stained with 250nM 
Mitotracker Red CMXRos and visualised at 40X. Bottom panels – WT (left) and CUL4B (right), 
less confluent area of slides visualised at 40X. All images captured with the same exposure 
timings. (b) Left panel: DAPI with MTR overlay. Right panel – MTR only, a significant number 
of CUL4B LBL’s appear to be ‘hyperpolarised’ but  the majority of the population exhibit very 
low fluorescence as indicated by DAPI stain but no MTR. 
DAPI + MTR MTR 
WT CUL4B 
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Figure 3.20 – Microscopy-based analysis of Mitotracker Red staining of CUL4B-deleted hTERT 
fibroblasts. (a) Left panels; 1BR control, Right panels; CUL4B-deleted fibroblast (9209537) top 
panel shows depolarised cells, bottom panel shows a more confluent area with hyper- and 
depolarised cells. Cells were incubated with 250nM Mitotracker Red CMXRos and visualised at 10X. 
Images were captured with the same exposure times. CUL4B-deleted fibroblasts exhibit 
depolarisation of the membrane potential as indicated by reduced Mitotracker Red fluorescence.   
(b) 40X magnification of a subset of cells from the cell populations in panel A. Top three panels; 
Mitotracker Red (red) with a DAPI (blue) overlay for 1BR control fibroblasts (1BR, right) and 
CUL4B-deleted fibroblasts (CUL4B, left). Bottom three panels: Mitotracker Red fluorescence only. 
Images were captured with the same exposure times of 0.1 seconds. (c) 40X magnification of a 
single CUL4B-deleted fibroblast from a different section of the same slide exhibiting 
hyperpolarization. This image was taken at the same exposure time as the images in panel B. MTR; 
Mitotracker Red. 
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3.2.2.4 CUL4B-deleted LBLs exhibit reduced ATP levels consistent with ETC 
dysfunction 
The respiratory chain and subsequent generation of a mitochondrial membrane 
potential is essential for the synthesis of ATP by Complex V of the ETC. This 
ubiquitous molecule is the main energy source for most cellular functions 
including the synthesis of DNA, RNA and proteins, extra and intracellular signalling 
pathways and also plays key roles in the maintenance of ion gradients. In addition, 
the mitochondria are crucial regulators of both intracellular calcium signalling and 
the generation of reactive oxygen species. Furthermore, a reciprocal relationship 
between all three has been suggested where each factor can influence the others 
and therefore, disruption to one will have knock on effects on the others (Brookes 
et al, 2004). The correct regulation of all three factors relies on an intact 
membrane potential and is fundamental for various neuronal and muscle -related 
processes, both of which are disrupted in CUL4B patients. It is therefore likely that 
one or more of these factors are disrupted in the context of CUL4B loss and 
identification of these alterations may provide clues into the underlying 
pathomechanistic aetiology and progression of this disorder.   
The data reported so far indicated that loss of CUL4B imparts detrimental effects 
on respiratory chain functioning suggesting that ATP production may be sub-
optimal. Intracellular ATP concentrations were assayed using a colorimetric ATP 
assay kit (ab8335; Abcam). Wild type and CUL4B-deleted LBLs (1 x 107 cells) were 
lysed according to the manufacturer’s protocol and loaded into a 96-well plate. 
Samples were incubated with a reaction mix for one hour and the absorbance was 
then read at 570nm using the Nanodrop spectrophotometer. The data presented in 
Figure 3.21 indicated that CUL4B-deleted LBLs exhibited reduced ATP 
concentrations compared with wild type controls. CUL4B-deleted LBLs displayed 
50% reduction in ATP levels relative to wild type controls. The membrane 
potential is the driving force behind ATP production therefore, this data is 
consistent with my previous finding of a reduced mitochondrial membrane 
potential in CUL4B-deleted LBLs.  
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Figure 3.21 – ATP concentration is reduced in CUL4B-deleted LBLs. 1 x 107 cells were lysed in 50µL 
provided assay buffer and loaded into a 96-well plate. The reaction mix was made according to the 
manufacturer’s protocol and 50µL was added to each sample well. After a 1 hour incubation the 
absorbance was read at 570nm using the Nanodrop spectrophotometer. All measurements 
represent the mean of three independent experiments ±SD. This histogram shows the fold change 
in ATP concentrations of CUL4B-deleted LBLs (0.5 fold) relative to wild-type (AG87) control LBLs 
(1 fold). CUL4B-deleted LBLs display a 50% reduction in ATP levels compared to WT control LBLs 
(p< 0.05, Student t-test). A.U; Arbitrary Units, CUL4B-; CUL4B-deleted.  
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3.2.2.5: Reactive Oxygen Species; the good and the bad 
The generation of reactive oxygen species (ROS) is inevitable for aerobic 
organisms and normally occurs at a controlled rate. It is noteworthy that although 
ROS have long been thought of as damaging to the cell, cumulating evidence 
suggests that ROS are not only detrimental by-products of cellular metabolism but 
also play a key role in regulating several pathways. The potential for ROS to 
mediate cell signalling has gained significant attention in recent years and ROS is 
thought to play key roles in important pathways such as autophagy, the regulation 
of immunity, gene expression and the activation of cell signalling cascades (Bulua 
et al, 2011; Chandel et al, 1998; Fleury et al, 2002; Hancock et al, 2001; Lee & Wei, 
2000; Rhee, 1999; Tal & Iwasaki, 2009).  It appears that a threshold exists for ROS 
levels and when this threshold is exceeded, ROS become detrimental to the cell 
leading to oxidative stress. There are several pathways associated with the 
production of reactive species under normal physiological conditions. These 
include but are not limited to; membrane-bound NADPH oxidases, Xanthine 
oxidase, uncoupled NO synthases and mitochondrial respiration (Bedard & Krause, 
2007; Satoh et al, 2005). 
 
3.2.2.5.1: Mitochondria-derived ROS 
The first report identifying the respiratory chain as a generator of ROS came in 
1966 followed closely by the work of Chance and co-workers in the 1970’s, who 
showed that mitochondria produce hydrogen peroxide (H2O2) (Jensen, 1966; 
Loschen et al, 1974; Loschen et al, 1971). Later, it was confirmed that this H2O2 
arose from the dismutation of superoxide generated in the mitochondria (Loschen 
et al, 1974). In agreement with these studies the discovery of a mitochondrial 
manganese superoxide dismutase, MnSOD, confirmed the significance of 
mitochondrial ROS production.   
The mitochondria produce significant amounts of superoxide (O2- ) as a normal by-
product of oxidative phosphorylation (Murphy et al, 2011). In the electron 
transport chain, electrons are passed through the respiratory complexes via a 
series of oxidation-reduction reactions (discussed previously in section 3.2.2.3 and 
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illustrated in Fig 3.15). The resulting oxygen molecule is reduced to produce water 
however approximately 1-3% of oxygen is incompletely reduced, giving rise to the 
superoxide radical (O2-). O2- is formed via the transfer of a free electron to oxygen 
and is thought to be produced mainly from Complexes I and III of the ETC (Muller 
et al, 2004) (Bleier & Drose, 2013; Dröse & Brandt, 2012) and Fig 3.22. The 
location of O2- within the mitochondria is important as it is unable to diffuse across 
membranes. Recent studies suggest that Complex I releases O2- into the matrix 
whereas Complex III can release O2- into the matrix and the IMS (Muller et al, 
2004). O2- is moderately reactive and thought of as the ‘primary ROS’ which itself 
can be toxic, especially through inactivation of proteins that contain iron-sulphur 
centres such as aconitase and succinate dehydrogenase. Ferrous iron released 
during the inactivation of these proteins is an important reactant for the Fenton 
Reaction. This reaction involves the oxidation of ferrous iron by hydrogen peroxide 
to produce ferric iron, a hydroxyl radical and a hydroxyl anion (equation 1 below). 
Ferric iron is reduced back to ferrous iron, a peroxide radical and a proton by 
hydrogen peroxide (equation 2 below). 
 
Equation 1 - Fe2+ + H2O2  Fe3+ + OH· + OH- 
Equation 2 - Fe3+ + H2O2  Fe2+ +OOH· + H+ 
 
Hydrogen peroxide (H2O2) is formed through the dismutation of O2- by superoxide 
dismutase’s (SODs) but can also occur spontaneously (Equation 1 below and Fig 
3.19). Three SOD’s exist in mammalians: a cytosolic CuZn SOD (SOD1), an 
intramitochondrial manganese SOD (SOD2) and an extracellular CuZn SOD (SOD3).  
H2O2 generated by these SOD1 and SOD2 is membrane permeable and can diffuse 
out of the mitochondria however H2O2 can, in turn, produce the highly reactive 
hydroxyl species (OH·) (Equation 2). This species has an estimated physiological 
half-life of 10-9 seconds (Pryor, 1986) and causes peroxidative damage to proteins, 
lipids and DNA. In addition O2- can react with nitric oxide (NO-), formed by the 
mitochondrial nitric oxide synthase (NOS), to generate peroxynitrate, another 
highly reactive species (Equation 3-5).  
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Equation 3 - 2 O2- + 2H+  H2O2+O2 
Equation 4 - H2O2 +Fe2+  Fe3+ + OH· + OH- 
Equation 5 - O2 + NO-  ONOO- 
The deleterious effects of ROS are to a large extent prevented by antioxidant 
systems within the cell. Antioxidant enzymes such as the superoxide dismutase, 
thioredoxins and peroxiredoxins play important roles in combating oxidative 
stress. H2O2, formed from the reduction of O2- by SOD’s, can be readily converted to 
water by mitochondrial glutathione peroxidase (GPX), oxidising reduced 
glutathione (GSH) to oxidised glutathione (GSSG) (Cadenas & Davies, 2000; 
Esworthy et al, 1997; Fridovich, 1995; Han et al, 2003) and Fig 3.22. The 
significance of MnSOD in particular is clearly demonstrated in models of MnSOD -
knockout mice, where superoxide produced in the mitochondria is not removed by 
the normal mechanisms. Mice develop lactic acidemia, cardiomyopathy, 
degradation of basal ganglia and neuronal axonopathy mimicking many of the 
symptoms seen in children with genetic defects of the respiratory chain (Lebovitz 
et al, 1996; Li et al, 1995; Melov et al, 1998). In addition to GSH, peroxiredoxins are 
also effective in scavenging H2O2 by using thioredoxin (Trx) to detoxify H2O2 in the 
following reactions; 
 
Equation 6 - Prx (reduced) + H2O2

 Prx (oxidized) +2 H2O 
Equation 7 - Prx (oxidized) + Trx (reduced)  Prx (reduced)  
+ Trx (oxidised) 
 
Interestingly Peroxiredoxin III encoded by the PDRX3 gene, is localized in the 
mitochondria and has recently been identified as a CUL4B substrate (Li et al, 
2011). Several other low-molecular weight antioxidants including α-tocopherol 
and ubiquinol are also present and are particularly effective in scavenging lipid 
peroxyl radicals. 
The scavenging actions of antioxidants are not absolute and the reactive species 
that evades them can damage proteins, lipids and DNA. An important point to 
remember here is that this includes the mtDNA which lacks histones and is 
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therefore though to be less protected from ROS-induced damage compared to 
nuclear DNA (Duchen, 2004). Furthermore, the products of protein and lipid 
oxidation can cause secondary damage to proteins which may result in a loss of 
catalytic function and subsequent selective degradation. Mitochondrial proteins 
are an important target of oxidative damage and protein oxidation and nitration 
results in disruption to functioning of components of the ETC. One such example is 
the adenine nucleotide translocator (ANT), a target of nitric oxide and 
peroxynitrate. Oxidative damage impairs the influx of ADP into the mitochondrial 
matrix resulting in disrupted ATP synthesis (Vieira et al, 2001). Respiratory chain 
dysfunction, as a consequence of elevated ROS levels, can lead to further increases 
in reactive species generation with following oxidative stress and cellular damage   
thereby creating a ‘vicious circle’ (Rottenberg et al, 2009). 
Elevated ROS production has been associated with many pathophysiological 
settings including the aging process, epilepsy and neurodegenerative disorders 
(Cadenas & Davies, 2000; Lin & Beal, 2006; Navarro & Boveris, 2007; Seo et al, 
2010; Trojanowski, 2003; Winklhofer & Haass, 2010). Ataxia-Telangiectasia is a 
progressive neurodegenerative condition caused by mutations in the ATM gene 
(McKinnon, 2012). ATM plays an important role in DNA DSB signalling but cells 
from A-T patients exhibit elevated oxidative stress associated with mitochondrial 
dysfunction. A-T cells exhibit a decreased membrane potential and elevated 
production of ROS (Pallardó et al, 2010). As the name suggests, one of the main 
clinical features of this disorder is ataxia and for over 30 years researchers have 
assumed that this is due to impaired DNA repair (reviewed in (McKinnon, 2012). 
However, some suggest that an increase in ROS generation and disruption of 
respiratory chain function could also be relevant (reviewed in (Ditch & Paull, 
2012). In section 3.2.2.3, I have shown that CUL4B LBLs display disruption of the 
mitochondrial membrane potential which could have profound impacts on the 
generation of ROS from the ETC. Interestingly, CUL4B patients also present with an 
ataxic phenotype and this suggests that mitochondrial dysfunction may play a role 
here. Furthermore, another invariant clinical feature of CUL4B patients is epileptic 
seizures (Tarpey et al, 2007a). Epilepsy has long been associated with 
mitochondrial dysfunction and ROS production. In fact, many patients with 
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mitochondrial disorders present with seizures from an early age (Cock & Schapira, 
1999; Folbergrová & Kunz, 2012; Kudin et al, 2009; Waldbaum & Patel, 2010). It is 
conceivable that the seizures experienced by CUL4B patients may also, in part, be a 
consequence of mitochondrial dysfunction (Folbergrová & Kunz, 2012; Waldbaum 
& Patel, 2010; Wu et al, 2010; Zsurka et al, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22: Sources of mitochondrially-derived reactive oxygen species. Mitochondrially derived 
superoxide is generated mainly from complexes I and III of the electron transport chain. 
Superoxide is scavenged by the superoxide dismutases; MnSOD and CuZnSOD to form hy drogen 
peroxide (H2O2). Glutathione peroxidase (GPX) then converts this to water.  H2O2.can also form the 
highly reactive hydroxyl species (OH-). Nitric Oxide (NO-) formed by mtNOS can react with 
superoxide to form peroxynitrate (ONOO -), another highly reactive species. OMM; Outer 
mitochondrial membrane, IMS; intermembranal space, IMM; inner mitochondrial membrane. Red 
lightning bolt indicates harmful hydroxyl species. 
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3.2.2.5.2: MitoSOX; CUL4B LBLs show increased levels of mito-specific ROS 
To investigate the levels of ROS within CUL4B-mitochondria, I employed the 
fluoro-probe, MitoSOX. This probe allows the selective detection of the 
mitochondrial-specific superoxide. This novel probe enters the mitochondria 
where it subsequently emits a bright red fluorescence once oxidised specifically by 
superoxide. In addition to the CUL4B-XLMR patient-derived LBLs, I obtained LBLs 
from a patient with MERRF syndrome, an established mitochondrial disorder, for 
use as a positive control when using this probe. LBLs were incubated with 250nM 
MitoSOX for 15 minutes and then analysed on the FACS Canto Flow Cytometer. 
Wild-type LBLs exhibited low fluorescence indicative of low levels of 
mitochondrial-superoxide (Black line Fig 3.23a). MERRF LBLs, as expected, 
exhibited a right-shifted peak with high fluorescence where 48% of the total 
events fell within a ROS positive range (Red line Fig 3.23a). This result is 
consistent with reports of increased levels of mtROS associated with this disease 
(Wu et al, 2010). Interestingly, CUL4B-deleted LBLs exhibited a similar profile to 
that of MERRF LBLs; a wide peak spanning across high fluorescent intensity values 
with 40.4% of the total events falling within a ROS positive range (Green line Fig  
3.23a and Fig 3.23b). To confirm that the ROS production was specifically 
mitochondrially-derived, I employed another cell-permeant dye; Cell ROX Red to 
determine total cellular ROS levels. Data is shown in Figure 3.23c-d and indicates 
that total cellular ROS levels in CUL4B-deleted LBLs appear similar to those of a 
WT control. 
The data presented here provides evidence that the elevated generation of ROS in 
CUL4B-deleted LBLs is mitochondria-specific, indicative of a potential 
mitochondrial dysfunction. ROS production is heavily influenced by the coupling 
state of the mitochondria therefore these results are consistent with a disruption 
of the membrane potential as previously indicated by Mitotracker Red (section 
3.2.2.3.2). Whether elevated ROS generation is a cause or consequence of altered 
OXPHOS (and subsequent disruption to ATP production) is still under debate 
within the literature. However, these two processes are intimately linked and 
disruption of one will lead to disruption of the other thus creating a continually 
damaging cycle. The association of a highly polarised membrane potential and 
95 
 
increased generation of ROS is widespread in the literature and is thought to be 
due to slowed electron transport (Madamanchi & Runge, 2007; Ohashi et al, 2006). 
In support of this are the observations that mitochondrial membrane 
depolarisation, either by chemical uncouplers or overexpression of mitochondrial 
uncoupling proteins, results in decreased ROS production (Brennan et al, 2006; 
Toime & Brand, 2010). With this in mind, the results presented here would be 
inconsistent with the depolarisation indicated by reduced Mitotracker Red 
fluorescence. However, there is evidence to suggest that depolarisation of the 
mitochondrial membrane potential is associated with increased ROS gener ation 
(Lebiedzinska et al, 2010). It has been proposed that physiological ROS signalling 
occurs within an optimised membrane potential, however oxidative stress occurs 
either at extreme hyperpolarization or depolarization (Aon et al, 2010). 
Furthermore, excessive ROS generation can promote opening of the mitochondrial 
permeability transition pore which, once opened, leads to loss of the mitochondrial 
membrane potential and further mitochondrial dysfunction (Brenner & Moulin, 
2012). Therefore, the depolarisation seen in CUL4B-deleted mitochondria may be a 
consequence of chronic ROS generation and subsequent mPTP induction. This will 
be further discussed in section 3.2.2.8.  
 
3.2.2.6: ETC Complex I activity is unaltered in CUL4B-deleted LBLs 
As briefly mentioned in section 3.2.2.5.1, mitochondrial ROS is mainly generated 
from Complexes I and III of the ETC (Bleier & Drose, 2013). Complex I (NADH: 
ubiquinone oxidoreductase), located in the inner mitochondrial membrane, is the 
largest enzyme in the respiratory chain and provides the entry point for electrons 
into the ETC. Complex I deficiency is the most frequent mitochondrial disorder 
presenting in childhood and is characterised by marked clinical and genetic 
heterogeneity, The most common clinical presentations include; Leigh Syndrome, 
cardiomyopathy, MELAS and early-onset neurodegenerative disorders (Fassone et 
al, 2011; Liolitsa et al, 2003; Rahman et al, 1996). Altered complex I activity has 
also been implicated in the pathogenesis of Parkinson’s disease and Bipolar 
Disorder (Andreazza Ac, 2010; Esteves et al, 2010).  As mentioned in section 
3.2.2.5.1, Complex I is one of the main sites of electron leakage and subsequent 
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generation of superoxide within the mitochondria (Han et al, 2003; Talbot et al, 
2004). As CUL4B LBLs display marked increases in mtROS generation with 
disruption of the mitochondrial membrane potential, I looked to investigate 
whether this was a result of altered complex I activity. 
I employed the Complex I Enzyme Activity Dipstick Assay Kit to determine the 
relative specific activity of immunocaptured Complex I. A dipstick with 
immunocaptured Complex I is immersed in a buffer solution containing NADH and 
nitrotetrazolium blue (NBT). Complex I oxidises NADH which in turn reduces NBT 
to form a blue precipitate at the antibody line on the dipstick (~7mm from the 
bottom). The signal intensity, corresponding to the relative activity of 
immunocaptured Complex I, can then be read using standard imaging software   
(Image J) (Abcam: http://www.abcam.com/Complex-I-Enzyme-Activity-Dipstick-
Assay-Kit-ab109720.html). The data shown in Figure 3.24 indicates that the 
relative Complex I activity in CUL4B LBLs was similar to that of WT-LBLs 
indicating that Complex I activity is not altered by the loss of CUL4B. As discussed 
in 3.2.2.5, ROS are mainly generated from complexes I and III of the ETC. There is 
also evidence that ROS can be produced from Complex II (Ganesh et al, 2013; 
Rustin & Rotig, 2002). Although the data presented here is not suggestive of 
increased levels of Complex I-generated ROS, the excessive ROS could be produced 
from one or more of the other ETC complexes such as Complex II and/or III. 
Specific analysis of the activity of other ETC complexes may allow the identification 
of the site of excessive ROS generation in this setting. 
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Figure 3.23 - CUL4B LBL’s show elevated levels of mitochondria-specific ROS. (a) Overlaid 
MitoSOX FACS profiles showing PE-A intensity of 20,000 events. Cells were incubated with 250nM 
MitoSox for 15 mins (Black; Wild-type LBLs, Red; MERRF LBLs, Green; CUL4B LBLs). (b) Histogram 
showing overall PE-A (measured by FACS) mean fluorescence intensity fold change of CUL4B-
deleted LBLs and MERRF LBLs relative to WT controls (red dashed line). MERRF and CUL4B-
deleted LBLs exhibit increased production of O2- (p<0.05 Student t-test). Data represents the mean 
±SD of 5 independent experiments. (c) Total cellular ROS levels in CUL4B-deleted LBLs are similar 
to wild type controls as determined by Cell ROX Red fluorescence. Cell ROX Red FACS profiles 
showing PE-A intensity of 20,000 events. Black; Wild type, Green; CUL4B-deleted. (d) As a positive 
control for total cellular ROS, WT (top panel) and CUL4B-deleted (bottom panel) LBLs were treated 
with 100M tertiary-butyl peroxide (t-BOOH) for one hour prior to Cell ROX Red incubation. The 
rightward shift in the FACS PE-A profile of LBLs treated with t-BOOH (indicated in red) compared 
to untreated LBLs (black for WT, green for CUL4B) is indicative of increased cellular ROS.  
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Figure 3.24 – Complex I enzyme activity appears unaltered in the context of CUL4B loss.    
Increasing amounts of extract (10-g) were analysed for Complex I activity using a dipstick 
assay method.  Immunocaptured Complex I oxidises NADH, reducing NBT to form a blue precipitate 
at the antibody level ~7mm from the bottom of the dipstick. Signal intensity of this blue precipitate 
was scanned and measured using Image J software. A.U; arbitrary units from Image J analysis. Data 
represents the mean ± SD of 3 independent experiments. 
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3.2.2.7: Intracellular calcium levels are increased in CUL4B-deleted LBLs 
Mitochondria play a substantial role in calcium (Ca2+) homeostasis. The 
mitochondria are the main repository for Ca2+ in the cell through their action as 
spatial Ca2+ buffers regulating local Ca2+ concentrations and so regulating the 
activity of calcium dependent processes (Duchen, 2000; Wong et al, 2012). Ca2+ 
transport across the IMM is achieved by the action of various transporters through 
a complex system consisting of two modes of influx and two of efflux. The most 
intensely studied Ca2+ influx mechanism is that of the uniporter (UP), which 
functions to transport calcium without coupling it to the transport of any other ion 
or molecule (Patron et al, 2013). The transport of Ca2+ via this route is dependent 
on the electrochemical gradient for Ca2+ which is developed and maintained by the 
mitochondrial membrane potential. The primary role of this Ca2+ transport system 
is to relay changes in cytosolic Ca2+ into the mitochondrial matrix to increase the 
H+ extrusion important for both the maintenance of the driving force behind Ca 2+ 
uptake and for ATP production (Gunter et al, 2000; McCormack & Denton, 1993). 
Under normal physiological conditions, Ca2+ is an overall positive regulator of 
mitochondrial function, however perturbations in Ca2+ homeostasis have negative 
effects and can be a stimulus for excessive mitochondrial-ROS generation, 
cytochrome c release, opening of the mitochondrial permeability transition pore 
and apoptosis. Conversely, increases in ROS generation can both inhibit and 
stimulate calcium signalling (Baumgartner et al, 2009; Brookes et al, 2004; 
Duchen, 2000; Gordeeva et al, 2003).  
The results presented so far indicated that in the context of CUL4B deletion in 
patient-derived cells, both OXPHOS and the generation of ROS are disrupted. 
Therefore, in light of the striking mitochondrial phenotypes identified so far, I set 
out to investigate intracellular calcium levels in the context of CUL4B loss. I 
employed the long-wave calcium indicator, Calcium Green -1 AM. This probe is 
prepared in its cell-permeant acetoxymethyl (AM) ester form and upon binding to 
calcium, exhibits an increase in fluorescence emission intensity with little shift in 
wavelength, as measured by flow cytometry. FACS analysis revealed that CUL4B 
LBLs exhibit increased calcium 1-AM fluorescence indicative of increased 
intracellular calcium levels (Fig 3.25). The phenotype revealed here is consistent 
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with my previous findings of disruption to the membrane potential and elevated 
ROS levels which contribute to mitochondrial dysfunction in the context of CUL4B 
loss. Furthermore, optimal calcium regulation is essential for many neuronal 
processes including neurotransmitter release, integration and propagation of 
postsynaptic signals and neurite outgrowth. In particular, both increased and 
decreased intracellular calcium have been reported to be cytotoxic to neurons 
(Arundine & Tymianski, 2003; Choi, 1988). Therefore, the increased levels of 
calcium observed here may have important implications for neuronal 
development, maturation and function thus potentially contributing to some of the 
neurological deficits associated with CUL4B-deficiency. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 – Intracellular calcium levels are increased in CUL4B-deleted LBLs. Wild-type and 
CUL4B-deleted LBLs were incubated with  Calcium 1-AM for 20 minutes at 37 °C. Cells were 
then washed in PBS and analysed by flow cytometry for FITC fluorescence. Excitation/emission 
filters; 506/531. This data represents the mean of 3 independent experiments ± standard deviation, 
relative to wild-type controls (red dashed line). 
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3.2.2.8: CUL4B-deleted LBLs exhibit hypersensitivity of the mitochondrial 
transition pore 
Calcium uptake by the mitochondria evokes a rise in mitochondrial matrix calcium 
concentrations which, in turn, exerts control over several steps of energy 
metabolism and ATP production. In a healthy cell, as calcium is taken up and 
released by mitochondria, a low conductance permeability transition pore, the 
mitochondrial Permeability Transition Pore (mPTP), appears to flicker between 
open and closed states (Brenner & Moulin, 2012). The mPTP is a non-selective 
voltage-dependent mitochondrial channel whose precise molecular constitution is 
still largely unknown (Siemen & Ziemer, 2013). With regards to its location, the 
PTP component forming the channel is proposed to reside in the IMM. Although 
the exact composition of the mPTP is ill-defined, several reports have suggested 
ANT, VDAC, CypD and Hexokinase as promising constituents (Cesura et al, 2003; 
Giorgio et al, 2013; Leung et al, 2008; Shimizu et al, 2001; Siemen & Ziemer, 2013; 
Zhivotovsky et al, 2009). 
Opening of the transition pore leads to the onset of mitochondrial permeability 
transition (MPT). MPT is defined as a sudden increase in the unselective 
permeability to ions and metabolites >1.5kDa across the mitochondrial inner 
membrane. In response to various stimuli such as ROS, increased cytoplasmic Ca2+ 
concentrations and misfolded mitochondrial proteins, sustained and irreversible 
opening of the mPTP ensues allowing solutes to accumulate within the matrix. 
Furthermore, rising mitochondrial Ca2+ concentrations can stimulate the 
generation of ROS which, in turn, contribute to mPTP activation (Peng & Jou, 
2010). One major consequence of sustained mPTP opening is the dissipation of the 
membrane potential leading to the uncoupling of OXPHOS which prevents ATP 
production. A second consequence of mPTP opening is the expansion of the matrix 
space with subsequent rupturing of the OMM. This leads to the release of the 
intermembranal space contents, including the release of accumulated Ca 2+, release 
of cytochrome c, ultimately resulting in cell death via apoptosis or necrosis.  
PTP function is central to many key mitochondrial functions and can play a 
considerable role in many pathophysiological conditions. Recent studies have 
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shown that the threshold for mPTP opening is significantly reduced by 
pathological conditions such as heart failure and diabetes in addition to several 
well-known neurodegenerative disorders such as Parkinson’s Disease (Abou-
Sleiman et al, 2006; Gautier et al, 2012). A common mechanism underlying this 
increased sensitivity is the excessive generation of ROS. Here, I have shown that 
CUL4B LBLs exhibit elevated levels of ROS suggesting that mPTP opening may also 
be altered by CUL4B loss. Furthermore, CUL4B-deleted LBLs display considerably 
increased levels of intracellular calcium in addition to depolarisation of the 
mitochondrial membrane, both activatory stimuli for mPTP opening. I set out to 
determine whether these imbalances had a knock-on effect on the opening of the 
permeability pore in response to treatment with ionomycin. Ionomycin is an 
ionophore which increases the permeability of the membrane to calcium ions. It is 
possible that the mPTP of CUL4B-deleted cells has adapted to the local 
environment of high calcium and ROS levels and therefore does not respond to 
further elevations in calcium. Similarly, it is also possible that this environment 
could render the mPTP hypersensitive to even very small increases in  
mitochondrial calcium, induced by low concentrations of ionomycin. 
The MitoProbe Transition Pore Assay Kit employs calcein AM, a colourless and 
non-fluorescent esterase substrate, and cobalt chloride (CoCl2), a quencher of 
calcein fluorescence, to provide a direct method to selectively label mitochondria 
(Life TechnologiesTM, http://products.invitrogen.com/ivgn/product/M34153) (Fig 
3.26). This assay involves 4 key steps; 
1. Cells are loaded with the acetoxymethyl ester form of calcein dye, calcein 
AM (Ca-AM). This passively diffuses across into the cell accumulating in the 
cytosolic compartments (including the mitochondria) (Fig 3.26a A). 
2. Once inside the cell, intracellular esterases function to cleave the 
acetoxymethyl ester, liberating the very polar fluorescent dye, calcein. This 
form is unable to cross the mitochondrial or plasma membranes and 
exhibits high fluorescence (Fig 3.26aB and Fig 3.26b grey line) 
3. Addition of CoCl2 quenches the fluorescence from cytosolic calcein only 
therefore maintaining the mitochondrial-specific calcein fluorescence (Fig 
3.26aC and Fig 3.26b green line).  
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4. Cells can then be treated with the ionophore, ionomycin, to allow the entry 
of excess calcium into the mitochondria triggering activation and opening of 
the mPTP. This allows the mitochondrial calcein fluorescence to be 
quenched by the CoCl2 resulting in a loss of fluorescence indicative of 
continuous pore activation (Fig 3.26b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 - The Mitoprobe ™ Transition Pore Assay Kit (Molecular Probes M34153).  
(a) Schematic illustration of the assay mechanisms. (A) The Calcein dye is prepared in its 
acetoxymethyl ester form and added to cells, (B) Once inside the cells it is then cleaved by esterases 
and emits a bright green fluorescence. This fluorescent calcein is present in both the cytosol and the 
mitochondria, (C) In the presence of CoCl2 , calcein in the mitochondria emits a signal, but the 
cytosolic calcein fluorescence is quenched resulting in reduced overall fluorescence compared to 
the addition of calcein alone, D) When CoCl2 and ionomycin are added to cells at the same time as 
calcein AM, the fluorescence signals from both the cytosol and the mitochondria are largely 
abolished resulting in a dramatic reduction in fluorescence. The change in fluorescence from C  D 
indicates the continuous activation or the mitochondrial permeability transition pores.  
(b) Illustration of the FACS profiles at each step of the pathway illustrated in (a). The dark green 
profile represents calcein fluorescence of cells treated with calcein only - whole cell fluorescence. 
The light green profile represents the shift in calcein fluorescence intensity following the addition 
of CoCl2 - mitochondrial calcein fluorescence only. The red profile represents the calcein 
fluorescence intensity upon addition of CaAM, CoCl2 and ionomycin. The shift in fluorescence from 
the light green profile to the red profile indicates the opening of the transition pores. CaAM; calcein 
AM, CoCl2; cobalt chloride. 
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Addition of CoCl2 to WT and CUL4B-/- LBLs resulted in a fluorescence shift 
corresponding to the mitochondrial-specific calcein fluorescence. Initially, it 
appeared that the addition of ionomycin (500nM as per the manufacturers’ 
protocol) to both WT and CUL4B LBLs resulted in a dramatic reduction (~50-80%) 
in FITC fluorescence intensity (Fig 3.27; Unt vs. 500nM). This reduction was 
indicative of mPTP opening and appeared to be comparable between WT and 
CUL4B-/- LBLs. This data suggested that CUL4B loss did not affect the functioning 
of the mPTP. However, upon titration of the ionomycin concentration to a much 
lower level (0.5nM-500nM), it became apparent that CUL4B-deleted LBLs 
responded differently to WT LBLs in this assay. Opening of the mPTP and the 
subsequent loss of calcein fluorescence in CUL4B-/- LBLs was evident upon 
addition of very low concentrations of ionomycin (0.5nM, 5nM), concentrations of 
which did not result in opening of the pore in WT LBLs. In particular, the addition 
of 5nM ionomycin to WT LBLs led to a 7% reduction in fluorescence intensity 
suggesting that the mPTP was not activated at this concentration (Fig 3.27; WT 
white bar). However, addition of 5nM ionomycin to CUL4B LBLs led to a dramatic 
80% reduction in fluorescence intensity indicating that the mPTP was activated 
and opened (Fig 3.27; CUL4B white bar). 
The results presented here suggest that CUL4B-deleted LBLs appear to show 
hypersensitivity to overloads of intracellular calcium induced by the addition of 
ionomycin. I have previously shown that CUL4B-deleted LBLs exhibit elevated 
levels of intracellular calcium and ROS, both of which are known to activate the 
mPTP. Therefore, in this setting, an imbalance acting in favour of pore opening 
already exists and thus it appears that the mPTP is rendered hypersensitive to any 
further perturbations. This hypersensitivity could have detrimental effects on 
cellular homeostasis as continuous activation of this pore results in membrane 
depolarization and cell death. Consistent with this, I have already shown in section 
3.2.2.3.2 that the majority of CUL4B-deleted cells appear depolarized with a 
minority exhibiting a dramatic hyperpolarization. 
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Figure 3.27 –CUL4B-deleted mitochondria exhibit mPTP hypersensitivity. Wild-type (WT) and 
CUL4B-deleted (CUL4B) LBLs were suspended in Hanks Balanced Salt Solution with Calcium 
(HBSS/Ca2+) at final concentration of 1 x 106 cells/ml. 5 tubes were prepared containing one ml of 
cells per cell line; tube 1 (Unt): calcein AM and CoCl2 only, tube 2 (500nM): Calcein AM, CoCl2 and 
500nM ionomycin, tube 3 (50nM) Calcein AM, CoCl2 and 50nM ionomycin, tube 4 (5nM): Calcein 
AM, CoCl2 and 5nM ionomycin, tube 5 (0.5nM): Calcein AM, CoCl 2 and 0.5nM ionomycin. Cells were 
incubated at 37°C for 15 minutes and then washed with 3.5ml HBSS/Ca2+. Cells were resuspended 
in PBS for FACS analysis. Cells were analysed using the FACS Canto Flow cytometer with 488nm 
excitation and emission filters appropriate for fluorescein. A change in fluorescence between 
untreated (no ionomycin) and treated (+ ionomycin) samples indicate the continuous activation of 
mitochondrial permeability transition pores. Wild-type cells showed activation of the pores upon 
addition of 500nM and 50nM ionomycin but not at lower concentrations of 0.5-5nM. CUL4B-deleted 
cells also exhibited activation of the pores upon the addition of 50-500nM ionomycin but activation 
of the pores also occurred in response to much lower (0.5 and 5nM) ionomycin concentrations. The 
reduction in % calcein fluorescence indicates the opening of mitochondrial transition pores; this is 
observed at all concentrations in CUL4B-deleted cells but only at higher concentrations in WT cells 
(WT versus CUL4B: 5nM/0.5nM, p<0.05 Student t-test, as indicated).  
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3.2.3: CUL4B is present within isolated mitochondrial extracts  
The CUL4B gene harbours a nuclear localization signal and therefore the CUL4B 
protein is thought to be predominantly localized in the nucleus. Due to the severe 
mitochondrial dysfunction associated with its loss, I speculated that CUL4B may 
have unknown roles within the mitochondria specifically and thus may be present 
in or on the mitochondria. To investigate the presence of CUL4B in isolated 
mitochondrial extracts, I employed the µMACS Mitochondrial Isolation Kit to 
isolate mitochondria using an affinity purification method.  Using this kit, cells are 
lysed on ice using a stokes homogenizer and then magnetically labeled with Anti-
TOM22 (OMM translocase)  MicroBeads. The monoclonal Anti-TOM22 antibody 
then binds to the TOM22 of human mitochondria. This lysate is subsequently 
loaded into a MACS column which is then placed inside the magentic field of a 
MACS separator. The magnetically labeled mitochondria are retained in the 
column whilst the unlabelled cell components are run through. Once the column is 
removed from the magnetic field, the retained mitochondria can be eluted (See 
Figure 3.28). 
Mitochondria were isolated using the technique described above and resuspended 
in 60µL of urea buffer. Increasing amounts of mitochondrial extract were 
immunoblotted for CUL4B protein expression levels. Interesingly, CUL4B 
expression was detected in isolated mitochondrial extracts from Wild-type 
controls. However, consistent with CUL4B deletion, CUL4B protein expression was 
absent in mitochodnria derived from CUL4B-deleted patient derived LBLs (Fig 
3.29). This is the first report identifying CUL4B as a mitochondrially-localized 
protein and this novel data suggests that CUL4B loss may impart negative effects 
on mitochondrial function, such as those reported here. However, the precise roles 
for CUL4B within the mitochondria or more likely, associated with the 
mitochondrial membrane are unknown. The Miltenyi affinity mitochondrial 
isolation kit isolates intact, live mitochondria. It is possible that the CUL4B 
detected here is interacting with the outer mitochondrial membrane. 
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Figure 3.28 – A schematic representation of the Miltenyi Biotech Human Mitochondrial Isolation 
Kit (Miltenyi Biotech, Surrey, UK: Cat no – 130-094-532). (a) Cells are lysed using a stokes 
homogenizer, (b)  lysates are then incubated with Anti-TOM22 Microbeads for 2 hours. (c) This 
labelled lysate is then loaded into a MACS separation column, placed into the magnetic field of the 
Miltenyi Quadro MACS separator and then washed several times with the supplied buffer. (d) The 
column is removed from the magnetic field and the mitochondria are eluted into an ependorff tube. 
Mitochondria are then either centrifuged a 13,000g and resuspended in storage buffer (supplied 
with the kit) or resuspended in urea-based extraction buffer for extract preparation.  
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Figure 3.29 – CUL4B is present in mitochondrial extracts from WT LBLs. Mitochondria were 
isolated from 1 x 107 LBLs per cell line using the Miltenyi QuadroMACS Mitochondria Isolation Kit. 
Isolated mitochondria were then resuspended in 60µL urea buffer and sonicated for 15 seconds to 
create a mitochondrial protein extract. 5-15µL of mitochondrial extract was loaded onto a gel, 50µg 
whole cell extracts (WCE) were also  loaded as input controls. CUL4B protein expression was 
visible in WT mitochondria extracts but absent in CUL4B-deleted mitochondria extracts. The blot 
was reprobed for the mitochondrial protein Hexokinase 1 (HK1) which serves as a loading control. 
WT; wild-type, CUL4B; CUL4B-deleted. 
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3.2.4:  siRNA-mediated knockdown of Cul4b confirms the 
mitochondrial phenotypes observed in patient cells 
Here, I have uncovered novel phenotypes associated with CUL4B deletion using 
unique patient-derived cell lines; LBLs and fibroblasts. Employing two 
independent mouse cell lines, one of neuronal providence: Neuro-2A (N2A) and 
the other a myoblast cell line: C2C12, I investigated mitochondrial function 
following siRNA-mediated knockdown of Cul4b. The cell line C2C12 is an immortal 
line of mouse skeletal myoblasts which, under appropriate culture conditions, can 
differentiate into myoblasts/myocytes. The N2A cell line is a mouse neural crest-
derived cell line frequently used to study neuronal differentiation, axonal growth 
and signalling pathways. These cell lines were chosen based on the clinical deficits 
in these tissue systems in account of CUL4B loss in humans 
Sequential (double) transfection of both C2C12 and N2A cells with siRNAs directed 
against the 3’UTR of Cul4b efficiently reduced expression of the Cul4b protein 
(C2C12; ~94%, N2A; ~60%) (Fig 3.30a-c). Consistent with observations in CUL4B-
deleted patient-derived cells, siRNA mediated knockdown of Cul4b in both N2A 
and C2C12 cell lines was associated with mitochondrial dysfunction. 
Immunofluorescence-based microscopic analysis of Mitotracker Red staining 
revealed that siRNA-mediated knockdown of Cul4b in C2C12 myoblasts resulted in 
depolarisation of the mitochondrial membrane potential (Fig 3.31). Furthermore, 
some cells exhibited striking hyperpolarisation following silencing of  Cul4b 
compared to non-transfected controls, consistent with data from a CUL4B-deleted 
patient line (Fig 3.31). siRNA-transfected N2A and C2C12 cells were also analysed 
for ROS generation. Flow cytometry analysis of MitoSOX fluorescence revealed a 
~1.6 fold increase in mitochondrial-specific ROS following knockdown of Cul4b in 
both cell lines (Fig 3.32a-c). Collectively, these data are consistent with the 
phenotypes observed in patient-derived cells and suggest that loss of CUL4B has 
important implications for mitochondrial function and homeostasis. 
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Figure 3.30- siRNA mediated knockdown of Cul4b results in alterations to mitochondrial 
membrane potential. (a) Whole cell extracts were examined for expression levels of cul4b 48 hours 
post-transfection (double transfection) into mouse myoblast line C2C12. The blot was reprobed for 
β-tubulin as a loading control. Unt; Untransfected + 10µL metafectene pro, siCul4b; Cul4b-specific 
siRNA. (b) Whole cell extracts were examined for expression levels of cul4b 48 hours post-
transfection (double transfection) into mouse neuroblastoma line N2A. The blot was reprobed for 
α-tubulin as a loading control. Unt; Untransfected + 10µL metafectene pro, siCul4b; Cul4b-specific 
siRNA. (c) Representative histogram of CUL4B protein expression levels in C2C12 and N2A 
untransfected cells (blue bar) vs. Cul4b siRNA-transfected C2C12 and N2A cells (shown in orange) 
as measure by Image J.  
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Figure 3.31 – Microscopy based analysis of Mitotracker Red fluorescence of Cul4b siRNA 
transfected myoblasts. siRNA-transfected C2C12 myoblasts exhibit depolarisation and 
hyperpolarisation following Cul4b knockdown. (a) Unt; untreated, untransfected + 10µL 
Metafectene pro (Biotec). siCul4b; Cul4b-specific siRNA + 10µL metafectene pro. Following a 48 
hour sequential (2x) transfection, C2C12 myoblasts were incubated with 250nM Mitotracker Red 
for 15 minutes, cytospun onto Poly-lysine slides and visualised at 10X. All images were captured at 
the same exposure time of 0.01 seconds. (b) Higher magnification of a subset of cells captured in 
(a), Cul4b siRNA-transfected C2C12 myoblasts visualised at 40X 48 hours post transfection. Yellow 
arrows indicate those cells exhibiting hyperpolarisation. 
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Figure 3.32 – siRNA-mediated knockdown of Cul4b in C2C12 and N2A cell model systems leads to 
elevations in ROS generation. (a) C2C12 myoblasts; Overlaid MitoSox FACS profiles showing the 
PE-A intensity of 20,000 events. 48 hours post double transfection, C2C12 myoblasts were 
incubated with 250nM MitoSOX for 15 minutes and analysed by flow cytometry for PE-A 
fluorescence. Grey profile; untreated, untransfected, Red line; Cul4b siRNA profile overlay.  
(b) N2A neuroblastoma cells; Overlaid MitoSox FACS profiles showing the PE-A intensity of 20,000 
events. 48 hours post double transfection, N2A cells were incubated with 250nM MitoSOX for 15 
minutes and analysed by flow cytometry for PE-A fluorescence. Grey profile; untreated, 
untransfected, Red line; Cul4b siRNA profile overlay. (c) Representative histogram showing the 
mean fold change in mean MitoSOX fluorescence intensity (PE-A) of Cul4b siRNA-transfected 
Neuro-2A cells (p<0.05 Student t-test) and C2C12 myoblasts (p<0.05 Student t-test) relative to 
untransfected controls (red dashed line; control untransfected cells). The data represents the mean 
±SD of three independent experiments.  
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3.2.5: Autophagy 
Autophagy is a homeostatic process occurring in all eukaryotic cells involving the 
degradation of cellular components via the lysosomal pathway. When a pro -
autophagy stimulus is received such as nutrient deprivation or energy imbalance, a 
membrane called the phagophore is formed. Initial phagophore formation requires 
the assembly of the beclin-1 interacting complex consisting of Beclin-1 and the 
vacuolar sorting proteins 15 and 34 (Beclin1-VPS34 Class III PI3K complex). 
Phagophore elongation is mediated by two systems; the ATG5-ATG12-ATG16 
conjugation system and the ATG8/LC3 conjugation system functioning in the 
conversion of the cytosolic truncated form of LC3 (LC3-I) to its phagophore 
membrane- associated phosphatidylethanolamine conjugated form (LC3-II) 
(Kabeya et al, 2004; Mizushima et al, 1999). The resultant double-membraned 
structure, known as an autophagosome, then fuses with a lysosome for breakdown 
by resident hydrolases (Mizushima et al, 2008). Although autophagy plays a 
prominent role during nutrient deprivation, it also plays crucial housekeeping 
roles to maintain quality control through the regulated turnover of specific 
organelles and protein aggregates (Hanna et al, 2012; Quinsay et al, 2010). 
Key regulators of autophagy include the BCL-2 family of proteins (BCL-1, BCK-XL, 
BNIP3 and NIX), AMP-activated protein kinase, mTOR pathway, Reactive Oxygen 
Species and p53 (Brady et al, 2007; Budanov & Karin, 2008; Feng et al, 2011; Feng 
et al, 2007; Høyer-Hansen et al, 2007; Pattingre et al, 2005; Quinsay et al, 2010; 
Sandoval et al, 2008; Schweers et al, 2007). Furthermore, the autophagy process is 
regulated by intracellular calcium levels. Evidence suggests that elevations in 
cytosolic free calcium can act as inhibitory or activating autophagic stimuli 
(Reviewed in (Cárdenas & Foskett, 2012). However, the majority of data suggests 
that Ca2+ can induce autophagy by a signal transduction pathway involving Ca 2+ 
activation of CaMKKβ, its phosphorylation of AMPK (AMPK-activated protein 
kinase) and AMPK-mediated inhibition of mTOR (discussed further in Chapter 4 
section 4.1.2.4).  
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3.2.5.1: Mitochondria-specific autophagy; mitophagy 
There are two types of autophagy; selective and non-selective. Non-selective 
occurs in response to starvation and nutrient deprivation to provide cells with 
essential nutrients for survival. Selective autophagy occurs specifically to remove 
damaged or excessive organelles and several organelle-specific autophagy 
processes have been reported including pexophagy (removal of peroxisomes), 
ribophagy (ribosomes) and mitophagy (mitochondria) (Kraft et al, 2008; 
MacIntosh & Bassham, 2011). 
The mitochondria are able to defend themselves against the harmful effects of 
aberrant mitochondria by selective sequestration and degradation of dysfunctional 
mitochondria through the process of mitochondrial specific autophagy; mitophagy. 
The mechanisms behind the regulation of mitophagy are not fully understood 
however multiple pathways have been proposed to regulate mitochondrial 
homeostasis such as mitochondrial fragmentation, the Hsp90-cdc37 and ATG-
ULK1 complexes and the PINK1/Parkin pathway (Barsoum et al, 2006; Egan et al, 
2011; Gomes & Scorrano, 2008; Joo et al, 2011; Kundu et al, 2008; Narendra et al, 
2008; Narendra et al, 2010b). Furthermore, Ding et al (2012) recently proposed a 
two-step mitophagy model involving the induction of canonical ATG-dependent 
macroautophagy followed by subsequent mitochondrial priming, occurring 
through multiple Parkin-dependent or independent mechanisms (Fig 3.33) (Ding 
& Yin, 2012).  
The PINK1/Parkin pathway is a central regulator of mitophagy and loss of function 
mutations in the PARK2 gene are associated with early onset Parkinson’s Disease. 
PINK1 (PTEN-induced putative kinase) is a serine/threonine kinase with a 
mitochondrial targeting sequence. PINK1 is present at very low levels within 
mitochondria harbouring an intact membrane potential due to its cleavage by 
PARL1 at the IMM (Jin et al, 2010; Narendra et al, 2010b). However, collapse of the 
membrane potential allows PINK1 to accumulate on the mitochondrial membrane, 
form a complex with the translocase of the OMM and recruit Parkin (Narendra et 
al, 2010b). Parkin, an E3 ubiquitin ligase that is mutated in familial forms of 
Parkinson’s Disease (PD), is primarily located in the cytosol. Parkin is also known 
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to catalyse its own ubiquitination and proteosomal-mediated degradation, thus 
regulating its own cellular levels (Choi et al, 2000; Zhang et al, 2000).  
Upon dissipation of the mitochondrial membrane, Parkin rapidly translocates to 
the mitochondria where it functions to ubiquitinate a subset of mitochondrial 
proteins such as VDAC, MFN1/2 and MIRO (Gegg et al, 2010; Geisler et al, 2010; 
Wang et al, 2011). These ubiquitinated proteins then serve as markers for 
autophagy adaptor proteins such as p62/SQSTM1 and NBR1 which function to 
tether the mitochondria to the LC3 positive autophagosomes (Ding et al, 2010; Lee 
et al, 2010a; Pankiv et al, 2007). However, the importance of this mechanism 
requires clarification as studies using p62 null cells find that p62 is crucial for 
perinuclear aggregation of damaged mitochondria but not for mitophagy 
(Narendra et al, 2010a; Okatsu et al, 2010). In addition, following mitochondrial 
membrane depolarization both proteasomes and p97 (an AAA+ ATPase) are 
recruited to mitochondria in a Parkin-dependent manner (Chan et al, 2011; Tanaka 
et al, 2010; Yoshii et al, 2011). Although the role of parkin in mitophagy is not 
disputed, the molecular mechanisms occurring between parkin-mediated 
ubiquitination of mitochondrial proteins and the subsequent degradation of  the 
mitochondria by the autophagy process remain unresolved.  
Parkin is also able to interact with AMBRA1, a protein which promotes general 
autophagy by activating the class III phosphatidylinositol 3-kinase complex (PI3K). 
Specifically, this interaction is enhanced during prolonged mitochondrial 
depolarisation (Fimia et al, 2007; Van Humbeeck et al, 2011). Although there is no 
evidence for ubiquitination of AMBRA1 by Parkin, AMBRA1 is recruited to 
perinuclear clusters of depolarized mitochondria in a Parkin-dependent manner 
where it contributes to their clearance (Van Humbeeck et al, 2011). Interestingly, 
AMBRA1 is also termed DCAF3. As discussed in section 3.1, DCAFs forms the 
substrate receptor of cullin 4 based E3 ligases. However, whether this CUL4-
AMBRA1 E3 ligase complex directly functions in the mitophagy process is not 
known. Due to the central roles of both AMBRA1 and the ubiquitin pathway in 
mitophagy, it is tempting to speculate that the loss of CUL4B here may impart 
effects on mitophagy through the non-formation of a CUL4-based E3 ligase 
complex.  
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Figure 3.33 – Two-step mitophagy model in mammalian cells proposed by Ding et al (2012)-the 
induction of canonical ATG-dependent macroautophagy and mitochondrial priming. The induction 
of macroautophagy requires ATG proteins and involves mTOR suppression mediated by 
mitochondrial damage-generated ROS production and ATP-depletion mediated AMPK activation. 
Priming of the mitochondria is mediated by multiple parkin-dependent or independent 
mechanisms. In the presence of Parkin, one common mechanism is that mitochondrial 
depolarisation results in impaired PARL-mediated PINK1 cleavage leading to PINK1 stabilisation 
and recruitment of Parkin to the mitochondria. Mitochondria-localized Parkin promotes the 
ubiquitination of mitochondrial proteins such as VDAC and the Mitofusins. These ubiquitinated 
proteins may be degraded by the proteasome or serve as markers for p62.  P62 can then act as an 
adaptor molecule through interaction with LC34 which recruits autophagosomes. Parkin can also 
interact with AMBRA1, activating the Class III PI3K complex around mitochondria to facilitate 
mitophagy. Parkin-independent mechanisms include; 1) the increased expression of FUNDC1 and 
Nix which the recruit autophagosomes to the mitochondria, 2) SMURF1 which targets mitochondria 
and promotes mitophagy, most likely through the ubiquitination of mitochondrial proteins and 3) 
the activation of ULK1 by the Hsp90-cdc37 complex which functions to phosphorylate ATG13. This 
phosphorylated form of ATG13 is then recruited to damaged mitochondria to promote mitophagy. 
Ub; Ubiquitin. p; phosphate. 
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3.2.5.2 CUL4B-deleted LBLs exhibit disrupted autophagic flux 
Loss of CUL4B imparts negative effects on the regulation of the mTOR pathway, a 
central player in the regulation of autophagy (Ghosh et al, 2008; Wang et al, 2013) 
(discussed in section 3.1.4.4). Furthermore, CUL4B-deleted LBLs display 
characteristics consistent with a significant level of mitochondrial dysfunction; 
altered membrane potential, increased levels of ROS and disrupted calcium 
homeostasis. The presence of such a high proportion of non-functioning 
mitochondria suggests that the process of autophagy may be disrupted in the 
context of CUL4B loss which could result in the accumulation of dysfunctional 
mitochondria. Conversely, this striking level of mitochondrial dysfunction may up-
regulate autophagy in an attempt to destroy those dysfunctional mitochondria. 
However, loss of CUL4B and the mitochondrial dysfunction associated with it may 
in turn affect mitochondrial biogenesis whereby newly synthesised mitochondria 
also quickly become dysfunctional, creating a continuous pool of sub-optimal 
mitochondrial function. 
One of the most striking mitochondrial phenotypes observed in CUL4B-deleted 
LBLs is that of excessive ROS production. As discussed in section 3.2.2.5, the 
mitochondria are both the source and target of reactive oxygen species and have 
developed sophisticated antioxidant systems to protect themselves from ROS 
under normal conditions (Turrens, 2003). However, dysfunctional mitochondria 
frequently produce excessive amounts of ROS which can overwhelm these 
antioxidant mechanisms. ROS can cause damage to mitochondrial proteins, lipids 
and mtDNA which can subsequently result in mitochondrial dysfunction and 
mitophagy. In fact, superoxide has been shown to be the major ROS regulating 
autophagy and treatment with ROS scavengers or overexpression of SOD2 has 
been shown to decrease rotenone-induced autophagy in HeLa cells (Chen et al, 
2009; Chen et al, 2007). ROS have also been shown to directly regulate the 
formation of autophagosomes by targeting a conserved cysteine (82) on ATG4 and 
inhibiting its protease activity (Scherz-Shouval et al, 2007). Furthermore, recent 
evidence suggests that hydrogen peroxide activates PARP-1, which stimulates the 
LKB1-AMPK pathway leading to activation of autophagy (Huang et al, 2009). As 
CUL4B LBLs show excessive production of ROS, it is likely that disruption of 
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mitophagy will result.  Furthermore, CUL4B-deleted LBLs display elevated levels of 
intracellular calcium. Calcium is a key player in the regulation of autophagy and 
thus this suggests that altered calcium levels in the context of CUL4B deficiency 
may contribute to disruption of the autophagy process.  
LC3 (Microtubule-associated protein light chain 3) is a key constituent of the 
autophagosome. During autophagy, the cytoplasmic form of LC3; LC3-I, is recruited 
to the autophagosome where it is then conjugated with phosphatidylethanolamine 
to form LC3-II, present on the autophagosome membrane. The most widely used 
method to test cells for autophagic activity is LC3 immunoblotting where tracking 
the conversion of LC3-I to LC3-II is indicative of autophagic activity. The amount of 
LC3-II correlates with the number of autophagosomes present and is therefore a 
good indicator of autophagosome formation. However, LC3-II itself is degraded by 
autophagy therefore it is important to measure the amount of LC3-II by comparing 
LC3-II levels in the presence of either a lysosomal protease inhibitor such as 
pepstatin A or an autophagosome-lysosome fusion inhibitor such as Bafilomycin A. 
Autophagic flux is represented by differences in the total amount of LC3-II 
between samples in the presence or absence of one of these inhibitors (Mizushima 
& Yoshimori, 2007).  
To investigate mitophagy in the context of CUL4B-XLMR, CUL4B-deleted patient 
derived LBLs and WT controls were first treated with 10nM Bafilomycin A for 2 
hours. Whole cell extracts were then immunoblotted for LC3-I and LC3-II 
expression. Following treatment with 10nM Bafilomycin A, wild type LBLs showed 
a 1.4 fold increase in LC3-II expression levels, indicative of autophagic flux  
(Fig 3.34). This was in striking contrast to CUL4B-deleted LBLs where very little 
increase in LC3-II levels was observed following Bafilomycin A treatment  
(Fig 3.34). This indicates that autophagy is disrupted in the context of CUL4B loss 
whereby accumulation of autophagosomes is already apparent even without the 
addition of an autophagy flux inhibitor. This suggests that CUL4B-deleted LBLs 
exhibit disruption of the autophagy process at the autophagosome-lysosome 
fusion step. Furthermore, CUL4B-deleted LBLs exhibit this phenotype without the 
addition of an autophagy stimulus suggesting that the basal levels of autophagy in 
CUL4B LBLs are increased compared to WT. Disruption to the autophagy process 
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could lead to the accumulation of defective (depolarized) organelles and protein 
aggregates. In addition, it could begin to explain the presence of a substantial 
number of depolarised mitochondria in the context of CUL4B loss, whereby the cell 
is unable to degrade defective mitochondria and thus they accumulate and 
contribute to the mitochondrial dysfunction identified here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.34 – CUL4B-deleted LBLs exhibit disrupted autophagic flux. (a) Wild-type and CUL4B-
deleted LBLs were treated with 10nM Bafilomycin A for 2 hours and immunoblotted for LC3 
protein expression. Addition of Bafilomycin A to WT LBLs resulted in the increased expression of 
LC3-II (lanes 1 and 2 of panels 1 and 3). Bafilomycin treatment in CUL4B-deleted LBLs however did 
not increase LC3-II protein expression to the same extent as WT LBLs (lanes 3 and 4 of panels 1 and 
3). Western blots from 2 separate experiments are shown here. Each blot was reprobed for PCNA as 
a loading control (panels 2 and 4). (b) A representative histogram showing the mean fold change in 
LC3-II expression ± BafA. This data represents the mean of 3 independent experiments ± SD. Blots 
were scanned and the band intensity was determined by Image J.  
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3.2.5.3: Parkin ubiquitination is altered in the context of CUL4B loss 
The data reported so far indicates that CUL4B loss imparts effects on autophagic 
flux without the addition of an autophagy inducing stimuli. As described in section 
3.2.5.1, the PINK1/Parkin pathway is a key regulator of mitophagy; mitochondria-
selective autophagy. Parkin is recruited to mitochondria following collapse of the 
mitochondrial membrane potential. To investigate whether CUL4B loss imparts 
deleterious effects on mitophagy specifically, I looked at the protein levels of 
endogenous Parkin in response to complete dissipation of the mitochondrial 
membrane potential. Wild-type and CUL4B-deleted LBLs were treated with  
CCCP for 0-24 hours and analysed by western blotting for Parkin expression. I 
detected comparable levels of Parkin in WT and CUL4B-deleted whole cell extracts. 
Parkin protein expression was increased at 2 and 4 hours and subse quently 
reduced following a 24 hour CCCP treatment (Fig 3.35). This protein expression 
pattern was similar between WT and CUL4B-deleted whole cell extracts. However, 
additional bands of high molecular weight were observed possibly corresponding 
to ubiquitinated Parkin (indicated in Fig 3.35). The expression of these bands 
appeared to differ between control and CUL4B-deleted samples; following 1-4 
hours CCCP treatment these high molecular weight bands were visible in WT 
whole cell extracts (WCE) but were not visible in treated CUL4B-deleted WCE. If 
these higher bands correspond to ubiquitinated Parkin (and their size would be 
consistent with this), this suggests that Parkin ubiquitination may be altered in the 
context of CUL4B loss. I also analysed the protein expression levels of AMBRA1 
following treatment with  CCCP. AMBRA1 is known to interact with Parkin 
following mitochondrial depolarisation to promote mitophagy; however no 
difference in the protein expression levels of AMBRA1 was observed between WT 
and CUL4B-deleted LBLs following CCCP-induced mitochondrial depolarisation 
(Fig 3.36). 
To demonstrate whether the observed Parkin antibody immunoreactive bands of 
higher molecular weight were due to ubiquitination of Parkin, I performed 
immunoprecipitation experiments to identify both mono- and poly-ubiquitinated 
species. Indeed, western blot analysis of Parkin immunoprecipitates from WT cells 
revealed the presence of highly ubiquitinated species following a 3 hour CCCP 
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treatment detected using an Anti-FK2 antibody which specifically detects 
conjugate ubiquitin and not free ubiquitin (K29, K48 and K63 linkages) (Fig 3.37 
lanes 1-2). Interestingly, CUL4B-deleted immunoprecipitates exhibited a distinct 
lack of ubiquitinated species following CCCP treatment suggesting that Parkin 
ubiquitination or parkin-mediated autoubiquitination may be impaired in the 
context of CUL4B loss (Fig 3.37 lanes 3-4). Moreover, this reduced ubiquitination 
could either represent a very high turnover of the parkin protein or conversely it 
could represent impaired enzymatic activity in response to prolonged 
mitochondrial depolarisation in the context of CUL4B loss. This data is consistent 
with the data presented in section 3.2.5.2 and collectively suggests that the 
autophagy/mitophagy process is disrupted by loss of CUL4B. 
 
3.2.6: Summary 
Here, I have investigated how loss of CUL4B impacts upon mitochondrial function 
in patient-derived lymphoblastoid cells and fibroblasts. I have uncovered novel 
mitochondrial phenotypes in this context consistent with substantial 
mitochondrial dysfunction. I have provided the first evidence to show that CUL4B 
is present within isolated mitochondria extracts suggesting that CUL4B may play 
an essential role in maintaining mitochondrial function and homeostasis. 
Furthermore, using a variety of approaches and flow cytometry analyses I have 
revealed that although the enzymatic activity of Complex I appears unchanged, 
there is considerable disruption to the mitochondrial transmembrane potential. 
Consistent with this, CUL4B-deleted LBLs display reduced ATP production and 
increased generation of mitochondria-specific ROS. Calcium homeostasis and 
signalling is altered in the context of CUL4B-deficiency whereby intracellular 
calcium levels are increased in conjunction with hypersensitivity of the mPTP to a 
calcium ionophore. Finally, I have presented evidence suggestive of altered 
mitophagy in the context of CUL4B loss. Collectively, these data indicate that loss of 
CUL4B leads to severe mitochondrial dysfunction which may in part begin to 
explain the clinical phenotypes of CUL4B-XLMR patients such as MR, epilepsy and 
peripheral neuropathy.  
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Figure 3.35 – Expression levels of Parkin and AMBRA1 are unchanged following CCCP treatment. 
Cells were treated with 10µM CCCP for up to 24 hours and immunoblotted for Parkin protein 
expression. Levels of Parkin were comparable between WT and CUL4B-deleted LBLs, however 
higher molecular weight bands, possibly representing ubiquitin, were visible in CCCP-treated WT 
extracts but not in CCCP-treated CUL4B-deleted extracts.   
 
 
 
 
 
 
 
 
 
 
Figure 3.36 – AMBRA expression is similar in wild type and CUL4B-deleted LBLs following 10uM 
CCCP treatment.  LBLs were treated with 10µM CCCP for 0-4 hours, cells were harvested and urea-
based protein extracts were subjected to SDS-PAGE and immunoblotted for AMBRA1 expression 
levels. MCM2 protein expression was used as a loading control. 
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Figure 3.37 - Parkin ubiquitination is altered in the context of CUL4B loss. Wild type (WT) and 
CUL4B-deleted (CUL4B) LBLs were treated with 20µM CCCP for 3 hours.  Soluble extracts prepared 
from each cell line (400µg) were subjected to IP using an anti-Parkin antibody and probed for FK2 
expression following SDS-PAGE and immunoblotting. CCCP-treated CUL4B-deleted LBLs exhibited 
decreased levels of Parkin ubiquitination compared with WT controls.  
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3.3: Discussion 
 
The CUL4B protein forms the core backbone of many CRL4-containing E3 ubiquitin 
ligase complexes which catalyse the polyubiquitination of a diverse range 
substrates within the cell. Due to the ever-increasing number of CUL4B-specific 
substrates being identified, CUL4B is implicated in a wide range of cellular 
processes ranging from DNA transcription and repair to signal transduction 
networks such as the mTOR pathway. CUL4B-mutated and/or deleted patients 
exhibit a syndromal form of MR whereby the exhibit many other clinical features 
aside from the MR (Tarpey et al, 2007a). Interestingly, a number of these features 
overlap with those of mitochondrial disorders suggesting a potential overlapping 
pathomechanism. 
Here, I have provided the first evidence of novel mitochondrial consequences of 
CUL4B-deficiency in human patient-derived cell lines. Despite harbouring a 
functional NLS, I have shown that a fraction of CUL4B is localised within 
mitochondrial extracts consistent with a to date, unappreciated role for CUL4B in 
the maintenance of mitochondrial function. Furthermore, I have uncovered a 
distinct set of mitochondrial phenotypes associated specifically with CUL4B loss 
including transmembrane potential disruption, reduced ATP synthesis, increased 
superoxide generation and impaired calcium handling. These mitochondrial 
features may potentially underlie some of the clinical phenotypes associated with 
CUL4B deficiency in humans and provide a basis for future investigations with 
respect to understanding their aetiology. For example, CUL4B-mutated and/or 
deleted patients exhibit ataxia, seizures and evidence of peripheral neuropathy, 
and it is tempting to speculate that perturbed mitochondrial function may underlie 
these clinical features. 
The organs with the highest demand for aerobic energy are the brain, heart and 
skeletal muscle and thus it is these organs that are the most commonly affected by 
mitochondrial dysfunction. Post mitotic cells such as neurons and muscle cells are 
unable to filter out energy-deficient cells through mitotic division and it is this 
feature that makes them most at risk from energy failure. Given the brains high 
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dependency on oxidative metabolism, it is hardly surprising that most, if not all, 
primary mitochondrial disorders present with neurological and cognitive deficits. 
Some of the most common features of mitochondrial disorders include seizures, 
ataxia, myopathy and peripheral neuropathies with ataxia being the most invariant 
clinical feature. In particular, patients with Leigh syndrome harbouring mutations 
in the ATPase 6 gene highlight the importance of neuronal ATP for development 
(Schon et al, 2001). Additionally, impaired calcium handling is a predominant 
feature of cytoplasmic hybrid (cybrid) cells harbouring the MERRF mutation (cells 
which are depleted of their endogenous mtDNA and replaced with the mtDNA of 
interest) indicating that mis-regulated Ca2+ signalling has major implications for 
seizure generation (Brini et al, 1999). Furthermore, mitochondrial disorders are 
often associated with peripheral neuropathy. The roles of neuronal and axonal 
mitochondria in peripheral nerve disease are well appreciated but more recent 
work has implicated mitochondrial deficits in Schwann cells specifically in the 
pathogenesis of peripheral neuropathies (Viader et al, 2011). 
CUL4B-deleted mitochondria exhibit marked increases in the generation of ROS 
despite the vast majority of CUL4B-deficient mitochondria displaying striking 
depolarisation of the Ѱm. Although it is widely stated in the literature that ROS 
production is decreased by membrane depolarisation, it is now thought that 
excessive ROS generation and subsequent oxidative stress can occur as a result of 
either high or low membrane potential (Aon et al, 2010). Furthermore, excessive 
ROS generation has also been shown to stimulate mitochondrial uncoupling 
resulting in membrane depolarisation (Echtay et al, 2002). Therefore, it is likely 
that the mitochondrial depolarization observed here may in fact be secondary to 
increased ROS generation. Moreover, it is well documented that ROS production 
can be modulated by Ca2+, irrespective of the membrane potential (Brookes et al, 
2004; Camello-Almaraz et al, 2006). CUL4B-deleted mitochondria appear to 
display cellular alterations consistent with impaired calcium handling and this may 
be one mechanism underlying the excessive ROS generation observed. 
Additionally, increased levels of ROS are known to reciprocally stimulate Ca2+ and 
thus a viscous cycle is established. Interestingly, the observations of increased ROS 
generation are in contrast to a recent study reporting a significant decrease in 
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cellular ROS production in CUL4B-silenced cells (Li et al, 2011). The reasons 
behind this discrepancy are not clear but may be due to a transient effect of CUL4B 
loss on ROS generation; ROS may accumulate over time and thus excessive levels of 
ROS are not observed after an acute CUL4B knockdown. The significance and more 
so the mechanisms underlying the striking hyperpolarisation of some CUL4B-
deleted mitochondria also remain unclear but point towards a po tential 
fission/fusion defect. Therefore, it may be interesting to investigate the impacts of 
DRP1/FIS1 knockdown on mitochondrial function in CUL4B-deleted cells.  
CUL4B-deleted LBLs also exhibit increased opening of the mPTP in response to low 
levels of ionomycin. Transient opening of the mPTP is associated with dissipation 
of the Ѱm; therefore it is reasonable to suggest that the culmination of increased 
ROS and impaired calcium homeostasis may lead to mPTP hypersensitivity. This, in 
turn, may induce membrane uncoupling that eventually results in reduced ATP 
production. In fact, this has recently been observed in a Pink1-/- mouse model of 
Parkinson’s Disease suggesting that increased opening of the mPTP may play 
important roles in the pathogenesis of a wide array of neurological deficits 
(Gautier et al, 2012).  Future work to fully understand the consequences of mPTP 
hyperactivity could involve investigating whether treatment with an mPTP 
inhibitor such as Cyclosporin A (which locks the mPTP closed) is sufficient to 
rescue the Ѱm in CUL4B-deleted cells. 
Under normal physiological conditions, the culmination of excessive ROS 
generation and increased intracellular calcium levels would result in activation of 
mitophagy in a bid to rid the cell of defective mitochondria. However, in the 
context of CUL4B loss, it appears that the autophagy process is halted at the 
autophagosome-lysosome fusion step. Moreover, the absence of Parkin 
ubiquitination in CUL4B-deleted LBLs is consistent with disrupted mitophagy. 
Therefore, in the context of CUL4B loss, defective mitochondria are not degraded 
which can only further exacerbate the situation. It would be interesting to see if a 
CUL4B-specific E3 ligase complex plays a role in the regulation of  specific 
mitophagy-related proteins. Interestingly, it was recently reported that inhibition 
of autophagy induces atrophy and myopathy in adult skeletal muscles and thus it is 
127 
 
possible that inhibited autophagy in the context of  CUL4B loss, could have similar 
implications for myofiber maintenance (Masiero and Sandri, 2010). 
Collectively, the observations reported here represent the first evidence 
identifying CUL4B-mutated/deleted XLMR as a disorder associated with 
mitochondrial dysfunction. It is likely that the mitochondrial features identified 
here could potentially underlie some of the neurological clinical features 
associated with CUL4B mutations/deletion in humans. It would be interesting to 
investigate the impacts of CUL4B loss on both mitochondrial morphology and 
transport in a CUL4B-deleted neuronal model. Recently, mitochondrial dysfunction 
has been observed in cells from patients with Kennedy’s Disease, a condition 
caused by mutations in the AR gene (See section 3.1.4.1). Mis-regulation of the AR 
has major implications for muscle and sexual development as well as neuronal 
processes such as synaptic plasticity.  Interestingly, a CRL4-containing E3 has been 
implicated in the regulated turnover of the AR suggesting that mis-regulation of 
the AR in the context of CUL4B loss may contribute to the mitochondrial 
dysfunction observed here (Ohtake et al, 2007). Furthermore, CUL4B has been 
implicated in regulating components of the mTOR pathway, a key pathway 
regulating autophagy which indicates that CUL4B loss may impact on 
mitochondrial function through multiple pathways (Papia Ghosh, 2008). Although 
no substrate has been identified here, these data strongly indicate that CUL4B may 
have mitochondria-specific substrates whose identification represents an 
important future challenge. Crucially, this data provides fundamental insight into 
the cellular consequences of CUL4B deficiency which may aid in the development 
of efficient therapeutic interventions to combat some of the most debilitating 
features of this disorder.  
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4.1: Introduction 
 
As described in Chapter 3, mental retardation affects approximately 1-3% of the 
general population (Leonard & Wen, 2002). Generally, it is believed autosomal 
recessive inheritance accounts for approximately 25% of all individuals with non-
syndromic MR (ARNSMR) (Afroze & Chaudhry, 2013; Bartley & Hall, 1978; Priest 
et al, 1961; Wright et al, 1959). It is noteworthy that this form of MR is in contrast 
to the syndromic form described in Chapter 3, whereby ARNSMR patients exhibit 
intelligent quotients of 50-70 without any congenital anomalies or other 
neurological features. Whilst many X-linked genes have been identified as 
causative of non-syndromic forms of mental retardation, there is a distinct lack of 
data regarding the genetic basis of ARNSMR (Afroze & Chaudhry, 2013a). 
Identification of causative genes for ARNSMR through genetic linkage analysis is 
hindered by the lack of large family pedigrees with multiple affected and non-
affected members. In fact only ten genes have been implicated in ARNSMR, to date 
(See table 4.1). The subsequent sections will focus on one gene in particular, CRBN 
which encodes Cereblon, its association with ARNSMR and its putative roles within 
the cell. 
 
4.1.1: A gene for non-syndromal MR maps to chromosome 3p25-
pter 
In an attempt to identify a mental retardation disease locus, Higgins et al 
performed linkage analysis in five nuclear families from a single pedigree with 10 
affected individuals with non-syndromic MR (Higgins et al, 2000). They identified a 
genetic locus for ARNSMR on chromosome 3 which they termed ‘MRT2A’. Further 
analysis refined this region to an interval flanked by loci D3S3525 and D3S1560 
and provided evidence that a gene located in the telomeric region of chromosome 
3 is associated with ARNSMR. In fact, evidence already exists to suggest that this 
region harbours an MR-related gene due to breakpoint deletion mapping studies of 
3p deletion syndrome; a syndrome arising from terminal 3p deletions resulting in 
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a loss of material from 3p25 to 3pter, manifesting with MR as a key clinical feature 
(Belichenko et al, 1994; Chen et al, 2012; Fu et al, 2012; Sarikas et al, 2011).  It is 
important to realize that the 3p syndrome phenotype is distinct to ARNSMR. 
Terminal 3p deletions encompass many genes and therefore patients exhibit a 
wide range of physical anomalies aside from the MR such as growth failure, 
microcephaly, deafness and craniofacial and skeletal abnormalities. (Chen et al, 
2012).  
By comparing their data to previous breakpoint deletion studies in 3p deletion 
syndrome, Higgins et al revealed that a single susceptibility gene for MR resides 
within the MRT2A candidate region (Higgins et al, 2000). They further suggested 
CALL, ITPR and AD7c-NTP as possible candidates for the nonsyndromic MR 
phenotype due to their known roles in brain development and neuronal signalling. 
In 2004, homozygosity mapping focused the previously identified ‘MRT2A’ region 
to a 4.2Mb interval between loci D3S3630 and D3S1304 on chromosome 3p25-
pter (Higgins et al, 2004a). This region contains nine genes (IL5RA, TRNT1, LRRN1, 
SETMAR, SUMF1, ITPR1, BHLHB2, EDEM and MRPS36P1) however Higgins et al 
reported that a mutation did not exist in any of these genes and suggested that an 
unknown transcript in this region contributed to cognitive deficits in ARNSMR. 
Subsequently that same year, Higgins et al further reported that the MRT2A region 
contains five uncharacterised transcripts; LOC51185, LOC375321, LOC132049, 
LOC377019, and FLJ10702 (Higgins et al, 2004b). SSCP (Single-Strand 
Conformation Polymorphism) analysis of these transcripts identified a variation in 
LOC51185 that segregated with the ARNSMR phenotype and this transcript was 
subsequently assigned the gene name Cereblon (CRBN). Further DNA sequencing 
revealed that a homozygous CT nonsense mutation causing a premature stop 
codon in exon 11 of the CRBN gene resulting in p.R419X was causative of ARNSMR 
(Higgins et al, 2004b).  
The human CRBN gene is located on chromosome 3 (3p26.2) coding for 
approximately 442 amino acids with a molecular weight of ~51kDa (Higgins et al, 
2004b). The nomenclature of the CRBN gene was based upon the presence of a 
large highly conserved ATP-dependent Lon protease domain and the putative role 
of CRBN in cerebral development. Human CRBN contains the N-terminal portion of 
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the ATP-dependent Lon protease domain (237 amino acids) which was shown to 
function in protein-protein interactions but does not have any protease or ATPase 
activity (Lee et al, 2004). Aside from this domain, CRBN also contains 11 casein 
kinase II phosphorylation sites, 4 protein kinase C phosphorylation sites, 1 N-
linked glycosylation site and 2 myristolyation sites (Higgins et al, 2004b). CRBN is 
located in the cytoplasm, nucleus and peripheral membrane and is widely 
expressed in the testis, prostate, lung, kidney, spleen, pancreas, placenta, skeletal 
muscle, ovary, small intestine, colon, brain, retina and peripheral blood leukocyte  
(Aizawa et al, 2011; Hohberger & Enz, 2009; Mathias et al, 1996; Xin et al, 2008). In 
rodents, the Crbn protein is highly expressed in the hippocampus (HPC) and 
neocortex and localised to the cytosol and plasma membrane (Aizawa et al, 2011; 
Mathias et al, 1996).   
Identification of the p.R419X mutation and its association with ARNSMR indicates 
that CRBN may play an important role in memory and learning.  In fact, CRBN is 
highly expressed in the brain which further supports this conclusion (Aizawa et al, 
2011; Higgins et al, 2004b). The p.R419X mutation interrupts an N-myristoylation 
site and eliminates a casein kinase II phosphorylation site at the C-terminus. Casein 
kinase II, highly expressed in the hippocampus (HPC), is activated during the 
induction of long-term potentiation therefore this mutation may disrupt its 
subcellular targeting and alter long term potentiation in the HPC (Charriaut-
Marlangue et al, 1991; Fukunaga et al, 1996). Furthermore, Lon proteases are 
localized in the mitochondria where they function to degrade short-lived 
polypoptides and thus it is possible that this mutation may perturb mitochondrial 
homeostasis resulting in altered memory and learning. Nevertheless, the exact 
mechanisms of how this mutation and the subsequent truncation of CRBN lead to 
ANSMR are not understood, nor indeed are the precise physiological functions of 
this protein.  
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Table 4.1 - Genes identified to date as causative of ARNSMR. MIM #; Online Mendelian 
Inheritance in Man number (www.ncbi.nlm.nih.gov/omim). 
Gene MIM # Protein functions References 
PRSS12 606709 
Neurotrypsin; neuronal serine 
protease 
(Molinari et al, 2002) 
CRBN 609262 
Cereblon; putative roles in 
cerebral development 
(Higgins et al, 2004b) 
CC2D1A 610055 
Coiled-coil and C2 domain 
containing protein 1A; 
transcriptional repressor 
(Basel-Vanagaite et al, 
2006) 
GRIK2 138244 
Ionotropic kianate glutamate 
receptor 2; neurotransmitter 
receptor in the brain 
(Motazacker et al, 
2007) 
TUSC2 601385 Tumour suppressor candidate 2 
(Garshasbi et al, 2008; 
Khan et al, 2011; 
Molinari et al, 2008) 
TRAPPC9 311966 
Trafficking protein particle 
complex 9; roles in NFkB 
signalling, neuronal cell 
differentiation 
(Mir et al, 2009; 
Mochida et al, 2009; 
Najmabadi et al, 2007) 
TECR 610057 
Trans-2,3-enoyl-CoA reductase; 
fatty acid elongation 
(Caliskan et al, 2011; 
Nolan et al, 2008) 
ST3GAL3 606494 
Beta-galactosidase alpha 2,3 
sialyitransferase II; catalyzes the 
transfer of sialic acid to 
galactose containing substrates 
(Hu et al, 2011) 
MED23 605042 
Mediator complex subunit 23; 
involved in transcriptional 
activation 
(Hashimoto et al, 
2011) 
MAN1B1 604346 
Mannosidase alpha class 1B 
member 1; roles in N-glycan 
biosythesis 
(Rafiq et al, 2011) 
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4.1.2: Potential roles for CRBN  
 
4.1.2.1: CRBN and CNS development; a putative role in memory and learning 
Following on from studies identifying a potential role for CRBN in memory and 
learning, rat Crbn was identified as a large Ca2+ activated potassium channel (BKCa) 
α subunit (Slo) binding protein in the rat brain (Jo et al, 2005) . In rodents, Crbn is 
abundant in the cerebellum and its intracytoplasmic distribution in neurons is 
similar to the reported immunostaining pattern of the BKCa channel (Grunnet & 
Kaufmann, 2004; Higgins et al, 2010; Jo et al, 2005; Misonou et al, 2006). Crbn 
regulates BKCa channel surface expression and ionic currents by directly binding to 
the cytosolic C-terminal of BKCa in brain regions involved in learning and memory.  
Consistent with a role for CRBN in regulating BKCa channel expression, human 
lymphoblastoid cell lines expressing the p.R419X change in CRBN exhibit 
persistent expression of an immature BKCa channel splice variant, KCNMA1 SIT 2 
INSERT (Higgins et al, 2008). The authors suggest that the continued expression of 
this variant will alter Ca2+-mediated signal transduction. Specifically, this 
transduction is crucial for processes of learning such as synaptic maturation and 
connectivity (MacDonald et al, 2006).  
Interestingly, a functional defect of BKCa channels has previously been associated 
with autism and mental retardation (Laumonnier et al, 2006). This suggests that 
the altered expression of BKCa channels in developing neurons of patients with 
CRBN mutations may contribute to the MR phenotype. However, it is noteworthy 
that CNS functioning also requires the action of neurotransmitter transporters and 
receptors therefore BKCa channels are only one of many channels regulating CNS 
function. In fact, the Lon domain of CRBN has been shown to interact with the C-
terminal of a voltage-gated chloride channel-2 (CIC-2) which functions to regulate 
cellular excitability and cell volume homeostasis (Hohberger & Enz, 2009). 
Collectively, these data provide support of a role for CRBN in memory and learning. 
CRBN has also been shown to bind the UL14 protein of the Herpes Simplex Virus 1 
(HSV1) (Wu et al, 2011). The abundant expression of CRBN in HPC neurons 
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correlates with the selective regional damage to the HPC induced by HSV1 
suggesting that CRBN may be a target for HSV1-mediated hippocampal injury 
(Ando et al, 2008). In particular, it may play a key role in the pathogenesis of 
memory deficits in patients surviving HSV1 encephalitis (Ando et al, 2008; Kapur 
et al, 1994). 
 
4.1.2.2: CRBN, a novel thalidomide binding protein 
Thalidomide was prescribed in the 1950-1960s to pregnant women to alleviate the 
symptoms of morning sickness. However, this drug had unanticipated side effects 
which resulted in a tragedy from 1957-1962. More than 10,000 children 
worldwide were born with severe birth defects as a consequence of thalidomide 
exposure in the first trimester of pregnancy. Malformations of the limbs were the 
most commonly reported defect. Limb anomalies ranged from mild to severe with 
two forms of limb deformities; phocomelia (limbs consist of a truncated or absent 
zeugopod) and Amelia (complete absence of one of more limbs) being the most 
severe (Fraser, 1988; Taussig, 1962). Approximately 2,000 UK babies were 
affected, with around 50% dying within a few months of birth. Thalidomide was 
subsequently withdrawn as a morning sickness treatment. Since its withdrawal, 
thalidomide has been the subject of significant research aiming to uncover the 
mechanisms of thalidomide-induced teratogenicity (Franks et al, 2004; Hansen et 
al, 2002; Hansen & Harris, 2004; Ito et al, 2011; Knobloch & Ruther, 2008; 
Therapontos et al, 2009).  
Many hypotheses have been proposed (~30) including anti-angiogenesis and 
oxidative stress models as causative of thalidomide’s teratogenic effects (D'Amato 
et al, 1994; Hansen et al, 2002; Hansen & Harris, 2004; Knobloch & Ruther, 2008; 
Parman et al, 1999; Therapontos et al, 2009). However, the fundamental question 
as to the direct targets of thalidomide remained unanswered until recently. In an 
attempt to identify targets of thalidomide, Ito et al developed ferriteglycidyl 
methacrylate-bound thalidomide-affinity beads to enable the separation and 
purification of thalidomide-binding molecules (Ito et al, 2010; Sakamoto et al, 
2009). Using this approach they identified CRBN as a thalidomide binding protein 
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and subsequently found it to be the primary target of thalidomide (Ito et al, 2010). 
In addition they reported that CRBN forms an E3 ligase complex with DDB1, CUL4 
and ROC1. This CUL4-CRBN complex was shown to have autoubiquitination 
activity (in vitro and in vivo) and CRBN was therefore suggested to be a novel 
substrate receptor. Interestingly, Ito and co-workers reported that the expression 
of this E3 ligase complex was important for the expression of fibroblast growth 
factor 8; an essential regulator of limb development in zebrafish and chicks. They 
also reported that the autoubiquitination of CRBN was inhibited by thalidomide in 
vitro and furthermore, expression of a drug binding deficient mutant of Crbn in 
zebrafish and chicks suppressed thalidomide-induced effects (Ito et al, 2011; Ito et 
al, 2010). Collectively, their data suggests that thalidomide binds to cereblon and 
inhibits the function of the CRBN-CUL4 E3 ligase complex. Moreover, it suggests 
that inhibition of its ubiquitin ligase activity may be a mechanism by which 
thalidomide induces its teratogenic effects.  Although this data clearly provides 
evidence of a role for CRBN in thalidomide-induced teratogenicity, several 
questions remain to be addressed in order to fully understand the mechanisms 
underlying the teratogenic effects of thalidomide. 
In spite of its teratogenic effects, thalidomide is now widely recognised as an 
effective drug in the treatment of leprosy and myeloma (Singhal et al, 1999; van 
Rhee et al, 2008). Novel thalidomide derivatives such as lenalinomide and 
pomalinomide have been developed and possess very strong anti-cancer 
properties with fewer adverse side effects. Interestingly, CRBN expression is 
required for the anti-myeloma effects exerted by these IMiDs (Immunomodulatory 
Drugs) suggesting an important role for CRBN not only in mediating the 
teratogenic effects of thalidomide but also in mediated its anti-cancer properties 
(Zhu et al, 2011). Furthermore, this suggests that these pathways may overlap 
through CRBN.  
 
4.1.2.3: A putative role in the cellular antioxidant response system 
Recently, Lee et al reported that CRBN expression (mRNA and protein) was 
increased following exposure of mouse neuroblastoma N2A cells to 
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hypoxia/reoxygenation (Lee et al, 2010b). In addition, they reported that a 
hydrogen peroxide insult lead to similar increases in CRBN expression. These 
results suggested that CRBN gene expression may be controlled by ROS-dependent 
signalling. To further investigate this, Lee et al functionally characterised the 
promoter region of mouse Crbn and identified a single Nrf2/ARE – binding site 
(Lee et al, 2010b). They reported that overexpression of Nrf2 or treatment with an 
Nrf2-activating compound induced the expression of the endogenous Crbn gene. 
Nrf2 is a basic region leucine-zipper transcription factor which, by binding to the 
antioxidant response element (ARE), regulates the expression of more than 200 
genes involved in antioxidant defence (Kang et al, 2005). These include the phase 2 
detoxification enzyme NAD (P) H quinone oxyreductase, extracellular superoxide 
dismutase and glutathione S-transferase A1 and A2 (Shih et al, 2005; van 
Muiswinkel & Kuiperij, 2005; Zhang et al, 2006). Nrf2 has also been shown to 
regulate the expression of mitochondrial transcription factors and thus 
mitochondrial biogenesis (Shih et al, 2005). In light of this data, it is tempting to 
speculate that CRBN may play a key role in the cellular antioxidant defence system. 
 
4.1.2.4: CRBN and the AMPK signalling pathway 
AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase with 
key functions in the regulation of cellular energy homeostasis. Once activated by 
falling energy status and/or environmental stress; AMPK inhibits ATP-consuming 
pathways and promotes catabolic pathways to increased ATP production and 
maintain energy balance (Hardie et al, 2012). Mammalian AMPK is a trimeric 
enzyme consisting of a catalytic α subunit and the non-catalytic β and γ subunits, 
interacting through the C-terminal half of the α subunit. There are 12 different 
isoforms of AMPK due to multiple genes encoding the various subunits (Hardie, 
2007). The α2 isoform is predominantly found in skeletal and cardiac muscle 
whereas the α1 isoform is found pancreatic β-islet cells and white adipose tissue    
AMPK is regulated in response to stresses that deplete ATP such as hypoxia, 
ischemia, low glucose and heat shock (See Fig 4.1). An increase in the AMP:ATP 
ratio, even if very small, allosterically activates the complex. ADP or AMP can bind 
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the  subunit and protect the activating phosphorylation of AMPK. In addition, 
phosphorylation of AMPK on Thr172 of the α-subunit is also required for its 
activation. This occurs by at least 3 different upstream AMPK kinases (AMPKK) 
such as LKB1 (Woods et al, 2003). LKB1 appears to be responsible for mediating 
the majority of AMPK activation in most tissues. However, AMPK can also be 
activated by CaMKK2 (Calcium/calmodulin-dependent protein kinase kinase 2) in 
response to calcium flux (Hurley et al, 2005).  The release of intracellular stores of 
calcium creates a demand for ATP and thus activation of AMPK in this setting 
provides a mechanism for cells to anticipate this increased demand for ATP. In 
particular, CaMKK2 appears to be particularly involved in the activation of AMPK 
in T cells and neurons (Racioppi & Means, 2012; Takemoto-Kimura et al, 2010; 
Wayman et al, 2008). 
AMPK activation by low levels of ATP positively regulates pathways such as fatty 
acid oxidation (via phosphorylation of Acetyl CoA Carboxylase) and autophagy (via 
mTOR) in a bid to replenish the ATP supply (Egan et al, 2011; Gwinn et al, 2008). 
Activation of AMPK negatively regulates ATP consuming pathways such as protein 
synthesis. One of the most well-known mechanisms by which AMPK regulates cell 
growth is via suppression of the mTORC1 pathway; a pathway central to the 
regulation of cell growth, mitochondrial homeostasis and the control of autophagy 
(discussed in detail in Chapter 3).  In 2003, Tokunaga et al reported a possible 
interplay between the mTOR signalling pathway and AMPK by showing that 
treatment of epithelial cells with an AMPK activator lead to the inhibition of p70 S6 
kinase (p70), a key component of the mTOR signalling pathway. Furthermore, 
AKT was shown to be a negative regulator of AMPK and it has been suggested that 
AKT-mediated inhibition of AMPK is needed for the activation of mTOR signalling 
in the cell. More recently, it was shown that AMPK-mediated mTOR suppression is 
achieved through direct phosphorylation of key enzymes involved in this pathway, 
TSC2 and Raptor, which block the ability of the mTORC1 kinase complex to 
phosphorylate its substrates (Gwinn et al, 2008).  
In addition to suppressing the mTOR signalling pathway, AMPK can also trigger 
autophagy by directly activating ULK1, a core component of the autophagy 
pathway (Egan et al, 2011). Activation of AMPK and the subsequent stimulation of 
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ULK1 triggers the destruction of defective mitochondria through mitophagy. In 
addition to stimulating mitophagy, AMPK activation stimulates de novo 
mitochondrial biogenesis through PGC-1α dependent transcription (Jager et al, 
2007). Therefore, this interplay between AMPK and mTOR plays a central role in 
regulating mitochondrial homeostasis through the process of degrading defective 
mitochondria and replacing them with fuel-efficient ATP generators. AMPK 
activation also exerts control over metabolism through direct effects on metabolic 
enzymes such as Acetyl-CoA carboxylase (ACC1 and ACC2) and HMG-CoA 
reductase, which function in fatty-acid and sterol synthesis (Carling et al, 1987; 
Watt et al, 2006). In addition, AMPK has been reported to regulate a number of 
transcription factors, coactivators such as p300, corepressors such as CtBP1 and 
even histones, for example histone H2B  (Bungard et al, 2010; Kim et al, 2013; 
Zhang et al, 2011). Therefore, AMPK plays a key role in a variety of growth, 
metabolism, and autophagy processes in order to maintain cellular energy 
homeostasis (See Fig 4.1). 
Recently, using a yeast two hybrid system to screen rat brain cDNA Lee et al 
identified that rat CRBN directly interacts with the α subunit of AMPK preventing 
the formation of a holoenzyme with the regulatory subunits β and γ (Lee et al, 
2011). Non-formation of this complex resulted in decreased activation of AMPK. 
Furthermore, over-expression of rat, mouse or human CRBN in HEK293FT cells 
significantly reduced the activation of endogenous AMPK whereas knockdown of 
endogenous CRBN up-regulated the activity of AMPK. This indicates that CRBN is a 
negative regulator of AMPK (Lee et al, 2011). As discussed above, AMPK is a 
master sensor of energy balance, therefore binding of CRBN with the α1 subunit of 
AMPK may play a role in regulating AMPK function. In addition, long term storage 
of explicit memory uses a core signalling pathway involving cAMP-dependent 
protein kinase (PKA), mitogen-activated protein kinase (MAPK) and cAMP 
response element binding protein-1 (CREB-1). As CRBN has been shown to bind 
and inhibit AMPK, which in turn modulates CREB signalling, some have suggested 
that this may be a potential molecular mechanism by which CRBN affects HPC-
mediated memory in mice (Rajadhyaksha et al, 2012). 
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Figure 4.1 – The AMPK signalling pathway. AMPK is activated when AMP and ADP levels in the cell 
rise. This can be due to a variety of physiological stresses such as low nutrient and exercise and also 
in response to pharmacological inducers such as AICAR. LKB1, an upstream kinase, activates AMPK 
in response to AMP increase. AMPK can also be activated by CAMKK2 in response to rises in 
calcium levels. Activated AMPK directly phosphorylates a number of substrates invilved in cellular 
growth metabolism and autophagic processes. In addition, AMPK phosphorylates a number of 
transcriptional regulators that mediate long term metabolic reprogramming. Those substrates 
which need further in vivo investigation are italicized. 
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4.1.3: CRBN mouse models 
Recently, Rajadhyaksha et al generated a conditional Crbn knockout mouse model 
by inactivating Crbn in forebrain neurons, mimicking the human condition 
associated with CRBN mutations (Rajadhyaksha et al, 2012). Exons 3 and 4 were 
deleted by Cre recombinase under the direction of a Ca 2+/calmodulin-dependent 
protein kinase II promoter (CamIIKcre/+, cbrn-/-). Contextual fear conditioning 
showed a significant decrease in the percentage of freezing time in these mice and 
thus the results of this study demonstrate that specific deletion of Crbn in 
forebrain neurons of postnatal mice affects hippocampal (HPC)-dependent 
memory without any impairment of motor function, anxiety-related behaviours or 
social interaction (Rajadhyaksha et al, 2012). The generation of this Crbn knockout 
mouse model provides a promising model for studying the mechanisms by which 
Cereblon may lead to alterations in neuronal pathways.  
Previously, Lee et al reported that CRBN negatively regulates the function of AMPK 
in vitro by binding directly to the α1 subunit of the AMPK complex (Lee et al, 2013). 
However, the in vivo role of CRBN was not studied. Recently, in an attempt to 
elucidate the physiological roles of CRBN, Lee et al generated a Crbn knockout 
mouse model by targeting exon 1 of the Crbn gene. The Crbn KO mice displayed no 
apparent defects in gross morphology or basic behaviour (Lee et al, 2013).  
However, Lee et al reported that under normal conditions, endogenous AMPK was 
constitutionally hyperactivated in the liver of Crbn KO mice. They further reported 
that mice lacking Crbn appeared to have greater protection from body fat 
accumulation and obesity caused by high fat intake and are resistant to diet-
induced fatty liver (See Fig 4.2).  Moreover, Crbn expression in the liver was 
upregulated whereas that of pAMPK was downregulated in the long term by a high 
fat intake in wild type mice. The authors suggest that this may imply that Crbn is 
induced by a high fat diet and that Crbn regulates AMPK activity via a negative-
feedback loop in vivo. In conclusion, CRBN may be considered as a novel regulator 
of body metabolism and energy homeostasis (Lee et al, 2013). 
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Figure 4.2 – Cereblon deficiency in mice prevents HFD-induced (high fat diet) obesity. 
Representative images of wild type (Crbn+/+) and Crbn KO mice (Crbn-/-) mice after a 14-week 
experimental period of being fed a HFD. Image obtained from Lee et al,  2013. 
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4.1.4: Summary 
Mutations in CRBN have been identified as causative of a non syndromal form of 
mental retardation. Although the cellular functions of CRBN remain to be 
elucidated, they are thought to involve aspects of memory and learning and the 
regulation of key signalling pathways. Recently, CRBN was identified as the 
substrate-receptor component of a novel CRL4-containing complex which is 
inhibited by thalidomide in vitro. Thalidomide -induced inhibition of the E3 ligase 
activity of this complex is suggested to underlie the teratogenic effects of 
thalidomide treatment such as severe limb malformations.  However, thalidomide 
is now used today, albeit restricted use, in the treatment of multiple myeloma 
patients. Interestingly, one of the main side effects of thalidomide treatment in 
multiple myeloma patients is that of peripheral neuropathy. This is also a key 
feature of the CUL4B patients described in Chapter 3 and suggests that these 
clinical features may arise through disrupted assembly of the CUL4-CRBN complex.  
The CRBN protein has been shown to directly interact with the α-subunit of AMPK, 
inhibiting its actions. This provides a potential link for CUL4 in regulating AMPK 
via interaction with CRBN and thus supports a role for CUL4 in maintaining 
cellular homeostasis. In fact, loss of CUL4 has been associated with disrupted 
mTOR signalling, a pathway intimately linked to AMPK. Therefore, it is possible 
that loss of CUL4 could lead to disrupted levels of CRBN and impart a double-hit 
effect on both the mTOR and AMPK signalling pathways. Ultimately this may 
impart detrimental effects on mitochondrial homeostasis which may begin to 
explain some of the mitochondrial phenotypes identified in CUL4B-deleted LBLs. 
Furthermore, as discussed in section 3.1.4.4, the mTOR signalling pathway plays an 
essential role in mediating long term potentiation and misregulation of the mTOR 
signalling cascade is thought to be one of the molecular mechanisms underlying 
mental retardation. Mental retardation is a key feature of both CUL4B- and CRBN-
mutated/deleted patients suggesting that the CUL4-CRBN complex may play a 
fundamental role in neuronal development and maintenance.  
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I sought to investigate whether loss of CRBN by siRNA-mediated knockdown 
phenocopies that of CUL4B loss. More specifically, I investigated whether loss of 
CRBN mimicked the mitochondrial phenotypes associated with CUL4B loss such as 
increased ROS generation. Furthermore, I sought to determine whether 
thalidomide treatment in a wild-type setting, and thus inhibition of the CUL4-CRBN 
E3 ligase activity, was able to mimic the mitochondrial phenotypes of CUL4B loss. 
Identification of a reciprocal relationship here may provide novel insight into some 
of the mechanisms underlying the MR associated with both CUL4B and CRBN 
mutations/deletions. Moreover, it may provide fundamental insight into the 
functional roles of this novel E3 ligase complex. 
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4.2 Results 
 
4.2.1: Loss of CUL4B alters the expression of CRBN 
CRBN was recently identified as a novel substrate receptor of a CRL4-containing 
E3 ligase complex involving CUL4A and DDB1 (Ito et al, 2010). Although CUL4A 
was identified as the Cullin backbone of this complex, CUL4B was not specifically 
ruled out. CUL4A and CUL4B are 80% identical and this it is tempting to suggest 
that CUL4B may also form an E3 ligase complex with CRBN. In the same study, 
CRBN was shown to have autoubiquitination activity and this activity was 
inhibited by thalidomide in vitro. Here, thalidomide functions to inhibit the activity 
of the CUL4-CRBN E3 ligase, rendering it non-functional. This suggests that CRBN 
autoubiquitination and thus regulation is only possible when this complex is 
formed and functionally active. Although the physiologically relevant substrates of 
the CUL4-CRBN E3 ligase complex are unknown, both CUL4 and CRBN have been 
implicated in a number of fundamental processes such as the mTOR and AMPK 
signalling pathways. Therefore, it is likely that this E3 ligase complex may play 
crucial roles in maintaining cellular homeostasis. Furthermore, mutations in both 
CUL4B and CRBN have been associated with mental retardation in patients 
suggesting that this E3 ligase complex plays a fundamental role in neuronal 
development processes such as synaptic plasticity and connectivity.  
Initially I set out to investigate the impact of CUL4B loss, the core backbone of this 
E3 ligase complex, on the levels of CRBN protein expression. Cells from the CUL4B 
patients described in Chapter 3 provide a unique model for investigating the 
impacts of CUL4B loss on CRBN expression levels. Loss of CUL4B, and thus loss of 
the core component of this E3 ligase, would lead to non-formation of the complex 
and loss of E3 activity which may potentially impact on CRBN expression. As 
expected, Western blot analysis of whole cell extracts for CRBN protein expression 
levels revealed that CUL4B-deleted LBLs potentially display a subtle increase 
expression of CRBN protein compared to wild-type controls (Fig 4.3). This is 
consistent with previous reports of CRBN as a novel CUL4 substrate.  
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Figure 4.3 – CRBN protein expression levels are increased in CUL4B-deleted patient-derived LBLs. 
Increasing amounts of protein extract (25-g) were subjected to SDS-PAGE and immunoblotted 
for CRBN protein expression. α-tubulin was used as a loading control. WT; wild type control, 
CUL4B; CUL4B-deleted. 
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4.2.2: CRBN protein expression is reduced in CUL4B-deleted 
mitochondrial extracts 
ATP-dependent proteases are key enzymes responsible for intracellular selective 
proteolysis and are thus important for maintaining cellular homeostasis. These 
enzymes function to eliminate mutant and/or abnormal proteins in addition to 
playing important roles in the turnover of short-lived regulatory proteins. There 
are a number of ATP-dependent protease families, one of which is Lon proteases 
which function in the mitochondria. There are two Lon families; LonA and LonB. 
LonA family members consist of an N-terminal domain, an ATPase (AAA+) domain 
and an N-terminal proteolytic domain. In contrast, members of the LonB family 
lack the N-terminal domain. Human mitochondrial Lon protease (hLon) is a 
member of the LonA family and has been shown to degrade oxidised proteins such 
as aconitase. hLon has also been reported to play important roles in mtDNA 
maintenance where it is thought to be involved in mtDNA replication, translation 
and/or repair.  
Interestingly, human CRBN contains the N-terminal portion of the ATP-dependent 
Lon protease. However, it is reported to possess no protease or ATPase activity. 
Nevertheless, Lon proteases are found within the mitochondria suggesting that 
CRBN may be mitochondrially-localized. Interestingly, CUL4B was unexpectedly 
found to be present in isolated mitochondrial extracts (section 3.2.3). As CUL4B 
and CRBN have been identified as components of a novel CRL4-containing 
complex, the presence of CUL4B in/on the mitochondria further suggests that 
CRBN may also be present. If so, similar to whole cell extracts, loss of CUL4B may 
in turn affect the expression of CRBN within mitochondrial extracts. 
 
Wild type and CUL4B-deleted mitochondria were isolated using the affinity 
purification technique described in Chapter 3, section 3.2.3. Increasing amounts of 
mitochondrial extract (5-15µL) were subjected to SDS-PAGE and immunoblotted 
for CRBN protein expression levels. Substantial CRBN protein expression was 
detected in wild-type mitochondrial extracts (Fig 4.4 lanes 1-2). However, CUL4B-
deleted LBLs exhibited reduced CRBN protein expression levels compared with 
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WT controls (Fig 4.4 lanes 3-4). This data not only provides novel insight into the 
subcellular localisation of the CRBN protein but also suggests that loss of CUL4B 
imparts effects on the expression of CRBN. The protein expression levels of CRBN 
in whole cell extracts were increased in CUL4B-deleted LBLs yet they are found to 
be reduced in mitochondrial extracts from the same cells. This could potentially 
suggest that loss of CUL4B may disrupt the normal subcellular localisation of 
CRBN. In fact, CUL4B was also found to be present in mitochondrial extracts 
suggesting that the CUL4-CRBN complex may have as yet unidentified roles within 
or upon the mitochondria. Moreover, the reduced expression of CRBN in CUL4B-
deleted mitochondria could be suggestive of co-stabilization limiting CRBN 
function in the context of CUL4B-deficiency. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 – CRBN protein expression levels are reduced in CUL4B-deleted mitochondrial extracts.  
Mitochondria were isolated from 1x 107 LBLs per cell line using the Miltenyi QuadroMACS 
Mitochondria Isolation Kit. Isolated mitochondria were resuspended in 60µL urea-based extraction 
buffer and sonicated for 15 seconds to create a mitochondrial protein extract. 5-10µL of extract was 
subjected to SDS-PAGE and immunoblotted for CRBN protein expression. CRBN expression was 
visible in both WT (lanes 1-2) and CUL4B-deleted (lanes 3-4) mitochondrial extracts but expression 
was reduced in CUL4B-deleted extracts compared to WT controls. The blot was reprobed for 
LETM1 expression to ensure equal loading of each sample.  WT; wild-type, CUL4B; CUL4B-deleted. 
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4.2.3: AMPK phosphorylation in response to AICAR treatment is 
increased in CUL4B-deleted LBLs 
Previous studies have shown that CRBN inhibits the activation of AMPK in vitro by 
directly binding to the α1 subunit of AMPK. CUL4B-deleted LBLs display altered 
CRBN protein expression levels in both whole cell extracts and isolated 
mitochondria. Interestingly, CUL4B has previously been implicated in regulating 
the mTOR signalling pathway at multiple levels, a pathway intimately linked to 
AMPK activation. CUL4B-deleted LBLs display altered protein expression levels of 
CRBN which suggests that the regulation of AMPK may be altered in this context. 
CUL4B LBLs also exhibit elevated levels of intracellular calcium (see Chapter 3 
section 3.2.2.7) which may feed into the AMPK signalling pathway and activate 
AMPK through CaMKKβ. 
I investigated the impact of CUL4B loss on AMPK activation in response to the 
AMPK agonist, AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide).  Wild 
type LBLs displayed increased expression of pAMPK representing AMPK activation 
following a 5 minute AICAR treatment (Fig 4.5 lanes 1-4). CUL4B LBLs also 
exhibited AMPK activation following a 5 minute AICAR treatment but the protein 
expression levels of pAMPK were substantially increased compared to wild type 
controls (Fig 4.5 lanes 5-8). Moreover, CUL4B LBLs displayed a further increase in 
pAMPK expression at 15 minutes compared to wild type controls who exhibited a 
reduction in pAMPK at this time point. The data presented in figure 4.6 suggests 
that AMPK is hyperactivated in response to AICAR in CUL4B LBLs compared to 
wild type controls. This provides a potential link by which CUL4B may regulate 
AMPK via its interaction with CRBN and a possible role for CUL4-CRBN in 
mediating some aspects of mitochondrial homeostasis.  However, cause and effect 
here are unclear. 
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Figure 4.5 – AMPK is hyper-phosphorylated in response to AICAR in CUL4B-deleted LBLs. Wild 
type (WT) and CUL4B-deleted LBLs were treated with 2mM AICAR for 0-30 minutes. Urea-based 
whole cell extracts were then subjected to SDS-PAGE and immunoblotted for p-AMPK (top panel), 
p-ACC (middle panel) and native ACC protein expression levels. ACC; Acetyl -CoA Carboxylase,  
p-ACC; phospho-Acetyl-CoA Carboxylase, WT; Wild-type, CUL4B; CUL4B-deleted. 
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4.2.4: Thalidomide treatment mimics the cellular phenotypes of 
CUL4B loss 
Recently, CRBN was identified as a novel thalidomide-binding protein and 
subsequently reported as the primary target of thalidomide. CRBN forms an E3 
ligase complex with CUL4 and DDB1 and it is thought that thalidomide induces its 
teratogenic effects by inhibiting the E3 ligase activity of this complex. Thalidomide 
is widely used today in the treatment of multiple myeloma patients; however, one 
of the main side effects of its treatment is that of peripheral neuropathy. Peripheral 
neuropathy is a consistent feature of CUL4B-mutated and/or deleted patients so it 
is tempting to speculate that loss of CUL4B could underlie some aspect of both 
peripheral neuropathy observed in CUL4B patients through disrupted assembly of 
this E3 ligase complex. Moreover, MR is an overlapping clinical feature between 
CUL4B-deleted and/or mutated and CRBN-mutated patients suggesting that 
impaired activity of this E3 ligase complex may contribute to the MR observed in 
both disorders. 
I set out to investigate the effects of thalidomide and the subsequent inhibition of 
this CUL4-CRBN E3 ligase complex on mitochondrial homeostasis in a wild-type 
setting. More specifically, I aimed to investigate the impact of thalidomide on the 
generation of reactive oxygen species. If thalidomide treatment here is capable of 
phenocopying CUL4B loss, this may suggest a putative role for the CUL4-CRBN 
complex in maintaining mitochondrial homeostasis.  Wild-type LBLs were treated 
with 250µM thalidomide for 2 hours followed by 15 minute incubation with 
250nM MitoSOX. Cells were then analysed for MitoSOX (red) fluorescence using 
the FACS Canto flow cytometer. Interestingly, thalidomide treated cells exhibited a 
~2.5 fold increase in MitoSOX fluorescence compared to untreated controls (Fig 
4.6). This data mimics that of CUL4B-deleted LBLs (see section 3.2.2.5) and 
suggests that the CUL4-CRBN E3 ligase complex potentially plays a key role in 
maintaining mitochondrial homeostasis. Consistent with this, CRBN has previously 
been shown to regulate the antioxidant defence system of the cell further 
indicating a role for this E3 complex in mitochondrial function. 
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Figure 4.6 – Inhibition of the CUL4-CRBN complex by thalidomide treatment induces a ROS 
phenotype similar to that associated with CUL4B loss. (a) Wild type LBLs were treated with 250µM 
thalidomide for 2 hours followed by 15 minute incubation with 250nM MitoSOX. Cells (20,000 
events) were then analysed for MitoSOX fluorescence by flow cytometry (red). CUL4B-deleted LBLs, 
as described in Chapter 3, were also analysed for MitoSOX fluorescence without the addition of 
thalidomide (pink). (b) Histogram showing the fold change in MitoSOX fluorescence following a 2 
hour thalidomide treatment (250µM) compared to untreated (Unt) WT controls. MFI; mean fluorescence 
intensity of 20,000 events, Unt; untreated WT controls. 
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4.2.5: Crbn knockdown phenocopies the mitochondrial 
phenotypes associated with CUL4B loss 
The precise physiologically relevant functions of the CUL4-CRBN E3 ligase complex 
or indeed its substrates remain elusive. However, the data presented here suggests 
that this complex may play an important role in mitochondrial homeostasis.  
Inhibition of the CUL4-CRBN complex by thalidomide results in a striking increase 
in superoxide generation. Similarly loss of CUL4B, potentially a core backbone of 
the CUL4-CRBN complex, is associated with a ~2 fold increase in superoxide 
generation (as described in Chapter 3 section 3.2.2.5). Furthermore, CRBN has 
been identified as a negative regulator of AMPK. I have shown that 
phosphorylation of AMPK in response to an activating compound is increased in 
CUL4B-deleted LBLs. This provides a potentially novel link by which CUL4B 
regulates AMPK and mTOR signalling through interaction with CRBN. Both the 
AMPK and mTOR signalling pathways are central regulators of mitochondrial 
biogenesis and autophagy. This suggests that non-formation of a functional CUL4-
CRBN complex may impact on mitochondrial homeostasis at multiple levels. I have 
previously shown that loss of CUL4B or inhibition of the CUL4-CRBN complex by 
thalidomide results in a striking increase in ROS production. Therefore, I aimed to 
investigate whether loss of CRBN, the substrate receptor of this complex, results in 
similar mitochondrial phenotypes thereby suggesting of a novel role for the CUL4 -
CRBN complex within the mitochondria. 
I investigated the impact of Crbn knockdown in a mouse C2C12 myoblast cell 
model. If indeed the CUL4-CRBN complex plays a key role in mitochondrial 
function, it would be expected that loss of Crbn may partially mimic the 
phenotypes of both Cul4b loss and thalidomide treatment. C2C12 myoblasts were 
sequentially (double) transfected with a siRNA smartpool of oligos directed against 
Crbn and Crbn knockdown was confirmed by Western blotting (Fig 4.7a) . Flow 
cytometry analysis 48 hours post-transfection revealed a ~1.6 fold increase in 
MitoSOX fluorescence, indicative of increased superoxide levels (Fig 4.7b-c). 
Microscopy-based analysis of Mitotracker Red fluorescence revealed that Crbn 
siRNA-transfected C2C12 cells displayed a substantial reduction in Mitotracker 
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Red fluorescence indicative of transmembrane depolarisation (Fig 4.8). More 
interestingly, some cells appeared to exhibit extreme hyperpolarisation, a 
phenotype identical to that observed in CUL4B-deleted cells (Figure 4.7c and see 
Chapter 3 Fig 3.21). These results indicate that the CUL4-CRBN complex may play 
fundamental roles within the mitochondria whereby loss of CUL4B or CRBN gives 
rise to a distinct set of mitochondrial phenotypes indicative of mitochondrial 
dysfunction. 
 
4.2.6: Summary 
Loss of CUL4B is associated with a distinct set of mitochondrial phenotypes 
including elevated ROS production and disruption to the mitochondrial membrane 
potential. CRBN was recently identified as a novel substrate receptor of a CUL4-
containing E3 ligase complex however its functions are unknown. Here I have 
shown that loss of CUL4B affects the subcellular localisation of the CRBN protein 
whereby its expression is increased in WCE but decreased in mitochondrial 
fractions.  Loss of Crbn by siRNA-mediated knockdown has revealed mitochondrial 
phenotypes that are identical to those of both CUL4B-deleted patient derived LBLs 
and Cul4b siRNA-transfected cells. Furthermore, inhibition of the CUL4-CRBN E3 
complex by thalidomide induces a ROS phenotype similar to that of patient-
derived CUL4B-deleted LBLs. Collectively; these data suggest putative roles for the 
CUL4-CRBN complex in mediating some aspect of mitochondrial homeostasis such 
as redox status. CRBN has also been identified as a potential AMPK regulator. In 
the context of CUL4B-deficiency, AMPK phosphorylation is increased following 
AICAR treatment suggestive of a putative role for this E3 ligase complex in the 
regulation of AMPK. 
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Figure 4.7 – siRNA-mediated knockdown of Crbn in mouse C2C12 myoblasts mimics the 
mitochondrial phenotypes associated with CUL4B loss. (a) C2C12 myoblasts were transfected twice 
(0 hours and 24 hours) with a Crbn oligo smartpool in the presence of metafectene pro and 
harvested 48 hours after the first transfection. Urea-based whole cell extracted were subjected to 
SDS-PAGE and immunoblotted for Crbn protein expression levels compared to untransfected 
(metafectene only) controls. α tubulin was used as loading control. (b) Crbn siRNA transfected 
C2C12s were incubated with 250nM MitoSOX 48 hours post double transfection. Cells were then 
analysed by flow cytometry for MitoSOX fluorescence (20,000 events). The FACS plot shown 
indicates the MitoSOX PE-A profiles for untransfected C2C12’s (black), Crbn siRNA-transfected cells 
(red) and Cul4b siRNA-transfected cells (blue). (c) Representative histogram showing the mean 
fold change in MitoSOX mean fluorescence intensity (MFI) relative to untransfected C2C12 control 
cells (1 fold). The data represents the mean ± SD of three independent determinations.  
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Figure 4.8 – Microscopy-based analysis of Mitotracker Red fluorescence in Crbn siRNA-transfected 
C2C12 cells. This experiment was performed at the same time as that shown in Figure 3.31, 
therefore the ‘Unt’ image shown here is duplicated.  C2C12 myoblasts were grown on coverslips 
until 60% confluent. Cells were then incubated with 250nM Mitotracker Red for 15 minutes 
followed by a PBS wash. Coverslips were then mounted onto Poly-lysine slides and Mitotracker Red 
fluorescence was visualised using the Zeiss Axiovert microscope. Images were taken at the same 
exposure time. Crbn siRNA-transfected cells exhibited depolarization of the transmembrane 
potential, seen as an overall decrease in Mitotracker red fluorescence, but some cells displayed 
substantial hyperpolarisation as shown by the yellow circles. Unt; untransfected, Crbn siRNA; Crbn 
siRNA sequential transfection at 0 hours at 24 hours.  
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4.3: Discussion 
 
Despite recent advances with regards to CRBN, its physiological functions are still 
not fully understood. The nonsense mutation p.R419X of CRBN has been identified 
in patients with Autosomal Recessive Non-Syndromal Mental Retardation 
(ARNSMR). CRBN has recently been identified as the substrate receptor of a CRL4-
containing E3 ligase complex; however its substrates remain elusive. Interestingly, 
patients with CUL4B mutations/deletion also present with MR and thus the clinical 
overlap between these patients suggests that disruption of the CUL4-CRBN 
complex may play an important role in the pathogenesis of MR in these two 
conditions. 
It is reported that CRBN can be ubiquitinated in vitro and in vivo, likely via CRL4-
dependent auto-ubiquitination. Furthermore, this auto-ubiquitination activity can 
be inhibited by thalidomide suggesting that binding of thalidomide inhibits the 
activity of the CRBN-DDB1-CUL4-ROC1 E3 ligase complex (Ito et al, 2010). 
Consistent with these reports, I found that CRBN protein expression was increased 
in CUL4B-deleted patient-derived cells implicating CUL4B in this CRL4. 
Interestingly, although the protein expression of CRBN was increased in whole cell 
extracts, in contrast its expression levels were decreased in mitochondrial 
fractions. This could suggest that CUL4B deficiency not only results in the mis-
regulation of CRBN protein levels through inhibition of autoubiquitination activity 
but also disrupts the subcellular localisation of CRBN. Although the functions of 
CRBN are not fully understood yet, its presence within mitochondrial extracts 
suggests that it may have important roles in mitochondrial function. In Chapter 3 I 
reported the presence of CUL4B in isolated mitochondrial extracts (section 3.2.3) 
and thus the additional presence of CRBN supports a potential role for the CUL4-
CRBN complex within the mitochondria. Moreover, it indicates that this complex 
may have unidentified substrates residing within the mitochondria. Consistent 
with a role for CRBN in modulating some aspect of mitochondrial function, Crbn 
siRNA-mediated knockdown resulted in identical mitochondrial phenotypes to 
those seen in CUL4B-deleted LBLs; transmembrane depolarisation coexisting with 
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hyperpolarisation and marked increased in ROS production. This data further 
supports a role for the CUL4-CRBN complex specifically in maintaining 
mitochondrial homeostasis.  
It has been postulated that some of the teratogenic effects of thalidomide 
treatment may be mediated via inhibition of the CUL4-CRBN complex. I 
interrogated the effects of thalidomide treatment on mitochondrial functioning in 
wild type cells and found that increased ROS was a clear consequence of 
thalidomide treatment in wild type cells. This is suggestive of a putative role for 
the CUL4-CRBN complex in regulating some aspect of mitochondrial redox status 
specifically. In fact, it has been reported that the CRBN promoter region harbours a 
Nrf2/ARE- binding site which further implicates it in cellular antioxidant defence 
system (Lee et al, 2010b). Interestingly, one of the side effects of thalidomide 
treatment in multiple myeloma patients is peripheral neuropathy; also a feature of 
CUL4B-deleted patients. Thalidomide is thought to exert its effects through 
inhibition of the CUL4-CRBN complex and thus the mitochondrial phenotypes 
observed suggest that inhibition or non-formation of the CUL4-CRBN complex, in 
the context of CUL4B deficiency, may play a role in the pathogenesis of neuropathy 
in CUL4B-deleted/mutated patients. It is noteworthy that CRBN-mutated patients 
do not exhibit any syndromal features like those with CUL4B deletion/mutations; 
however it is not clear whether any residual CRBN function remains in CRBN-
mutated patients.  
Whilst carrying out this work it was reported that CRBN can directly bind to the 7 
subunit of the 20S core complex of the proteasome, inhibiting its enzymatic 
activity. The 20S proteasome plays a key role in selectively degrading oxidised 
proteins however; the products of severe oxidative stress can act as irreversible 
inhibitors of the 20S complex (Davies et al, 2001). CUL4B-deleted LBLs display 
both elevated levels of ROS and increased CRBN protein expression and thus the 
culmination of these two factors may inhibit 20S proteasome activity resulting in a 
vicious cycle of progressively worsening accumulation of protein oxidation 
products. This may be an area worthy of future investigation in order to fully 
elucidate the impact of CUL4B loss on CRBN function and redox status. 
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Furthermore, it may provide novel insight into the potential mechanisms 
underlying the MR in these patients. 
In conclusion, it is likely that mis-regulation of the CUL4-CRBN complex may 
underlie some of mitochondrial phenotypes identified here and thus may 
potentially contribute to the overlapping MR phenotype of these patients. 
Importantly, this data provides a stepping stone for further investigations into 
potential substrates of the CRL4-CRBN E3 ligase. However, much deeper 
investigation is needed to provide a valuable link between impaired function of the 
CUL4-CRBN complex and the molecular aetiology of MR in these two disorders. 
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Chapter Five 
16p11.2 Copy Number Variant Genomic Disorder; 
attempting to identify underlying and 
contributory genes  
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5.1: Introduction 
 
Array CGH screening of large patient cohorts with defined phenotypes of Mental 
Retardation and/or multiple congenital anomalies (MCA) has led to the 
identification of multiple novel microdeletion/duplication syndromes. These 
include, but are not limited to, 15q24, 17q21.31 and 15q13.3 deletion syndromes 
(Ballif et al, 2007; Koolen et al, 2006; Sharp et al, 2006; Sharp et al, 2008). 
Recently, recurrent reciprocal 16p11.2 deletions and duplications have been 
associated with autism and DD (Kumar et al, 2008; Marshall et al, 2008; Weiss et 
al, 2008). Previous studies have suggested that the great majority of 16p11.2 
deletions arise as de novo rearrangements but both inherited (autosomal 
dominant) and de novo patterns are observed in patients with 16p11.2 
duplications (Shinawi et al, 2010).  
Intensive phenotypic analyses of patients with 16p11.2 rearrangements has 
revealed strikingly opposing comorbidities; the 600kb deletion on 16p11.2 has 
been associated with autism, epilepsy, macrocephaly, obesity and Autism 
Spectrum Disorder (ASD) whereas the reciprocal duplication is associated with 
autism, schizophrenia, anorexia and microcephaly (Shinawi et al, 2010). These 
observations support the model of behavioural phenotypes in genomic sister 
disorders proposed by Crespi et al (Crespi et al, 2009). According to this model, 
diametric variation in gene copy number can generate contrasting cognitive and 
behavioural phenotypes associated with autistic spectrum and psychotic spectrum 
conditions which may represent development and evolution of the social brain. 
However, although 16p11.2 CNV have frequently been associated with autism, a 
more recent study has shown that autism is not always a presenting feature in 
many patients with 16p11.2 deletions (Bijlsma et al, 2009). Here, 16p11.2 
deletions were associated with a much broader and variable clinical phenotype 
ranging from MR and/or MCI autism, and learning and speech problems to a 
normal phenotype. Furthermore, certain facial features are shared among patients 
(Shinawi et al, 2010). Those individuals with 16p11.2 deletions typically share the 
following features; broad forehead, micrognathia, hypertelorism and a flat midface. 
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The broad forehead, macrocephaly and flat midface give these patients a distinct 
facial gestalt. However, in the case of 16p11.2 duplications, dysmorphism appears 
to be more severe but has no recognisable pattern (Figure 5.1).  This accumulating 
evidence indicates that 16p11.2 CNV is associated with a highly variable clinical 
spectrum.   
 
 
 
(a) 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
Figure 5.1 - Facial features of individuals with 16p11.2 CNVs. (a). 16p11.2 deletion patients exhibit 
a broad forehead and flat midface. Hypertelorism and micrognathia appear to be common. (b). 
16p11.2 duplication patients tend to be more grossly dysmorphic but with no recognisable pattern 
between affected individuals (Image taken from Shinawi et al, 2010). 
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5.1.1: The 16p11.2 region 
As described in Chapter one, recurrent CNVs are typically flanked by LCRs which 
serve as substrates for NAHR. In the case of 16p11.2 CNV, analysis of the genomic 
structure within the rearranged region has identified two major LCR families; (i). 
Two ~147kb LCRs in direct orientation sharing 99.6% sequence identity (147A/B) 
and (ii). three 72kb repeats in direct orientation which share ~98.6% sequence 
identity (72 A/B/C) (Figure 5.2) (Shinawi et al, 2010). The 16p11.2 rearrangement 
interval contains ~30 annotated genes, some of which are promising candidates 
for the different phenotypes in patients with these syndromes such as MAPK3, 
SEZ6L2, QPRT, MAZ and DOC2A (Feldblum et al, 1988; Kumar et al, 2009; 
Mazzucchelli et al, 2002; Okamoto et al, 2002).  
 
 
 
 
 
 
 
 
 
 
Figure 5.2 - Schematic representation of the two major LCR families in the 16p11.2 region. The 
blue arrows represent the two ~147kb LCRs which are in direct orientation and share 99.6% 
sequence identity. The red arrows, termed 72A, 72B and 72C, represent the three ~72kb LCRs. 
These are also in direct orientation and share ~98.6% sequence identity.  
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5.1.2: Mouse models of 16p11.2 CNV  
Using Cre/LoxP-based chromosome engineering,  Horev et al generated mice with 
either one copy (df/+) or three copies (dp/+) of the region corresponding to 
human 16p11.2 (Horev et al, 2011). Interestingly, the rate of certain behaviours 
appeared to be affected reciprocally by loss and gain of 16p11.2. In a novel 
environment, df/+ mice displayed longer distance travelled and walking time 
compared with WT controls. In contrast, dp/+ mice spent less time walking and 
travelled a shorter distance compared with WT controls. Additionally, assessment 
of light and dark cycling revealed that 16p11.2 dosage affected diurnal behaviours  
(active during the daytime and sleeping during the night).  More specifically, df/+ 
mice had a much higher ratio of light to dark activity compared with both dp/+ and 
control mice (Horev et al, 2011). Further behavioural analysis revealed that 
16p11.2 deletion mice displayed non-progressive, stereotypic motor behaviour. 
Interestingly, these behaviours were similar to the stereotypic behaviour observed 
in rats with lateral hypothalamic lesions and 6-hydroxydopamine-induced lesions, 
a well characterised model of Parkinson’s Disease (Golani et al, 1979; Schallert et 
al, 1978). 
Concordant with the macro/microcephaly observed in human subjects with 
16p11.2 deletion and duplication, MRI (Magnetic Resonance Imaging) scans 
revealed significant changes in eight different brain regions in 16p11.2 CNV mice. 
Brain structures significantly altered included the  basal forebrain, superior 
colliculus, fornix, hypothalamus, mammillothalamic tract, medial septum, midbrain 
and periaqueductal gray (Horev et al, 2011). Opposing volumetric changes 
indicated that loss and gain of 16p11.2 dosage affects these regions in a reciprocal 
manner. These findings are consistent with 16p11.2 CNVs as causative of brain and 
behavioural anomalies. 
 
5.1.3: KCTD13; a gene linked to head size  
Human brain development involves rapid and sustained cellular proliferation 
during embryogenesis and it is this feature that renders it highly sensitive to 
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perturbations in cell cycle dynamics. One of the most apparent clinical features of 
impaired neurogenesis is microcephaly.  The term ‘microcephaly’ refers to a 
clinical finding; a reduction in occipitofrontal or head circumference greater than 3 
standard deviations below the age-related mean. Conversely, the term 
‘macrocephaly’ represents an enlarged head circumference greater than 2.5 
standard deviations above the age-related mean. 
It is hypothesized that microcephaly is a consequence of reduced neurogenesis, 
potentially due to increased cell death and/or reduced neuroprogenitor 
proliferative capacity. This ultimately leads to a reduction in the final number of 
cells that populate the cortex. The converse is thought to be true for macrocephalic 
phenotypes.  There are many genetic and non-genetic causes of Primary 
Microcephaly (OMIM 251200). Interestingly, to date, all of the genes implicated in 
PM encode proteins with known/presumed roles in centrosome and/or spindle 
formation and maintenance (Table 5.1). Microcephaly is also a common feature of 
many DDR-defective disorders suggesting a fundamental role for the DDR in the 
developing nervous system. Microcephaly is seen in DDR-defective disorders such 
as ATR-Seckel syndrome, LIG4 syndrome, Fanconi Anaemia and XLF-Cernunnos-
SCID (reviewed in (O’Driscoll & Jeggo, 2008) (Table 5.2). Furthermore, recent 
findings using patient-derived cell lines from Meier-Gorlin syndrome and Wolf-
Hirschhorn syndrome have highlighted the importance of optimal DNA replication 
and S phase progression for normal human development (Kerzendorfer et al, 
2013). 
Patients with 16p11.2 CNV exhibit strong opposing clinical phenotypes, one of the 
most prominent being head size. Individuals harbouring 16p11.2 deletions present 
with absolute or relative macrocephaly, whereas patients with duplications of this 
region exhibit microcephaly. As shown in Figure 5.2, the 16p11.2 region harbours 
~30 annotated genes, some of which are involved in regulating cellular 
proliferation, cell cycle progression, DNA repair or the DNA Damage Response 
(DDR). These include; BOLA, TAOK2, INO80, PPP4C and MAPK3. One gene that has 
gained significant interest in recent years is KCTD13, or as it is otherwise termed, 
PDIP1. KCTD13 (potassium, channel tetramerisation domain containing 1) encodes 
the polymerase delta-interacting protein 1 (PDIP1), which can also interact with 
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PCNA (Proliferating Cell Nuclear Antigen) (He et al, 2001). PCNA is an 
evolutionarily conserved protein found in all eukaryotic species and was first 
shown to act a processivity factor of DNA polymerase which is required for DNA 
synthesis during replication (Kelman, 1997). However, besides its crucial role in 
DNA replication, PCNA also functions in other vital cellular processes such as 
chromatin remodelling, Okazaki fragment processing, DNA repair and cell-cycle 
control. The identification of this interaction that has led researchers to propose 
that KCTD13/PDIP1 may play key roles in cell cycle regulation (He et al, 2001). 
Consistent with a putative role for KCTD13 in neurogenesis, Golzio and co -workers 
reported that KCTD13 was strongly expressed in the developing brain and 
deregulation of KCTD13 levels were sufficient to establish neuroanatomical defects 
such as reduced or increased cell proliferation (Golzio et al, 2012). In an attempt to 
identify the critical loci whose dosage sensitivity could yield the microcephalic/ 
macrocephalic phenotypes associated with 16p11.2 duplications/deletions, Golzio  
et al investigated the effects of overexpression of each human 16p11.2 region 
transcript in zebrafish embryos at the two-cell stage. Systematic overexpression of 
29 of the genes within this region revealed that overexpression of KCTD13 
specifically yielded the microcephalic phenotype associated with the 16p11.2 
duplication, whereas reciprocal suppression of this locus using a Kctd13 
morpholino mirrored the corresponding  human 16p11.2del macrocephalic 
phenotype (Golzio et al, 2012) (Figure 5.3). Further analysis of zebrafish embryos 
revealed that the microcephalic phenotype induced by KCTD13 overexpression 
was accompanied by decreased proliferation of neuronal progenitors and 
increased cell death relative to controls. In contrast, the macrocephaly induced by 
Kctd13 downregulation (~70%) arose from increased proliferation. Moreover, 
these shifts in cellular proliferation and death were apparent before the 
differences in head size developed which argues that an altered balance in cell 
proliferation and/or death drove the micro-/macrocephaly phenotypes. 
To investigate whether downregulation of Kctd13 in mice could recapitulate the 
findings of increased head size in zebrafish, Golzio et al designed short hairpin 
RNAs (shRNAs) against murine Kctd13. Consistent with a relationship between 
KCTD13 expression and head size; injection of the Kctd13 shRNA and GFP-
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expressing plasmid into the ventricular space of developing brains of mouse 
embryos resulted in a twofold increase in BrdU/GFP labelling within the 
ventricular zone compared with controls (Golzio et al, 2012). This data suggests 
that Kctd13 somehow impacts upon the proliferative status of cortical progenitors 
in vivo. However, it is noteworthy that an overexpression model was not reported.  
Although the data presented by Golzio and colleagues supports a major 
contributory role for KCTD13 as a driver of the macro/microcephalic phenotypes 
of 16p11.2 CNV through regulation of early neurogenesis, it does not preclude a 
contribution from other genes towards head size in this context. Indeed, they 
reported that pairwise overexpression of KCTD13 with two other 16p11.2 gene 
transcripts; MAPK3 and MVP, enhanced the microcephalic phenotype in zebrafish.  
More importantly, five of transcripts within the mammalian 16p11.2 region (SPN, 
QPRT, C16orf54, TMEM219 and C16orf92) are not present in the zebrafish genome 
and thus the relative contributions of these genes cannot be excluded or excluded. 
Furthermore, a second study published in the same year, also using the zebrafish 
model, reported that the majority of genes within the 16p11.2 are required for 
nervous system development (Blaker-Lee et al, 2012). In most cases an effect was 
only observed following a ~75% reduction in gene expression, however a 50% 
reduction in gene expression of two genes; ALDOA and KIF22 was sufficient to 
cause narrowing of the forebrain and a reduction in brain volume, respectively 
(Blaker-Lee et al, 2012). Collectively, the data suggests there may be other genes 
within this region which may contribute to head size, but KCTD13 may be the 
major driver of this mirrored phenotype. 
 
5.1.4: A potential link between KCTD13 and autism 
In 2012, a submicroscopic ~118kb deletion in 16p11.2 that segregated with ASD 
was discovered in a single three-generation pedigree, encompassing only five 
genes; MVP, CDIPT1, SEZ6L2, ASPHD1 and KCTD13. This report was consistent with 
a role for haploinsufficiency of KCTD13 as a key contributor to 16p11.2del 
phenotypes. Following on from their work in zebrafish, Golzio and colleagues 
looked to deepen their investigations by screening this restricted region in 518 
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individuals with autism, compared with 8328 controls (Golzio et al, 2012). The 
reported full segment deletions in 1.54% of ASD subjects compared with 0.06% 
from controls. Interestingly, they noted a de novo deletion of a single probe 
spanning exon 4 of KCTD13 in one proband with a narrow diagnosis of autism. The 
deletion was restricted to the coding region of KCTD13; including exons 3, 4 and 5 
suggesting that haploinsufficiency of KCTD13 may contribute to the ASD 
phenotype associated with 16p11.2 CNV. However, when attempting to precisely 
localize the breakpoints by aCGH it was found that the individual harboured an 
additional, atypical ~300kb deletion distal to the 16p11.2 region and thus this 
finding obscured a potential direct link between KCTD13 and autism. 
 
5.1.5:  Summary 
16p11.2 deletion and reciprocal duplications have been identified in ~1% of 
autistic individuals. Interestingly, deletion vs. duplication patients present with 
mirrored anatomical phenotypes such as macro- or microcephaly, respectively.  
One of the most fundamental mechanisms proposed to underlie severe 
microcephaly in humans is that of altered DNA replication, centrosome function 
and/or spindle organisation. Moreover, recent findings in patient-derived cells 
lines from both Meier-Gorlin syndrome and Wolf-Hirschhorn Syndrome highlight 
the importance of optimal replication efficiency and S-phase progression for 
human development, including neurogenesis. These findings indicate that 
impaired replication efficiency may underlie the microcephalic phenotypes of 
these two complex human disorders.  (Kerzendorfer et al, 2012).  Additionally, 
accumulating evidence also implicates defective DDR pathways as crucial players 
in the aetiology of microcephaly. The 16p11.2 region encompasses ~30 genes, 
some of which function in cell cycle regulation and DNA repair pathways 
suggesting that altered DNA replication and/or repair proficiency may underlie the 
micro-/macrocephalic phenotypes of 16p11.2 CNV patients.  Employing a set of 
16p11.2 CNV patient-derived LBLs (deletion and duplication), I chose to 
interrogate the expression, and by extension the functional consequences of 
altered copy number variation of three genes in particular; KCTD13, TAOK2 and 
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MAPK3, in the context of 16p11.2 deletion/duplication. These genes were chosen 
based on the known or putative roles of the proteins they encode in cell cycle 
regulation (MAPK3), DNA replication (KCTD13) and DNA repair (TAOK2).  
Furthermore, I sought to investigate whether impairments in DNA replication and 
S-phase transit and/or elevated or reduced sensitivity to HU-induced DNA damage 
was a feature of these cells.  
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Table 5.1 - Defects in genes that encode proteins with centrosomal and/or spindle functions or 
localisations are associated with severe microcephaly in humans. 
 
Gene Disorder Protein location Function 
MCPH1 
Primary Microcephaly 
MCPH1 locus 
Centrosome 
Implicated in 
chromosome 
condensation and DDR 
ASPM 
Primary Microcephaly MCPH5 
locus 
Spindle pole Mitotic spindle regulation 
CDK5RAP2 
Primary Microcephaly MCPH3 
locus 
Centrosome 
Required for centrosome 
cohesion and microtubule 
nucleation of the -tubulin 
ring complex 
CENPJ 
Primary Microcephaly MCPH6 
locus and Seckel Syndrome 
Centrosome 
Functions in centriole 
duplication 
WDR62 
Primary Microcephaly MCPH2 
locus 
Spindle pole 
Proposed to play a role in 
cerebral cortical 
development 
CEP152 
Primary Microcephaly MCPH4 
locus and Seckel Syndrome 
Centrosome 
Required for the 
centrosomal loading of 
PLK4 and CPAP 
STIL 
Primary Microcephaly MCPH7 
locus 
Spindle pole 
Functions in precentriole 
formation and centriole 
duplication 
CEP63 
Primary Microcephaly with 
mild Seckel Syndrome 
Centrosome 
Forms a ring-like 
structure at the 
chromosome with 
CEP152 and controls 
centrosome number 
CEP153 
Primary Microcephaly MCPH8 
locus 
Centrosome 
Presumed role in 
centriole biogenesis 
PCNT 
Microcephalic 
Osteodysplastic Primordial 
Dwarfism-Type II (MOPDii) 
Centrosome Microtubule nucleation 
NIN 
Microcephalic Primordial 
Dwarfism (MPD) 
Centrosome 
Role in coordinating 
asymmetric cell division 
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Table 5.2: A selection of DNA damage response (DDR) disorders conferring microcephaly. 
 
Disorder DDR-defect 
NBS: Nijmegen breakage syndrome 
ATM and ATR signalling and Artemis-
ATM-dependent DSB repair 
ATR-S: ATR-Seckel syndrome ATR-signalling 
MCPH1:Microcephalin-dependent primary 
microcephaly 
ATR-dependent checkpoint activation 
XPA & ERCC1: Xeroderma pigmentosum 
complementation groups 
Nucleotide Excision Repair. Defective 
ATR-signalling in XP-A 
FA (-D2): Fanconi Anaemia Response to cross-linking agents 
LIG4: DNA Ligase IV syndrome NHEJ 
XLF/Cernunnos-SCID: Xrcc4-like factor/Cernunnos-
dependent severe combined immunodeficiency 
NHEJ 
BS: Bloom’s syndrome Unregulated HR 
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Figure 5.3: KCTD13 dosage changes lead to changes in head size of zebrafish. Dorsal (left) and 
lateral (right) views of representative embryos injected with kctd13 morpholino (MO), control 
or KCTD13 mRNA (Golzio et al, 2012). 
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5.2: Results 
 
5.2.1: 16p11.2 deletion and duplication LBLs exhibit 
corresponding protein expression of TAOK2 and MAPK3 
In collaboration with Dr. Evica Rajean-Separovic at the Department of Pathology, 
Women’s Health Centre of British Columbia and the University of British Columbia, 
I assembled a panel of EBV-transformed patient-derived lymphoblastoid cell lines 
(LBLs) from 5 patients harbouring either a hemizygous deletion of the 16p11.2 
region or the reciprocal duplication (See table 5.3). To assess the cellular 
consequences of 16p11.2 CNVs, I chose to interrogate the protein expression levels 
of three proteins in particular, encoded by genes residing within the 16p11.2 
region; TAOK2, MAPK3 and KCTD13. Protein expression data for 16p11.2 CNV has 
not previously been reported. All published data to date (June 2013) exclusively 
refers to mRNA levels. 
TAOK2 protein expression was found to be increased/decreased consistent with 
deletion or duplication of the TAOK2 gene in three different 16p11.2 CNV cell lines 
(Figure 5.4). LBLs derived from a male proband harbouring a paternal 16p11.2 
duplication (LBL 06-32) exhibited a 1.8 fold increase in TAOK2 protein expression 
compared with WT controls (Fig 5.4a lanes 1-6). LBLs derived from a female 
proband with a de novo 16p11.2 deletion (LBL 12-14) and from a male proband 
also with a de novo 16p11.2 deletion (LBL 09-22) exhibited a 0.43-0.6 fold change 
in the protein expression levels of TAOK2 compared with WT controls, consistent 
with deletion of 16p11.2 (Fig 5.4a lanes 7-9, Fig 5.4b and Fig 5.4c).  Also consistent 
with deletion/duplication of the 16p11.2 region in two patient-derived LBLs, 
western blot analysis of ERK1 (MAPK3) protein expression revealed 
increased/decreased expression respectively (Figure 5.5 panel 1).  Furthermore, 
protein expression of the phosphorylated form of MAPK3 was also consistent with 
16p11.2 copy number change (Figure 5.5 panel 3). 
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Table 5.3 – 16p11.2 CNV patient-derived LBL cell lines used in this thesis.  
 
Cell Line CNV 
LBL 09-22 Male proband with a de 
novo 16p11.2 deletion 
LBL 06-32 Male proband with a 
paternal 16p11.2 
duplication 
LBL 12-32 Male proband with a 
maternal 16[11.2 
duplication 
LBL 12-33 Father of 12-3; Not 
affected 
LBL 12-56 Mother of 12-32 with a 
16p11.2 duplication 
LBL 12-14 Female proband with a 
de novo 16p11.2 deletion 
and a maternal 4q 
duplication 
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Figure 5.4 - Characterisation of 16p11.2 deleted and duplicated patient-derived cell lines by 
western blotting for TAOK2 protein expression, del; 16p11.2 deletion, dup; 16p11.2 duplication.  
(a) Expression of TAOK2 was increased/decreased consistent with deletion or duplication of the 
16p11.2 region. 75µg of urea-based whole cell extracts for WT, 06-32 (16p11.2 duplication) and 
12-14 (16p11.2 deletion) cell lines were subjected to SDS-PAGE and immunoblotted for TAOK2 
protein expression. The blot was reprobed for α-tubulin expression as a loading control.  
(b) Expression of TAOK2 was decreased consistent with deletion of 16p11.2 region. 75µg of urea-
based whole cell extracts for WT and 09-22 (16p11.2 deletion) cell lines were subjected to SDS-
PAGE and immunoblotted for TAOK2 protein expression. The blot was reprobed for MCM2 
expression as a loading control. (c) Representative histogram showing the fold change in TAOK2 
protein expression levels in three 16p11.2 CNV patient-derived cell lines relative to WT controls as 
measured by Image J. Data represents the mean of 3 independent measures ± SD. Arb units; 
Arbitrary units, Image J.  
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  dup        del 
TAOK2 
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Figure 5.5 – Characterisation of 16p11.2 deleted and duplicated patient-derived cell lines by 
western blotting for ERK1 (MAPK3) and phospho-ERK1 (pMAPK) protein expression, del; 16p11.2 
deletion, dup; 16p11.2 duplication. (a) Expression of ERK1 was increased/decreased consistent 
with deletion or duplication of the 16p11.2 region. 50µg of urea-based whole cell extracts for WT, 
06-32 (16p11.2 duplication) and 09-22 (16p11.2 deletion) were subjected to SDS-PAGE and 
immunoblotted for ERK1/2 protein expression levels, the top band corresponds to ERK1/MAPK3. 
The blot was reprobed for α-tubulin expression as a loading control. (b) Expression of pERK1 was 
increased/decreased consistent with deletion or duplication of the 16p11.2 region. 50µg of urea-
based whole cell extracts for WT, 06-32 (16p11.2 duplication) and 09-22 (16p11.2 deletion) were 
subjected to SDS-PAGE and immunoblotted for pERK1/2 protein expression levels, the top band 
corresponds to pERK1/pMAPK3. The blot was reprobed for α-tubulin expression as a loading 
control. 
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5.2.2: KCTD13 copy number change does not segregate with head 
size in 16p11.2 patient-derived cells 
KCTD13 is encoded by the KCTD13 gene residing within the 16p11.2 region. Copy 
number change of this gene has recently been implicated as potentially causative 
of the mirroring head size phenotypes of 16p11.2 deletion/duplication patients. As 
discussed in section 5.1.3, KCTD13 encodes the polymerase delta-interacting 
protein 1 (PDIP1) which also interacts with PCNA, a protein involved in DNA 
replication (He et al, 2001). This suggests that KCTD13 may play a role in DNA 
replication and has subsequently led researchers to speculate that that copy 
number change  of KCTD13 may impact upon neurogenesis (Golzio et al, 2012). 
Employing LBLs from patients with a 16p11.2 deletion/duplication, I set out to 
interrogate the impact of copy number variation of 16p11.2 on the protein 
expression of KCTD13.  
Consistent with a decrease in copy number of the 16p11.2 region, KCTD13 protein 
expression levels were reduced in 16p11.2 deletion patient-derived LBLs. In 
contrast, increased copy number of the 16p11.2 region unexpectedly did not result 
in increased KCTD13 protein expression in patient-derived LBLs harbouring the 
16p11.2 duplication (Figure 5.6). I used two different commercially available anti-
KCTD13 antibodies yet failed to detect significant over-expression. Although 
increased copy number is generally assumed to increase protein expression, the 
data presented here suggests that the KCTD13 protein does not behave solely as 
predicted by copy number. Furthermore, this data is inconsistent with the work of 
Golzio and colleagues and indicates that KCTD13 copy number change does not 
segregate with the  micro/macrocephaly observed in 16p11.2 duplication patients 
(Golzio et al, 2012). 
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Figure 5.6 – KCTD13 protein expression is reduced consistent with 16p11.2 deletion but remains 
unaffected by 16p11.2 duplication in patient-derived LBLs, del; 16p11.2 deletion, dup; 16p11.2 
duplication.  (a) 50µg of urea-based whole cell extract for WT, 12-14 (16p11.2 deletion) and 12-56 
(16p11.2 duplication) were subjected to SDS-PAGE and immunoblotted for KCTD13 protein 
expression using two different antibodies. LBLs from a patient harbouring a 16p11.2 deletion (12-
14) displayed reduced KCTD13 protein expression levels consistent with the hemizygous deletion. 
However, LBLs from a patient harbouring 16p11.2 duplication (12-56) exhibit no increase in 
KCTD13 protein expression levels. (b) 50µg of urea-based whole cell extract for WT and 06-32 
(16p11.2 duplication) were subjected to SDS-PAGE and immunoblotted for KCTD13 protein 
expression. LBLs from this patient exhibited no increase in KCTD13 protein expression levels, 
similar to the findings observed in the 12-56 duplication line displayed in (a) lanes 7-9. 
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5.2.3: 16p11.2 CNV LBLs display normal S-phase progression 
Patients with 16p11.2 duplications present with relative or absolute microcephaly 
whereas those with 16p11.2 deletions present with macrocephaly. As discussed 
previously in section 5.1.3, impaired DNA replication has recently been postulated 
as a mechanism underlying the microcephalic phenotype and vice versa for 
macrocephaly. The 16p11.2 region contains many genes which encode proteins 
with known roles in DNA replication such as BOLA2, KIF22, PPP4C, INO80 and 
KCTD13. This suggests that copy number change of these genes may impact upon 
DNA replication and potentially underlie the head size phenotypes of 16p11.2 CNV 
patients.  
To determine whether delayed S-phase progression was a feature of 
unmanipulated, asynchronously growing 16p11.2 CNV patient-derived LBLs, I 
employed a bromodeoxyuridine (BrdU) pulse-chase approach in the presence of a 
colcemid trap. The colcemid trap ensures that these cells do not proceed past G2-
M. BrdU is incorporated into newly synthesised DNA strands of actively 
proliferating cells. Following partial denaturation of the dsDNA, BrdU is detected 
immunochemically allowing the assessment of the population of cells, which are 
actively synthesising DNA.  Progression through S-phase is indicated by movement 
of the BrdU-labelled population towards a 4N DNA content using two-dimensional 
flow cytometry. To monitor the speed of S-phase progression, I quantified the rate 
of loss of early S-phase cells (2N content, shown in red in Figure 5.7). Interestingly, 
both the 12-32 duplication line and 12-14 deletion line exhibited a modest delay in 
S-phase progression at 2 hours compared to WT; 80-90% of early S-phase cells 
remained compared with only 50% in WT controls (Figure 5.8). However, this 
difference was negligible at 6 hours indicating that all 16p11.2 CNV lines were 
efficient in progressing through S-phase and thus the significance of the observed 2 
hour delay in two of the lines is not fully understood. Collectively, this data 
indicates that delayed S-phase transition is not a marked feature of 16p11.2 
patient-derived LBLs. 
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Figure 5.7 – 16p11.2 CNV cells exhibit normal S-phase progression compared to WT controls. 
Logarithmically growing WT and 16p11.2 CNV LBLs were pulse labelled with 20µM BrdU for 30 
minutes. Colcemid was added to stop cells from cycling and BrdU incorporation was monitored 
every 2 hours for up to 6 hours. Cells were fixed in ice-cold ethanol and stored at -20°C overnight. 
Samples were prepared for FACS analysis the following day as described in the material and 
methods section. The p1 box indicates those cells with 2N DNA content (shown in red).  
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Figure 5.8 – 16p11.2 CNV (deleted and duplicated) exhibit normal S-phase progression compared 
to WT controls. Logarithmically growing WT and 16p11.2 CNV LBLs were pulse labelled with 20µM 
BrdU for 30 minutes. Colcemid was added to stop cells from cycling and BrdU incorporation was 
monitored every 2 hours for up to 6 hours. Cells were fixed in ice-cold ethanol and stored at -20°C 
overnight. Samples were prepared for FACS analysis the following day as described in the material 
and methods section. A representative histogram of the data shown in figure 5.6 is shown above; 
each bar represents the % of cells with 2N content remaining as shown in the p1 boxes depicted in 
figure 5.6 for each cell line. Data represents the mean of 3 independent experiments ± SD. The 
boxes underneath the graph indicate which cell lines represent de novo or inherited 
deletions/duplication and those lines which are derived from multiple family members.  
COL; Colcemid. 
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5.2.4: 16p11.2 CNV LBLs show altered sensitivity to replication 
arrest following HU treatment.  
Although 16p11.2 duplicated/deleted patient-derived LBLs did not display any 
impairment in endogenous S-phase progression, I established whether these cells 
were selectively sensitive to HU-induced replication stalling in S-phase. HU is an 
inhibitor of ribonucleotide reductase (RR), responsible for the reduction of 
ribonucleotides to deoxyribonucleotides, and increasing the pools of dNTPs during 
the G1 and S phases of the cell cycle necessary for normal DNA replication. Upon 
treatment with HU, the cells limited supply of dNTP rapidly decreases, leading to 
stalled replication forks, often associated with some degree of DNA breaks.  
WT and 16p11.2 CNV patient-derived LBLs were exposed to a low dose of HU and 
the replication rate was assessed by analysing the number of BrdU-incorporating 
cells by flow cytometry. HU treatments resulted in arrest of DNA replication in 
both WT and all five 16p11.2 CNV LBLs; however the rate of replication arrest 
exhibited subtle differences. Under these conditions, treatment with HU resulted in 
a less marked inhibition of DNA replication at 2 hours in two of the 16p11.2 CNV 
lines; 12-14 (deletion) and 06-32 (duplication) compared with wild-type controls 
and three other 16p11.2 CNV patient-derived cell lines (Figures 5.9 and 5.10). 
However, this difference was negligible at 6 hours post-treatment and resumption 
of the induced replication arrest appeared similar between WT and four of the 
16p11.2 CNV patient-derived cell lines. Interestingly, the 12-32 16p11.2 duplicated 
line appeared to be extremely sensitive to replication arrest induced by HU 
treatment and failed to resume DNA replication efficiency following a 6 hour 
treatment with HU (Figures 5.9 and 5.10). The basis of this dramatic effect 
uncovered here is unclear, specifically since this was in contrast to the other two 
duplication lines; 06-32 and 12-56 suggesting that it is not a consistent feature 
associated with duplication of the 16p11.2 region. This may be consistent with an 
additional, as yet, unidentified genomic alteration contributing to this distinct 
cellular phenotype. 
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Figure 5.9 – 16p11.2 CNV syndrome patient-derived LBLs show differing sensitivities to 
replication arrest following treatment with a low dose of HU. LBLs from wild-type (WT) and 
16p11.2 deletion/duplication syndrome were treated with 250µM HU and pulse labelled with BrdU 
30 minutes prior to the end of each time point. Cells were then fixed in ice-cold ethanol and left 
overnight at -20°C. Cells were prepared for FACS analysis as stated in the materials and methods.  
Representative flow cytometry profiles are shown above with BrdU labelled cells shown in green 
(P2 box). Under these conditions, treatment with HU results in a greater inhibition of DNA 
replication at each time points in the 12-32 16p11.2 duplicated line compared to WT controls 
indicating the inability of this line to recover from these replication stalling condition.  
HU, hydroxyurea; P2 box indicates cells which are BrdU positive.  
 
HU 
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Figure 5.10 – 16p11.2 CNV syndrome patient-derived LBLs show differing sensitivities to 
replication arrest following treatment with a low dose of HU. Representative histogram of Figure 
5.8 indicating the % of BrdU positive cells (events within the p2 gate shown in Figure 5.8) following 
a 0-6 hour treatment with HU. LBLs from wild-type (WT) and 16p11.2 deletion/duplication 
syndrome were treated with 250µM HU and pulse labelled with BrdU 30 minutes prior to the end 
of each time point. Samples were fixed in ice-cold ethanol, left overnight at -20°C and then prepared 
for FACS analysis the following day, as stated in materials and methods. A representative histogram 
of the data shown in figure 5.8 is shown above; each bar represents the % of BrdU positive cells as 
shown in the p2 boxes of figure 5.8 for each cell line. Data represents the mean of 3 independent 
experiments ± SD. The boxes underneath the graph indicate which cell lines represent de novo or 
inherited deletions/duplication and those lines which are derived from multiple family members. 
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5.2.5: 16p11.2 CNV LBLs exhibit normal DNA damage response 
activity 
There are various endogenous and environmental insults which cause DNA 
damage including ROS, stalled replication forks, UV and ionising radiation (IR). The 
DNA damage response (DDR) represents a signal transduction network integrating 
multiple pathways including checkpoint activation, transcriptional regulation, DNA 
repair pathways and apoptosis to protect the cell from damage. The DDR is 
primarily mediated by proteins of the PIKKs family; ATM (Ataxia-Telangiectasia 
Mutated) and ATR (ATM and Rad3-related) (Jackson & Bartek, 2009). Although, 
ATM and ATR appear to phosphorylate many of the same targets, they are 
generally activated in response to distinct types of DNA damage; ATM is the 
primary mediator in the response to DSBs whereas ATR is activated following 
recruitment to RPA-coated ssDNA regions generated at stalled replication forks 
and DSBs (Shiotani & Zou, 2009).  
In the canonical DDR pathway, DNA lesions are recognised by multiprotein 
“sensor” complexes which function to activate ATM/ATR. Once activated, 
ATM/ATR phosphorylates a large number of target substrate proteins in order to 
regulate various downstream pathways including DNA repair, checkpoint 
activation, and cell death. Activation of the DNA damage checkpoint is mediated by 
two checkpoint kinases; Chk1 and Chk2 (Smith et al, 2010). These kinases are 
phosphorylated and activated by ATR and ATM respectively and in turn 
phosphorylate important regulators such as Cdc25 and p53 to control cell cycle 
progression at the G1-S, intra-S and G2-M cell cycle checkpoints. The cell cycle is 
driven by the activities of the cyclin-dependent kinases (Cdk) which control the 
transitions from G1 into S phase and G2 into M phase. The phosphatase Cdc25 
functions as an essential activator of Cdk’s by dephosphorylating them at 
inhibitory sites. Therefore, phosphorylation of Cdc25 following DNA damage 
inactivates Cdk-cyclin complexes which acts to slow down or arrest cell-cycle 
progression allowing more time for DNA repair before mitosis proceeds (Mailand 
et al, 2000). Along with their pivotal roles in cell cycle checkpoints, Chk1 and Chk2 
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are also involved in other aspects of the DDR including DNA repair, induction of 
apoptosis and chromatin modelling.   
Cellular stressors such as osmotic stress induce cell cycle arrest via activation of 
p38 MAP kinase (MAPK). Furthermore, p38 also regulates cell-cycle checkpoints in 
response to DNA damage through its ability to activate MAPKAP Kinase-2 (MK2) 
which functions to phosphorylate and inactivate cdc25 phosphatases, preventing 
cell cycle progression (Chen et al, 2003; Manke et al, 2005). Thousand and one 
amino acid (TAO) kinases are serine/threonine protein kinases known to regulate 
p38 via their ability to phosphorylate and activate the MAPK kinases, MEK3 and 6 
(Chen et al, 2003).  Moreover, TAO kinases have also been shown to act as 
important regulators of the response to genotoxic stress. Raman and co -workers 
reported that TAO kinases are activated acutely by ionizing radiation, ultraviolet 
radiation and hydroxyurea (Raman et al, 2007). Furthermore, their findings 
revealed that TAOs are a primary component linking the DNA damage response 
induced by genotoxic insults through ATM/ATR to p38. Damage-induced p38 
activation was blocked by catalytically deficient TAOs or TAO siRNA (Raman et al, 
2007). Furthermore, siRNA-mediated knockdown of TAOs impaired the DNA 
damage activated G2-M cell cycle checkpoint indicating that TAO kinases are 
required for activation of p38 and the G2-M checkpoint upon DNA damage. Figure 
5.11 depicts the model proposed by Raman et al to explain the function of TAO 
kinases in the DDR.  
As previously mentioned, microcephaly is a common feature of many DDR-
defective disorders suggesting a fundamental role for the DDR in neuronal 
development (Table 5.2). Interestingly, one of the genes residing within the 
affected 16p11.2 region encodes the TAO kinase 2 (TAOK2) protein. Therefore, in 
light of the strong evidence presented by Raman et al indicating a fundamental role 
for TAO kinases in the response to DNA damage, I sought to investigate the impact 
of 16p11.2 deletion/duplication on the DDR. I have already described in section 
5.2.1 that CNV of 16p11.2 does impact upon TAOK2 expression (Fig 5.4) To 
determine whether CNV of the 16p11.2 region impacted upon the ATR/ATM-
dependent DDR, I examined UV- and IR-induced G2-M checkpoint arrest in patient-
derived LBLs. The response to UV is specifically dependent on ATR whereas the 
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response to DSBs induced by IR is dependent on ATM. 16p11.2 deletion and 
duplication LBLs (LBL 09-22 and LBL 06-32) arrested as efficiently as control cells, 
evident by a decreased mitotic index under both conditions (Fig 5.12a). ATR-
Seckel LBLs were used as a control for this experiment and, as expected, exhibited 
defective UV-induced G2/M checkpoint arrest (Fig 5.12a).  This data indicates that 
copy number variation of the 16p11.2 region does not impact upon ATR/ATM-
dependent G2/M checkpoint activation. I also investigated the impact of 16p11.2 
CNV on the ATR-dependent phosphorylation of Chk1 in response to HU-induced 
replication stress.  WT and 16p11.2 CNV (LBL 12-32, LBL 12-33 and LBL 12-14) 
patient-derived cell lines were treated with 500µM hydroxyurea (HU) for 2 hours. 
50µg of urea-based whole cell extracts were then subjected to SDS-PAGE and 
immunoblotted for phospho-Chk1 protein expression levels. Chk1 phosphorylation 
was observed in all treated cell lines suggesting that 16p11.2 CNV (deletion and 
duplication) were not impaired in ATR-dependent Chk1 phosphorylation (Fig 
5.12b). Interestingly, Chk1 phosphorylation did appear to be subtly reduced  in the 
16p11.2 duplicated cell line (LBL 12-32) compared with control cells and two 
other 16p11.2 CNV lines, however the physiological significance of this is not clear 
(Fig 5.12b lanes 3 and 4). 
 
5.2.6: Summary 
Here, I have shown that the expression of two proteins (TAOK2 and MAPK3) 
encoded by genes residing in the 16p11.2 region are increased/decreased 
consistent with deletion or duplication in patient-derived LBLs. Interestingly, the 
protein expression of KCTD13, also encoded by a gene within the 16p11.2 region, 
is reduced in patient-derived LBLs harbouring a hemizygous 16p11.2 deletion but 
its expression remains unaltered in those harbouring 16p11.2 duplications. All 
16p11.2 CNV patient-derived cell lines are efficient in progressing through S-
phase, however one 16p11.2 duplicated cell line (LBL 12-32) exhibits sensitivity to 
HU-induced replication stress in S-phase, the relevance of which remains unclear. I 
also present evidence to indicate that activation of the DDR appears to be normal 
in 16p11.2 patient derived-cell lines (deletion and duplication). 
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Figure 5.11 – TAO kinases are required for activation of p38 and the G2M checkpoint in response to 
DNA damage, as proposed by Raman et al, 2007. In the canonical ATR/ATM-dependent model of 
G2M checkpoint activation (left hand pathway), DNA damage is sensed by mutiprotein sensor 
complexes which lead to activation of ATM/ATR. ATM functions primarily in response to DSBs 
whereas ATR is activated  in response to single stranded DNA.  Once activated, ATM/ATR relay two 
parallel cascades that ultimately serve to inactivate Cyclin B-cdc2 complexes. The first cascade 
shown on the left involves the phosphorylation and inactivation of Cdc25 by Chk1/2 which 
prevents the activation of cdc2 (also termed cdk1). The slower second parallel pathway shown on 
the right involves the binding of 14-3-3 to the phosphorylated Cyclin B-cdc2 complex resulting in 
its export from the nucleus. This occurs through activation of a p53-dependent pathway (not 
shown). In the TAO kinase-dependent pathway of G2M checkpoint activation postulated by Raman 
et al,  ATM/ATR activate TAO kinases 1-3 which lead to the phosphorylation and activation of 
MEK3/6 (shown in the middle). Through a downstream cascade involving p38 and MK2, Cdc25C is 
inactivated leading to persistent phosphorylation of the Cyclin B-cdc2 complex and thus prevents 
cell cycle progression. ATM, Ataxia-Telangectasia Mutated; ATR, Ataxia Telangectasia and Rad 3-
related; Chk1/2, Checkpoint kinase 1/2; TAO1-3, Thousand and one amino acid kinase 1-3; 
MEK3/6, Mitogen-activated protein kinase kinase 3/6; p38, p38 mitogen-activated protein kinases; 
MK2, MAPK-activated protein kinase 2; Cdc25, M-phase inducer phosphatase 3; Cdc2, cyclin-
dependent kinase-1. 
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Figure 5.12 – G2M checkpoint arrest is activated in response to UV and IR-induced damage in 
16p11.2 CNV LBLs (del; 16p11.2 deletion, dup; 16p11.2 duplication). (a) Wild type (WT), 16p11.2 
CNV and ATR-Seckel (ATR-S) cells were untreated, irradiated with 7 J m-2 UV (UV) or treated with 3 
gray IR (IR), incubated for 4 hours in the presence of 0.2µg/ml colcemid and the percentage of 
mitotic cells counted using the E400 microscope, 100X lens. The results shown represent the mean 
±SD of three independent experiments. LBL 06-32; 16p11.2 duplication, LBL 09-22; 16p11.2 
deletion, ATR-S; ATR-Seckel LBLs.  Work was carried out in associated with Gillian Carpenter. (b) 
Chk1 phosphorylation in response to HU-induced DNA damage is normal in 16p11.2 CNV patient-
derived LBLs. WT and 16p11.2 CNV LBLs were treated with 500µM HU for 2 hours. 50µg urea-
based whole cell extracts were then subjected to SDS-PAGE and immunoblotted for pChk1 protein 
expression. The blot was reprobed for MCM2 protein expression as a loading control. LBL 12-32 
dup; 16p11.2 duplication, LBL 12-33 control; unaffected father of 12-32, LBL 12-14 del; 16p11.2 
deletion.  
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5.3: Discussion 
 
16p11.2 CNV genomic disorder is associated with a range of neurocognitive 
deficits including autism, epilepsy and schizophrenia. Intensive phenotypic 
analyses of patients with 16p11.2 deletions or duplications has revealed 
incomplete penetrance and variable expressivity of clinical features in patients 
(Shinawi et al, 2010). However, these analyses have also uncovered strong 
mirroring phenotypes; the 16p11.2 deletion is associated with macrocephaly 
whereas the reciprocal duplication is associated with microcephaly.  
One gene residing within the 16p11.2 region is KCTD13, which has been reported 
to interact with PCNA and Pol   (He et al, 2001). This interaction suggests that 
KCTD13 may play a role in the regulation of DNA replication, defects within which 
has been shown to impact upon neurogenesis (Kerzendorfer et al, 2013). 
Consistent with this, Golzio and colleagues recently provided evidence to suggest 
that KCTD13 copy number change is causative of the mirroring head size 
phenotypes of 16p11.2 CNV patients through the regulation of early neurogenesis 
(Golzio et al, 2012). I examined the impact of 16p11.2 CNV on the protein 
expression of three genes; TAO2K, MAPK3 and KCTD13 and revealed unexpected 
results. The protein expression levels of two genes, TAOK2 and MAPK3, 
corresponded with the copy number change; protein expression was increased in 
cell lines from duplication patients and decreased in cells from those patients  
harbouring a 16p11.2 deletions. However, expression of KCTD13 did not change 
according to copy number of the KCTD13 gene whereby expression remained 
unchanged in cell lines from patients with a 16p11.2 duplication. It is possible that 
this inconsistency may have arisen due to non-specificity of the KCTD13 antibodies 
or alternatively, it may reflect the limitations of using patient-derived 
lymphoblastoid cell lines. 
Impaired DNA replication is a fundamental mechanism frequently reported to 
underlie microcephaly (Kerzendorfer et al, 2013). Many of the genes within the 
16p11.2 region encode proteins whose products contribute to both DNA 
replication and repair. These include; BOLA2, KIF22, PPP4C and KCTD13. 
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Therefore, it is conceivable to suggest that copy number change of these genes may 
impact on replication/repair and potentially contribute to the 
macro/microcephalic phenotypes of 16p11.2 deletion/duplication patients 
respectively. However, I have observed generally normal rates of S-phase transit in 
16p11.2 CNV LBLs compared to WT controls. Furthermore, four of the five 16p11.2 
CNV cell lines do not exhibit increased sensitivity to HU-induced replication arrest. 
This is similar to what has been observed in ORC1-mutated Meier-Gorlin 
Syndrome (Kerzendorfer et al, 2013). These findings indicate that copy number 
variation of the 16p11.2 region is not associated with a generalized aberrant DNA 
replication, at least as detectable using patient-derived LBLs. Moreover, the 
microcephaly seen in 16p duplication patients is therefore not a consequence of 
impaired DNA replication. It is interesting to note that one of the 16p11.2 
duplicated cell lines (12-32) did show increased sensitivity to HU-induced 
replication stress; however this was in contrast to two other 16p11.2 duplicated 
lines suggesting that it is not a consistent feature associated with 16p11.2 
duplication. The basis of this observation is unclear but may suggest that this 
patient in particular may harbour additional genomic alterations including 
mutations which may underlie this specific cellular phenotype and highlights the 
need for further molecular analysis to clarify this. High density whole genome 
aCGH combined with whole exome sequencing is actively being pursued in this 
instance. For example, the CNV could have additional consequences of recessive 
variant expression (Chapter 1 section 1.3.1 and Fig 1.3). 
Defects in the DDR pathway have also frequently been reported as a mechanism 
underlying microcephaly in certain genomic disorders such as LIG4 and XLF -
mutated SCID. Here, the genomic defect manifests as a functional defect in the 
DDR. Interestingly, microcephaly is observed in patients with a 16p11.2 
duplication which is suggestive of a potential dominant negative effect. The 
16p11.2 region harbours genes whose products contribute to DNA repair including 
the TAO2K gene. TAO2K has been shown to be involved in the DDR through the 
p38 MAPK pathway and thus a change in copy number of this gene may be 
predicted to impact upon the DDR. I observed normal G2/M checkpoint arrest in 
16p11.2 CNV LBLs compared to WT controls indicating that activation of both the 
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ATM- and ATR-dependent DDR is normal. Furthermore, ATR-dependent DNA 
damage signalling appeared normal in 16p11.2 CNV LBLs compared to WT 
controls; as shown by an increase in Chk1 phosphorylation in response to HU 
treatment.  Collectively, this data indicates that neither impaired replication nor 
defective DDR signalling are overtly consistent features associated with 16p11.2 
CNV. 
In summary, the data I have presented here is in contrast to the report by Golzio et 
al derived from zebrafish models suggesting that KCTD13 copy number is the 
major determinant of head size in 16p11.2 CNV patients. Here, I have found that 
KCTD13 protein expression does not segregate with the micro/macrocephaly 
phenotype of 16p11.2 CNVs indicating that increased or decreased dosage of this 
gene is not the sole cause of the opposing head size phenotypes, as had been 
previously suggested. Additionally, cells from patients with a 16p11.2 deletion or 
reciprocal duplication do not exhibit a functional cell cycle or DNA repair defect 
that I can attribute to genes within the CNV region. This indicates that defective 
DNA replication and/or repair does not underlie the opposing head size 
phenotypes observed in these patients. It is conceivable to speculate that the 
consequences of 16p11.2 CNV are fixed during embryogenesis and thus are not 
observed postnatally; a process termed ‘intrauterine programming’ (Murga et al, 
2009).  If this is the case, it poses the question as to whether LBLs are an 
appropriate model for studying the functional consequences of 16p11.2 CNV, 
specifically KCTD13 copy number change. To address this issue, future work 
should be centred upon investigating the functional consequences of KCTD13 
overexpression alone upon cell replication via ectopic/regulated over -expression 
systems, particularly in a mammalian neuronal cell model such as N2A or SH-5Y5Y 
cells. Mutations in genes encoding chromatin remodelling proteins have b een also 
implicated in the pathogenesis of microcephaly (Kerzendorfer et al, 2013). 
Interestingly, the 16p11.2 region harbours the INO80E gene which encodes a 
subunit of the INO80 chromatin modelling complex.  It would be very interesting 
to investigate the functional consequences of INO80E copy number change in the 
context of micro/macrocephaly. Crucially, this data indicates that much more 
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intensive investigation is essential to fully understand the functional consequences 
of 16p11.2 CNV and their relevance to micro/macrocephaly. 
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Chapter Six 
Genotype to Phenotype relationships in Wolf 
Hirchhorn Syndrome (WHS): a novel impact of 
CNV of LETM1 
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6.1: Introduction 
 
Wolf Hirschhorn Syndrome (WHS) (OMIM 194190) was first identified 
independently by Wolf et al and by Hirschhorn et al in 1965. (Hirschhorn et al, 
1965; Wolf et al, 1965). WHS is caused by a small hemizygous sub-telomeric 
deletion of the short arm of chromosome 4 typically involving two critical regions  
(Figures 6.1 – 6.3). The first described WHS patients had large 4p deletions all 
associated with a severe phenotype, however an increasing number of smaller 
4p16.3 deletions have been identified in recent years due to advances in 
techniques for molecular karyotyping.  
WHS occurs in approximately one in 50,000 births and WHS patients can be 
categorized as ‘typical’ or ‘atypical’ according to the clinical features and deletion 
size they present with (Battaglia et al, 2008). Typical (also termed “classical) WHS 
patients exhibit growth delay, craniofacial dysmorphism, microcephaly, 
developmental delay, epilepsy and heart defects. The craniofacial features of 
typical WHS were originally referred to as ‘Greek helmet face’; a combination of 
microcephaly, prominent glabella, broad forehead, hypertelorism, broad nasal 
bridge, short philtrum, micrognathia and down-turned corners of the mouth. Cleft 
lip/palate is occasionally present, as is coloboma of the eye (Battaglia et al, 2008). 
Typical WHS patients have deletions encompassing many genes within the two 
defined critical regions and deletions measure on average 5-18Mb. In contrast, 
atypical WHS patients usually harbor smaller deletions not exceeding 3.5Mb, some 
of which lie outside of the critical regions. Atypical WHS patients present with 
milder clinical features, however major malformations are uncommon and patients 
do not usually present with seizures (Fig 6.1d). 
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Figure 6.1: Wolf Hirschhorn Syndrome. (a) Chromosome 4 pair indicating location (red line) of the 
subtelomeric deletions causative of WHS. (b) Pictures of the first WHS patients identified by Wolf 
(1965) (left two panels) and Hirschhorn (1965) (right two panels). (c) Typical WHS patient with a 
3.85Mb deletion identified by Maas et al (2008). (d) Atypical WHS patient identified by Engbers et 
al (2007) whose 1.6Mb deletion lies outside the demarcated critical regions. The patient presents 
with mild-WHS like facial features such as down-turned corners of the mouth. tel; telomere, cen; 
centromere. 
 
 
 
Tel Cen Tel 
(a) 
(b) 
(c) (d) 
     4p16 HSA 4   
     4p16 HSA 4   
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6.1.1: The WHS critical regions 
WHS is a contiguous gene deletion disorder as it arises from the deletion of 
multiple genes located adjacent to one another on the same chromosome (See 
table 6.1 and Fig 5.2). A minimal region of overlap between WHS-like patients led 
to the demarcation of the ‘Wolf-Hirschhorn Critical Region 1’ (WHSCR-1). This 
region is limited to a 165kb interval ~2 Mb from the telomere defined by the loci 
D4S166 and D4S3327 (Wright et al, 1997). The WHSCR-1 encompasses the WHSC2 
gene and the 3’ portion of the WHSC1 gene (Figure 6.3 green section). However, 
reports of patients harboring deletions distal to the WHSCR1 presenting with a 
‘typical’ WHS facial appearance led to the demarcation of a second critical region 
termed ‘WHSCR-2’ (Zollino et al, 2003). This re-defined critical region  lies within 
an interval of 300-600kb between loci DS43327 and D4S98-D4S168 (Zollino et al, 
2003). This region includes LETM1, the 5’ portion of the WHSC1 gene but does not 
involve WHSC2 (Fig 6.3 pink section). The identification of these two critical 
regions in WHS has strongly implicated the haploinsufficiency of WHSC1 as a key 
contributor to core WHS-phenotypes. 
 
6.1.1.1: WHSC1 
The WHSC1 gene, also known as NSD2 (Nuclear receptor SET domain containing) 
or  MMSET (multiple myeloma SET domain containing) encodes a 136kDa protein 
that is ubiquitously expressed in early development and contains four domains; a 
PWWP domain, a HMG box, a SET domain and a PHD-type zinc finger (Stec et al, 
1998). Recently, WHSC1 was identified as a putative histone methyltransferase 
involved in the trimethylation of histone 3 lysine 36 (H3K36) (Kim et al, 2008a; 
Marango et al, 2008). WHSC1 is also reported to be involved in the response to 
DNA damage through its activity on the H4K20 residue (Hajdu et al, 2011; Pei et al, 
2011). In addition to WHS, WHSC1 has been identified as a gene involved in the t 
(4:14) (p16:q32) translocation present in approximately 15-50% of multiple 
myelomas (Chesi et al, 1998; Keats et al, 2005; Kim et al, 2008a; Marango et al, 
2008). WHSC1 has also been implicated in gliobastoma, neuroblastoma and 
urinary bladder and prostate cancers (Ezponda et al, 2012; Hudlebusch et al, 2011; 
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Li et al, 2008). Many WHS patients harbour deletions encompassing the WHSC1 
gene and its expression pattern, especially in the tissues affected in WHS, suggests 
that it is a prime candidate causing WHS phenotypes. However, other genes aside 
from WHSC1 have been suggested as causative of specific features such as growth 
retardation and microcephaly (Maas et al, 2008; South et al, 2008). 
 
6.1.1.2: WHSC2 
The WHSC2 gene, also known as NELF-A, encodes a component of the Negative 
ELongation Factor complex (Narita et al, 2007; Yung et al, 2009). The NELF is a 
four subunit protein complex which plays an important role in suppressing 
transcription elongation through promoter-proximal pausing of RNA Polymerase II 
during early stages of transcription. It has also been reported to play a role in the 
3’-end processing of histone mRNAs and furthermore, siRNA knockdown of 
subunits of the NELF result in decreased overall transcription of histone genes 
(Sun & Li, 2010; Yung et al, 2009). SLBP, located telomeric to WHSC2 is required 
for optimal histone biogenesis. Replication-dependent histone mRNAs terminate in 
a conserved stem-loop structure. SLBP is essential for the correct processing of 
these stem-loop-containing pre-mRNAs and therefore regulates the amount of 
histone synthesis during S-phase. Recently WHSC2 was found to be required for 
optimal recruitment of SLBP to the 3’ end of histone pre-mRNA. Furthermore, 
recent work in the O’Driscoll lab reports novel cellular defects associated with 
WHS, including delayed S-phase progression, reduced DNA synthesis and impaired 
histone deposition (Kerzendorfer et al, 2012). They provide evidence that the most 
likely underlying defect is haploinsufficiency of SLBP and/or NELF-A thus 
providing insight into the functional consequences of haploinsufficiency of specific 
genes on 4p16.3 associated with WHS (Kerzendorfer et al, 2012). 
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Figure 6.3 – A highly simplified representation of the two WHS critical regions and the genes 
encompassed by each (relative positioning is shown for simplification). The 165kb WHSCR1 lies 
~2Mb from the telomere encompassing all of WHSC2 and the 3’ portion of WHSC1 (green). The 300-
600kb WHSCR2 encompasses the 5’ portion of WHSC1 and all of LETM1 but specifically not WHSC2 
(pink). Tel: telomere, Cen: centromere. 
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6.1.1.3: Other genes within 4p16.3 contribute to key WHS features 
Although the identification of the two critical regions strongly suggested that 
haploinsufficiency of the WHSC1 gene is crucial for key WHS phenotypes, 
accumulating evidence indicates that haploinsufficiency of genes aside from 
WHSC1 contribute to some of the core features such as microcephaly, 
characteristic facial appearance and growth retardation. Rauch et al reported one 
unique patient with a micro deletion of the entire WHSCR but minimal adjoining 
sequences, who presented with a mild WHS-like phenotype (Rauch et al, 2001). 
The male patient had mild MR and his facial characteristics were subtle suggesting 
that genes outside of this critical region contribute to some of the key WHS clinical 
features (Figure 6.5b). Furthermore, reports of a number of atypical patients 
whose deletions lie outside of both critical regions presenting with mild WHS-like 
features, again indicate that full-blown WHS is unlikely due to haploinsufficiency of 
the WHSCR alone (Engbers et al, 2008; South et al, 2007). 
 
6.1.2: Animal models of WHS 
Various mouse models carrying deletions of genes within the WHSCRs have been 
established which display phenotypes that are consistent with those of WHS 
patients. However, each model fails to recapitulate all aspects of the human 
phentoype and therefore the specific genes contributing to each phenotype still 
remain somewhat ill-defined. The region of the mouse genome that is orthologous 
to the human 4p16.3 is 5B1. Mouse models have been generated for 6 of the genes 
within the WHSCRs; Fgfr3, Tacc3, Fam53A, Sax2, Maea and Ctbp, four of which are 
discussed in further detail below (also shown in Table 6.1). 
 
6.1.2.1: Fgfr3 
Fibroblast growth factor receptor 3 is a tyrosine kinase receptor expressed in  the 
developing bone, cochlea and spinal cord. Mice homozygous for conditional null 
mutations in Fgfr3 exhibit severe kyphosis and long curved femurs. Subsequently 
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it was found that these phenotypes were secondary to bone dysplasia and 
prolonged endochondral bone growth (Colvin et al, 1996; Deng et al, 1996). Fgfr3-
/- mice also display inner ear changes leading to profound deafness (Puligilla et al, 
2007). In addition, fgfr3 has been shown to play important roles in neurological 
development and thus these studies indicate the hemizygosity of the human FGFR3 
gene may contirubute to skeletal and neurological aspects of WHS (Saarimaki-Vire 
et al, 2007). Furthermore, a small proportion of WHS patients exhibit 
sensorineural hearing loss and therefore mouse studies suggest that FGFR3 may 
contribute to this characteristic (Battaglia and Carey, 1999).  
 
6.1.2.2: Tacc3 and Hspx153 
Mouse models for the human TACC3 and HSPX153 genes both exhibit growth 
retardation. The Tacc3 protein has established roles in mitosis and transcriptional 
regulation and mice homozygous for null mutations of  Tacc3 are embryonically 
lethal (Piekorz et al, 2002). Furthermore, mice homozygous for a hypermorphic 
allele die immediately after birth showing signs of intrauterine growth retardation 
and skeletal abnormalities (Yao et al, 2007). In the case of HSPX153, which encodes 
a homeobox transcription factor of the Nxk1 family, mouse models (Sax2 null) 
exhibit growth retardation post birth and subsequently die within 3 weeks (Simon 
& Lufkin, 2003). This is in contrast to the GR exhibited by WHS as the GR in mouse 
models is only evident post birth. Studies have further suggested that Sax2 is 
required for the maintenance of energy homeostasis and that the GR exhibited in 
these null mice is a consequence of energy homeostasis imbalance, something 
which has not been reported for the GR of WHS patients (Simon & Lufkin, 2003; 
Simon et al, 2007).  
 
6.1.2.3: Ctbp1 
CTBP1 is a well characterized transcriptional co-repressor. Ctbp null mice exhibit 
growth retardation at birth and also show evidence of abnormal skeletogenesis 
(Hildebrand & Soriano, 2002). WHS frequently experience profound epileptic 
seizures and it is known that certain forms of epilepsy can be managed by a 
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ketogenic diet (Cross, 2013). Recent work has suggested that this management is 
achieved through stimulating Ctbp activity and subsequently repressing the 
expression of BDNF (Garriga-Canut et al, 2006). BDNF is suspected to be an 
epileptogenic signaling molecule; therefore CTBP1 hemizygosity in WHS patients 
should be considered and investigated as a potential contributor to the seizure 
phenotype of WHS. 
 
6.1.2.4: Whsc1 and Letm1 
WHSC1 has frequently been linked to the characteristic facial features associated 
with WHS. In 2009, Nimura et al generated a Whsc1 mouse model and reported 
that Whsc1-/- mice exhibited growth retardation and died within 10 days. 
Heterozygous (Whsc1-/+) mice exhibited growth retardation and some WHS-like 
midline defects similar to those seen in WHS patients indicating that 
haploinsufficiency of the WHSC1 gene contributes to some of the key features of 
WHS (Nimura et al, 2009).  
Haploinsufficiency of LETM1 has been postulated as potentially causative of the 
seizure phenotype of many WHS patients (discussed further in section 6.1.5). A  
Drosophila model of LETM1 knockdown (dmLETM1) has been reported which 
recapitulates several hallmark features of WHS; small body size and delayed 
development, reduced locomotor activity and reduced neurotransmitter release at 
synapses (McQuibban et al, 2010). Until recently, no LETM1 mouse models had 
been reported. However this year, Jiang and colleagues reported that Letm1 
deletion in mice is embryonically lethal before gastrulation (E6.5). They also 
reported that 50% of heterozygous mice, which mimic the situation in WHS 
patients, died before the day 13.5 of embryogenesis. However, those that survived 
exhibited altered glucose metabolism, impaired control of brain ATP levels and 
increased seizure activity. This data is consistent with another report published 
this year (2013) by Zhang et al, who also demonstrated an association between 
Letm1 and epileptic seizures in rats (Zhang et al, 2013). Collectively, these reports 
support a role for LETM1 haploinsufficiency in the seizure phenotype of many 
WHS patients. 
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Table 6.1 - The predicted and confirmed genes in the region 1.2-2.3Mb from the telomere of  
Chromosome 4. Also listed are mouse orthologues and predominant features of null mouse models .  
Human gene Mouse 
orthologue 
Function Null mouse 
phenotype 
MXD4 Mxd4 Transcription NR 
POLN Poln DNA repair NR 
LOC401115 - - NR 
C4orf15/ HAUS3 NR Subunit of the human augmin 
complex; a microtubule-
binding complex 
NR 
FLJ37478/NAT8L NR Neuron specific member of 
the N-acyltransferase family; 
NAA synthesis  
NR 
WHSC2/NELF-A Whsc2/Nelfa Transcription and translation NR 
SCARNA23 NR RNA modification NR 
WHSC1 Whsc1 transcription Growth retardation and 
postnatal death 
LETM1 Letm1 Mitochondrial homeostasis Seizures and altered glucose 
oxidation 
FGFR3 Fgfr3 Growth factor receptor Skeletal abnormalities 
TACC3 Tacc3 Mitosis Embryonically lethal 
TMEM129 Tmem129  Transmembrane protein NR 
SLBP Slbp Translation and RNA stability NR 
FAM53A Fam53a Transcription Embryonically lethal 
HSPX153 Sax2 transcription Post natal growth defects 
CRIPAK NR Protein kinase inhibitor NR 
NKX1-1 NR Transcription factor activity NR 
UVSSA Uvssa Transcription-coupled 
nucleotide excision repair 
NR 
MAEA maea Enucleation, mitosis Haemopoietic dysgenesis 
MGC21675/CTBP-AS1 NR  unknown NR 
CTBP1 ctbp Transcriptional repressor Growth defects, 
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6.1.3: Atypical patients highlight correlations between LETM1 
haploinsufficiency and a seizure phenotype 
The clinical spectrum and severity of WHS typically depends on deletion size, but 
clear genotype-phenotype relationships are assumed here and often not 
experimentally validated. Aside from a few examples (WHSC1/WHSC2/LETM1), 
there is a distinct lack of functional data linking the haploinsufficiency of genes 
with dysfunctional pathways that may underlie specific features associated with 
WHS. One such feature is that of the profound, intractable seizures experienced by 
WHS patients, often obvious before the age of 2 years. During infancy, these 
seizures can result in permanent disability and even death. The origin of the 
seizures is unclear yet the literature frequently links haploinsufficiency of the 
LETM1 gene (leucine zipper-EF-hand containing transmembrane protein 1) with 
the seizure phenotype of WHS. However, this is purely assumed based upon 
deletion size in patients (see examples below) and the proposed functions of 
LETM1 within the cell (Endele et al, 1999a). To date no functional evidence exists 
to substantiate the proposed relationship. 
Rauch et al described a WHS patient with one of the smallest interstitial deletions 
of 191.5kb encompassing the WHSCR1, therefore not involving LETM1 (Rauch et 
al, 2001). The male patient presented with a mild WHS-like phenotype exhibiting 
growth retardation, minor facial dysmorphism and some learning deficits. 
Interestingly, the patient experienced no seizures (Figure 6.4a-c). Furthermore, 
Engbers et al reported a female patient with a 1.69Mb deletion which did not 
encompass the LETM1 gene nor either of the WHSCR’s. This atypical female patient 
also presented with a mild-phenotype but again, specifically no seizures (Figure 
6.4b-c). Further correlations between LETM1 haploinsufficiency and seizures are 
documented by South et al. They report two unique patients, one presenting with 
profound seizures whose deletion encompasses LETM1 and one with no seizure 
phenotype whose deletion excludes the LETM1 gene (South et al, 2007). 
Collectively, these reports provide a strong correlation between LETM1 
haploinsufficiency and the seizure phenotype of WHS.  
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Figure 6.4: Atypical WHS patients refine genotype-phenotype correlations. (a) Patient reported by 
Rauch et al, 2001 with the first known microdeletion (191.5kb) within the WHS critical region. 
Patient presents with low body weight for height, speech delay, ADHD and minor facial anomalies.  
(b) 1.9 year old female patient reported by Engbers et al, 2008 with a 1.6Mb deletion of 4p16.3. 
Down-turned corners of the mouth, big eyes and short philtrum are well seen in the top two panels. 
Bottom two panels are the patient at 4.4 years from frontal and aside; big eyes and short philtrum 
can be seen. (c) Schematic and simplified representation of deletion size in the two patients shown 
in (a) and (b). Note that neither deletion encompasses the LETM1 gene. Tel; telomere, Cen; 
centromere. 
  
(a) (b) 
(c) 
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6.1.4: LETM1; a candidate gene for seizure phenotype of WHS? 
LETM1 is located <80kb distal to the WHSCR1 and is encompassed by the WHSCR2 
(Fig 6.2). It encodes an 83.5kDa putative inner mitochondrial membrane protein 
with a single transmembrane domain (Endele et al, 1999a; Nowikovsky et al, 2004; 
Schlickum et al, 2004) and Fig 6.5.  All members of the LETM1 family contain a 
hydrophobic N-terminal spanning the IMM and a large hydrophilic portion within 
the matrix. The C-terminal amino acid sequence predicts at least two coiled coil 
domains and two Ca2+ binding EF hand like motifs, the latter of which is not 
present in the yeast protein. The N-terminal region contains a mitochondria 
targeting sequence conserved in all orthologues (Nowikovsky et al, 2004; 
Schlickum et al, 2004). There are two yeast (S.cerevisiae) orthologues of LETM1; 
mdm38 and Mrs7/ylh47. Mdm38 was originally identified in a screen for mutants 
affecting mitochondrial morphology and therefore was given its named based on 
its roles in mitochondrial distribution and morphology (Dimmer et al, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: A schematic representation of selected members of the LETM1 family with the highly 
conserved transmembrane domain highlighted in light blue. ims; intermembranal space.   
IMS Matrix 
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6.1.4.1:  LETM1 and potassium-hydrogen exchange activity 
LETM1 was identified in a genome-wide unbiased RNAi screen as a Ca2+/H+ 
antiporter catalysing the 1:1 electrogenic exchange of Ca2+ for H+ (Jiang et al, 
2009a).This report was received with great interest, however subsequent studies 
have challenged it and propose that LETM1 rather functions in K+/H+ exchange 
(KHE) (Dimmer et al, 2008b; Froschauer et al, 2005a; Nowikovsky et al, 2004; 
Nowikovsky et al, 2007). Studies have suggested a role for mdm38 in potassium 
homeostasis by acting either as a K+/H+ antiporter or a regulator of its activity. 
Potassium acetate induced swelling in isolated mitochondria demonstrated that 
mdm38 is essential for KHE in yeast. Consistent with this data, mitochondria 
isolated from an mdm38 mutant lacked this activity confirming that mdm38 is an 
essential element of the mitochondrial KHE (Froschauer et al, 2005b; Nowikovsky 
et al, 2004). In addition, mdm38 depletion resulted in mitochondrial matrix 
swelling and cristae loss suggesting a role for K+ in regulating mitochondrial 
volume and morphology. This hypothesis was further supported by the finding 
that the effects of mdm38 downregulation could be restored by treatment with 
nigericin, an ionophore which catalyses electroneutral KHE (Hasegawa & van der 
Bliek, 2007; Nowikovsky et al, 2007) (Figure 6.6).  
Dimmer et al provided evidence of a role for LETM1 in the regulation of 
mitochondrial morphology in human HeLa cells. Downregulation of LETM1 
(~60%) led to altered mitochondrial morphology where mitochondria appeared 
fragmented and clustered in the perinuclear region (Dimmer et al, 2008b). 
Interestingly, nigericin was able to fully reverse these phenotypes suggesting a 
causal link between altered KHE activity and disrupted mitochondrial morphology. 
They further report that these changes did not require activation of the DRP1-
dependent fission pathway and suggest that the fragmentation caused by silencing 
of LETM1 could therefore represent a mitochondrial morphological response to 
the inhibition of ion homeostasis. In fact, disruption of K+ homeostasis would result 
in increased levels of mitochondrial K+ leading to the influx of water which may 
underlie the mitochondrial swelling induced by loss of LETM1 (Dimmer et al, 
2008b). More recent work has confirmed that siRNA-mediated LETM1 
downregulation (~90%) is associated with loss of mitochondrial tubular networks, 
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mitochondrial swelling and cristae disorganization in HeLa cells (Tamai et al, 
2008a). Mitochondrial membrane potential was found to be reduced in LETM1 
siRNA-transfected cells, consistent with previous reports in yeast mdm38 mutants 
(Frazier et al, 2006; Nowikovsky et al, 2004; Tamai et al, 2008a). Furthermore, 
studies in yeast, Drosophila and mammalian cells have also observed that 
downregulation of LETM1/mdm38/dmLETM1 leads to on-going mitophagy as a 
consequence of mitochondrial dysfunction and osmotic swelling caused by KHE 
activity shutoff (McQuibban et al, 2010; Nowikovsky et al, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 – LETM1, mitochondrial K+ and volume homeostasis as described by Nowikovsky et al 
(Nowikovsky et al, 2012a). LETM1 depletion leads to KHE activity shutoff and mitochondrial 
swelling and cristae loss. These phenotypes can be reversed by the addition of a K+ ionophore such 
as nigericin. RC, respiratory chain; KHE, potassium hydrogen exchange; Kc, potassium channels.   
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6.1.4.2: A putative role for LETM1 in Ca2+ transport 
As mentioned, LETM1 was identified in a genome-wide unbiased RNAi screen in 
Drosophila as a Ca2+/H+ antiporter (Jiang et al, 2009a). The findings of this study 
led the authors to conclude that LETM1 is a H+-Ca2+ exchanger mediating RR 
(ruthenium red)-sensitive Ca2+ uptake in energized mitochondria. However, this 
has been disputed by other authors whereby they suggest that the findings are 
compatible with an antiporter mechanism but do not prove it (Nowikovsky et al, 
2012b) . Interestingly, in a more recent study investigating the roles of LETM1 and 
UCP2/3 in mitochondrial Ca2+ transport, knockdown of LETM1 strongly 
diminished the transfer of Ca2+ into mitochondria resulting in the reduction of 
store-operated Ca2+ entry (SOCE). This evidence suggests that LETM1 contributes 
to mitochondrial Ca2+ uptake pathways in endothelial cells however much more 
work is needed to determine whether LETM1 does in fact play an essential role in 
calcium homeostasis in other cell types (Waldeck-Weiermair et al, 2011). 
 
6.1.4.3: LETM1, mitochondrial biogenesis and the formation of the respiratory 
chain complexes 
Frazier and colleagues reported that mutations in mdm38 severely affected the 
transport and insertion of two mtDNA encoded proteins;  ATP6 and cytochrome b 
into respiratory chain complexes (Frazier et al, 2006). They attributed the 
defective assembly of respiratory complexes III and IV to destabilised interactions 
of mdm38 with mitochondrial ribosomes however, subsequent investigation 
revealed that these defects were rescued by the addition of low concentrations of 
nigericin (Nowikovsky et al, 2007). This suggested that the K+ overload induced by 
mdm38 downregulation led to the destabilisation of respiratory chain complexes. 
Tamai et al also reported evidence indicating that LETM1 downregulation induced 
disassembly of respiratory chains. In particular, complexes I, III and IV failed to 
form supercomplexes. Further evidence of a role for LETM1 in mitochondrial 
biogenesis came from the finding that a double deletion of mdm38 and mba1 (a 
ribosome receptor) led to defective translation and the complete loss of cox1 and 
cytochrome b (Bauerschmitt et al, 2010). In fact, in a previous study by Piao and 
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co-workers they demonstrated that LETM1 binds the ribosomal protein, L36 
causing an L36-dependent reduction in ATP production (Piao et al, 2009b). These 
findings suggest that LETM1 plays key roles in mitochondrial biogenesis 
independent of its essential roles in KHE activity. Indeed, cells with inactivated 
components of the respiratory complexes do not show signs of mitochondrial 
swelling as seen in cells lacking LETM1 (Hasegawa & van der Bliek, 2007; Tamai et 
al, 2008b).  
It would be expected that impaired K+ extrusion, altered morphology and 
disrupted assembly of respiratory complexes would impart detrimental effects on 
mitochondrial functioning. Indeed, this is certainly the case in some yeast and 
human cell models of LETM1 downregulation where depolarisation of the 
membrane potential, impaired assembly of respiratory complexes and decreased 
ATP production have been observed (Frazier et al, 2006; McQuibban et al, 2010; 
Nowikovsky et al, 2007; Tamai et al, 2008b). However, Dimmer et al were unable 
to provide evidence of mitochondrial dysfunction in LETM1-silenced HeLa cells 
further complicating the picture (Dimmer et al, 2008b). Furthermore, studies 
employing WHS patient derived cell lines have failed to identify any mitochondrial 
dysfunction similar to those observed in yeast, C.elegens and cultured mammalian 
cell models of LETM1 downregulation such as disruption to the mitochondrial 
membrane potential and altered assembly of respiratory complexes. Dimmer at al 
investigated mitochondrial morphology and the levels of LETM1 in two WHS-
patient derived cell line models; lymphoblastoid cells and fibroblasts. 
Unexpectedly, although genetic analysis revealed that one allele of LETM1 was 
lacking, the levels of LETM1 protein in the lymphoblastoid cell line were 
unchanged, also consistent with the findings of van der Bleik and colleagues 
(Hasegawa & van der Bliek, 2007). They suggested that this could be a cell-specific 
effect and proceeded to deepen their analysis by generating primary fibroblasts 
from a different WHS patient where they demonstrated a 50% reduction of the 
LETM1 gene, messenger and protein. Interestingly, these patient-derived 
fibroblasts did not exhibit any mitochondrial morphology-related changes 
(Dimmer et al, 2008a). 
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One important consideration here is that many of the studies employing yeast and 
mammalian cell models utilize a full knockdown of LETM1. In contrast, WHS 
patient-derived cell lines display haploinsufficiency of LETM1 (50%) suggesting 
that the residual protein here is sufficient to maintain some protein function. In 
fact, Tamai et al reported that disassembly of the respiratory chain proceeded 
slowly with increasing LETM1 inactivation. Cells that were transfected only once 
with LETM1 siRNA exhibited swollen mitochondria but the respiratory chain 
complexes were assembled normally compared to those that were transfected 2 -3 
times (Tamai et al, 2008). Furthermore, Dimmer et al reported mitochondrial 
morphological changes following a 60% siRNA-mediated reduction of LETM1 in 
HeLa cells, but observed no alterations to respiratory chain activity (Dimmer et al, 
2008).  
 
6.1.4.4: Additional roles for LETM1 
Mutations in BCS1L, an AAA-ATPase, are causative of three different human 
disorders; Complex III deficiency, GRACILE (Growth Retardation, Amino aciduria, 
Cholestasis, Iron overload, Lactic acidosis and Early death) syndrome and 
Bjornstad syndrome. Bjornstad syndrome is a congenital condition involving 
deafness and hair abnormalities. Interestingly, certain patients with GRACILE 
syndrome present with neurological symptoms such as seizures which is also a 
common feature of WHS patients. Recently, Tamai et al provided the first evidence 
for a functional relationship between BCS1L and LETM1 in mito chondrial 
biogenesis (Tamai et al, 2008a). Figure 6.7 depicts the working model that they 
have proposed whereby LETM1 and BCS1L function in the assembly of the 
respiratory chain complexes. This evidence may begin to provide some insight that 
altered LETM1 copy number could disrupt some aspect of mitochondrial function. 
 
 
 
 
 
212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 - Model of the functions of BCS1L and LETM1 in mitochondrial biogenesis. BCS1L is 
required for respiratory chain assembly, mitochondrial morphology maintenance and LETM1 
major complex formation. LETM1 has a distinct role in the maintenance of mitochondrial volume 
and shape which helps to achieve efficient assembly of respiratory chains.  Blue arrows indicate 
functions reported by Tamai et al, 2008, grey arrows indicate the BCS1L functions reported 
previously (Cruciat et al, 1999; de Lonlay et al, 2001). 
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6.1.5: Mitochondrial dysfunction is frequently associated with 
epilepsy 
Epilepsy is a frequent neurological disorder affecting approximately 0.5-0.7% of 
the population (Folbergrová and Kunz 2012). The mitochondria have gained 
significant interest over recent years as playing important roles in epileptogenesis 
(Cock & Schapira, 1999; Folbergrová & Kunz, 2012; Fukuhara et al, 1980; Kudin et 
al, 2009; Kunz & S, 2002; Patel, 2002; Torbergsen et al, 1991; Waldbaum & Patel, 
2010). Neurons are highly differentiated cells requiring large amounts of ATP for 
the maintenance of ionic gradients and for neurotransmission. Since the majority 
of neuronal ATP is generated by oxidative phosphorylation, neurons heavily rely 
on optimal mitochondrial function. Furthermore, the morphology of neurons is 
highly complex and thus different segments of neurons i.e. dendrites, soma and 
axon have different energy demands. Mitochondrial dysfunction resulting in 
reduced production of ATP may increase neuronal excitability by impairing Na +-K+ 
ATPase activity and decreasing the neuronal plasma membrane potential. 
Furthermore, energy depletion enhances both synaptosomal and astrocytic 
glutamate release by interfering with the mitochondrial glutamate-aspartate 
transporter (McKenna, 2007). In addition to ATP production, neuronal 
mitochondria also play important roles in Ca2+ sequestration and thus 
mitochondria are able to modulate neuronal excitability and synaptic transmission 
(Kann & Kovacs, 2007).  
The importance of the mitochondria for neuronal function is evident from the 
neurological phenotypes observed in patients with mutations in genes affecting 
mitochondrial functions such as oxidative phosphorylation and ATP production 
(Discussed in detail in Chapter 3 section 3.1.6). Seizures are observed in numerous 
mitochondrial disorders but are most frequently reported in MERRF, Leigh 
Syndrome, MELAS and KSS (See Table 3.4 for the key clinical features of these 
conditions) (Zeviani et al, 1993; Zsurka et al, 2008; Zsurka et al, 2010). 
Furthermore, consistent with a role for disrupted Ca2+ homeostasis as a 
contributor to seizure predisposition, impaired mitochondrial Ca 2+ handling is a 
predominant feature of cybrid cells harbouring the mitochondrial T8356C 
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mutation associated with MERRF syndrome (Brini et al, 1999). It is proposed that 
this cellular alteration may potentially underlie  the increased excitability seen in 
this form of myoclonic epilepsy (Brini et al, 1999).  Accumulating evidence also 
suggests that free radicals and oxidative stress are important in the pathogenesis 
of epilepsy (Jarrett et al, 2008; Waldbaum & Patel, 2010). For example, astroglial 
and glutamate receptors are extremely sensitive to oxidative damage and thus 
excessive ROS generation can have direct effects on neuronal excitability (Trotti et 
al, 1998). Conversely, ROS are thought to be not only a key player in the 
pathogenesis of seizures but also a key factor resulting from seizures. However, in 
addition to the well-established role of the mitochondria in energy metabolism, it 
has recently emerged that mitochondrial dysfunction can trigger neuronal cell 
death, a prominent feature of therapy-resistant epilepsy (Ott et al, 2007). This may 
provide insight into the role of the mitochondria in more sporadic forms of 
epilepsy and also highlights the mitochondria as promising targets for 
neuroprotective strategies in epilepsy (Kunz, 2002).  
The distinct correlation between LETM1 haploinsufficiency and the presence of 
seizures in many WHS patients has led many researchers to suggest that 
haploinsufficiency of the LETM1 gene may be causative of the seizure phenotype 
here. However, it is noteworthy that other reports have also recently suggested 
roles for CTBP1 in the generation of seizures here. The idea that haploinsufficiency 
of LETM1 could play an important pathomechanistic role in the generation of 
seizures in WHS is substantiated by the findings of altered mitochondrial function 
and morphology in numerous cell models of LETM1 downregulation (Dimmer et al, 
2008a; Hasegawa & van der Bliek, 2007; McQuibban et al, 2010; Nowikovsky et al, 
2004; Tamai et al, 2008a). This degree of mitochondrial dysfunction may have 
important implications for neuronal development and function in WHS patients. 
Furthermore, LETM1 was previously identified as a Ca2+-H+ antiporter which 
suggests that it may play critical roles in Ca2+ regulation and thus may indirectly 
modulate neuronal excitability and synaptic transmission. In fact, very recently 
Zhang et al have provided data to indicate that downregulation of Letm1 increases 
seizure susceptibility in a rat pilocarpine-induced epilepsy model. This provides 
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further supportive evidence of a potential role for LETM1 in the seizure phenotype 
of WHS (Zhang et al, 2013). 
 
6.1.6: Summary 
No single gene is fully responsible for the complete spectrum of the WHS 
phenotype and thus it is widely accepted that WHS has a multigenic aetiology. 
Furthermore, emerging evidence identifying patients with deletions outside of the 
WHSCRs adds to the complexity of this disorder and suggests that other genes, 
aside from those residing in the critical regions (WHSCR1 and WHSCR2), can 
contribute to the severity of the disease. Many genotype-phenotype correlation 
studies have implicated LETM1 in the pathogenesis of seizures here, however to 
date no functional evidence derived from patient material exists to support this; it 
is purely assumed based on deletion size in WHS patients and its proposed roles in 
the cell. LETM1, encompassed by the WHSCR2, encodes a mitochondrial protein 
with several proposed roles including KHE activity and the regulation of 
mitochondrial morphology. It is well documented that epilepsy/seizures are 
frequently associated with mitochondrial dysfunction. Therefore, it is plausible to 
suggest that haploinsufficiency of LETM1 may impart detrimental effects on 
mitochondrial functioning which may underlie the seizure phenotype of WHS.  
Using a unique panel of WHS-patient derived lymphoblastoid cell lines (LBLs) from 
patients carrying variously sized sub-microscopic deletions within 4p16.3, 
including the patients described by Rauch et al and Engberts et al, I aimed to 
ascribe a functional deficit to LETM1 haploinsufficiency which may be relevant in 
the underlying aetiology of seizures in WHS, particularly those relating to 
mitochondrial function and dynamics (Figure 6.8). Furthermore, understanding 
the cellular consequences of LETM1 haploinsufficiency may enable future advances 
towards more effective management therapies in WHS. The mitochondria are the 
biological powerhouse of all cells. In particular, neurons critically rely on 
mitochondria not only for development and maturation but also for processes such 
as synaptic transmission and excitability which rely heavily on ATP production and 
ion signalling. Nevertheless, no studies have been performed in a neuronal model 
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of LETM1 haploinsufficiency and this is an area worthy of intensive investigation 
due to the numerous neurological deficits associated with WHS. Employing a 
neuronal model of mouse N2A neuroblastoma cells, I investigated the impacts of 
partial LETM1 knockdown on mitochondrial function to address this issue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.8: A schematic representation of the five WHS patient cell lines employed in this 
thesis. The commonly deleted critical regions are indicated in green and pink (WHSCR1 and 
WHSCR2) and the locations of several genes implicated in this condition are shown 
underneath. The red bars indicate the deleted regions in 5 WHS patients, from whom we 
derived LBLs for use in this project. The two atypical patients identified by Rauch et al and 
Engbers et al are illustrated. Tel; telomere, Cent; Centromere. 
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6.2: Results 
 
6.2.1: LETM1 expression levels; whole cell and mitochondrial-
specific  
Haploinsufficiency of LETM1 has been strongly associated with the seizure 
phenotype of WHS. However, this association is made with very limited 
biochemical evidence. In addition, it is yet to be shown that patients with 4p 
deletions encompassing the LETM1 gene exhibit reduced expression at the protein 
level consistent with haploinsufficiency of the gene. In collaboration with Prof. 
Joris Vermeesch, UZ Leuven, Belgium, I assembled a unique panel of EBV-
transformed patient-derived lymphoblastoid cell lines (LBLs) from patients 
harbouring variously sized submicroscopic deletions within 4p16.3, as illustrated 
previously in figure 6.8. I characterised these five patient-derived cell lines for 
LETM1 protein expression levels. As shown in Figure 6.8, LBL: 83, LBL: 78 and 
LBL: 88 are from patients with hemizygous deletions encompassing both WHS 
critical regions and clinically manifesting as typical WHS. Their deletions include 
the LETM1 gene. These patients are therefore haploinsufficient for LETM1. In 
contrast, LBL: 355 and LBL: CR are from atypical WHS individuals whose deletions 
do not incorporate the LETM1 gene and thus remains bi-allelic for LETM1.  
LETM1 protein levels were found to be reduced consistent with haploinsufficiency 
in LBL: 83, LBL: 78 and LBL: 88 (Fig 6.9). LETM1 protein levels in LBL: 355 and 
LBL: CR show similar expression to that of wild-type (WT) LBLs consistent with 
the normal copy number of the LETM1 gene in these two lines (Fig 6.9). As LETM1 
is a putative mitochondrial protein I investigated the expression levels of LETM1 in 
isolated mitochondrial extracts. Employing the same magnetic bead technology as 
described in Chapter 3 section 3.2.4, I isolated mitochondria from four of the WHS 
patient-derived LBLs; LBL: 83, LBL: 78, LBL: 88 and LBL: 355. Consistent with the 
findings in whole cell extracts, expression of LETM1 in mitochondrial extracts was 
reduced in cell lines that are haploinsufficient for LETM1; LBL: 83, LBL: 78 and 
LBL: 88 (Fig 6.10). The mitochondrial protein expression levels of LETM1 were 
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comparable to those of wild-type LBLs in LBL: 355, consistent with the deletion 
size in this patient-derived cell line (Fig 6.10). This is the first report 
demonstrating reduced expression at the protein level of the product of the LETM1 
gene within mitochondrial preparations in addition to whole cell extracts, in cell 
material derived from WHS patients. 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
Figure 6.9 - WHS patient-derived LBLs exhibit reduced LETM1 protein expression consistent with 
deletion size. (a) 1-10µg of urea-based whole cell extracts for LBL: 83, LBL: 88, LBL: 78, LBL: 355 
and LBL: CR were subjected to SDS-PAGE and immunoblotted for LETM1 protein expression levels. 
Each blot was then reprobed for β-tubulin as a loading control. (b) Histogram showing LETM1 
protein expression levels measured by Image J.  Data represents the mean of 3 independent 
measurements ±SD. A.U; arbitrary units. 
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Figure 6.10 - WHS patient-derived mitochondria show reduced LETM1 protein expression 
consistent with deletion size. (a) Mitochondria were isolated from 1 x 107 cells using the Miltenyi 
Biotec mitochondrial isolation kit and lysed in 60uL urea buffer. 0.1-2µL of urea-based 
mitochondrial extract (M) from each WHS cell line (WHS) were loaded respectively and compared 
to WT expression levels (WT). 10µg of whole cell extract (WCE) was loaded in the last two columns 
to serve as a control. Each blot represents extract from wild-type LBLs in wells 1-3 and extracts 
from WHS patient-derived cell lines, as labelled on the left of each blot, in wells 4-7. (b) Loading 
control inputs; mitochondria were isolated from 1 x 107 cells from WT and four WHS-patient 
derived cell lines. 8µL of each mitochondrial extract was loaded and immunoblotted for Hexokinase 
1 protein expression. M; mitochondrial extract, WCE; Whole cell extract. (c) Histogram showing 
LETM1 protein expression levels in mitochondrial extracts measured by Image J.  Data represents 
the mean of 3 independent measurements ±SD. Arb units; arbitrary units.  
M 
LETM1 
LETM1 
LETM1 
LETM1 
LBL 83 
LBL78 
LBL 88 
LBL 355 
WT  
WCE 
WT WHS 
WHS 
M 
Hexokinase 1  
(a) 
(b) 
0
0.2
0.4
0.6
0.8
1
1.2
WT LBL 83 LBL 78 LBL 88 LBL 355
L
E
T
M
1
 e
x
p
re
s
s
io
n
 le
v
e
ls
 
A
U
 (
Im
a
g
e
 J
) 
(c) LETM1 +/- LETM1 +/+ 
220 
 
6.2.2: Mitochondrial dysfunction segregates with LETM1 
haploinsufficiency 
The role of the mitochondria was initially thought only to be to generate energy in 
the form of ATP, and hence they are commonly referred to as the “biological 
powerhouse” of the cell. However, over the past few decades’ research has 
uncovered irrefutable evidence to suggest that the mitochondria play key roles in a 
variety of cellular processes ranging from calcium homeostasis to cell death, as 
discussed previously in Chapter 3. The mitochondria are vital components of all 
eukaryotic cells however their size, shape and distribution can very between cell 
types according to cellular need. Neurons in particular rely heavily on the 
mitochondria where they are actively transported along axons and accumulate in 
sites with high-energy demands such as the presynaptic terminal and Nodes of 
Ranvier (Hollenbeck & Saxton, 2005). Mitochondrial disorders arising from 
mutations in both the mtDNA (mitochondrial DNA) and in the nDNA (nuclear DNA) 
encoding a mitochondrial protein highlight the importance of correct 
mitochondrial function in maintaining cellular homeostasis (McKenzie et al, 2004). 
Moreover, given the multitude of roles for mitochondria within the cell it is not 
surprising that mitochondrial dysfunction has been implicated in the pathogenesis 
of many disorders including Parkinson’s Disease, Alzheimer’s Disease and Ataxia-
Telangiectasia (Ambrose et al, 2007; Winklhofer & Haass, 2010). 
LETM1 is an inner mitochondrial membrane protein proposed to be involved in 
ion exchange within the mitochondria (Nowikovsky et al, 2012a). However, there 
is debate within the literature as to whether it functions as a Ca2+/H+ antiporter or 
plays essential roles in K+/H+ activity.(Dimmer et al, 2008b; Endele et al, 1999b; 
Froschauer et al, 2005a; Jiang et al, 2009a). Nevertheless, the mitochondria rely 
heavily on the correct functioning of ion exchange pathways and any perturbations 
here can have detrimental effects on mitochondrial dynamics and physiology 
(O'Rourke, 2007).  With regards to calcium, the primary role of mitochondrial 
calcium is the stimulation of oxidative phosphorylation. This occurs at many levels 
including allosteric activation of pyruvate dehydrogenase, isocitrate 
dehydrogenase and α-ketoglutarate and stimulation of ATP synthase and ANT 
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(Brookes et al, 2004; McCormack & Denton, 1993). Overall, calcium is a positive 
regulator of mitochondrial function and thus any disruption to calcium 
homeostasis will have profound implications for mitochondrial function (Duchen, 
2000; Rizzuto et al, 2000). It is well documented that excessive increases in 
calcium appear to have negative effects on mitochondrial function such as; opening 
of the mPTP, mitochondrial fragmentation and the generation of reactive oxygen 
species (Cárdenas & Foskett, 2012; Gordeeva et al, 2003; Wong et al, 2012).  
Given the recently identified roles for LETM1 in ion exchange, possibly calcium, it 
is likely that its loss, in the context of WHS, could negatively impact on 
mitochondrial function. Furthermore, correct mitochondrial functioning is 
fundamental for neurons and many neuronal processes such as synaptic plasticity 
and transmission rely heavily on mitochondria for ATP production and Ca 2+ 
sequestration (Kann & Kovacs, 2007). Moreover, mitochondrial dysfunction has 
long been associated as a pathomechanistic contributor to epilepsy (Folbergrová & 
Kunz, 2012; Kang et al, 2013).  Therefore, due to its key roles in mitochondrial 
homeostasis, it is likely that haploinsufficiency of LETM1 may impart detrimental 
effects on mitochondrial function which could potentially contribute to the 
pathogenesis of seizures in WHS.  
Although multiple studies employing LETM1 knockdown models have reported 
mitochondrial dysfunction and altered morphology as a consequence of LETM1 
loss, data from WHS patient-derived material has failed to support this (Dimmer et 
al, 2008b; Nowikovsky et al, 2007). To date, no mitochondrial dysfunction has 
been identified in WHS patient-derived cells. Therefore, using the unique panel of 
WHS patient-derived LBLs described in section 6.2.1, I investigated mitochondrial 
function in the context of LETM1 haploinsufficiency. I employed the same set of 
Mitotracker probes described in Chapter 3 to investigate various aspects of 
mitochondrial function and physiology in the context of WHS.  
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6.2.2.1:  Mitotracker Red: WHS LBLs exhibit hyperpolarisation of the 
mitochondrial membrane potential, Ψm  
The mitochondrial membrane potential, as described in Chapter 3, is generated 
and maintained by the concerted actions of electron donors and acceptors of the 
electron transport chain, ultimately resulting in the production of ATP. The 
membrane potential is highly sensitive to changes in ion flux and mitochondrial 
morphology. Previous studies investigating the cellular consequences of LETM1 
downregulation have reported that its loss is associated with altered KHE activity 
and mitochondrial swelling. Therefore, this suggests that haploinsufficiency of 
LETM1 in the context of WHS may impart effects on the generation of the 
mitochondrial membrane potential and thus contribute to mitochondrial 
dysfunction. In fact, previous reports have indicated that LETM1-siRNA transfected 
HeLa cells and mitochondria isolated from yeast mdm38 mutants exhibit low 
membrane potential. Furthermore, some studies have suggested a role for LETM1 
in respiratory chain biogenesis whereby loss of LETM1 is associated with 
disrupted assembly of respiratory chain complexes (Frazier et al, 2006; 
Nowikovsky et al, 2004; Tamai et al, 2008b). 
Mitotracker Red CMXRos (MTR) accumulation within the mitochondria is 
dependent upon an intact and active mitochondrial membrane potential. 
Decreased or increased MTR fluorescence is therefore indicative of membrane 
potential disruption and thus mitochondrial dysfunction.  Inconsistent with 
previous reports, the results presented in Figure 6.11a indicates that Mitotracker 
Red fluorescence was increased in WHS cell lines exhibiting haploinsufficiency of 
LETM1 (LBL: 83, LBL: 78 and LBL: 88) compared to WT controls. In contrast, the 
two WHS patient-derived cell lines that are bi-allelic for LETM1 (LBL: 355 and LBL: 
CR) show Mitotracker Red fluorescence of a similar intensity to WT levels (see 
figure 6.12 for example FACS profiles). This data is inconsistent with previous 
reports in yeast and mammalian cell models and suggests that haploinsufficiency 
of LETM1 is associated with a subtle hyperpolarisation of the membrane potential. 
However, it is worthy to note that previous reports observed mitochondrial 
membrane depolarisation upon complete knockdown of LETM1 which is in 
contrast to the haploinsufficiency of LETM1 found in WHS patient-derived LBLs. 
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Knockdown of LETM1 in yeast, Drosophila and mammalian models has provided 
evidence to suggest that loss of LETM1/mdm38 results in on-going mitophagy as a 
result of altered KHE activity (McQuibban et al, 2010; Nowikovsky et al, 2004; 
Nowikovsky et al, 2007). Mitophagy is a selective form of autophagy which 
functions to rid the cell of defective mitochondria (Ding & Yin, 2012). If on-going 
mitophagy were in fact a phenotype of WHS patient derived cells, one may expect 
to observe a decrease in total mitochondrial mass or content. Furthermore, to 
ensure that the increase in Mitotracker Red fluorescence was not simply a 
reflection of increased mitochondrial content, I employed the Mitotracker Green 
probe (MTG) to analyse mitochondrial mass. MTG accumulates within the 
mitochondria regardless of the membrane potential giving an indication of 
mitochondrial mass or content of a cell population. I found that the mitochondrial 
mass in all 5 WHS patient-derived LBLs was similar to that of WT controls (Fig 
6.11b). This suggests that mitochondrial mass is not affected by LETM1 
haploinsufficiency and thus if on-going mitophagy is a phenotype of these cells, as 
suggested in the literature, it is possible mitochondrial biogenesis may be up 
regulated as a compensatory mechanism. 
Collectively, these data suggests that LETM1 haploinsufficiency is associated with 
an increased mitochondrial membrane potential without a concomitant increase in 
mitochondrial mass. It is frequently stated in the literature that a hyperpolarised 
(more negative) membrane potential is associated with a higher generation of 
mitochondrial-derived ROS and this is thought to be due to slowed electron 
transport (Brookes et al, 2004; Echtay et al, 2002; Hancock et al, 2001). As LETM1 
haploinsufficient mitochondria exhibit hyperpolarisation this suggests that the 
generation of mitochondrial ROS may also be increased. Furthermore, calcium 
transport within the mitochondria is highly dependent on an intact membrane 
potential suggesting that calcium-mediated signalling may be also disrupted by the 
membrane potential alteration, in this context. 
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Figure 6.11 - WHS LBLs exhibit hyperpolarisation of the mitochondrial membrane potential  with 
no increase in mitochondrial mass. (a) LBLs were incubated with 250nM Mitotracker Red for 15 
minutes and then analysed for PE fluorescence using the FACS canto. WHS LBLs exhibiting 
haploinsufficiency of LETM1 show hyperpolarisation of the membrane potential (p<0.05 Student t-
test), whereas those bi-allelic for LETM1 show similar mean fluorescence relative to wild-type 
controls (black dashed line). (b) WHS LBLs show similar mitochondrial mass compared to wild-
type controls (black dashed line) LBLs. LBLs were incubated with 250nM Mitotracker green for 15 
mins and analysed for FITC fluorescence using the FACS Canto flow cytometer. The data represents 
the mean of 3 independent determinations ± SD.  
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Figure 6.12: LETM1 -/+ WHS LBLs exhibit hyperpolarisation of the mitochondrial membrane 
potential compared to LETM1 +/+ WHS LBLs and WT controls. LBLs were incubated with 250nM 
Mitotracker Red for 15 minutes and washed once in 1X PBS. Cells were then resuspended into 
500L PBS, filtered in BD FACS Falcon tubes and analysed for PE-A fluorescence using the FACS 
Canto Flow Cytometer. PE-A MItotracker Red flow cytometry profiles for WT and WHS patient-
derived LBLs are shown above. Those cells lines haploinsufficient for LETM1 (83/78/88) exhibit 
hyperpolarisation of the mitochondrial membrane potential indicated by a rightward shift in the 
peak (right side of the black vertical line). 
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6.2.2.2: Haploinsufficiency of LETM1 is associated with an increase in 
mitochondria-specific ROS generation 
The primary function of the mitochondria is the production of ATP through the 
process of oxidative phosphorylation. However, in response to various different 
stimuli, the mitochondria can quickly change into death-promoting organelles 
producing excessive reactive oxygen species (ROS) and the release of pro -
apoptotic proteins which ultimately result in disrupted ATP synthesis and the 
activation of cell-death pathways. As discussed in detail in Chapter 3, 
mitochondrial-derived ROS, in the form of superoxide, is generated mainly from 
complexes I and III of the ETC as a normal by-product of oxidative 
phosphorylation. Antioxidant systems within the mitochondria such as SODs, 
glutathione and peroxidases exist to scavenge and remove ROS to prevent 
deleterious damage to proteins, lipids and DNA (Rabilloud et al, 2001). However, 
when the generation of ROS surpasses these systems, oxidative stress can ensue. 
Due to its close proximity to the mtDNA, excessive ROS can damage the mtDNA 
leading to further mitochondrial dysfunction and thus a cycle is established.  
As previously discussed, mitochondrial dysfunction and the excessive generation 
of ROS is strongly associated with  epileptic seizures (Folbergrova & Kunz, 2012). 
Interestingly, WHS patient-derived LBLs exhibit disruption of the mitochondrial 
membrane potential resulting in its hyperpolarization. Disruption of this 
membrane potential has major implications for mitochondrial homeostasis, not 
only through altered electron transport chain functioning and the subsequent 
production of ATP but also for the generation of reactive oxygen species. In fact, 
ETC dysfunction is causally associated with the elevated production of ROS. This 
suggests that in addition to disruption of the mitochondrial membrane potential, 
LETM1 copy number change may be also associated with elevated levels of ROS.  
To determine the levels of mitochondria-specific ROS production (O2-), I employed 
the MitoSOX probe previously described in Chapter 3 (section 3.2.2.5). LBLs were 
incubated with 250nM MitoSOX for 15 minutes and analysed for PE-fluorescence 
by flow cytometry. WHS patient-derived LBLs haploinsufficient for LETM1 
exhibited dramatically increased levels of superoxide. LBL: 83, LBL: 78 and LBL: 88 
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exhibited a 1.7-1.8 fold increase in MitoSOX fluorescence relative to wild type 
controls (Fig 6.13 and Fig 6.14). In contrast, those WHS cell lines with normal 
LETM1 copy number (LBL: 355 and LBL: CR) displayed similar levels of ROS to 
wild type controls (Fig 6.13 and Fig 6.14). Using an additional probe; Cell Rox Red, 
that detects cellular-wide levels of ROS, it was confirmed that the elevation in ROS 
levels was specifically mitochondrially-derived (Fig 6.15). Flow cytometry analysis 
of Cell ROX Red fluorescence revealed similar mean fluorescence intensity 
between WT and WHS patient-derived LBLs indicating that total ROS was not 
affected by LETM1 CNV. Further investigation revealed that this increase in ROS 
generation was not associated with altered Complex I activity (Fig 6.16). This 
suggests that the increased generation of ROS in this setting is being produced 
from an additional complex such as Complex II and III.  
Here, using sophisticated mitochondrial probes I have uncovered novel 
mitochondrial phenotypes which segregate with LETM1 haploinsufficiency in WHS 
patient-derived cells. Mitochondrial dysfunction is frequently associated with 
mitochondrial disorders that present with a seizure phenotype and thus the data 
presented here may provide novel insight into the underlying aetiology of the 
seizure phenotype of typical WHS. Furthermore as briefly mentioned, the 
mitochondrial membrane potential and consequent mitochondrial ROS are 
intimately linked to calcium homeostasis. Therefore, it is possible that 
misregulation of calcium also exists in this setting, which I subsequently set out to 
investigate.   
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Figure 6.13  - Haploinsufficiency of LETM1 correlates with elevated levels of mitochondria-specific 
ROS; FACS profiles. LBLs were incubated with 250nM MitoSOX for 15 minutes and analysed for PE-
A flourescence using the FACS Canto flow cytometer. PE-A MitoSOX flow cytometry profiles for WT 
and WHS patient-derived LBLs are shown above. Those cell lines haploinsufficient for LETM1 
(83/78/88) exhibit elevated ROS levels indicated by a rightward shift in the peak (right side of the 
red vertical line).  
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Figure 6.14 - Haploinsufficiency of LETM1 correlates with elevated levels of mitochondria-specific 
ROS. A representative histogram showing the mean PE-A fold change in  MitoSOX flourescence 
intensity relative to wildtype (black dashed line). LBLs were incubated with 250nM MitoSOX and 
analysed for PE-A flourescence using the FACS Canto platform. WHS LBL 83, LBL 78 and LBL 88 
exhibit elevated Mitotracker SOX indicative of elevated O2- production compared to WT LBLs and 
LBL 355 and CR (p<0.05 Student t-test). This data represents the mean ± SD of 5 independent 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15 – Total cellular ROS is normal in WHS patient-derived LBLs compared to WT control 
LBLs. A representative histogram showing the mean PE-A fold change relative to wild-type (black 
dashed line). LBLs were incubated with Cell ROX Red as per manufacturers protocol and analysed 
for PE-A fluorescence on the FACS Canto flow cytometer. Control WT LBLs were also treated with 
100M tBOOH for 1 hour prior to Cell Rox Red incubation, to induce ROS.  All of the WHS LBLs, 
irrespective of LETM1 copy number , exhibit a comparable level of Cell Rox Red fluorescence to WT. 
This data represents the mean ± SD of three independent determinations. WT; wild-type. 
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Figure 6.16 - Complex I activity is unchanged in LETM1 -/+ WHS patient-derived LBLs (LBL 88). 
Extracts were prepared as per the manufacturers protocol. Increasing amounts of protein extract 
were loaded onto the complex I assay dipstick and the resultant antibody line was scanned and 
intensity measured in Image J. A.U; Arbituary units. The data represents the mean of 3 independent 
determinations ± SD. 
  
0
5
10
15
20
25
30
35
40
45
50
10 50 100
C
o
m
p
le
x
 I
 a
c
ti
v
it
y
, 
A
.U
 
 
µg protein loaded  
WT
LBL 88
LETM1-/+
231 
 
6.2.2.3: WHS patient LBLs exhibit elevated levels of intracellular calcium 
The report that the putative IMM protein LETM1, previously described as a K+/H+ 
exchanger, could be a Ca2+ /H+ antiporter was received with great interest (Jiang et 
al, 2009b; Waldeck-Weiermair et al, 2011).  However, some suggest that the effects 
of downregulation or overexpression of LETM1 on mitochondrial calcium 
transport could be a secondary effect of altered K+/H+ exchange activity 
(Nowikovsky et al, 2012b).  In addition to producing ATP, the mitochondria serve 
as central players in cellular Ca2+ signalling by acting as very efficient mobilisable 
intracellular Ca2+ buffering systems. Ca2+ uptake is achieved primarily by the 
mitochondrial Ca2+ uniporter (MCU) and this is highly dependent on the gradient 
established by the electron transport chain across the inner mitochondrial 
membrane, the Ψm  (Gunter et al, 2000; O'Rourke, 2007).  Other pathways of Ca2+ 
entry into the mitochondria include the “rapid mode” mechanism (RaM) and the 
mitochondrial Ryanodine Receptor (mRyR). Conversely, Ca2+ efflux is achieved by 
exchange for Na+ which, in turn, is exchanged for H+ (reviewed in Gunter, 2000). 
Both influx and efflux of Ca2+ consumes the mitochondrial membrane potential and 
are thus highly reliant on optimal mitochondrial functioning.  
Ca2+ itself is a key regulator of mitochondrial function, acting at several levels to 
stimulate oxidative phosphorylation and ATP production (reviewed in Tarasov, 
2012). Physiological increases in mitochondrial calcium ([Ca2+m]) lead to activation 
of various TCA cycle enzymes such as pyruvate dehydrogenase and isocitrate 
dehydrogenase (McCormack & Denton, 1993). Ca2+ also stimulates ANT (Complex 
V) and ATP synthase which upregulates ATP production and thus Ca2+ is an overall 
positive regulator of mitochondrial function (Tarasov, 2012 and Feissner, 20 09). 
However, when overloaded, Ca2+ becomes a pathological signal leading to opening 
of the mPTP and the initiation of apoptosis (Crompton, 1999). ROS generated as a 
consequence of ATP production in the mitochondria regulate the function of redox 
sensitive enzymes and ion channels within the cell, including Ca2+. ROS can 
modulate Ca2+ homeostasis at several levels and thus stimulate and inhibit Ca2+ 
channels, pumps and exchangers. Some examples include the oxidation of 
ryanodine receptors (RyR) resulting in their activation, stimulation of IP3R 
mediated Ca2+ release from the ER, oxidation and subsequent inhibition of SERCA 
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and PMCA, and modulation of NCX activity (plasma membrane Na+/Ca2+ exchange) 
(Scherer & Deamer, 1986; Xu et al, 1997; Xu et al, 1998; Zaidi & Michaelis, 1999). It 
is also important to mention that just as redox state can significantly modulate Ca 2+ 
signalling, a reciprocal relationship exists where Ca2+ also plays a role in the 
generation of ROS through a number of mechanisms. These include but are not 
limited to; 1) stimulation of TCA cycle enzymes (isocitrate dehydrogenase and 
pyruvate dehydrogenase) which enhances oxidative phosphorylation and thus ROS 
production, 2) stimulation of NOS generates NO which inhibits complex IV 
enhancing ROS generation, 3) enhancing cytochrome c dislocation from the IMM 
resulting in respiratory chain blockage at complex III and 4) induction of the mPTP 
and the loss of antioxidants from the mitochondria which diminishes the 
antioxidant capacity of the mitochondria (Reviewed in Feissner et al, 2009). 
Furthermore, evidence also indicates that Ca2+ can minimize oxidative stress by 
stimulating catalase and GSH reductase (Brookes et al, 2004).  The underlying 
mechanisms for Ca2+-induced mitochondrial ROS generation are not fully 
understood. Nevertheless, it appears that calcium is both a positive and negative 
regulator of redox state. 
The data presented so far indicates the haploinsufficiency of LETM1 is associated 
with disruption of the mitochondrial membrane potential and an increased 
generation of ROS from the mitochondria. Therefore, the mitochondrial 
phenotypes uncovered so far suggest that altered Ca2+ homeostasis may also 
potentially exist in this setting, consistent with previous reports of a role for 
LETM1 in Ca2+ exchange (Jiang et al, 2009a; Waldeck-Weiermair et al, 2011). I 
investigated the impact of LETM1 haploinsufficiency on intracellular Ca2+ levels in 
WHS patient-derived LBLs using the long-wave calcium indicator; Calcium 1-AM. 
The mechanism of action of Calcium 1-AM has previously been described in detail 
in Chapter 3, section 3.2.2.7. Flow cytometry analysis of calcium 1-AM fluorescence 
(FITC/green) revealed that WHS patient-derived LBLs exhibited increased levels of 
intracellular calcium which segregated with LETM1 haploinsufficiency (Fig 6.17a 
and 6.17b). This data is consistent with the phenotypes of excessive ROS 
generation and disrupted mitochondrial membrane potential presented in the 
previous sections.  
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An intricate crosstalk between Ca2+, ROS and membrane potential exists whereby 
perturbations to one factor can significantly impact on the others. It appears that 
in the context of LETM1 copy number change, all three factors are significantly 
affected, however whether any of these are merely a secondary consequence of 
altered KHE activity, as suggested in the literature, is unclear.  Whilst physiological 
increases in Ca2+ are overall positive regulators of mitochondrial function, Ca2+ 
overloads are detrimental and can quickly become pathological. One important 
consequence of increased intracellular Ca2+ or Ca2+ overload is the opening of the 
mitochondrial permeability transition pore, especially when coupled with 
increased levels of ROS (Baumgartner et al, 2009; Wong et al, 2012). Therefore, in 
light of the phenotypes identified so far, I investigated whether opening of the 
mPTP may be mis-regulated in WHS patient-derived cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.17a – Histogram; LETM1 haploinsufficiency is associated with elevated intracellular 
calcium levels (WT versus LBL 83 or LBL 78; p<0.05 Student t-test). Cells were incubated with  
Calcium-1 AM for 20 minutes at 37°C. Cells were then washed in PBS, resuspended in 500µL PBS 
and analysed by flow cytometry for FITC fluorescence, excitation/emission filters; 506/531. The Y 
axis represents that fold change in mean fluorescence intensity (MFI) relative to wild type controls 
(WT). The data represents the mean ±SD of 3 independent experiments relative to wild type 
controls (black dashed line). 
LETM1-/+ LETM1+/+ 
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Figure 6.17b – Flow cytometry profiles;  LETM1 haploinsufficiency is associated with elevated 
levels of intracellular calcium. These FACS profiles represent one single experiment of the mean 
data shown in Figure 6.17a. The FACS profiles for WT control LBLs are shown in blue, LETM1+/- 
LBLs are shown in green and exhibit a rightward shift in FITC fluorescence intensity (x-axis) and 
LETM1 +/+ LBLs are shown in red and exhibit a similar profile to WT controls.  
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6.2.2.4: Decreased opening of the mPTP in LETM1-/+ WHS patient-derived LBLs 
As previously described in Chapter 3 section 3.2.2.8, the mitochondrial 
permeability transition pore (mPTP) is a non-selective, voltage-dependent 
mitochondrial channel proposed to reside in the IMM. Opening of the mPTP 
increases the permeability of the IMM to solutes >1.5kDa. Under normal 
physiological conditions the pore can flicker between an open and closed state, 
however various stimuli such as ROS and increased levels of Ca 2+ promote the 
sustained opening of this pore.  Chronic opening of this pore has many 
consequences; damage to mitochondrial ultrastructure such as mitochondrial 
swelling, depolarisation of the mitochondrial membrane potential leading to 
impaired OXPHOS, reduced ATP production and stimulation of ROS generation. 
Unless pore closure occurs, irreversible damage can ensue leading to cell death via 
necrotic or apoptotic pathways. The primary trigger stimulating mPTP opening is a 
rise in mitochondrial Ca2+, especially when accompanied by increased ROS, ATP 
depletion, increased phosphate concentrations and mitochondrial membrane 
depolarisation. In contrast, increased ATP production, low pH and increased 
mitochondrial membrane potential can stabilise the pore in its closed state. In 
addition Mg2+ levels are also reported to inhibit pore opening however the 
mechanisms behind their inhibitory action are not fully understood (Brenner & 
Moulin, 2012).  
In this chapter I have so far shown that WHS patient-derived LBLs 
haploinsufficient for LETM1 display hyperpolarisation of the mitochondrial 
membrane potential, increased generation of ROS and elevated levels of 
intracellular Ca2+. Both oxidative stress and rising mitochondrial Ca2+ levels can 
stimulate the sustained opening of the mPTP, whereas the increased membrane 
potential favours a closed pore state (Baumgartner et al, 2009; Brenner & Moulin, 
2012; Wong et al, 2012). It is possible that mitochondrial dysfunction here could 
lead to hypersensitivity of the mPTP, a phenotype observed in the CUL4B-deleted 
LBLs described in Chapter 3.  However, CUL4B-deleted LBLs exhibited a striking 
depolarisation of the mitochondrial membrane potential which is in contrast to the 
hyperpolarisation seen in this setting. Therefore, it is possible that the altered 
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mitochondrial physiology here may inhibit pore opening and render the mPTP 
insensitive to Ca2+ overloads, even in the presence of excessive ROS. 
I employed the MitoProbe Transition Pore Assay Kit, previously described in 
Chapter 3, to investigate ionomycin-induced opening of the mPTP in WHS patient-
derived LBLs.  Briefly, cells are loaded with the acetoxylmethyl ester form of 
calcein which emits bright green fluorescence once cleaved by esterases inside the 
cell. The addition of CoCl2 quenches the cytosolic calcein fluorescence but 
maintains mitochondrial-specific fluorescence resulting in a slight shift in FITC 
fluorescence intensity. Cells can be treated with CoCl2 and ionomycin at the same 
time which allows the entry of excess calcium into the mitochondria, triggering 
opening of the mPTP.  Once open, the fluorescing calcein within the mitochondria 
can exit into the cytosol and be quenched by the CoCl2 resulting in a dramatic shift 
in fluorescence intensity. It is this shift in fluorescence intensity that indicates the 
continuous activation of the mPTP (See Chapter 3, Figure 3.26 for schematic). 
I evaluated opening of the mPTP under basal conditions; that is with the addition 
of CaAM and CoCl2 only. This gives indications of the basal level of mPTP flickering 
between open and closed states without the addition of an activating stimulus. 
Analysis of calcein fluorescence in the absence of CoCl2 was comparable in all cells 
lines examined, indicating similar calcein loading. In the presence of CoCl2, calcein 
fluorescence was higher in LETM1-/+ LBLs (LBL: 83) compared to WT controls 
and WHS LBLs carrying normal copy number for LETM1 (LBL: 355) (Fig 6.18a). 
This suggests that flickering of the mPTP between open and closed states was 
more favoured towards the closed state under basal conditions in LETM1 
haploinsufficient cells. I further investigated whether treatment with ionomycin, a 
Ca2+ ionophore, would induce a decrease in calcein fluorescence, indicative of 
mPTP opening. As expected, following ionomycin treatment the calcein signal was 
considerably reduced (~ -60%) in WT and WHS LBLs with normal LETM1 copy 
number (LBL: 355), consistent with opening of the mPTP (Fig 6.18b). However, 
treatment of WHS patient-derived LBLs haploinsufficient for LETM1 (LBL: 83) with 
ionomycin had little effect on the calcein signal. WHS83 LBLs exhibited a 20% 
reduction in calcein signal in comparison to the 60% reduction observed in cells 
with normal LETM1 copy number (Fig 6.18b). These observations indicated that 
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the mPTP was insensitive to Ca2+ overloads and thus potentially inhibited. This 
data also provided support that the higher mitochondrial-specific calcein signal in 
LETM1 -/+ LBLs was due to decreased opening of the mPTP under basal 
conditions. 
Although LETM1-/+ LBLs exhibit phenotypes reported to stimulate opening of the 
mPTP, they also display characteristics which favour mPTP inhibition. These 
inhibitory signals may be sufficient to surpass the activatory signals of excessive 
ROS and increased Ca2+ levels associated with LETM1 haploinsufficiency and thus 
inhibition dominates.  Furthermore, LETM1 downregulation has been shown to 
induce mitochondrial swelling due to altered KHE activity (Nowikovsky et al, 
2004). Although this has not been investigated here, it is possible that 
mitochondrial swelling may physically inhibit the pore’s capacity to open. It would 
be interesting to investigate whether treatment with an ionophore, functioning to 
restore KHE activity, could restore mPTP opening. Alternatively, due to the chronic 
exposure to ROS and Ca2+ overloads, the mPTP may, over time, may be rendered 
insensitive and thus does not respond to further perturbations. 
 
   
   
  
 
 
 
 
 
Figure 6.18 - Opening of the mPTP is disrupted in the context of LETM1 haploinsufficiency. (a) Bar 
graph of the mitochondrial-specific calcein signal in the presence of CoCl2 measured by FACS 
analysis shows increased mitochondrial calcein signals in LETM1-/+ WHS cell line 83 (LBL 83). (b) 
Bar graph of % calcein signal in the presence of CoCl2 ± 500nM ionomycin treatment. LETM1-/+ 
WHS patient cell line 83 (LBL 83) shows increased calcein signal following ionomycin treatment 
indicative of mPTP inhibition. The student t-test was used for statistical analysis, as indicated. 
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6.2.3: siRNA mediated knockdown of Letm1 
I have uncovered novel mitochondrial phenotypes associated with LETM1 
haploinsufficiency using a unique panel of WHS patient-derived LBLs with 
different sized deletions. To confirm that the under-expression of LETM1 
specifically could underlie these phenotypes I investigated mitochondrial function 
in mouse Neuroblastoma 2A (N2A) cells following siRNA-mediated depletion of 
LETM1. As WHS patients exhibit many features consistent with a neurological 
deficit, such as seizures and MR, this N2A cell line provides an excellent model for 
investigating LETM1 haploinsufficiency in a neuronal setting. 
It is important to note that WHS patient-derived LBLs exhibit haploinsufficiency of 
LETM1 which leads to a 50% reduction in the protein expression levels. Therefore, 
I aimed to mimic this setting with a 50% siRNA-mediated knockdown of Letm1. 
Western blot analysis confirmed a 50% reduction in Letm1 protein expression 
levels following a single transfection, thus mimicking the patient genotype (Figure 
6.19a). I then sought to investigate the impacts of a 50% Letm1 knockdown on 
membrane potential maintenance and ROS generation and found that depletion of 
Letm1 imparted striking effects on both, consistent with the phenotypes observed 
in patient-derived LBLs. Partial knockdown of Letm1 led to a ~1.6 fold increase in 
the mitochondrial membrane potential with no increase in mitochondrial mass  
(Fig 6.19b-c). In addition, Letm1 downregulation led to a dramatic increase in 
mitochondrial ROS generation whereby siRNA transfected cells exhibited a ~1.7 
fold increase in superoxide levels compared to untransfected controls  (Fig 6.19b-
c). Collectively, these data are identical to the mitochondrial phenotypes observed 
in WHS patient-derived LBLs and provide further support of a vital role for LETM1 
in mitochondrial function and homeostasis. 
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Figure 6.19 – Reduced expression of LETM1 is associated with mitochondrial dysfunction (a) N2A 
cells were transfected with siRNA oligo against Letm1 and harvested 24-48 hours post-transfection. 
Whole cell extracts were immunoblotted for Letm1 protein expression levels and confirmed a 50% 
knockdown of Letm1. α-tubulin expression was used a loading control. (b) FACS profiles for 
Mitotracker Red (Mito RED) and MitoSOX (Mito SOX) 48 hours post transfection with siRNA oligo 
against Letm1. Upper panel shows the Mitotracker Red PE-A profiles for untransfected (black) and 
Letm1 siRNA-transfected cells (red) N2A cells. Lower panel shows MitoSOX PE-A FACS profile for 
untransfected (black) and Letm1 siRNA-transfected (red) N2A cells 48 hours post-transfection. 
Untransfected cells were treated with Metafectene Pro only. (c) Histogram shows the mean fold 
change in mean fluorescence intensity (MFI) for each Mitotracker probe, as analysed on the FACS 
Canto flow cytometer, 48 hours post transfection relative to untransfected N2A cells (black dashed 
‘Ctrl’ line). siRNA of Letm1 is associated with increased hyperpolarisation (elevated ∆Ѱmito) and 
elevated O2- production, without impacting on mitochondrial mass. Data represents the mean ± SD 
of 3 independent determinations. p values were obtained by student t-test statistical analyses, as 
indicated. 
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6.2.4: Ectopic antioxidant treatment fails to rescue the 
mitochondrial phenotypes associated with LETM1 
haploinsufficiency 
ROS are a by-product of mitochondrial respiration and the levels of ROS are kept at 
a low level by various antioxidant systems within the cell. The definition of an 
antioxidant as proposed by Halliwell is; any substance that, when present at low 
concentrations compared with those of an oxidisable substrate, significantly delays 
or prevents oxidation of that substrate (Halliwell, 1995). An important part of the 
endogenous antioxidant systems are the antioxidant enzymes such as superoxide 
dismutases and peroxidases. In addition to these enzymes, cells possess small-
molecule antioxidants such as α-tocopherol (the active form of Vitamin E) which 
play equally important roles in the antioxidant defence mechanisms. When the 
generation of ROS is so excessive that it surpasses these systems, oxidative stress 
and cellular damage can occur.  The data reported here reveals that LETM1 
haploinsufficiency, in the context of WHS, is associated with considerable increases 
in the generation of mitochondria-specific ROS, specifically superoxide (O2-). I 
investigated whether antioxidant treatment in WHS patient-derived LBLs could 
rescue the mitochondrial phenotypes observed here.  
 
N-acetyl-Cysteine and Lipoic Acid 
I employed the antioxidants N-acetyl-Cysteine (NAC) and Lipoic Acid (LA) in an 
attempt to rescue the ROS phenotype associated with haploinsufficiency of LETM1. 
WHS patient LBLs were treated with NAC or LA at varying concentrations (500µM 
– 50mM NAC or 0.1µM-50µM LA) for 1 hour and then analysed for MitoSOX 
fluorescence by flow cytometry. Neither NAC nor LA treatment resulted in a 
decrease in the levels of superoxide, under these conditions (Fig 6.20). 
Furthermore, at some concentrations treatment was found to increase ROS 
production. This was particularly evident at concentrations of NAC above 20mM 
however this was later attributed to a change in pH of the media (observed as a 
colour change from pink to yellow) caused by the very high concentration of NAC. 
With regards to LA treatment, no considerable difference in ROS levels was 
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observed following treatment of varying concentrations. Neither NAC nor LA are 
mitochondrial-specific antioxidants and this could explain why their use here was 
unable to rescue the mitochondrial-specific phenotypes observed in WHS patient 
LBLs.  
 
α-tocopherol  
Addition of NAC and LA failed to rescue the ROS phenotype of LETM1-/+ LBLs 
possibly due to their non-specific nature. α-tocopherol, also known as Vitamin E, is 
enriched in the mitochondrial membrane, the site of Complex I and ubiquinone; 
two complexes that produce ROS. Therefore, I investigated whether treatment 
with this mitochondria-specific antioxidant could rescue to ROS phenotype of 
LETM1 -/+ cells. Following treatment with 1-100µM of α-tocopherol for 24 hours, 
LETM1-/+ LBLs displayed similar levels of ROS to their untreated counterparts 
indicating that this treatment was not sufficient to decrease the levels of ROS (Fig 
6.21a). It is possible that this acute treatment did not allow sufficient time to 
rescue the phenotype and I therefore investigated the effects of a chronic α-
tocopherol treatment. However, chronic treatment of LETM1-/+ LBLs (LBL: 83) 
with 10µM α-tocopherol for 7 days was not sufficient to induce a considerable 
change in ROS levels either (Fig 6.21b).  
 
Nigericin 
Nigericin, a potassium ionophore, has previously been reported to rescue the 
mitochondrial swelling associated with LETM1 downregulation (Nowikovsky et al, 
2004). Whether the phenotypes I have observed are a cause or consequence of the 
mitochondrial swelling and loss of KHE associated with LETM1 haploinsufficiency 
is unknown, however it is possible that this altered mitochondrial morphology 
could impart negative effects on mitochondrial function particularly OXPHOS. 
Therefore, I speculated that treatment with nigericin may rescue the mitochondrial 
phenotypes identified here by restoring KHE activity and reducing the 
mitochondrial swelling. Cells were treated with 2M nigericin for up to 24 hours 
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and then analysed by flow cytometry for Mitotracker Red and MitoSOX 
fluorescence. The data presented in Figure 6.22 indicated that the addition of 
nigericin was not able to restore the mitochondrial membrane potential to a WT 
level nor was it sufficient to decrease the production of mitochondrial ROS. This 
suggested that the mitochondrial dysfunction observed here could not be rescued 
by attempting to restore KHE activity and suggests that LETM1 possesses crucial 
roles within the mitochondria aside from the regulation of KHE activity and 
mitochondrial morphology. 
Collectively, these data indicate that the addition of exogenous antioxidants fails to 
restore the ROS phenotype of LETM1-/+ mitochondria. This could indicate that the 
ROS phenotype observed here is a consequence, rather than the underlying cause, 
of the mitochondrial dysfunction. It is also possible that there is a maximum 
antioxidant capacity for the cell and modifying the levels of one antioxidant causes 
compensatory changes in the levels of others. Treating cells with exogenous 
antioxidants may decrease the rate of synthesis or uptake of endogenous 
antioxidants, so that the antioxidant capacity of the cell remains unalter ed. 
Furthermore, low levels of ROS are beneficial for many signalling processes and 
antioxidants cannot distinguish between harmful and beneficial reactive species. 
Therefore, increased intake of antioxidants may disrupt the redox balance and 
negatively impact on cellular processes which use ROS as signalling molecules thus 
leading to cellular dysfunction. 
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Figure 6.20 – Antioxidant treatment fails to reduce ROS levels in WHS LETM1 -/+ LBLs. (a) LETM1 
-/+ patient-derived LBLs (LBL 83) were treated with varying concentrations of N-acetyl-cysteine 
one hour. LBLs were then incubated with 250nM MitoSOX for 15 minutes and analysed for PE 
fluorescence using the FACS Canto Flow cytometer. Y axis represents the MitoSOX MFI of 20,000 
events. (b) LETM1 -/+ patient-derived LBLs (LBL 83) were treated with varying concentrations of 
Lipoic Acid for one hour. LBLs were then incubated with 250nM MitoSOX for 15 minutes and 
analysed for PE fluorescence using the FACS Canto Flow cytometer. The black dashed line 
represents the mean MitoSOX fluorescence intensity of untreated WT control LBLs for each 
experiment. MFI; mean fluorescence intensity, Unt; untreated cells. 
  
0
500
1000
1500
2000
2500
Unt 0.5 1 10 25 50 100
M
it
o
S
O
X
 P
E
-A
 M
F
I 
[NAC] 1 hour (mM) 
LBL 83
0
200
400
600
800
1000
1200
1400
1600
Unt 0.1 0.5 1 10 50 100
M
it
o
so
x
 P
E
-A
 M
F
I 
[Lipoic Acid ]1 hour (µM) 
LBL 83
(a) 
(b) 
244 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.21 – Treatment with the mitochondria-specific antioxidant, α-tocopherol fails to restore 
ROS levels. (a) LETM1 -/+ patient-derived LBLs (LBL 83) were treated with 1-100µM α-tocopherol 
for 24 hours and the incubated with 250nM MitoSOX. MitoSOX PE fluorescence was analysed using 
the FACS Canto flow cytometer. (b) Two LETM1 -/+ WHS patient-derived cell lines were used here; 
LBL 83 and LBL 78. LBLs were treated with 10µM α-tocopherol for 7 days followed by 15 minute 
incubation with 250nM MitoSOX. MitoSOX mean PE-A fluorescence of 20,000 events was then 
analysed on the FACS Canto flow cytometer relative to untreated WT control LBLs (black dashed 
line). 
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Figure 6.22 – Nigericin treatment fails to reduce ROS generation. LETM1-/+ WHS patient-derived 
LBLs (LBL 83) were incubated with 2µM nigericin for the indicated time points. Cells were 
incubated with 250nM MitoSOX for 15 minutes following nigericin treatment and analysed for PE-A 
fluorescence using the FACS Canto flow cytometer. Untreated controls were also analysed for 
MitoSOX fluorescence at 0 hours and 24 hours post seeding. The histogram represents the % of 
events with a high fluorescence/ROS positive. 20,000 events were analysed per sample.  Unt; 
untreated. 
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6.2.5: Treatment with Valproic Acid fails to restore mitochondrial 
homeostasis in WHS LBLs 
Seizures occur in many children with WHS and are frequent cause of death 
(Battaglia A, 2000; Battaglia et al, 2009; Kagitani-Shimono et al, 2005). The age of 
onset varies from 3 - 23 months with a peak incidence of 6-12 months. The 
seizures observed in WHS are frequently triggered by fever  and are either 
unilateral clonic or tonic seizures or generalised tonic-clonic seizures from the 
onset (Battaglia et al, 2009). Other seizure types observed in WHS patients include 
alternative hemiconvulsions, myoclonus, focal clonic seizures and epileptic spasms 
(Kagitani-Shimono et al, 2005). In addition, status epilepticus occurs in 
approximately 50% of WHS individuals. However, it is worthy to note that 90% of 
WHS patients display distinctive EEG abnormalities which are not always 
associated with seizures (Battaglia et al, 2009).  
Valproic acid, a simple branched-chain fatty acid, is routinely used as an 
anticonvulsant and mood-stabilising drug. In particular, it is primarily used in the 
treatment of epilepsy, bipolar disorder, schizophrenia and major depression 
(Chronicle & Mulleners, 2004; Fountoulakis et al, 2005; Loscher, 2002). As an 
anticonvulsant, valproic acid (VPA) is commonly used to control absence seizures, 
tonic-clonic seizures, myoclonus and complex partial seizures (Loscher, 2002). The 
mechanisms behind its antiepileptic effects are not fully understood but are 
thought to involve the enhancement of GABA-mediated neurotransmission, 
inhibitory effects on voltage-gated Na+ channels and activation of the ERK 
signalling pathway (Monti et al, 2009). However, the mechanisms of action of 
valproate not only involve biochemical effects but also induce changes at the 
genomic level. HDACs are key enzymes controlling histone acetylation sites and 
hence epigenetic regulation of gene expression. Recent research suggests that 
valproate can affect the expression of multiple genes by inhibiting many HDACs 
(Bosetti et al, 2003; Eyal et al, 2004; Gottlicher et al, 2001; Newton & Duman, 
2006; Phiel et al, 2001; Tang et al, 2004). However the contributions of HDAC 
inhibition to the antiepileptic effects of valproate are unknown. It is likely that 
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valproate-mediated changes in the expression of multiple genes play an important 
role in the long-term effects of this drug (Eyal et al, 2004). 
It is well documented that the seizures associated with WHS can be well-controlled 
with VPA treatment (Battaglia A, 2000; Battaglia et al, 2009). Aside from VPA, 
other drugs such as sodium bromide and benzodiazepines can also be used to 
control seizures in the form of status epilepticus, clonic and tonic-clonic seizures 
(Kagitani-Shimono et al, 2005; Valente et al, 2003). Many WHS individuals later 
develop valproic acid-responsive atypical absences and thus it is important that 
valproic acid treatment is started soon after the first seizure. In the early years, 
treatment of seizures can prove difficult however, when properly controlled, 
seizures tend to disappear with age (Battaglia et al, 2009). In fact, Battaglia et al 
(2009) recently reported that epilepsy was well-controlled with valproate and 
phenobarbital in 81% of WHS patients, 55% of which are now seizure-free.   
Mitochondrial dysfunction and the excessive generation of ROS are key players in 
the pathogenesis of seizures. In fact, seizures are a frequently reported clinical 
feature of many known mitochondrial disorders such as MERRF and MELAS. 
Therefore, in light of the mitochondrial phenotypes uncovered here I investigated 
whether treatment with VPA could restore mitochondrial homeostasis in WHS 
patient-derived LBLs  (Folbergrova & Kunz, 2012). More specifically, I sought to 
identify whether VPA treatment was sufficient to reduce ROS levels in WHS 
patient-derived LBLs exhibiting LETM1 haploinsufficiency. If so, this may provide 
support for a causative role for elevated ROS in the seizure phenotype of WHS.  
LETM1 -/+ WHS patient-derived LBLs were incubated with 500µM-1mM VPA for 
0-60 minutes followed by incubation with 250nM MitoSOX for 15 minutes. The 
MitoSOX PE fluorescence of treated cells in comparison to  untreated controls was 
analysed by flow cytometry. The results in Figure 6.23a show that 0-60 minute 
treatments with VPA were not able to reduce ROS levels in LETM1-/+ LBLs (LBL: 
83). In fact, 15 minute treatments led to a substantial rise in ROS levels. The data in 
Figure 6.23a indicated that acute VPA treatments were not sufficient to reduce ROS 
levels in this setting and suggested that a chronic treatment may be more effective. 
However, cells treated with VPA for 7 days displayed no reduction in ROS levels 
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(Fig 6.23b). In fact, on day 7 ROS levels were dramatically increased suggestive of 
apoptosis and cell death. The data reported here suggests that VPA-mediated 
control of seizures in WHS is not simply a result of restoring mitochondrial 
homeostasis. However, WHS patients require long-term treatment with VPA and it 
is likely that a 7 day treatment here is not sufficient to induce long lasting positive 
effects on mitochondrial function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.23 – Treatment with an anticonvulsant drug does not rescue the MitoSOX phenotype of 
LETM1 -/+ WHS LBLs. (a) LETM1-/+ LBLs (LBL 83) were treated with 500µM-1mM valproic acid 
for 0-60 minutes followed by a 15 minute incubation with 250nM MitoSOX. MitoSOX PE 
fluorescence of untreated vs. treated WHS patient-derived LBLs was analysed by flow cytometry. 
(b) WHS patient-derived LBLs (LBL 83) were treated with 1mM valproic acid for 7 days and 
analysed for MitoSOX fluorescence by flow cytometry at the indicated time points. The black dashed 
line indicated the MitoSOX MFI of WT controls for each separate experiment. MFI; mean 
fluorescence intensity of 20,000 events, VPA; valproic acid, Unt; untreated WHS LBL control . 
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6.2.6: Increased LETM1 copy number is associated with 
overlapping mitochondrial phenotypes 
As discussed in Chapter 1, for many deletion syndromes there is a corresponding 
reciprocal duplication-associated syndrome. Until recently, no submicroscopic 
duplications covering the WHSCR had been reported. However in 2010, Hannes et 
al reported a 15 month old male child with a submicroscopic de novo 560 kb 
interstitial duplication including the WHSCR (Hannes et al, 2010). In particular, 
this duplication encompassed the LETM1 gene. The patient presented with 
features that partially overlapped with the WHS deletion phenotype such as; 
speech delay, developmental delay and a facial dysmorphism with low set ears. 
Interestingly, this patient also suffered from seizures suggesting that 
overexpression of LETM1 may also result in epilepsy.  Subsequently, in 2011 Cyr 
and co-workers reported a second patient with novel 4p16.3 microduplication 
(Cyr et al, 2011b). The male patient presented with seizures, delayed psychomotor 
development and dysmorphic features.  However in this case, the duplication was 
distal to WHSC1 and WHSC2.  Using a high-density oligonucleotide microarray they 
identified that this submicroscopic duplication involved the dosage sensitive genes 
TACC3, FGFR3 and LETM1. The presence of seizures in this second reported 
duplication case further suggested a role for increased LETM1 copy number in the 
underlying aetiology of seizures. In addition, as this duplication resides outside of 
the WHSCR it further supports the notion that additional genes outside of the 
WHSCR cause some of the key features of this disorder. 
The data presented so far suggests that LETM1 haploinsufficiency is detrimental to 
mitochondrial function. I aimed to investigate whether LETM1 overexpression 
imparted similarly negative effects on mitochondrial function. Unfortunately, 
patient-derived material from either of the patients described above was 
unavailable. Therefore, I employed the human glioblastoma cell line T98G to 
investigate the impacts of modest LETM1 overexpression on mitochondrial 
function. Cells were transfected with 2µg of a plasmid encoding LETM1 (pCMV6-
XL4) in the presence of 5µL Metafectene-Pro and harvested 24 hours post-
transfection. Western blot analysis of urea-based whole cell extracts revealed a 1.7 
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fold increase in LETM1 protein expression levels and therefore this provided an 
excellent model for investigating the mitochondrial consequences of LETM1 
overexpression (Fig 6.24a).  
Overexpression of LETM1 resulted in the elevated generation of superoxide as 
indicated by a ~1.7 fold increase in MitoSOX fluorescence 24 hours post 
transfection in comparison to untransfected controls (Fig 6.24b and Fig 6.24c). 
These results are consistent with a previous report of mitochondrial dysfunction 
associated with LETM1 overexpression in HeLa cells (Piao et al, 2009a). This data 
suggests that a change in copy number of LETM1, whether an increase or decrease, 
is detrimental to mitochondrial function and may potentially underlie the 
overlapping seizure phenotype associated with 4p16.3 deletions and duplications 
encompassing the LETM1 gene. 
 
6.2.7: LETM1 complementation in a human glioblastoma cell line 
Transfection of a plasmid encoding LETM1 (pCMV6-XL4, OriGene) with 
Metafectene-Pro failed to complement LETM1 expression in LETM1-/+ WHS 
patient-derived LBLs, even when used in conjunction with the Neon 
electroporation system (Invitrogen). This is likely a consequence of the poor 
transfection efficiency of LBLs. Therefore, I aimed to complement LETM1-/+ WHS 
patient-derived LBLs using a lentiviral-based transduction method (pReciever-
Lv105 expressing LETM1 cDNA from GeneCopoeia). Frustratingly, transduction 
with commercially produced lentiviral particles was unable to complement LETM1. 
In fact transduction was associated with a very high degree of toxicity. Therefore, I 
developed a model in a human gliobastoma cell line (T98G) that coupled siRNA 
knockdown of endogenous LETM1 and add-back of a LETM1 cDNA construct 
(pCMV6-XL4, OriGene). The LETM1 siRNA construct was designed to the 3’-UTR of 
the endogenous gene, hence the cDNA construct is siRNA-resistant. Therefore, in 
this setting any phenotypes observed following LETM1 siRNA should be rescued by 
the addition of the siRNA-resistant LETM1 cDNA construct. 
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Western blot analysis confirmed that LETM1 siRNA transfection in human T98G 
cells was effective in knocking down LETM1. The protein expression levels of 
LETM1 following siRNA were reduced by 60% (Fig 6.25a lane 3). Transfection with 
the siRNA-resistant LETM1 cDNA construct alone revealed a 1.7 fold increase in 
LETM1 protein expression levels (Fig 6.25a lane 2). In section 6.2.6 I reported that 
marked overexpression of LETM1 imparts detrimental effects on mitochondrial 
function similar to those of reduced LETM1 expression. Therefore, it was 
important to ensure that add back of the LETM1 cDNA construct did not result in 
overexpression of LETM1. Cells transfected with both LETM1 siRNA and the LETM1 
cDNA construct exhibited LETM1 protein expression levels comparable to 
untreated controls confirming complementation (Fig 6.25a lanes 1 and 4). As 
expected, siRNA-mediated knockdown of LETM1 in the T98G cell line led to a 
striking increase in MitoSOX fluorescence indicative of elevated ROS production 
(Fig 6.25c). Cells that were co-transfected with both LETM1 siRNA and the siRNA-
resistant LETM1 cDNA construct exhibited MitoSOX fluorescence that was 
comparable to that of untransfected controls (Fig 6.24c). Collectively, this data 
confirms that the mitochondrial dysfunction observed here is LETM1 expression 
specific. Furthermore, this data provides novel insight into the potential 
mitochondria-based mechanisms by which loss of LETM1 may contribute to the 
pathogenesis of seizures in WHS. 
 
6.2.8: Summary 
In this chapter, I have provided the first evidence of a mitochondrial dysfunction in 
WHS patient-derived LBLs which segregates with haploinsufficiency of LETM1 
specifically. WHS patient-derived LBLs whose deletions encompass the LETM1 
gene exhibit reduced LETM1 expression, not only in urea-based whole cell extracts 
but similarly in pure mitochondrial extracts. Flow cytometry-based analyses have 
revealed that LETM1-/+ mitochondria display elevated levels of ROS (O2-). LETM1 
was previously identified as a Ca2+/H+ antiporter, yet many have questioned this. 
However, I have uncovered novel evidence indicating that LETM1-/+ is associated 
with elevated levels of intracellular Ca2+ which appear to be localised in the 
mitochondria. Furthermore, treatment of LETM1-/+ mitochondria with the Ca2+ 
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ionophore, ionomycin, does not induce opening of the mPTP suggesting that the 
pore is inhibited or insensitive indicative of altered Ca2+ signalling in the context of 
LETM1 haploinsufficiency.  Using a siRNA knockdown cDNA add back method, I 
have further shown that complementation of LETM1 reduced ROS production to a 
level similar to that of wild type cells. This indicates that the mitochondrial 
dysfunction identified here is a consequence of LETM1 haploinsufficiency 
specifically. I have also provided evidence to suggest that increased LETM1 copy 
number is detrimental to mitochondrial function. More specifically, overexpression 
of LETM1 led to disruption of the mitochondrial transmembrane potential and the 
increased generation of ROS. This is consistent with overexpression of LETM1 
contributing to the seizure phenotype of individuals with the rare duplication of 
4p16. 
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Figure 6.24 – Overexpression of LETM1 is associated with depolarisation of the membrane and 
increased generation of ROS. (a) T98G cells were transfected with 2µg LETM1 cDNA and 5µL 
metafectene and harvested 24 hours post transfection. Whole cell extracts were immunoblotted for 
LETM1 protein expression levels. Blots were reprobed for β-tubulin as a loading control. (b) 
MitoSOX PE-A FACS profile of untransfected (black line) and 24 hour post-transfection (red line) 
T98G cells. (c) A histogram showing the fold change in MitoSOX mean PE-A fluorescence intensity 
(MFI) of transfected cells relative to untransfected cells (black dashed line). Cells were incubated 
with 250nM MitoSOX for 15 mins 24 hours post transfection and analysed on the FACS Canto flow 
cytometer. Untransfected cells were treated with 5µL metafectene only (black dashed ‘Ctrl’ line). 
Cells transfected with the LETM1 encoding plasmid exhibit a ~1.4-.16 fold increase in Mitotracker 
SOX fluorescence (p<0.05 Student t-test). Data represents the mean of 3 independent experiments ± 
SD.  
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Figure 6.25 – siRNA-mediated knockdown of LETM1 coupled with addback of a LETM1-cDNA 
construct restores mitochondrial function. (a) Human T98G glioblastoma cells were transfected 
with a cDNA construct alone (g), LETM1 siRNA alone (5L) or both cDNA and siRNA in the 
presence of metafectene. Whole cell extracts were prepared in urea-based lysis buffer and 10µg of 
protein was subjected to SDS-PAGE and immunoblotted for LETM1 protein expression. Western 
blot analysis confirmed knockdown of LETM1 following siRNA (lane 3) and subsequent LETM1 
complementation with the addition of the cDNA construct (lane 4). (b) Representative histogram of 
relative LETM1 protein expression compared to untransfected controls, measured by Image J 
software (arbitrary units). (c) MitoSOX fluorescence intensity is increased 3 fold following LETM1 
knockdown using a 3’-UTR directed oligonucleotide directed against the endogenous gene,  
compared to untransfected controls (Unt versus siRNA p<0.05 Student t-test). Co-transfection with 
LETM1 siRNA and an siRNA-resistant LETM1 cDNA construct reduces the level of Mitotracker SOX 
fluorescence to that of control cells (siRNA only versus siRNA+cDNA p<0.05 Student t-test, as 
indicated). Unt; untransfected, A.U; arbitrary units. The data represents the mean of 3 independent 
determinations ± SD. 
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6.3: Discussion 
 
The clinical spectrum and severity of WHS depends on deletion size and genotype 
to phenotype relationships are often assumed but not experimentally validated. In 
particular, WHS patients frequently experience seizures as an invariant clinical 
feature and much of the literature to date has suggested a role for LETM1 in the 
seizure phenotype. However, this linkage has been made with no associated 
explanatory, underlying biochemical deficits and is purely assumed based upon 
deletion size in patients. Many authors investigating the impacts of LETM1 
downregulation in yeast and mammalian cell models have reported altered 
mitochondrial morphology as a consequence of LETM1 deficiency (Dimmer et al, 
2008b; Froschauer et al, 2005a; Hasegawa & van der Bliek, 2007; Nowikovsky et 
al, 2004; Tamai et al, 2008a). Some have also reported disrupted mitochondrial 
functioning such as mitochondrial membrane depolarization (Nowikovsky et al, 
2004). Furthermore, whilst this thesis was being prepared, Jiang et al reported a 
Letm1 -/+ mouse and provided compelling evidence to support a role for LETM1 
haploinsufficiency in the seizure phenotype of WHS likely by  affecting 
mitochondrial pathways (Jiang et al, 2013). However, to date, no mitochondrial 
dysfunction has been identified specifically in WHS-patient derived cells. I 
employed a unique panel of WHS patient-derived LBLs with differing sized 
deletions to investigate the cellular consequences of LETM1 haploinsufficiency.  I 
have provided the first evidence that LETM1 protein levels are reduced consistent 
with haploinsufficiency in LBLs from WHS patients’ haploinsufficient for LETM1. 
Furthermore, consistent with a role for LETM1 in the mitochondria, I found that 
WHS patient-derived LBLs whose deletions encompass the LETM1 gene exhibit a 
considerable degree of mitochondrial dysfunction. More specifically, LETM1 
haploinsufficiency segregates with the distinct mitochondrial phenotypes of 
increased intracellular free Ca2+ concentrations, excessive ROS levels and 
insensitivity of the mitochondrial transition pore. 
The mitochondria are essential components of all cells where they function not 
only as ATP producers but also act as highly effective Ca2+ buffering systems.  The 
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central nervous system (CNS) has an enormous metabolic demand due to the fact 
that neurons are highly differentiated cells which need large amounts of ATP to 
maintain ionic gradients necessary for neurotransmission. Since most neuronal 
ATP is generated by oxidative phosphorylation in the mitochondria, neurons 
heavily rely on correct mitochondrial function (Kann & Kovacs, 2007). 
Mitochondrial dysfunction and oxidative stress are frequently regarded as both 
contributing factors to seizure generation and key factors resulting from epileptic  
seizures (Chang & Yu, 2010; Frantseva et al, 2000). Mitochondrial dysfunction can 
disrupt ATP levels, alter Ca2+ homeostasis and disrupt neurotransmitter 
biosynthesis, all of which can impact on neuronal excitability. Furthermore, 
mitochondria are a primary source of ROS, a feature which renders the 
mitochondria particularly susceptible to oxidative damage which may play a 
critical role in controlling neuronal excitability (Folbergrová & Kunz, 2012; Kang et 
al, 2013; Patel, 2004). However, the mechanisms by which mitochondrial 
dysfunction contributes to epileptogenesis remain ill-defined. Nevertheless, 
precedent for a role for mitochondrial dysfunction in seizure generation comes 
from the observation that the most prominent neurological symptom of many 
mitochondrial disorders is that of profound seizures (Folbergrova & Kunz, 2012). 
Specifically, patients with well-characterised mitochondrial disorders such as 
MELAS, MERRF and Leigh Syndrome experience seizures more frequently (Wu et 
al, 2010). Furthermore, the use of animal models of epilepsy has greatly aided our 
understanding of the mechanisms underlying seizure generation  (Liang et al, 
2000; Waldbaum et al, 2010). 
It is well established that mitochondria are important for intracellular Ca 2+ 
sequestration in neurons (Duchen, 2000). Therefore, this provides an important 
pathway by which the mitochondria are able to modulate neuronal excitability and 
synaptic transmission, both of which are altered in epilepsy. Many authors have 
concluded that LETM1 functions in ion exchange and that loss of LETM1 impairs 
KHE activity (K+-H+ exchange) (Froschauer et al, 2005b; McQuibban et al, 2010; 
Nowikovsky et al, 2012a). However, this is currently under debate within the 
literature with others claiming that LETM1 functions as a Ca2+-H+ antiporter (Jiang 
et al, 2009a). Some have further suggested that disrupted Ca2+ homeostasis may be  
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secondary to altered KHE activity (Nowikovsky et al, 2012a). Here, I have shown 
that intracellular Ca2+ levels are increased in LETM1-/+ WHS patient-derived LBLs 
and there is evidence to suggest that the elevated Ca2+ levels are specifically 
localized in the mitochondria. In fact, consistent with the data reported here, Jiang 
et al recently reported that Letm1 is crucial for mitochondrial Ca2+ and H+ 
homeostasis.  They speculate that the primary impact of Letm1 haploinsufficiency 
in mice manifests as a defect in glucose oxidation, consistent with Ca 2+ regulation 
of TCA enzymes such as pyruvate dehydrogenase (Jiang et al, 2013). 
In addition to impaired Ca2+ homeostasis, I have found that opening of the mPTP in 
response to a Ca2+ ionophore is inhibited or insensitive. However, the precise 
mechanism/s underlying this inhibition are unclear and are worthy of much 
deeper investigation. Although not investigated here, it is possible that LETM1-/+ 
mitochondria may display altered morphologies similar to those seen in LETM1 
knockdown models, such as matrical swelling. If so, swelling may physically block 
the pore rendering it unresponsive, even under conditions that should result in its 
activation such as calcium overloads. Conversely, as LETM1-/+ mitochondria 
exhibit elevated levels of intracellular Ca2+, indicative of disrupted Ca2+ 
homeostasis, chronic exposure to high levels of intracellular Ca2+ could render this 
pore insensitive.  
The importance of oxidative stress in lowering seizure threshold is highlighted by 
studies in Sod2-deficient mice. Sod2 is an important antioxidant and Sod2-deficient 
mice exhibit age-dependent spontaneous seizures thus highlighting the 
importance of redox balance for maintaining correct neuronal function (Liang & 
Patel, 2004; Liang et al, 2012). LETM1-/+ WHS patient-derived cells exhibit 
remarkable increases in superoxide levels. One mechanism by which excessive 
ROS may contribute to increased neuronal excitability is via ROS-induced 
alterations to ion channels and neurotransmitter transporters. For example, the 
high-affinity astroglial and neuronal glutamate receptors are required for 
maintaining low synaptic glutamate levels but are extremely sensitive to oxidative 
damage (Trotti et al, 1998).  Furthermore, a number of ligand- gated ion channels 
have been shown to be regulated by ROS such as nicotinic acetylcholine receptors, 
glycine receptors and GABAA receptors (Campanucci et al, 2008). In particular, 
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hippocampal large-conductance Ca2+- activated K+ channels (BKCa) are proposed to 
play crucial roles in regulating neuronal excitability (Hou et al, 2009). The role of 
ROS-induced alterations to these channels has been investigated in many cell types 
including neurons (Faber & Sah, 2003).  It is likely that excessive ROS generation, 
as a consequence of LETM1 haploinsufficiency, may increase neuronal excitability 
above the threshold for seizure generation. On the other hand, prolonged seizure 
activities are known to result in the production of ROS leading to oxidative stress 
and thus creating a vicious damaging cycle (Folbergrova & Kunz, 2012). Therefore, 
it is reasonable to suggest that the excessive ROS generation identified here may in 
fact be both a cause and consequence of increased neuronal excitability and 
seizures in WHS. 
Interestingly, I found that several antioxidants failed to reduce mitochondrial ROS 
levels. This may be due to a number of factors; 1). the antioxidant capacity of the 
mitochondria has already reached a maximum threshold; the addition of 
exogenous antioxidants will have no beneficial effect, 3). the ROS may be a 
consequence of mitochondrial dysfunction and simply scavenging the ROS does 
not stop its excessive production, 4). at low levels, ROS are important signalling 
molecules and the increased uptake of antioxidants may disrupt the redox balance 
and negatively impact on pathways which rely on low levels of ROS for signalling. 
Although cause and effect are somewhat unclear, the marked mitochondrial 
dysfunction identified here could begin to explain the increased neuronal 
excitability and subsequent seizure generation associated with WHS. 
Previous work has identified that the mitochondrial swelling induced by LETM1 
downregulation could be reduced by the addition of a K+ ionophore, nigericin 
(Nowikovsky et al, 2004). Therefore, I speculated that the increase in 
mitochondrial ROS generation may also be a consequence of altered KHE activity 
and morphology. However, it is noteworthy that KHE activity was not investigated 
here, it was purely assumed based on previous reports in the literature. I found 
that ROS levels could not be restored by treatment with nigericin which suggests  
its excessive generation either occurs upstream of the altered KHE activity or is a 
phenotype which manifests independently of altered KHE activity. Consistent with 
these findings, earlier this year (2013) Zhang et al generated a Letm1 knockout rat 
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model via stereotaxic intra-hippocampus injection of shRNA against Letm1 and 
showed that loss of LETM1 is associated with increased seizure susceptibility. 
They subsequently showed the nigericin was unable to reduce the seizures and 
suggest that seizure generation here is not simply a consequence of altered KHE 
activity (Zhang et al, 2013). 
 
Many mitochondrial processes such as Ca2+ handling and ROS generation are 
highly interconnected and perturbations in one process can impact on numerous 
other processes. One highly relevant example here is that ROS can positively 
stimulate mitochondrial Ca2+ signals and mitochondrial Ca2+ can increase ROS 
generation (Camello-Almaraz et al, 2006). This creates a positive feedback loop 
which may exacerbate mitochondrial dysfunction. It is likely that such a feedback 
loop exists in LETM1-/+ cells which makes it difficult to identify the primary cause 
of the observed mitochondrial dysfunction. However, it is reasonable to speculate 
that if LETM1 does in fact function as a Ca2+-H+ antiporter, loss or impairment of 
this efflux mechanism will lead to increased mitochondrial Ca2+ concentrations. 
Furthermore, the addition of mPTP insensitivity will further attenuate Ca2+ efflux 
from the mitochondria leading to mitochondrial Ca2+ overloads. Through the 
feedback loop described above, increased Ca2+ will stimulate excessive ROS 
generation and a damaging cycle may be established. Therefore, it is tempting to 
speculate that impaired Ca2+ handling observed here is the primary cause of 
mitochondrial dysfunction in LETM1 haploinsufficient LBLs, consistent with a role 
for LETM1 in Ca2+ transport.  
Recently, duplication of LETM1 within a 560Kb interstitial duplication overlapping 
the WHS critical region, has been associated with neurodevelopmental delay and 
seizures (Cyr et al, 2011a; Hannes et al, 2010). This suggests that increased LETM1 
copy number may impart similar detrimental effects on mitochondrial 
homeostasis. Employing a human T98G cell line LETM1 overexpression model, I 
have shown that overexpression of LETM1 is associated with a strikingly similar 
level of mitochondrial dysfunction to that described here for LETM1 
haploinsufficiency. Cells overexpressing LETM1 display elevated production of 
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ROS. This datum provides further support of a role for LETM1 in regulating 
mitochondrial function and homeostasis.  
In conclusion, my data represents the first evidence of a mitochondrial dysfunction 
associated with LETM1 haploinsufficiency in WHS patient-derived cells. 
Furthermore, I have presented data to indicate that increased LETM1 copy number 
is also associated with a substantial degree of mitochondrial dysfunction. It is 
plausible to suggest that the striking mitochondrial phenotypes identified here 
may render the brain more susceptible to epileptic seizures. Importantly, these 
findings provide fundamental insight into the potential underlying aetiology of 
seizures in both WHS and LETM1 duplication syndromes, and could serve as a 
platform for the development of targeted clinical therapies. 
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In this thesis I have presented novel insight into the functional consequences of 
specific CNVs associated with three Genomic Disorders; CUL4B-deleted XLMR, 
16p11.2 CNV Disorder and Wolf Hirschhorn Syndrome. Many of the clinical 
features of CUL4B-XLMR patients overlap with those of mitochondrial disorders 
including ataxia, neuropathy, seizures and muscle wasting, suggesting that 
mitochondrial dysfunction may play a role here. In Chapter three I provided the 
first evidence indicating that CUL4B is present in/on the mitochondria. 
Furthermore, I have identified a distinct set of mitochondrial phenotypes in 
CUL4B-deleted patient-derived cells including disruption to the mitochondrial 
membrane potential, increased ROS generation and impaired Ca 2+ homeostasis. It 
is likely that the mitochondrial dysfunction observed here may contribute to many 
of the clinical features exhibited by these patients such as ataxia and neuropathy. 
With regards to the MR exhibited by these patients, it is not clear whether the 
mitochondrial dysfunction identified here may underlie this phenotype. As 
mentioned, CUL4B has been implicated in regulating aspects of the mTOR 
pathway; perturbations in which have been associated with MR. Nevertheless, it is 
conceivable that mitochondrial dysfunction may be a contributing factor to MR in 
this instance. This data is the first evidence identifying CUL4B-mutated and/or 
deleted XLMR as a disorder associated with mitochondrial dysfunction and 
suggests that CUL4B has, as yet, unappreciated roles within the mitochondria. 
The data in presented in Chapter Four is suggestive of a reciprocal relationship 
between CUL4B and Cereblon (CRBN). CRBN has been identified as a novel 
substrate receptor of a CUL4A-containing E3 ligase complex; however a role for 
CUL4B here was not excluded (Ito et al, 2010). Interestingly, siRNA-mediated 
knockdown of Crbn mimicked that of CUL4B loss in patient-derived cells 
suggesting that CRBN may also interact with CUL4B. This could be consistent with 
the existence of a putative CUL4B-CRBN E3 ligase complex that plays a pivotal role 
in the maintenance of mitochondrial homeostasis, particularly regulating redox 
status. Due to the MR associated with CUL4B loss, some have suggested that CUL4B 
may have unidentified neuronal-specific substrates, however the data reported 
here has been carried out in patient-derived LBLs which suggests that the impacts 
upon mitochondrial homeostasis in this context are not limited to neuronal cells. 
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Crucially, these findings open up new avenues for further investigations to identify 
potential mitochondrial-related CUL4B-specific substrates and provide novel 
insight into the underlying aetiology of CUL4B-XLMR. 
I also investigated the functional impacts of 16p11.2 CNV and revealed unexpected 
results. Copy number change of KCTD13, which encodes a protein with interacts 
with both pol   and PCNA, was recently postulated as a causative of the strikingly 
opposing head size phenotypes in 16p11.2 deletion and duplication patients 
(Golzio et al, 2012). However, despite harbouring a 16p11.2 duplication 
incorporating the KCTD13 gene, duplication of this gene was not translated at the 
protein level in patient-derived LBLs. This data indicates that KCTD13 copy 
number change does not segregate with head size as previously thought and 
suggests that other genes within the 16p11.2 region may contribute to this 
phenotype. One provocative candidate worthy of further investigation is INO80E, a 
component of the INO80 chromatin-remodelling complex. 
Some of the genes within the 16p11.2 region encode proteins which contribute to 
DNA replication and/or the DDR. Aberrant DNA replication and/or DDR pathways 
are frequently postulated as mechanisms underlying microcephaly, possibly 
through reduced neurogenesis and thus I sought to investigate, based on the genes 
involved, whether impaired replication or repair may be a feature of 16p11.2 CNV 
LBLs. Unexpectedly, I failed to identify any consistent deficit in either of these 
pathways in 16p11.2 CNV patient-derived LBLs. However, it is noteworthy that 
although Golzio and co-workers identified that Kctd13 downregulation led to 
increased proliferative status of cortical progenitors in mice consistent with 
macrocephaly associated with 16p11.2 deletion in humans, they did not report a 
Kctd13 overexpression model (Golzio et al, 2012). One 16p11.2 duplicated cell line 
did show increased sensitivity to HU-induced replication stress yet this was in 
contrast to two other 16p11.2 duplicated cell lines suggesting that an additional 
genomic alteration or mutation may be contributing to this cellular phenotype. 
Importantly, these data highlight the importance of employing patient-derived 
material as opposed to knockout and/or overexpression cell models to study the 
functional impacts of copy number variation. However, in this instance this data 
also raises the question as to whether LBLs are an appropriate model to 
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investigate the cellular impacts of 16p11.2 CNV. Furthermore, this data strongly 
emphasizes the need for more intensive investigation in mammalian model 
systems into the functional consequences of 16p11.2 CNV, particularly with 
regards to KCTD13 copy number change. 
Finally, I have uncovered novel mitochondrial phenotypes associated with copy 
number variation of LETM1, supporting a role for LETM1 in mitochondrial 
maintenance and function. These findings potentially have relevance to the 
profound seizure phenotype of Wolf-Hirschhorn Syndrome. I have shown that 
haploinsufficiency of LETM1 specifically is associated with elevated ROS 
generation and impaired Ca2+ handling; alterations which are strongly associated 
with seizure generation and epilepsy. I propose that mitochondrial dysfunction, as 
a consequence of LETM1 copy number change, is likely to underlie or largely 
contribute to seizure predisposition in both WHS patients with deletions 
encompassing LETM1 and those with the rarer reciprocal duplication of 4p16.  
Furthermore the CUL4B-XLMR patients described in Chapter 3 also exhibit 
profound seizures as a clinical phenotype. Therefore, the identification of 
overlapping mitochondrial deficits in both WHS and CUL4B-deleted patient-
derived LBLs emphasises the importance of optimal mitochondrial function for 
development. 
In conclusion, in this thesis I have uncovered novel cellular phenotypes and 
provided crucial insight into genotype-phenotype relationships of three Genomic 
Disorders. It is hoped that the data presented here may not only improve our 
understanding of the underlying aetiology of these three complex disorders, but in 
addition may aid the development of more effective management therapies for 
these patients. Moreover, it stresses the importance of further molecular analysis 
to address some of the unanswered questions with regards to 16p11.2 CNV 
Disorder.  
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